CA2522535C - Chemokine receptor binding heterocyclic compounds with enhanced efficacy - Google Patents

Chemokine receptor binding heterocyclic compounds with enhanced efficacy Download PDF

Info

Publication number
CA2522535C
CA2522535C CA2522535A CA2522535A CA2522535C CA 2522535 C CA2522535 C CA 2522535C CA 2522535 A CA2522535 A CA 2522535A CA 2522535 A CA2522535 A CA 2522535A CA 2522535 C CA2522535 C CA 2522535C
Authority
CA
Canada
Prior art keywords
mmol
compound
ch2c12
solution
stirred
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2522535A
Other languages
French (fr)
Other versions
CA2522535A1 (en
Inventor
Gary J. Bridger
Al Kaller
Curtis Harwig
Renato Skerlj
David Bogucki
Trevor R. Wilson
Jason Crawford
Ernest J. Mceachern
Bem Atsma
Siqiao Nan
Yuanxi Zhou
Dominique Schols
Christopher Dennis Smith
Maria Rosaria Di Fluri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of CA2522535A1 publication Critical patent/CA2522535A1/en
Application granted granted Critical
Publication of CA2522535C publication Critical patent/CA2522535C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infections of target cells by a human immunodeficiency virus (HIV).

Description

DEMANDE OU BREVET VOLUMINEUX

LA PRRSENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:

NOTE POUR LE TOME / VOLUME NOTE:

CHEMOHINE RECEPTOR BINDING HETEROCYCLIC
COMPOUNDS WITH ENHANCED EFFICACY
Technical Field
[0002] This invention generally relates to novel compounds, pharmaceutical compositions and their use. This invention more specifically relates to novel heterocyclic compounds that bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects; against infection of target cells by a human immunodeficiency virus (HIV), as well as enhance the population of progenitor and/or stem cells, or stimulate the production of white blood cells.

Background of the Invention
[0003] Approximately 40 human chemokines have been described, that fimction, at least in part, by modulating a complex and overlapping set of biological activities important for the movement of lymphoid cells and extravasation and tissue infiltration of leukocytes in response to inciting agents (See, for example: P. Ponath, Exp. Opin. Invest.
Drugs (1998) 7:1-18). These chemotactic cytoeines, or chemokines, constitute a family of proteins, approximately 8-10 kDa in size. Chemokines appear to share a common structural motif, that consists of 4 conserved cysteines involved in maintaining tertiary structure.
There are two major subfamilies of chemokines: the "CC" or Q-chemoldnes and the "CXC" or a-chemokines. The receptors of these chemokines are classified based upon the chemokine that constitutes the receptor's natural ligand. Receptors of the f3-chemokines are designated "CCR"; while those of the a chemokines are designated "CXCR."
[0004] Chemokines are considered to be principal mediators in the initiation and maintenance of inflammation (see Chemokines in Disease published by Humana Press (1999), Edited by C. Herbert; Murdoch, et al., Blood (2000) 95:3032-3043).
More specifically, chemokines have been found to play an important role in the regulation of endothelial cell function, including proliferation, migration and differentiation during angiogenesis and re-endothelialization after injury (Gupta, et al., J. Biolog.
Chem. (1998) 7:4282-4287). Two specific chemokines have been implicated in the etiology of infection by human immunodeficiency virus (HIV).
[0005] In most instances, HIV initially binds via its gp 120 envelope protein to the CD4 receptor of the target cell. A conformational change appears to take place in the gp 120 which results in its subsequent binding to a chemokine receptor, such as CCR5 (Wyatt, et al., Science (1998) 280:1884-1888). HIV-1 isolates arising subsequently in the infection bind to the CXCR4 chemokine receptor. In view of the fact that the feline immunodeficiency virus, another related retrovirus, binds to a chemokine receptor without needing to bind first to the CD4 receptor, suggests that chemokine receptors may be the primordial obligate receptors for immunodeficiency retroviruses.
[0006] Following the initial binding by HIV to CD4, virus-cell fusion results, which is mediated by members of the chemokine receptor family, with different members serving as fusion cofactors for macrophage-tropic (M-tropic) and T cell line-tropic (T-tropic) isolates of HIV-1 (Carroll, et al., Science (1997) 276:273-276; Feng, et al., Science (1996) 272:872-877;
Bleul, et al., Nature (1996) 382:829-833; Oberlin, et al., Nature (1996) 38.2:833-835; Cocchi, et al., Science (1995) 270:1811-1815; Dragic, et al., Nature (1996) 381:667-673; Deng, et al., Nature (1996) 381:661-666; Alkhatib, et al., Science (1996) 272:1955-1958).
During the course of infection within a patient, it appears that a majority of HIV
particles shift from the M-tropic to the more aggressive pathogenic T-tropic viral phenotype (Miedema, et al., Immune. Rev. (1994) 140:35; Blaak, et al., Proc. Natl. Acad. Sci. (2000) 97:1269-1274;
Simmonds, et al., J. Virol. (1996) 70:8355-8360; Tersmette, et al., J. Virol.
(1988) 62:2026-2032; Connor, R. I., et al., J. Virol. (1994) 68:4400-4408;
Schuitemaker, et al., I Virol. (1992) 66:1354-1360). The M-tropic viral phenotype correlates with the virus's ability to enter the cell following binding of the CCR5 receptor, while the T-tropic viral phenotype correlates with viral entry into the cell following binding and membrane fusion with the CXCR4 receptor. Clinically observations suggest that patients who possess genetic mutations in the CCR5 or CXCR4 appear resistant or less susceptible to HIV
infection (Liu, et al., Cell (1996) 86:367-377; Samson, et al., Nature (1996) 382:722-725;
Michael, et al., Nature Med. (1997) 3:338-340; Michael, et al., J Virol. (1998) 72:6040-6047;
Obrien, et al., Lancet (1997) 349:1219; Zhang, et al.. AIDS Res. Hum. Retroviruses (1997) 13:1357-1366;
Rana, et al., J. Virol. (1997) 71:3219-3227; Theodorou, et al., Lancet (1997) 349:1219-1220).
Despite the number of chemokine receptors which have been reported to HIV
mediate entry into cells, CCR5 and CXCR4 appear to be the only physiologically relevant coreceptors used by a wide variety of primary clinical HIV-1 strains (Zhang, et al., J. Virol.
(1998) 72:9307-9312; Zhang, et al., J. Virol. (1999) 73:3443-3448; Simonds, et al., J. Virol.
(1988) 72:8453-8457). Fusion and entry of T-tropic viruses that use CXCR4 are inhibited by the natural CXC-chemokine stromal cell-derived factor-1, whereas fusion and entry of M-tropic viruses that use CCR5 are inhibited by the natural CC-chemokines namely, Regulated on Activation Normal T-cell Expressed and Secreted (RANTES) and Macrophage Inflammatory proteins (MIP-1 alpha and beta).
[00071 However, the binding of chemokine receptors to their natural ligands appears to serve a more evolutionary and central role than only as mediators of HIV
infection. The binding of the natural ligand, pre-B-cell growth-stimulating factor/stromal cell derived factor (PBSF/SDF-1) to the CXCR4 chemokine receptor provides an important signaling mechanism: CXCR4 or SDF-1 knock-out mice exhibit cerebellar, cardiac and gastrointestinal tract abnormalities and die in utero (Zou, et al., Nature (1998) 393:591-594;
Tachibana, et al., Nature (1998) 393:591-594; Nagasawa, et al., Nature (1996) 382:635-638).
CXCR4-deficient mice also display hematopoietic defects (Nagasawa, et al., Nature (1996) 382:635-638); the migration of CXCR4 expressing leukocytes and hematopoietic progenitors to SDF-1 appears to be important for maintaining B-cell lineage and localization of CD34+
progenitor cells in bone marrow (Bleul, et al., J. Exp. Med. (1998) 187:753-762; Viardot, et al., Ann. Hematol. (1998) 77:195-197; Auiti, et al., J. Exp. Med. (1997) 185:111-120; Peled.
et al., Science (1999) 283:845-848; Qing, et al., Immunity (1999) 10:463-471;
Lataillade, et al., Blood (1999) 95:756-768; Ishii, et al., J. Immunol. (1999) 163:3612-3620;
Maekawa, et al., Internal Medicine (2000) 39:90-100; Fedyk, et al., J. Leukocyte Biol.
(1999) 66:667-673;
Peled, et al., Blood (2000) 95:3289-3296).

[00081 Blood cells play a crucial part in maintaining the health and viability of animals, including humans. White blood cells include neutrophils, macrophage, eosinophils and basophils/mast cells as well the B and T cells of the immune system. White blood cells are continuously replaced via the hematopoietic system, by the action of colony stimulating factors (CSF) and various cytokines, in particular on stem cells and progenitor cells in hematopoietic tissues. The nucleotide sequences encoding a number of these growth factors have been cloned and sequenced. Perhaps the most widely known of these is granulocyte colony stimulating factor (G-CSF) which has been approved for use in counteracting the negative effects of chemotherapy by stimulating the production of white blood cells and progenitor cells (peripheral blood stem cell mobilization). A discussion of the hematopoietic effects of this factor can be found, for example, in U.S. Patent No.
5,582,823.

[0009] Several other factors have been reported to increase white blood cells and progenitor cells in both human and animal subjects. These agents include granulocyte-macrophage colony stimulating factor (GM-CSF), Interleukin-l (IL-1), Interleukin-3 (IL-3), Interleukin-8 (IL-8), PIXY-321 (GM-CSF/II,-3 fusion protein), macrophage inflammatory protein, stem cell factor, thrombopoietin and growth related oncogene, as single agents or in combination (Dale, D., et al., Am. J. of Hematol. (1998) 57:7-15; Rosenfeld, C., et al., Bone Marrow Transplantation (1997) 17:179-183; Pruijt, J., et al., Cur. Op. in Hematol. (1999) 6:152-158; Broxmeyer, H., et al., Exp. Hematol. (1995) 23:335-340; Broxmeyer, et al., Blood Cells, Molecules and Diseases (1998) 24:14-30; Glaspy, J., et al., Cancer Chemother.
Pharmacol. (1996) 38(suppl):S53-S57; Vadhan-Raj, S., et al., Ann. Intern. Med.
(1997) 126:673-81; King, k51 et al., flood (2001) 97:1534-1542; Glaspy, J., et al., Blood (1997) 90:2939-2951).
[0010] While endogenous growth factors are pharmacologically effective, the well known disadvantages of employing proteins and peptides as pharmaceuticals underlies the need to add to the repertoire of such growth factors with agents that are small molecules. In another aspect, such small molecules are advantageous over proteins and peptides where production in large quantities are desired.
[0011] The signal provided by SDF-1 on binding to CXCR4 may also play an important role in tumor cell proliferation and regulation of angiogenesis associated with tumor growth (See "Chemokines and Cancer" published by Humana Press (1999); Edited by B. J.
Rollins;
Arenburg, et al., J. Leukocyte Biol. (1997) 62:554-562; Moore, et al., J.
Invest. Med. (1998) 46:113-120; Moore, et al., Trends cardiovasc. Med. (1998) 8:51-58; Seghal, et al., J. Surg.
Oncol. (1998) 69:99-104); the known angiogenic growth factors VEG-F and bFGF, up-regulate levels of CXCR4 in endothelial cells, and SDF-1 can induce neovascularization in vivo (Salcedo, et al., Am. J. Pat/:ol. (1999) 154:1125-1135); Leukemia cells that express CXCR4 migrate and adhere to lymph nodes and bone marrow stromal cells that express SDF-1 (Burger, et al., Blood (1999) 94:3658-3667; Arai, et al., Eur. J.
Haematol. (2000) 64:323-332; Bradstock, et al., Leukemia (2000) 14:882-888).
[00121 The binding of SDF-1 to CXCR4 has also been implicated in the pathogenesis of atherosclerosis (Abi-Younes, et al., Circ. Res. (2000) 86:131-138), renal allograft rejection (Either, et aL, Transplantation (1998) 66:1551-1557), asthma and allergic airway inflammation (Yssel, et al., Clinical and Experimental Allergy (1998) 28:104-109;
J. Immunol. (2000) 164:5935-5943; Gonzalo, et al., J Immunol. (2000) 165:499-508), Alzheimer's disease (Xia, et al., J Neurovirology (1999) 5:32-41) and Arthritis (Nand, et al., J. Immunol. (2000) 164:5010-5014).
[0013] In attempting to better understand the relationship between chemokines and their receptors, recent experiments to block the fusion, entry and replication of HIV via the CXCR4 chemokine receptor were carried out through the use of monoclonal antibodies or small molecules that appear to suggest a useful therapeutic strategy (Schols, et al., J. Exp.
Mad (1997)186:1383-1388; Schols, et al., Antiviral Research (1997) 35:147-156;
Bridger, et al., J. Med Chem. (1999) 42:3971-3981; Bridger, et al.,, `Bicyclam Derivatives as HIV
Inhibitors" in Advances in Antiviral Drug Design, 3:161-229, published by JAI
press (1999), edited by E. De Clercq). Small molecules, such as bicyclams, appear to specifically bind to CXCR4 and not CCRS (Donzella, et al., Nature Medicine (1998) 4:72-77). These experiments demonstrated interference with HIV entry and membrane fusion into the target cell in vitro. More recently, bicyclams were also shown to inhibit fusion and replication of Feline Immunodeficiency Virus (FIV) that uses CXCR4 for entry (Egberinl , et al., J. Virol.
(1999) 73:6346-6352).
[0014] Additional experiments have shown that the bicyclam dose-dependently inhibits binding of 1251-labeled SDF-1 to CXCR4 and the signal transduction (indicated by an increase in intracellular calcium) in response to SDF-1. Thus, the bicyclam also functioned as an antagonist to the signal transduction resulting from the binding of stromal derived factor or SDF-la, the natural chemokine to CXCR4. Bicyclams also inhibited HIV gpl2O
(envelope)-induced apoptosis in non-HIV infected cells (Blanco, et al., Antimicrobial Agents and Chemother. (2000) 44:51-56).
[00151 U.S. Pat. Nos. 5,583,131; 5,698,546; 5,817,807; 6,506,770; 5,021,409;
6,001,826;
and 6,667,320 and published application US2002/0077339 disclose cyclic compounds that are active against HIV-1 and HIV-2 in in vitro tests. It was subsequently discovered and further disclosed in PCT WO 02/34745 that these compounds exhibit anti-HIV activity by binding to the chemokine receptor CXCR4 expressed on the surface of certain cells of the immune system. This competitive binding thereby protects these target cells from infection by HIV which utilize the CXCR4 receptor for entry. In addition, these compounds antagonize the binding, signaling and chernotactic effects of the natural ligand for CXCR4, the chemokine stromal cell-derived factor la (SDF-1). We further disclosed that these novel compounds demonstrate protective effects against HIV infection of target cells by binding in vitro to the CCR5 receptor.
[0016] Additionally we have disclosed in U.S. Pat. No. 6,365,583 that these cyclic polyamine antiviral agents described in the above-mentioned patents/patent applications have the effect of enhancing production of white blood cells as well as exhibiting antiviral properties. Thus, these agents are useful for controlling the side-effects of chemotherapy, enhancing the success of bone marrow transplantation, enhancing wound healing and bum treatment, as well as combating bacterial infections in leukemia.
[0017] The development and maturation of blood cells is a complex process.
Mature blood cells are derived from hematopoietic precursor cells (progenitor) cells and stem cells present in specific hematopoietic tissues including bone marrow. Within these environments hematopoietic cells proliferate and differentiate prior to entering the circulation. The chemokine receptor CXCR4 and its natural ligand stromal cell derived factor-1 (SDF-1) appear to be important in this process (for reviews see Maekawa, T., et al., Internal Med.
(2000) 39:90-100; Nagasawa, T., et al., Int. J. Hematol. (2000) 72:408-411).
This is demonstrated by reports that CXCR4 or SDF-1 knock-out mice exhibit hematopoietic defects (Ma, Q., et al., Proc. NatL Acad. Sci USA (1998) 95:9448-9453; Tachibana, K., et at., Nature (1998) 39-3:591-594; Zou, Y-R., et al., Nature (1998}393:595-599). It is also known that CD34+ progenitor cells express CXCR4 and require SDF-1 produced by bone marrow stromal cells for chemoattraction and engraftment (Peled, A., et al., Science (1999) 283:845-848) and that in vitro, SDF-1 is chemotactic for both CD34+ cells (Aiuti, A., et al., J. Exp. Med. (1997) 185:111-120; Viardot, A., et al., Ann. Hematol. (1998) 77:194-197) and for progenitor/stem cells (Jo, D-Y., et al., J. Clin. Invest. (2000) 105:101-111). SDF-1 is also an important chemoattractant, signaling via the CXCR4 receptor, for several other more committed progenitors and mature blood cells including T-lymphocytes and monocytes (Bleul, C., et al., J. Exp. Med. (1996) 184:1101-1109), pro-and pre-B
lymphocytes (Fedyk, E. R., et al., J. Leukoc. Biol. (1999) 66:667-673; Ma, Q., et al., Immunity (1999)
7 10:463-471) and megakaryocytes (Hodohara, K., et al., Blood (2000) 95:769-775;
Riviere, C., et al., Blood (1999) 95:1511-1523; Majka, M., et al., Blood (2000) 96:4142-4151; Gear, A., et al., Blood (2001) 97:937-945; Abi-Younes, S., et al., Circ. Res.
(2000) 86:131-138).
[00181 Thus, in summary, it appears that SDF-1 is able to control the positioning and differentiation of cells bearing CXCR4 receptors whether these cells are stem cells (i.e., cells which are CD34+) and/or progenitor cells (which result in formation of specified types, of colonies in response to particular stimuli; that can be CD34+ or CD34-) or cells that are somewhat more differentiated.
[00191 Recently, considerable attention has been focused on the number of CD34+ cells mobilized in the pool of peripheral blood progenitor cells used for autologous stem cell transplantation. The CD34+ population is the component thought to be primarily responsible for the improved recovery time after chemotherapy and the cells most likely responsible for long-term engraftrnent and restoration of hematopoiesis (Croop, J. M., et al., Bone Marrow Transplantation (2000) 26:1271-1279). The mechanism by which CD34+ cells re-engraft may be due to the chemotactic effects of SDF-1 on CXCR4 expressing cells (Voermans, C., Blood (2001) 97:799-804; Ponomaryov, T., et al., J. Clin. Invest. (2000) 106:1331-1339).
More recently, adult hematopoietic stem cells were shown to be capable of restoring damaged cardiac tissue in mice (Jackson, K., et al., J. Clin. Invest. (2001) 107:1395-1402; Kocher, A., et al., Nature Med. (2001) 7:430-436). Thus, the role of the CXCR4 receptor in managing cell positioning and differentiation has assumed considerable significance.
[00201 More recently, we disclosed in PCT WO 00/56729, PCT WO 02/22600, PCT WO 02/22599, and PCT WO 02/34745 a series of heterocyclic compounds that exhibit anti-HIV activity by binding to the chemokine receptors CXCR4 and CCR5 expressed on the surface of certain cells of the immune system. This competitive binding thereby protects these target cells from infection by HIV which utilize the CXCR4 or CCR5 receptors for entry. In addition, these compounds antagonize the binding, signaling and chemotactic effects of the natural ligand for CXCR4, the chemokine stromal cell-derived factor 1 cc (SDF-1) and/or the natural ligand for CCR5, the chemokine RANTES.
[00211 The chemokine receptor, CXCR4 has been found to be essential for the vascularization of the gastrointestinal tract (Tachibana, et al., Nature (1998) 393:591-594) as well as haematopoiesis and cerebellar development (Zou, et al., Nature (1998) 393:591-594).
Interference with any of these important functions served by the binding of pre-B-cell
8 growth-stimulating factor/stromal derived factor (PBSF/SDF-1) to the CXCR4 chemokine receptor results in lethal deficiencies in vascular development, haematopoiesis and cardiogenesis. Similarly, fetal cerebellar development appears to rely upon the effective functioning of CXCR4 in neuronal cell migration and patterning in the central nervous system. This G-protein-coupled chemokine receptor appears to play a critical role in ensuring the necessary patterns of migration of granule cells in the cerebellar anlage.
[0022] Herein, we disclose compounds that have unique chemical attributes and that exhibit protective effects against HIV infection of target cells by binding to chemokine receptor CXCR4 or CCR5 in a similar manner to the previously disclosed macrocyclic compounds. In addition, these compounds antagonize the binding, signaling and chemotactic effects of the natural ligand for CXCR4, the chemokine stromal cell-derived factor 1 a (SDF-1) and/or the natural ligand for CCR5 (the chemokine RANTES). Further, the components of the invention have the effect of increasing progenitor cells and/or stem cells.
Even further, the compounds have the effect of enhancing production of white blood cells as well as exhibiting antiviral properties. Thus, these agents are useful where treatment affects the activities within the bone marrow resulting in leukopenia, thus controlling the side-effects of chemotherapy, radiotherapy, enhancing the success of bone marrow transplantation, enhancing wound healing and burn treatment, as well as combating bacterial infections in leukemia.
[0023] Citation of the above documents is not intended as an admission that any of the foregoing is pertinent prior art. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents.
Disclosure of the Invention [0024] The present invention provides novel compounds that bind chemokine receptors and interfere with the binding of the natural ligand thereto. The compounds.
of the present invention are useful as agents demonstrating protective effects on target cells from HIV
infection, and which are useful to treat rheumatoid arthritis. Embodiments of the present invention are compounds that act as antagonists or agonists of chemokine receptors, which are useful as agents capable of reconstituting the immune system by increasing the level of CD4+ cells; as antagonist agents of apoptosis in immune cells, such as CD8+
cells, and
9 neuronal cells; as antagonist agents of migration of human bone marrow B
lineage cells to stromal-derived factor 1, as well as other biological activities related to the ability of these compounds to inhibit the binding of chemokines to their receptors.
[0025] In addition, the invention is directed to methods of treating animal subjects, in particular, veterinary and human subjects, to enhance the number of progenitor cells and/or stem cells. The progenitor and/or stem cells may be harvested and used in cell transplantation. Further, the invention is directed to methods of treating animal subjects, in particular, veterinary and human patients, who are defective in white blood cell (WBC) count, or who would benefit from elevation of WBC levels using the compounds disclosed herein.
[0026] More particularly, the present invention relates to macrocyclic compounds that can be described generally as consisting of a "core" nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzunidazolyl methyl and tetrahydroquinolinyl, and the third is a pendant group which contains an additional nitrogen.
[0026A] Various embodiments of this invention provide use of a compound of formula Me for mobilizing progenitor cells, stem cells or both into peripheral blood from bone marrow of a subject or for preparation of a medicament for such mobilization. Also provided is a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of a compound of formula IIIe in unit dosage form for use in such mobilization. The subject may exhibit a hematopoietic deficit from chemotherapy or radiation therapy. The subject may have a condition that is aplastic anemia, leukemia or a drug-induced anemia. The subject may be a transplantation recipient. The subject may be a healthy stem cell donor.

9a [0027] In one aspect, the invention is directed to a compound of the formula Rl X Z

A
9B' R Y

j (CR 2)nt (CR5 5)*na ( S2)8 NO2 R
C
a RAN C I~

R4 ~(xX and Y are independently N or CR1;
Z is S, 0, NR or CR2;
each R' -R6 is independently H or a noninterfering substituent;
n1 is 0-4;
n2 is 0-1, wherein the * signifies C m C may be substituted for CRS=CR5;
n3 is 0-4;
wherein nl+n2+n3 is greater than or equal to 2;

b is 0-2;

wherein the following combinations of R groups maybe coupled to generate a ring, which ring may be saturated or unsaturated:
R2+R2, one R2+R3, R3+ one R¾, RW, one R5+ another R5, one R5+ one R6, and R6+R6;

wherein the ring may not be aromatic when the participants in ring formation are two R5; and wherein when n2 is 1, neither nl nor n3 can be 0.
[0028] It should be noted that two R5 on the same atom (and two R2 or R6 on the same atom) may form a bridge.

[0029] Six-membered rings are preferred for ring B, with the preferred combination of rings A and B being tetrahydroquinolinyl.

[0030] Suitable noninterfering substituents include alkyl (C1_10), alkenyl (C2_10), alkynyl (C2_10), aryl ("C"5.12), arylalkyl, arylalkenyl, or arylalkynyl, each of which may optionally contain one or more heteroatoms selected from 0, S, and N and each of which may further be substituted; or optionally substituted forms of acyl, arylacyl, alkyl- alkenyl-, alkynyl- or arylsulfonyl and forms thereof which contain heteroatoms in the alkyl, alkenyl, alkynyl or aryl moieties. Other noninterfering substituents include OR, SR, NR2, COOR, CONR2, where R is H or alkyl, alkenyl, alkynyl or aryl as defined above. Where the substituted atom is C, the substituents may include, in addition to the substituents listed above, halo, OOCR, NROCR, where an R is H or a substituent set forth above, or may be =0.
[0031] In general, a "noninterfering substituent" is a substituent whose presence does not destroy the ability of the compound of formula Ito behave as a chemokine.
Specifically, the presence of the substituent does not destroy the effectiveness of the compound. Because the compounds of the present invention have been shown to inhibit HIV replication, and specifically to interact with the CXCR4 receptor, the compounds of the invention are shown to be effective in treating conditions which require modulation of CXCR4 and mediated activity.

[0032] In one aspect, the invention is directed to a method to elevate the progenitor cells and/or stem cells, in a subject. The method comprises administering to said subject an amount of a compound of formula I or of a pharmaceutical composition thereof effective to elevate progenitor cell and/or stem cell levels. In one embodiment, bone marrow progenitor and/or stem cells are mobilized for myocardial repair.
[0033] The methods of the invention also include treatment of cell populations ex vivo with the compounds of formula I and introducing the treated populations into a compatible subject. The compounds of formula I may be used alone or in combination with other compounds and compositions to enhance the population of stem cells and/or progenitor cells in the peripheral blood. An enhanced production of white blood cells in the bone marrow may result as well.

[0034] In another aspect, the invention is directed to a method to elevate the white blood cells (WBC) count, in a subject in need of such WBC elevation, which method comprises administering to the subject an amount of a compound of formula I or of a pharmaceutical composition thereof effective to elevate WBC levels.

[0035] In additional aspects, the invention is directed to pharmaceutical compositions containing the compound of formula I for use in effecting an elevation of progenitor cells and/or stem cells in animal subjects, and/or for use in effecting WBC count elevation in animal subject.

[0036] In other aspects, the invention is directed to pharmaceutical compositions containing at least one compound of Formula I, and to methods of ameliorating conditions that are modulated by the CXCR4 receptor or the CCR5 receptor. Such conditions include, HIV infection, diseases associated with inflammation, diseases that are associated with immunosuppression and certain tumors.

Modes of Carr ing Out the Invention [0037] The invention provides compounds described above of Formula I which are chemokines and thus modulators of chemokine receptors.
[0038] In more detail, the compounds bind chemokine receptors and interfere with the binding of the natural ligand thereto, and demonstrate protective effects on target cells from HIV infection. The compounds are also useful as antagonists or agonists of chemokine receptors, and are thus capable of reconstituting the immune system by increasing the level of CD4+ cells; as antagonist agents of apoptosis in immune cells, such as CD8+
cells, and neuronal cells; as antagonist agents of migration of human bone marrow B
lineage cells to stromal-derived factor 1, as well as other biological activities related to the ability of these compounds to inhibit the binding of chemokines to their receptors. The compounds also inhibit the binding and signaling induced by the natural ligand, the chemokine SDF-1. While not wishing to be bound by any theory, the compounds of formula I which inhibit the binding of SDF-1 to CXCR4 effect an increase in stem and/or progenitor cells by virtue of such inhibition. Enhancing the stem and/or progenitor cells in blood is helpful in treatments to alleviate the effects of protocols that adversely affect the bone marrow, such as those that result in leukopenia. These are known side-effects, of chemotherapy and radiotherapy. The compounds of formula I also enhance the success of bone marrow transplantation, enhance wound healing and burn treatment, and aid in restoration of damaged organ tissue. They also combat bacterial infections that are prevalent in leukemia. The compounds of formula I are used to mobilize and harvest CD34+ cells via apheresis with and without combinations with other mobilizing factors. The harvested cells are used in treatments requiring stem cell transplantations.
[0039] As used herein, the term "progenitor cells" refers to cells that, in response to certain stimuli, can form differentiated hematopoietic or myeloid cells. The presence of progenitor cells can be assessed by the ability of the cells in a sample to form colony-forming units of various. types, including, for example, CFU-GM (colony-forming units, granulocyte-macrophage); CFU-GEMM (colony-forming units, multipotential); BFU-E (burst-forming units, erythroid); HPP-CFC (high proliferative potential colony-forming cells); or other types of differentiated colonies which can be obtained in culture using known protocols.
[0040] As used herein, "stem" cells are less differentiated forms of progenitor cells.
Typically, such cells are often positive for CD34. Some stem cells do not contain this marker, however. These CD34+ cells can be assayed using fluorescence activated cell sorting (FACS) and thus their presence can be assessed in a sample using this technique.
[0041] In general, CD34+ cells are present only in low levels in the blood, but are present in large numbers in bone marrow. While other types of cells such as endothelial cells and mast cells also may exhibit this marker, CD34 is considered an index of stem cell presence.
[0042] Chemokine antagonists that interfere in the binding of a chemokine to its receptor are also useful to reconstitute the immune system by increasing the level of CD4+ cells (Biard-Piechaczyk, et al., Immunol. Lett. (1999) 70:1-3); as antagonist agents of apoptosis in immune cells, such as CD8+ cells (Herbin, et al., Nature (1998) 395:189-193), and as antagonist agents of apoptosis in neuronal cells (Ohagen, et al., J. of Virol.
(1999) 73:897-906; and Hesselgesser, et al., Curr. Biol. (1998) 8:595-598). Chemokine receptor antagonist agents also inhibit the migration of human bone marrow B lineage cells to stromal-derived factor 1 (See, for example: E. Fedyk, et al., J of Leukoc}ate Biol.
(1999) 66:667-783).
[0043] The invention includes pharmaceutical compositions comprising a therapeutically effective amount of a compound of Formula I along with at least one excipient, and methods of treating diseases of the human body or the bodies of other mammals with such compositions. The invention provides a method for blocking or interfering with the binding by a chemokine receptor with its natural ligand, comprising contacting of said chemokine receptor with an effective amount of the compound according to Formula I. Also included is a method of protecting target cells possessing chemokine receptors, the binding to which by a pathogenic agent results in disease or pathology, comprising administering to a mammalian subject a pharmaceutical composition comprising a therapeutically effective amount of the compound according to Formula I. The invention includes the use of a compound of Formula I in the manufacture of a medicament for the treatment of a disease in which blocking or interfering with binding of a chemokine receptor with its natural ligand is advantageous. The compound is formulated into a composition in amount corresponding to a therapeutically effective amount of a compound of Formula I.

The Invention Compounds [0044] The invention compounds are described generally by Formula I which is reproduced below for purposes of the present discussion.

R X Z
A B )b (I) R Y

N-(CR52)nl (CR5=CR5)*n2 (CR52)n3 NR62 R3-. N

R
[0045] In one embodiment, the compounds of the present invention are of Formula II:

A B (II) -(CR52)nl (CR5=CR5)*n2 (CR52)n3 NR62 0"IZZZ
-, -, N "'kN
C

or the salts and pro-drug forms thereof, representing a subset of the compounds of Formula I wherein b is 1, X is CR1, Y is N, and Z is CR12 and R1 to R6 and nl-n3 are as defined for Formula I. In this subgenus, the preferred tetrahydroquinolyl and imidazole/benzimidazolyl methyl groups are attached to the core nitrogen.
[0046] In one embodiment, no rings are formed in the portion of the molecule containing the non-core nitrogen (that to which two R6 are coupled). In another embodiment, any, two R5 (including two R5 on the same C), two R6 or one R5 and one R6 can be joined together via a 1-6 membered linker to form a ring. Also contemplated are rings formed by two R2, by, one R2 and R3, and by R3 and one W. Exemplary rings include, inter alia, cycloalkyl, cycloalkenyl, saturated or partially saturated heterocycles '(piperidine, piperazine, pyrrolidine, pyrroline, pyrazolidine, imidazoline, morpholine, thiomorpholine, pyrazoline, tetrahydrofuran, dihydrofuran, tetrahydrothiophene, dihydrothiophene, dihydropyran, tetrahydropyran and the like). However, rings formed from two R5 from other than the same C cannot be aromatic.
[0047] Thus, alternatively, the present invention provides compounds of Formulas IIIa-IIle:

R Rl R R;
Rz N R; N

Az:~- R. -__ N
R--.N N
---~~~( ~, R
R R~ R

ilb Rl Rl Ri Its ~.
A
N R N

CR ~ `CRS2 CR aN~R N- -Rs N
R J N
R~ R R
R

RC IUd I A B
RI N/

/N-(CH2)n4 NR 2 R3, O `N
N C

Me or salts or pro-drug forms thereof wherein:
d = 0-3 and n4 is 2-6 especially wherein both R6 are H or one R6 is H and the other includes an aryl moiety, or wherein two R6 form a ring.
[0048] The compounds may be supplied as "pro-drugs", that is, protected forms, which release the compound after administration to a subject. For example,,the compound may carry a protective group which is split off by hydrolysis in body fluids, e.g., in the bloodstream, thus releasing active compound or is oxidized or reduced in body fluids to release the compound. A discussion of pro-drugs maybe found in "Smith and Williams' Introduction to the Principles of Drug Design," H.J. Smith, Wright, Second Edition, London 1988.
[0049] The compounds may also be supplied as salts with organic or inorganic acids or bases that are nontoxic. Non-toxic in the present sense has to be considered with reference to the prognosis for the infected patient without treatment. Examples of inorganic bases with alkali metal hydroxides (e.g., sodium hydroxide, potassium hydroxide, etc.), alkaline earth metal hydroxides (e.g., of calcium, magnesium, etc.), and hydroxides of aluminum, ammonium, etc. Examples of organic bases include trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N,N'-dibenzylethylenediamine, etc. Examples of inorganic acids include hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, etc. Examples of organic acids include formic acid, oxalic acid, acetic acid, tartaric acid, methanesulfonic acid, benzenesulfonic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc. Also included are salts with basic amino acids such as arginine, lysine, ornithine, etc., and salts with acidic amino acids such as aspartic acid, glutamic acid, etc.

[0050] All of the compounds of the invention contain at least one chiral center. The invention includes mixtures of stereoisomers, individual stereoisomers, and enantiomeric mixtures, and mixtures of multiple stereoisomers. In short, the compound may be supplied in any desired degree of chiral purity.

[0051] As set forth above, the basic structure of the compounds of the invention is defined by. Formula I, and particular illustrative embodiments are found in Formulas 1-111.
The further definition of the compounds of the invention rest on the identification of the noninterfering substituents.

[0052] Preferred embodiments of R1 include H, halo, alkyl, alkoxy, CF3, and the like.
Preferably, all R1 are H or one R1 is other than H and the remaining two R1 are H.
[0053] Preferred embodiments of R2 include H alkyl, and alkenyl especially H
and methyl.

[0054] Preferred embodiments of R3 include H, alkyl, alkenyl, arylalkyl, and aryl.
[0055] Preferred embodiments of R4 include H, alkyl, alkenyl and especially those wherein the two R4 are bridged to form an aromatic ring so that the substituent on the core nitrogen is benzimidazolylmethyl, including a further heteroatom-containing form thereof.
[0056] Preferred embodiments of R5 include H, alkyl and alkenyl, each optionally substituted, including those wherein alkyl or alkenyl substituents on a single carbon or on adjacent or nonadjacent carbons form a saturated or unsaturated ring. This ring cannot be aromatic. Alternative embodiments for R5, oximes, alkylated oximes hydroxylamine, including alkylated hydroxylamine, halo and the like.

[0057] Preferred embodiments of R6 include H, arylalkyl, arylsulfonyl, including those wherein one or more nitrogen atoms is present in the ring, and including fused ring aryl groups such as indolyl. Also preferred for R6 are heteroatom containing groups such as guanidyl groups carboxyl and carbamino groups, amides, arylsulfonic acids and aryl acyl substituents, again including aryl groups which comprise one or more nitrogens, alkenyl, cycloalkyl, carboxyl, and optionally substitutes, alkyl and alkenyl moieties, including those that are substituted by alcohols or amines are also preferred. Two R6 may form a saturated, unsaturated or aromatic ring, optionally including one or more N, 0 and/or S.
An R5 and an R6 or two R6 may also constitute a shared alkylene or alkenylene bridge to obtain the saturated or unsaturated ring, which may, be aromatic. In all cases (R5+R5 or R5+R6 or R6+R6), the shared alkylene or alkenylene substituent may include one or more heteroatoms such as N, S or O.
[0058] It is preferred, that only 1-3, preferably 1-2 of the R5 groups be other than hydrogen. In one embodiment, all R5 are hydrogen, in another embodiment, one pair of R5 is a shared alkylene, alkenylene, or such moieties which include a heteroatom.
[0059] Examples of optionally substituted alkyl groups include methyl, ethyl, propyl, etc.
and including cycloalkyls such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc.; examples of optionally substituted alkenyl groups include allyl, crotyl, 2-pentenyl, 3-hexenyl, 2-cyclopentenyl, 2-cyclohexenyl, 2-cyclopentenylmethyl, 2-cyclohexenylmethyl, etc.; C1_6 alkyl and alkenyl are preferred.
[0060] Examples of halogen include fluorine, chlorine, bromine, iodine, etc., with fluorine and chlorine preferred.
[0061] Examples of optionally substituted hydroxyl and thiol groups include optionally substituted alkyloxy or alkylthio (e.g., C1_10 alkyl) such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc.); an optionally substituted arylalkyloxy or arylalkylthio (e.g., phenyl-C1-4 alkyl, e.g., benzyl, phenethyl, etc.). Where there are two adjacent hydroxyl or thiol substituents, the heteroatoms may be connected via an alkylene group such as O(CH2)õ O and S(CH2)r,S (where n=1-5). Examples include methylenedioxy, ethylenedioxy, etc.
Oxides of thio-ether groups such as sulfoxides and sulfones are also envisioned.
[0062] Examples of optionally substituted hydroxyl groups also include optionally, substituted C2_4alkanoyl (e.g., acetyl, propionyl, butyryl, isobutyryl, etc.), C1_4 alkylsufonyl (e.g., methanesulfonyl, ethanesulfonyl, etc.) and an optionally substituted aromatic and heterocyclic carbonyl group including benzoyl, pyridinecarbonyl, etc.
[0063] Substituents on optionally substituted amino groups may bind to each other to form a cyclic amino group (e.g., 5- to 6-membered cyclic amino, etc., such as tetrahydropyrrole, piperazine, piperidine, pyrrolidine, morpholine, thiomorpholine, pyrrole, imidazole, etc.). Said cyclic amino group may have a substituent, and examples of the substituents include halogen (e.g., fluorine, chlorine, bromine, iodine, etc.), nitro, cyano, hydroxy group, thiol group, amino group, carboxyl group, an optionally halogenated CI-4 alkyl (e.g., trifluoromethyl, methyl, ethyl, etc.), an optionally halogenated C1.4 alkoxy (e.g., methoxy, ethoxy, trifluoromethoxy, trifluoroethoxy, etc.), C2-4 alkanoyl (e.g., acetyl, propionyl, etc.), C1.4 alkylsulfonyl (e.g., methanesulfonyi, ethanesulfonyl, etc.) the number of preferred substituents are 1 to 3.

[00641 An amino group may also be substituted once or twice (to form a secondary or tertiary amine) with a group such as an optionally substituted alkyl group including C1_loalkyl (e.g., methyl, ethyl propyl etc.); an optionally substituted alkenyl group such as allyl, crotyl, 2-pentenyl, 3-hexenyl, etc., or an optionally substituted cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc. In these cases, C1_6 alkyl, alkenyl and cycloalkyl are preferred. The amine group may also be optionally substituted with an aromatic or heterocyclic group, aralkyl (e.g., phenylCp-4alkyl) or heteroalkyl for example, phenyl, pyridine, phenylmethyl (benzyl), phenethyl, pyridinylmethyl, pyridinylethyl, etc.
The heterocyclic group may be a 5 or 6 membered ring containing 1-4 heteroatoms.
[00651 An amino group may be substituted with an optionally substituted C2_4 alkanoyl, e.g., acetyl, propionyl, butyryl, isobutyryl etc., or a C1.4alkylsulfonyl (e.g., methanesulfonyl, ethanesulfonyl, etc.) or a carbonyl or sulfonyl substituted aromatic or heterocyclic ring, e.g., benzenesulfonyl, benzoyl, pyridinesulfonyl, pyridinecarbonyl, etc. The heterocycles are as defined above.

[00661 Examples of optionally substituted carbonyl groups, or sulfonyl groups include optionally substituted forms of such groups formed from various hydrocarbyls such as alkyl, alkenyl and 5- to 6-membered monocyclic aromatic group (e.g., phenyl, pyridyl, etc.), as defined above.

Utility and Administration [0067] The invention is directed to compounds of Formula I that modulate chemokine receptor activity. Chemokine receptors include but are not limited to CCR1, CCR2, CCR3, CCR4, CCR5, CXCR3, and CXCR4.
[0068] In one embodiment, the invention provides compounds of Formula I that demonstrate protective effects on target cells from HIV infection by binding specifically to the chemokine receptor thus affecting the binding of a natural ligand to the CCR5 and/or CXCR4 of a target cell.
[0069] In another embodiment, the compounds of the present invention are useful as agents which affect chemokine receptors, such as CCR1, CCR2, CCR3, CCR4, CCR5, CXCR3, CXCR4 where such chemokine receptors have been correlated as being important mediators of many inflammatory as well as immunoregulatory, diseases.

[0070] Other diseases that are also implicated with chemokines as mediators include angiogenesis, and turnorigenesis such as brain, and breast tumors. Thus, a compound that modulates the activity of such chemokine receptors is useful for the treatment or prevention of such diseases.

[0071] The term "modulators" as used herein is intended to encompass antagonist, agonist, partial antagonist, and or partial agonist, i.e., inhibitors, and activators. In one embodiment of the present invention, compounds of Formula I demonstrate a protective effect against HIV infection by inhibiting the binding of HIV to a chemokine receptor such.as CCR5 and/or CXCR4, of a target cell. Such modulation is obtained by a method which comprises contacting a target cell with an amount of the compound which is effective to inhibit the binding of the virus to the chemokine receptor.

[0072] Compounds that inhibit chemokine receptor activity and function may be used for the treatment of diseases that are associated with inflammation, including but are not limited to, inflammatory or allergic diseases such as asthma, allergic rhinitis, hypersensitivity lung diseases, hypersensitivity pneumonitis, eosinophilic pneumonias, delayed-type hypersensitivity, interstitial lung disease (ILD) (e.g., idiopathic pulmonary fibrosis, or ILD
associated with rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, systemic sclerosis, Sjogren's syndrome, polymyositis or dermatomyositis);
systemic anaphylaxis or hypersensitivity responses, drug allergies, insect sting allergies; autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, myastenia gravis, juvenile onset diabetes; glomerulonephritis, autoimmune throiditis, graft rejection, including allograft rejection or graft-versus-host disease;
inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis;
spondyloarthropathies; scleroderma;
psoriasis (including T-cell mediated psoriasis) and inflammatory dermatoses such as dermatitis, eczema, atopic dermatitis, allergic contact dermatitis, urticaria;
vasculitis (e.g., necrotizing, cutaneous, and hypersensitivity vasculitis); eosinphilic myotis, eosiniphilic fasciitis; and cancers.

[0073] In addition compounds that activate or promote chemokine receptor function are used for the treatment of diseases that are associated with immunosuppression such as individuals undergoing chemotherapy, radiation therapy, enhanced wound healing and bum treatment, therapy for autoimmune disease or other drug therapy (e.g., corticosteroid therapy) or combination of conventional drugs used in the treatment of autoimmune diseases and graft/transplantation rejection, which causes immunosuppression;
immunosuppression due to congenital deficiency in receptor function or other causes; and infectious diseases, such as parasitic diseases, including but not limited to helminth infections, such as nematodes (round worms); Trichuriasis, Enterobiasis, Ascariasis, Hookworm, Strongyloidiasis, Trichinosis, filariasis; trematodes; visceral worms, visceral larva migtrans (e.g., Toxocara), eosinophilic gastroenteritis (e.g., Anisaki spp., Phocanema ssp.), cutaneous larva migrans (Ancylostona braziliense, Ancylostoma caninum); the malaria-causing protozoan Plasmodium vivax, Human cytomegalovirus, Herpesvirus saimiri, and Kaposi's sarcoma herpesvirus, also known as human herpesvirus 8, and poxvirus Moluscum contagiosum.
[0074] Typical conditions which may be ameliorated or otherwise benefited by the method of the invention include hematopoietic disorders, such as aplastic anemia, leukemias, drug-induced anemias, and hematopoietic deficits from chemotherapy, or radiation therapy.
The method of the invention is also useful in enhancing the success of transplantation during and following immunosuppressive treatments as well as in effecting more efficient wound healing and treatment of bacterial inflammation. The method of the present invention is further useful for treating subjects who are imnmunocompromised or whose immune system is otherwise impaired. Typical conditions which are ameliorated or otherwise benefited by the method of the present invention, include those subjects who are infected with a retrovirus and more specifically who are infected with human immunodeficiency virus (HIV).
The method of the invention thus targets a broad spectrum of conditions for which elevation of progenitor cells and/or stem cells in a subject would be beneficial or, where harvesting of progenitor cells and/or stem cell for subsequent stem cell transplantation would be beneficial. In addition, the method of the invention targets a broad spectrum of conditions characterized by a deficiency in white blood cell count, or which would benefit from elevation of said WBC
count. Furthermore, the method of the present invention is useful for regenerating myocardium by mobilizing bone marrow stem cells.
[0075] The compounds of the invention maybe prepared in the form of prodrugs, i.e., protected forms which release the compounds of the invention after administration to the subject. Typically, the protecting groups are hydrolyzed in body fluids such as in the bloodstream thus releasing the active compound or are oxidized or reduced in vivo to release the active compound. A discussion of prodrugs is found in Smith and Williams Introduction to the Principles of Drug Design, Smith, H.J.; Wright, 2 d ed., London (1988).

[0076] The compounds of the invention, as they are polyamines, maybe administered prepared in the forms of their acid addition salts or metal complexes thereof.
Suitable acid addition salts include salts of inorganic acids that are biocompatible, including HCI, HBr, sulfuric, phosphoric and the like, as well as organic acids such as acetic, propionic, butyric and the like, as well as acids containing more than one carboxyl group, such as oxalic, glutaric, adipic and the like. Typically, at physiological pH, the compounds of the invention will be in the forms of the acid addition salts. Particularly preferred are the hydrochlorides.
In addition, when prepared as purified forms, the compounds may also be crystallized as the hydrates.
[0077] The compounds of the invention maybe administered as sole active ingredients, as mixtures of various compounds of formula I, and/or in admixture with additional active ingredients that are therapeutically or nutritionally useful, such as antibiotics, vitamins, herbal extracts, anti-inflammatories, glucose, antipyretics, analgesics, granulocyte-macrophage colony stimulating factor (GM-CSF), Interleukin-1 (IL-1), Interleukin-3 (IL-3), Interleukin-8 (IL-8), PIXY-321 (GM-CSF/IL-3 fusion protein), macrophage inflammatory protein, stem cell factor, thrombopoietin, growth related oncogene or chemotherapy and the like. In addition, the compounds of the invention may be administered in admixture with additional active ingredients that are therapeutically or nutritionally useful, such as antibiotics, vitamins, herbal extracts, anti-inflammatories, glucose, antipyretics, analgesics, and the like.
[0078] The compounds of the invention may be formulated for administration to animal subject using commonly understood formulation techniques well known in the art.
Formulations which are suitable for particular modes of administration and for compounds of the type represented by those of formula I may be found in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Company, Easton, PA.
[0079] Preferably, the compounds are administered by injection, most preferably by intravenous injection, but also by subcutaneous or intraperitoneal injection, and the like.
Additional parenteral routes of administration include intramuscular and intraarticular injection. For intravenous or parenteral administration, the compounds are formulated in suitable liquid form with excipients as required. The compositions may contain liposomes or other suitable carriers. For injection intravenously, the solution is made isotonic using standard preparations such as Hank's solution.
[0080] Besides injection, other routes of administration may also be used. The compounds maybe formulated into tablets, capsules, syrups, powders, or other suitable forms for administration orally. By using suitable excipients, these compounds may also be administered through the mucosa using suppositories or intranasal sprays.
Transdermal administration can also be effected by using suitable penetrants and controlling the rate of release.

[0081] The formulation and route of administration chosen will be tailored to the individual subject, the nature of the condition to be treated in the subject, and generally, the judgment of the attending practitioner.
[0082] Suitable dosage ranges for the compounds of formula I vary according to these considerations, but in general, the compounds are administered in the range of about 0.1 g/kg-5 mg/kg of body weight; preferably the range is about 1 p.g/kg-300 g/kg of body weight; more preferably about 10 ag/kg-100 ,ug/kg of body weight. For a typical 70-kg human subject, thus, the dosage range is from about 0.7 g-350 mg; preferably about 700 g-21 mg; most preferably about 700 g-7 mg. Dosages may be higher when the compounds are administered orally or transdermally as compared to, for example, i.v.
administration.

[0083] The compounds may be administered as a single bolus dose, a dose over time, as in i.v. or transdermal administration, or in multiple dosages.
[0084] In addition to direct administration to the subject, the compounds of formula I can be used in ex vivo treatment protocols to prepare cell cultures which are then used to replenish the blood cells of the subject. Ex vivo treatment can be conducted on autologous cells harvested from the peripheral blood or bone marrow or from allografts from matched donors. The concentration of the compound or compounds of formula I alone or in combination with other agents, such as macrophage inflammatory protein is a matter of routine optimization.

[0085] Compounds of the present invention further may be used in combination with any other active agents or pharmaceutical compositions where such combined therapy, is useful to modulate chemokine receptor activity and thereby prevent and treat inflammatory and immunoregulatory diseases.

[0086] The compounds may further be used in combination with one or more agents useful in the prevention or treatment of HIV. Examples of such agents include:
(1) nucleotide reverse transcriptase inhibitor such as tenofovir disoproxil fumarate; lamivudine/zidovudine; abacavir/lamivudine/zidovudine;
emtricitabine;
amdoxovir; alovudine; DPC-817; SPD-756; SPD-754; GS7340; ACH-126,443 (beta)-L-F d4C; didanosine, zalcitabine, stavudine, adefovir, adefovir dipivoxil, fozivudine todoxil, etc.;
(2) non-nucleotide reverse transcriptase inhibitor (including an agent having anti-oxidation activity such as immunocal, oltipraz, etc.) such as nevirapine, delavirdine, efavirenz, loviride, immunocal, oltipraz, TMC-125; DPC-083; capravarine;
calanolide A;
SJ-3366 series, etc.;
(3) protease inhibitors such as saquinavir, lopinavir/ritonavir, atazanavir, fosamprenavir, tipranavir, TMC-1 14, DPC-684, indinavir, nelfinavir, amprenavir, palinavir, lasinavir, etc.;
(4) entry inhibitors such as T-20; T-1249; PRO-542; PRO-140; TNX-355;
BMS-806 series; and 5-Helix;
(5) CCR5-receptor inhibitors such as Sch-C (or SCH351125); Sch-D, and SCH350634; TAK779; UK 427,857 and TAK 449;
(6) Integrase inhibitors such as L-870,810; GW-810781 (S-1360); and (7) Budding inhibitors such as PA-344; and PA-457.
[0087] Combinations of compounds of the present invention with HIV agents is not limited to (1), (2), and or (3), but includes combination with any agent useful for the treatment of HIV. Combinations the compounds of the invention and other HIV
agents may be administered separately or in conjunction. The administration of one agent may be prior to, concurrent to, or subsequent to the administration of other agent(s).
[0088] Like the compounds of the present invention, AMD3100 is an antagonist with the CXCR4 chemokine receptor (Gerlach, et al., J. Biol. Chem. (2001) 276:14153-14160). These compounds interfere with the binding of bone marrow stromal cell derived SDF-1 with CXCR4 on stem cells which leads to the release of hematopoietic stem cells from bone marrow into the circulation (Broxmeyer, et al., Blood (2001) 98:81 la (Abstract)). In a Phase 1 study at the University of Washington, Seattle, a single dose of 80 gg/kg of AMD-3 100 resulted in a WBC count of 17,000/ l and a peak 6-fold increase in circulating CD34+ progenitor/stem cells at the 6 hour time point (Liles, et al., Blood (2001) 98:737a (Abstract)). In another recent study mice were injected with rhG-CSF and recombinant rat Stem Cell Factor (rrSCF) in order to mobilize large numbers of bone marrow stem cells into the circulation and then we induced a heart attack. The combination of rrSCF
and rhG-CSF
provides a peak number of circulating stem cells after 5 daily injections. At 27 days post surgery there was a 68% improvement in survival in the treated group versus the controls. At this time the dead tissue was replaced with regenerating myocardium and all functional parameters tested were improved compared with controls (Orlic, et al., PNAS
(2001) 98:10344-10349). Thus, the compounds of the invention are useful to stimulate the production and proliferation of stem cells and progenitor cells.
[0089] A broad range of routes of administration are contemplated. Thus, the compounds according to the present invention may be administered by oral, intramuscular, intraperitoneal, intravenous, intracisternal injection or infusion, subcutaneous injection, transdermal or transmucosal administration or by, implant. They may also be administered by inhalation spray, nasal, vaginal, rectal, sublingual, or topical routes and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration.
[0090] The compounds of the invention are used to treat animals, including mice, rats, horses, cattle, sheep, dogs, cats, and monkeys and avians such as chickens and the like. The compounds of the invention are also effective for use in humans. In general, any subject who would benefit from an elevation of progenitor cells and/or stem cells, or whose progenitor cells and/or stem cells are desirable for stem cell transplantation are appropriate for administration of the invention method and/or any subject who has a WBC
deficiency or, more generally, who would profit from the elevation of white blood cell count is appropriate for administration of the invention method.
[0091] The invention also relates to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and an effective amount of compound of Formula I. The compounds. may be administered alone or as an admixture with a pharmaceutically acceptable carrier (e.g., solid formulations such as tablets, capsules;
granules, powders, etc.; liquid formulations such as syrups, injections, etc.) may be orally or non-orally administered. Examples of non-oral formulations include injections, drops, suppositories, pessaryies.
[0092] In the treatment or prevention of conditions which require chemokine receptor modulation an appropriate dosage level will generally be about 0.01 to 500 mg per kg subject body weight per day which can be administered in singe or multiple doses.
Preferably, the dosage level will be about 0.1 to about 250 mg/kg per day. It will be understood that the specific dose level and frequency, of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound used, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the patient undergoing therapy.
[0093] The following examples are offered to illustrate but not to limit the invention.
Examples [0094] The intermediates 8-hydroxy-5,6,7,8-tetrahydroquinoline and 8-amino-5,6,7,8-tetrahydroquinoline were prepared according to the procedures described in Bridger et al.
PCT Patent Application WO 00/56729. The intermediate N'-(1H-benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine was prepared as described by Bridger, et al, U.S. patent applications USSN 60/232,891, USSN 60/234,510.
The intermediate 1-N-tert-butoxycarbonyl-2-chloromethylbenzimidazole was prepared as described by An, H., et al., Tetrahedron (1998) 54:3999-4012.

General Synthesis Procedures:

General Procedure for N-Alkylation of (1-tert-butoxycarbonyl-1H-Benzimidazol-2-des ylmethy)-(5 6 7 8-tetrah dy ro-quinolin-8-yl)-amine with Mesylates or Alkyl Chlori [0095] To a solution of (1-tert-butoxycarbonyl-lH-Benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine (or amine) (1-1.4 equivalents), N,N,-diisopropylethylamine (or K2C03) (1.5-2 equivalents) and KI (0.05-0.16 equivalent) in CH3CN
(concentration -0.1-0.2 M) was added the mesylate or alkyl chloride (such as 1-N-tert-butoxycarbonyl-2-chloromethylbenzimidazole) (1-1.4 equivalents) and the mixture stirred at 50-70 C for 3-25 hours, as monitored by analytical thin layer chromatography. The reaction mixture was cooled, diluted with CH2C12 (10 mL/mmol amine) and poured into either saturated aqueous NaHCO3 or brine (10 mL/mmol alcohol). The phases were separated and the aqueous phase extracted with CH2C12 (3 x 10 mL/mmol amine). The combined organic phases were dried (Na2SO4 or MgSO4) and concentrated under reduced pressure. The crude material was purified by chromatography to afford the desired N-alkylated product.

General Procedure A: Direct Reductive Amination with NaBH3CN
[0096] To a stirred solution of the amine (1 equivalent) in anhydrous methanol (concentration -0.1 M), at room temperature, was added the carbonyl compound (-equivalents) in one portion. Once the carbonyl had dissolved (-P5 minutes), NaBH3CN (-2-4 equiv.) was added in one portion and the resultant solution was stirred at room temperature.

The solvent was removed under reduced pressure and CH2Cl2 (20 mL/mmol of amine) and brine or 1.0 M aqueous NaOH (10 mL/mmol amine) were added to the residue. The phases were separated and the aqueous phase was extracted with CH2Cl2 (3 x 10 mL/mmol amine).
The combined organic phases were dried (Na2SO4) and concentrated under reduced pressure.
The crude material was purified by chromatography.

General Procedure B: Direct Reductive Amination with NaBH(OAc)3 or NaBH4 [0097] To a stirred solution of the amine (1 equivalent) in CH2Cl2 (concentration -0.2 M), at room temperature, was added the carbonyl compound (-1-2 equivalents), glacial acetic acid (0-2 equivalents) and NaBH(OAc)3 (-1.5-3 equivalents)- and the resultant solution stirred at room temperature. The reaction mixture was poured into either saturated aqueous NaHCO3 or 1.0 M aqueous NaOH (10 mL / mmol amine). The phases separated and the aqueous phase extracted with CH2Cl2 (3 x 10 mL /mmol amine). The combined organic phases were dried (Na2SO4) and concentrated under reduced pressure. The crude material was purified by chromatography.
[0098] Similarly, to a stirred solution of the amine (1 equivalent) in anhydrous MeOH
(concentration -0.1 M), at room temperature, was added the carbonyl compound (1 equivalent). The resultant solution was stirred at room temperature or heated to reflux for 4-24 hours. NaBH4 (1-2 equivalents) was added and the resultant mixture stirred at room temperature for -20 minutes. The reaction mixture was concentrated, dissolved in CH2Cl2, washed consecutively with saturated aqueous NaHCO3 and saturated aqueous NaCl.
The aqueous layers were extracted with CH2Cl2 (2x) and the combined organic extracts were dried (MgSO4) and concentrated.

General Procedure C: Reaction of Alcohols with Methanesulfonyl Chloride [0099] To a stirred solution of the alcohol (1 equivalent) and Et3N (1.5-2 equivalents) in CH2Cl2 (or THF) (concentration -0. 1 M) at room temperature (or 0 C) was added methanesulfonyl chloride (-1.5 equivalents) and the reaction stirred at room temperature for 0.5-1 h. The reaction mixture was poured into either saturated aqueous NaHCO3 or saturated NH4Cl (10 mL/mmol alcohol). The phases were separated and the aqueous phase extracted with CH2Cl2 (3 x 10 mL/mmol amine). The combined organic phases were dried (Na2SO4) and concentrated under reduced pressure. The crude material was either purified by chromatography or used without further purification in the N-alkylation step.

General Procedure D: Salt formation using saturated HBr(g) in acetic acid:
[01001 To a solution of the free base in glacial acetic acid (2 mL) was added, a saturated solution of HBr(g) in acetic acid (2 mL). A large volume of ether (25 mL) was then added to precipitate a solid, which was allowed to settle to the bottom of the flask and the supernatant solution was decanted. The solid was washed by decantation with ether (3 x 25 mL) and the remaining traces of solvent were removed under vacuum. For additional purification, the solid was dissolved in methanol and re-precipitated with a large volume of ether. Washing the solid with ether by decantation, followed by drying of the solid in vacuo (0.1 Torr) gave the desired compound.

Intermediates:
Preparation of 4-hxymethylbenzaldehYde:
[01011 Terephthaldicarboxaldehyde (30.02g, 224 mmol), methanol (200 mL), palladium on activated carbon, (10%, 3.02 g) and 2-(aminomethyl)pyridine (2.3 mL, 22 mol, 0.01 mol equiv) were combined in a hydrogenation vessel and the reaction mixture was shaken on a Parr hydrogenator for 2.5 hours at 40 psi of hydrogen. The mixture was filtered through celite, the cake washed with methanol and the solvent from the eluent removed in vacuo.
Purification of the crude product by column chromatography on silica gel (EtOAc/Hexanes, 1:1) afforded the title compound (23.8 g, 78%) as a white solid. 1H NMR
(CDC13) 8 4.80 (s, 2H), 7.53 (d, 2H, J= 9 Hz), 7.87 (d, 2H, J= 9 Hz), 10.00 (s, 1H).

Preparation of 6,7-Dihydro-5H-quinolin-8-one:
CN);) [01021 To a stirred solution of 8-hydroxy-5,6,7;8-tetrahydroquinoline (13.96 g, 93.6 mmol) in dry CH2C12 (400 mL) was added activated manganese dioxide (85%
purity, 82.22 g, 804 mmol). The resulting heterogeneous mixture was stirred 18 h, at which point the black slurry was filtered through a cake of celite and washed with CH2C12 (3 x 50 mL).
The combined washings were concentrated to afford 11.27 g (82%) of the title compound as a pale yellow solid, which was used in subsequent reactions without further purification. 1H
NMR (CDC13) 6 2.17-2.25 (m, 2H), 2.82 (t, 2H, J= 7 Hz), 3.04 (t, 2H, J= 6 Hz), 7.37 (dd, 1H, J= 9, 6 Hz), 7.66 (dd, 1H, J= 9, 1 Hz), 8.71 (dd, 1H, J= 6, 1 Hz); 13C NMR
(CDC13) 8 22.2, 28.6, 39.2, 126.6, 137.3, 140.5, 147.6, 148.6, 196.5. ES-MS m/z 148 (M+H).
Preparation of (1-tent-butoxycarbonyl-1H-Benzimidazol-2-ylmethyl)-(5,6,7, 8-tetrahydro-quinolin-8-yl)-amine:

CT N
~NH
N N-boc [0103] Using General Procedure for N-Alkylation: To a stirred solution of 8-amino-5,6,7,8-tetrahydroquinoline (7.34 g, 49.6 mmol) in dry CH3CN (250 mL) was added 1-N-tert-butoxycarbonyl-2-chlorornethylbenzimidazole (13.22 g, 49.6 mmol), N,N-diisopropylethylamine (15.51nL, 89.2 mmol) and potassium iodide (0.41 g, 8.2 mmol) and the mixture was stirred at 60 C for 3.5 h. Purification by column chromatography on silica gel (CH2C12/MeOH, 99:1 followed by 97:3 and 96:4) gave the intermediate amine (6.38 g, 34%) as an orange, sticky oil. 1H NMR (CDC13) 8 1.76 (s, 9H), 1.81-2.10 (m, 2H), 2.25-2.37 (m, 1H), 2.72-2.89 (m, 2H), 3.77-3.84 (m, 1H), 4.39 (d, 1H, J= 15.0 Hz), 4.56 (d, 1H, J
= 15.0 Hz), 7.00-7.06 (m, 1H), 7.27-7.37 (m, 1H), 7.64-7.74 (m, 1H), 7.90-7.96 (d, 2H, J=
8.1 Hz), 8.34 (d, 1H, J= 3.0 Hz); 13C NMR (CDC13) 6 20.13, 28.48, 29.00, 29.20, 47.15, 56.89, 86.20, 115.32, 120.28, 122.06, 124.43, 124.85, 132.77, 133.74, 137.01, 142.44, 147.10,149.22,154.90,157.72; ES-MS m/z 279 (M+H-boc).

Preparation of (1H-Benzimidazol-2-ylmethyl)-(5 6 7 8-tetrahydro-quinolin-8-yl)-amine:

NH
N ~ NH
b [0104] To a stirred solution of (2-aminomethyl)benzimidazole dihydrochloride hydrate (5.96 g, 27.1 mmol) in dry MeOH (225 mL) was added 6,7-dihydro-5H-quinolin-8-one (3.99 g, 27.1 mmol) and the mixture stirred at room temperature for 69 h. To the resultant solution was added sodium borohydride (2.06 g, 54.2 mmol) in two portions and the mixture stirred for 1.5 h. The reaction mixture was concentrated in vacuo and diluted with CH2C12 (150 mL). The organic layer was washed with saturated aqueous sodium bicarbonate (200 mL), the aqueous layer extracted with CH2C12 (2 x 50 mL) and the combined organic layers dried (Na2SO4), filtered, and concentrated in vacuo. Purification by column chromatography on silica gel (CH2C12/MeOH, 99:1 followed by 98:2 and 96:4) gave the intermediate amine (3.59 g, 50%) as a yellow foam. 1H NMR (CDC13) 8 1.66-1.90 (m, 3H), 1.91-2.00 (m, 1H), 2.00-2.17 (m, 1H), 2.33-2.69 (br m, 1H), 3.88-3.96 (m, 1H), 4.37 (d, 1H, J= 3.0 Hz), 7.18-7.26 (m, 4H), 7.48 (d, 1H, J= 6.0 Hz), 7.58-7.78 (br in, 1H), 8.55-8.58 (m, 1H);

(CDC13) 6 19.66, 29.12, 30.24, 46.62, 57.28, 122.21, 122.83, 133.55, 138.07, 146.98, 156.17, 157.73.

Preparation of 1-(2-trimethylsilylethoxymethyl-2-formyl-benzimidazole:
SEM
CIC
N O

[0105] To a stirred solution of 2-hydroxymethylbenzimidazole (31.94, 0.216 mol) in dry DMF (450 mL) was added N,N-diisopropylethylamine (90 mL, 0.52 mol) followed by 2-(trimethylsily)ethoxymethyl chloride (75% in pentane, 55 g, 0.25 mol) and the mixture heated to 60 C for 2 h. The mixture was cooled to room temperature, concentrated under reduced pressure and partitioned between EtOAc (400 mL) and distilled water (700 mL).
The phases were separated and the aqueous layer extracted with EtOAc (2 x 200 mL). The combined organic extracts were washed with brine (1 x 400 mL), dried (Na2SO4), filtered and concentrated under reduced pressure. Purification of the crude oil by column chromatography on silica gel (4% McOH/CH2C12) afforded the desired 1-(2-trimethylsilylethoxymethyl)-2-hydroxymethylbenzimidazole (26.28 g, 44%) as a yellow oil. 1H NMR (CDC13) S -0.04 (s, 9H), 0.89 (t, 2H, J= 9 Hz), 1.75 (br s, 1H), 3.55 (t, 2H, J=
9 Hz), 4.94 (s, 2H), 5.58 (s, 2H), 7.26-7.30 (m, 2H), 7.43-7.45 (m, 1H), 7.70-7.72 (m, 1H).
[0106] To a stirred solution of the alcohol from above (26.58 g, 0.096 mol) in dry CH2C12 (450 mL) was added activated Mn02 (<5 micron, - 85%, 93 g, 0.91 mol) and the suspension stirred at room temperature overnight. The mixture was filtered through celite` (175 g) and the cake was washed with CH2C12. The solvent was removed from the eluent under reduced pressure and the resultant residue purified by column chromatography on silica gel (3%
MeOH/CH2C12) to provide the title aldehyde (14.41 g, 55%) as a pale yellow oil. 1H NMR
(CDC13) S -0.07 (s, 9H), 0.90 (t, 2H, J= 9 Hz), 3.56 (t, 2H, J= 9 Hz), 6.04 (s, 2H), 7.43-7.51 (m, 2H), 7.66 (d, 1H, J= 9 Hz), 7.95 (d, 1H, J = 9 Hz), 10.13 (s, 1H); 13C NMR
(CD3OD) 6 -1.19, 17.94, 66.62, 73.30, 112.22, 122.51, 124.64, 127.43, 136.62, 143.11, 146.39, 185.10;
ES-MS mlz (M+H).

Preparation of [1 -(2-trimethylsil leimethyl)-1H-Benzimidazol-2- lmeth 1-(5,6,7,8-tetrah ydro-quinolin-8-yl)-amine:

CN-~?
NH
/ N-SEM
N

[01071 To a stirred solution of 1-(2-trimethylsilylethoxymethyl)-2-formyl-benzimidazole (4.26 g, 15.4 mmol) in dry MeOH (50 mL) was added a solution of 8-amino-5,6,7,8-tetrahydroquinoline (2.20 g, 14.8 mmol) in dry MeOH (20 mL) and the mixture stirred for 2 h at room temperature under an argon atmosphere. The reaction mixture was concentrated under reduced pressure and the resultant residue analyzed by 1H NMR to confirm imine formation. The residue was re-dissolved in dry MeOH (80 mL) and to the resultant solution was added sodium borohydride (1.17 g, 30.8 mmol). The mixture was stirred for 5 h, concentrated in vacuo and diluted with CH2C12 (100 mL) and saturated aqueous NaHCO3 (125 mL). The phases were separated and the aqueous layer was extracted with CH2C12 (2 x 75 mL). The combined organic extracts were dried (Na2SO4), filtered and concentrated in vacuo. Purification of the crude material through a plug of silica gel (CH2C12/MeOH 96:4) afforded the desired amine (5.91 g, 98%) as an orange oil. 1H NMR (CDCl3) 6 -0.07 (s, 9H), 0.90 (t, 2H, J= 9 Hz), 1.72-1.83 (m, 2H), 1.95-2.01 (m, 1H), 2.76-2.85 (m, 2H), 3.54 (t, 2H, J
= 9 Hz), 4.33 (m, 2H), 5.68 (d, 1H, J= 12 Hz), 5.75 (d, 1H, J= 12 Hz), 7.05-7.09 (m, 1H), 7.25-7.30 (m, 2H), 7.38 (d, 1H, J= 9Hz), 7.44-7.46 (m, 1H), 7.71-7.73 (m, 1H), 8.36-8.38 (m, 1H).

Preparation of N1-(5 6 7 8-tetrah dy ro-quinolin-8-yl)-N1-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2- lymethyl]-butane-1,4-diamine:

N---"--NH2 -SEM
N N

[0108] A solution of (5,6,7,8-tetrahydro-quinolin-8-yl)-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-ylmethyl]-amine (2.86 g, 6.93 mmol), bromobutyronitrile (1.4 mL, 14.1 mmol) and DIPEA (3.0 mL, 17.2 mmol) in CH3CN

(75 mL) was stirred at 80 C for 2 days. KI (54 mg, 0.33 mmol) was added and the resultant mixture stirred at 80 C for 20 hours. The mixture was concentrated under reduced pressure, diluted with CH2C12 (100 mL) and washed with saturated aqueous NaCl. The aqueous layer was extracted with CH2C12 (3 x 50 mL) and the combined organic extracts were dried (MgSO4), filtered and concentrated under reduced pressure. Purification by column chromatography on silica gel (CH2C12/MeOH, 80:1) afforded the desired nitrile (1.19 g, 36%) as an orange syrup. 1H NMR (CDC13) S -0.09 (s, 9H), 0.81-0.87 (m, 2H), 1.56-1.75 (m, 2H), 1.87-2.07 (m, 2H), 2.01-2.26 (m, 1H), 2.29-2.53 (m, 2H), 2.62-2.86 (m, 4H), 3.35-3.48 (m, 2H), 3.95-4.01 (m, 1H), 4.16 (d, 1H, J=13.8 Hz), 4.26 (d, 1H, J= 13.5 Hz), 5.76 (d, 1H, J= 11.1 Hz), 6.17 (d, 1H, J= 11.0 Hz), 7.04 (dd, 1H, J= 7.5, 4.5 Hz), 7.22-7.28 (m, 2H), 7.32 (d, 1H, J= 7.5 Hz), 7.43-7.46 (m, 1H), 7.69-7.73 (m, 1H), 8.46 (dd, 1H, J=
4.8, 1.3 Hz).
[0109] 4-{(5,6,7,8-Tetrahydro-quinolin-8-yl)-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzoimidazol-2-ylmethyl]-amino}-butyronitrile (840 mg, 1.75 mmol) was dissolved in NH3 saturated MeOH (15 mL), treated with Raney nickel (excess), and placed under 45 psi H2 on a Parr shaker for 16 hours. The mixture was diluted with MeOH and filtered through Celite.
The cake was washed with MeOH and the combined filtrate was concentrated under reduced pressure. Purification by, column chromatography on silica gel (CH2C12/MeOH/NH4OH, 50:2:1) afforded the desired amine (560 mg, 66%) as an orange syrup. 1H NMR
(CDC13) S -0.10 (s, 9H), 0.81 (t, 2H, J= 9.0 Hz), 1.43-1.50 (m, 4H), 1.59-1.76 (m, 1H), 1.86-2.09 (m, 2H), 2.08-2.23 (m, 1H), 2.56-2.71 (m, 4H), 2.76-2.85 (m, 2H), 2.41 (t, 2H, J=
8.1 Hz), 4.07-4.12 (m, 3H), 5.71 (d, 1H, J=11.1 Hz), 7.37 (d, 1H, J=11.1 Hz), 7.05 (dd, 1H, J= 7.5, 4.5 Hz), 7.21-7.29 (in, 2H), 7.34 (d, 1H, J= 6.6 Hz), 7.40-7.45 (m, 1H), 7.71-7.76 (m, 1H), 8.58 (d, 1H, J= 3.6 Hz).

Preparation of Nt-(1H-Benzimidazol-2-ylmethyl)-M-(5,6,7,8-tetrahydro-quinolin-yl)-cyclohexane-trans-1,4-diamine:

Preparation of N-tert-butoxycarbonyl-trans-1,4-cyclohexanediamine (Smith, J., et al., J. Ore. Clzem. (1996) 61:8811-8818):
[0110] To a solution of trans-1,4-cyclohexanediamine (8.01 g, 70.1 mmol) in CHC13 (230 mL) was added a solution of di-tert-butyl dicarbonate (7.67 g, 35.1 mmol) in CHC13 (50 mL) via syringe pump over a period of 6 hours. The resultant white suspension was stirred at room temperature for an additional 10 hours then concentrated in vacuo and diluted with CH2C12 (100 mL) and saturated aqueous Na2CO3 (100 mL). The layers were separated and the organic layer was washed saturated aqueous Na2CO3 (2 x 30mL). The combined organic phases were dried (Na2SO4), filtered and concentrated to give the title compound (5.30 g, 71 % based on Boc2O) as a white solid.
[0111] Following General Procedure for Reductive Amination Using NaBH(OAc)3:
To a stirred solution of 6,7-dihydro-5H-quinolin-8-one (3.04 g, 20.65 mmol) and N-tert-butoxycarbonyl-trans-1,4-cyclohexanediamine (4.42 g, 20.65 inmol) in dry THE
(100 mL) was added AcOH (3 mL) and NaBH(OAc)3 (5.69 g, 26.85 mmol) and the mixture stirred overnight at room temperature. Purification by column chromatography on silica gel (CH2Cl2/MeOH/NH4OH, 96:4:0 then 94:5:1) afforded the desired amine (3.79 g, 53%) as a white solid.

Example 1 ('N-N NH
H
N' NH

COMPOUND 1: Preparation of (1H-Benzimidazol-2- l~yl)-piperidin-3- llmethl-(5,6,7,8-tetrah dquinolin-8-yl)-amine (hydrobromide salt) Preparation of 3-formal-N-tent-butoxycarbonyl-piperidine:
boc i N

UCHO
[0112] To a solution of 3-piperidinemethanol (0.544 g, 4.72 mmol) in THE (20 mL) was added di-tert-butyl dicarbonate (1.01 g, 4.63 mmol) and the mixture stirred at room temperature for 2 hours. The mixture was concentrated under reduced pressure and the resultant crude product was used without further purification in the next reaction.
[0113] To a suspension of the alcohol from above (-4.7 mmol) and powdered 3 A
molecular sieves (1.17 g) in CH2C12 (10 mL) was added 4-methylmorpholine N-oxide (0.672 g, 5.74 mmol) and tetrapropylammonium perruthenate (0.084 g, 0.24 mmol) and the mixture stirred overnight. The reaction was concentrated under reduced pressure and purified by column chromatography through a plug of silica gel (ethyl acetate/hexanes, 1:2) to afford the title compound (0.429 g, 43% over 2 steps) as a clear oil. 1H NMR (CDC13) S
1.46 (br s, 9H), 1.48-1.55 (m, 1H), 1.65-1.73 (m, 2H), 1.91-1.99 (m, 1H), 2.40-2.44 (m, 1H), 3.04-3.13 (m, 1H), 3.32 (dd, 1H, J= 15, 9 Hz), 3.60-3.65 (m, 1H), 3.89-3.94 (m, 1H), 9.70 (s, 1H).
[0114] Using General Procedure B: To a stirred solution of (1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine (159 mg, 0.57 mmol) and 3-formyl-N-tert-butoxycarbonyl-piperidine (125 mg, 0.59 mmol) in CH2C12 (5 mL) was added NaBH(OAc)3 (157 mg, 0.74 mmol) and the resultant mixture was stirred at room temperature for 2.5 hours. Purification of the crude material by column chromatography on silica gel (CH2C12/MeOH, 96:4) afforded the alkylated product (185 mg, 68%) as a mixture of diastereomers.
[0115] The yellow foam from above (185 mg, 0.39 mmol) oil was dissolved in CH2C12/TFA (1:1, 2 mL) and the mixture stirred overnight. The reaction was then concentrated and diluted with CH2C12 (30 mL) and 1 N NaOH (30 mL). The aqueous layer was washed with CH2Cl2 (2 x 10 mL) and the combined organic extracts were dried (Na2SO4), filtered and concentrated to afford the Boc-deprotected material as, a mixture of diastereomers. Purification and separation of the diastereomers by radial chromatography on silica gel (1 mm plate, 50:1:1 CH2C12/MeOH/NH4OH) afforded a top, less polar diastereomer (25 mg, 17%) and a bottom, more polar one (20 mg, 14%), both as clear foams.
[0116] Using General Procedure D: Conversion of the more polar, bottom diastereomer from above (20 mg, 0.05 mmol) to the hydrobromide salt followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 1 (34 mg, 97%) as a white solid.
1H NMR (D20) 6 0.97-1.09 (m, 1H), 1.44-1.57 (m, 1H), 1.72-1.88 (m, 2H), 1.90-2.07 (m, 2H), 2.13-2.36 (m, 4H), 2.53 (br t, 1H, J= 12 Hz), 2.74-2.90 (m, 2H), 2.98-3.00 (m, 2H), 3.27-3.32 (m, 2H), 4.38 (d, 1H J= 16.5 Hz), 4.48 (d, 1H J= 16.5 Hz), 4.50-4.55 (m, 1H), 7.62 (dd, 2H, J= 6.3, 3.3 Hz), 7.81 (dd, 2H, J= 6.3, 3.3 Hz), 7.89 (dd, 1H, J=
7.8, 6 Hz), 8.37 (d, 1H, J= 8.1 Hz), 8.67 (d, 1H, J= 5.6 Hz); 13C NMR (D20) 6 19.89, 20.27, 21.58, 26.64, 27.79, 31.91, 44.57, 47.09, 48.00, 54.69, 59.91, 114.34, 126.18, 127.09, 131.14, 139.59, 141.23, 148.32, 150.59, 150.76. ES-MS in/z 376 (M+H). Anal. Calcd. for C23H29N5=3.OHBr=2.2H2O: C, 41.99; H, 5.58; N, 10.65; Br, 36.44. Found: C, 42.05; H, 5.44;
N, 10.50; Br, 36.40.

Example 2 N _ NH
J H
N" NH

COMPOUND 2: Preparation of (1H-Benzimidazol-2-ylmethyl)-piiperidin-3- lmethyl-(5,6,7,8-tetrah .do-quinolin-8-yl)-amine hydrobromide salt) [0117] Using General Procedure D: Conversion of the top, less polar diastereomer from above (see COMPOUND 1) (25 mg, 0.07 mmol) to the hydrobromide salt followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 2 (39 mg, 88%) as a white solid. 1H NMR (D20) 8 1.07-1.19 (m, 1H), 1.54-1.68 (m, 1H), 1.74-1.90 (m, 3H), 1.97-2.07 (m, 2H), 2.13-2.22 (m, 1H), 2.30-2.43 (m, 2H), 2.52 (br t, 1H, J= 12 Hz), 2.80 (td, 1H, J= 13.2, 2.4 Hz), 2.92 (dd, 1H, J= 13.8, 4.5 Hz), 2.98-3.00 (m, 2H), 3.32-3.36 (m, 1H), 3.61-3.65 (m, 1H), 4.38 (d, 1H J=16.5 Hz), 4.46 (d, 1H J=16.5 Hz), 4.52 (dd, 1H, J =10.5, 5.7 Hz), 7.63 (dd, 2H, J = 6.3, 3.3 Hz), 7.82 (dd, 2H, J = 6.3, 3.3 Hz), 7.90 (dd, 1 H, J= 7.5, 6.3 Hz), 8.37 (d, 1H, J= 7.8 Hz), 8.68 (d, 1H, J= 6 Hz); 13C NMR (D20}
8 18.97, 19.39, 21.05, 26.03, 26.91, 31.14, 43.69, 46.67, 47.04, 54.41, 58.71, 113.46, 125.31, 126.27, 130.15, 138.77, 140.30, 147.54, 149.50, 149.74. ES-MS m/z 376 (M+H). Anal.
Calcd. for C23H29N5=3.0HBr=2.6H20: C, 41.54; H, 5.64; N, 10.53; Br, 36.04. Found: C, 41.47; H, 5.41;
N, 10.22; Br, 36.19.

Example 3 09(Th XNN) NNH /

COMPOUND 3: Preparation of (1H-Benzimidazol-2-ylmethyl)-piperidin-2-ylmethyl-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine hydrobromide salt) Preparation of 2-formyl-piperidine-l-carboxylic acid tert-butyl ester:
[0118] To a solution of 2-piperidinemethanol (561mg, 4.9mmol) in dry THE
(10mL) was added di-tert-butyl dicarbonate (1.14g, 5.2mmol) and the mixture stirred overnight at room temperature. The reaction mixture was concentrated in vacuo to afford a colourless oil which was used in the next step without any further purification.

[0119] To a stirred solution of 2-hydroxymethyl-piperidine-l-carboxylic acid test-butyl ester (0.737 g, 3.4 mmol) in dry CH2C12 (10 mL) was added 3 A molecular sieves (1.03 g), N-methylmorpholine N-oxide (0.644 g, 5.5 mmol), and tetrapropylammonium perruthenate (72 mg, 0.21 mmol) and the mixture stirred at room temperature for 3 h. The reaction mixture was purified through a silica gel plug (Hexanes/EtOAc, 70:30 followed by 100:0) to afford the title aldehyde (0.500 g, 70%) as a pale yellow oil.

[0120] Using General Procedure B: To a stirred solution of 2-formyl-piperidine-l-carboxylic acid tent-butyl ester (0.163 g, 0.76 mmol) in dry CH2C12 (3.5 mL) was added (1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine (0.210 g, 0.76 mmol) and sodium triacetoxyborohydride (0.240 g, 1.1 mmol) and the mixture stirred overnight at room temperature. Purification by column chromatography on silica gel (CH2C12/MeOH, 98:2 followed by 96:4) gave a pale yellow foam containing a mixture of diastereomers (0.305 g).
[0121] To a stirred solution of the diastereomers (0.305 g) in dry CH2C12 (2 mL) was added trifluoroacetic acid (1 mL) dropwise and the mixture stirred at room temperature for 3.5 h. The reaction mixture was diluted with CH2C12 (10 mL) and then concentrated in vacuo. The concentrate was diluted with CH2C12 (20 mL) and extracted with IN
NaOH
(30 mL). The aqueous layer was washed with CH2C12 (2 x 15 mL) and then the combined organic layers were dried (Na2SO4), filtered, and concentrated in vacuo.
Purification and separation of the two diastereomers by radial chromatography on a 1 mm TLC
grade silica gel plate (CH2C12/MeOH/NH4OH, 100:1:1 followed by 50:1:1) afforded a less polar diastereomer (63 mg, 22%) and a more polar one (22 mg, 8%) (stereochemistry unknown), both as colourless oils.

[0122] Using General Procedure D: Conversion of the less polar diastereomer from above (63 mg, 0.17 mmol) to the hydrobromide salt gave COMPOUND 3 (83 mg) as a white solid. 1H NMR (D20) 8 1.34-1.68 (m, 3H), 1.73-1.93 (m, 3H), 1.93-2.08 (m, 2H), 2.08-2.23 (m, 1H), 2.24-2.38 (m, 1H), 2.79 (dd, 1H, J= 14.7, 9.9 Hz), 2.94-3.07 (m, 3H), 3.27 (dd, 1H, J=14.7, 9.9 Hz), 3.38-3.56 (m, 2H), 4.33 (s, 2H), 4.57 (dd, 1H, J= 9.9, 5.7 Hz), 7.56-7.62 (m, 2H), 7.70-7.83 (m, 3H), 8.28 (d, 1H, J= 7.8 Hz), 8.57 (d, 1H, J= 4.8 Hz);

(D20) b 19.84, 20.28, 21.76, 22.16, 26.99, 27.83, 45.34, 47.01, 54.30, 54.82, 58.86, 114.55, 125.99, 127.08, 131.59, 140.23, 141.046, 147.96, 149.03, 149.84; ES-MS m/z 376 (M+H);
Anal. Calcd. for C23H29N5.3.OHBr=1.2H2OØ3C4H100: C, 43.90; H, 5.69; N,
10.58; Br, 36.20. Found: C, 43.78; H, 5.47; N, 10.54; Br, 36.41.

Example 4 ~N- TM Q

N N ~ NH

COMPOUND 4: Preparation of (1H-Benzimidazol-2-ylmethyl)-piperidin-2-ylmethyl-(5 6 7 8-tetrahydro-guinolin-8-yl)-amine (hydrobromide salt) [0123] Using General Procedure D: Conversion of the more polar diastereomer from above (see COMPOUND 3) (22 mg, 0.059 mmol) to the hydrobromide salt gave COMPOUND 4 (35 mg) as a white solid. 1H NMR (D20) S 1.22-1.39 (m, 1H), 1.39-1.68 (m, 2H), 1.71-1.93 (m, 3H), 2.03-2.24 (m, 3H), 2.31-2.42 (m, 1H), 2.79-2.89 (m, 1H), 2.91-3.07 (m, 3H), 3.16 (dd, 1H, J= 13.8, 6.0-Hz), 3.32-3.49 (m, 2H), 4.34 (d, 1H, J= 15.9 Hz), 4.43 (d, 1H, J= 16.2 Hz), 4.53 (dd, 1H, J=10.2, 6.0 Hz), 7.54-7.61 (m, 2H), 7.65-7.77 (m, 3H), 8.25 (d, 1H, J= 7.8 Hz), 8.49 (d, 1H, J= 5.4 Hz); 13C NMR (D20) 6 20.04, 20.25, 21.54, 22.23, 27.04, 27.75, 45.22, 46.43, 54.61, 55.98, 60.69, 114.46, 125.90, 127.01, 131.66, 139.70, 140.96, 148.03, 149.70; ES-MS nt/z 376 (M+H); Anal. Calcd. for C23H29N5=3.OHBr=2.2H2O: C, 41.99; H, 5.58; N, 10.65; Br, 36.44. Found: C, 42.22; H, 5.46; N, 10.47; Br, 36.23.

Example 5 N

H H
N / NH

COMPOUND 5: Preparation of (1H-Benzimidazol-2-ylmethyl)-(S)-1-pyrrolidin-2-ylmethyl-(5 6 7 8-tetrahydro-quinolin-8-vl -amine (hydrobromide salt) [01241 Using General Procedure B: To a stirred solution of (1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine (148 mg, 0.53 mmol) and N-tert-butoxycarbonyl-L-prolinal (110mg, 0.55 mmol) in CH2Cl2 (5 mL) was added NaBH(OAc)3 (146 mg, 0.69 mmol) and the resultant mixture was stirred at room temperature overnight.
Purification of the crude material by radial chromatography on silica gel (2 mm plate, 50:1:1 CH2C12/MeOH/NH4OH then 10:1:1 CH2C12/MeOH/NH4OH) afforded the desired amine (73 mg, 30%) as a yellow oil.
[0125) Using General Procedure D: Conversion of the oil from above (40 mg, 0.11 mmol) to the hydrobromide salt followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 5 (53 mg, 73%) as a beige solid. 1H NMR
(D20) 61.22-1.28 (m, 1H), 1.61-1.74 (m, 1H), 1.75-1.89 (m, 1H),1.99-2.09 (m, 3H), 2.16-2.31 (m, 1H), 2.33-2.39 (m, 1H), 2.92 (dd, 1H, J= 14.4, 9.3 Hz), 2.97-3.03 (m, 1H), 3.25 (q, 1H, J=
7.2 Hz), 3.33-3.41 (m, 1H), 3.35 (td, 2H, J= 7.5, 2.4 Hz), 3.86-3.96 (m, 1H), 4.34 (d, 1H, J=
16.2 Hz), 4.42 (d, 1H, J=16.2 Hz), 4.59 (dd, 1H, J= 10.2, 6 Hz), 7.59 (dd, 2H, J= 6.3, 3.3 Hz), 7.78 (dd, 2H, J= 6.3, 3.3 Hz), 7.79-7.83 (m, 1H), 8.31 (d, 1H, J= 8.7 Hz), 8.60 (d, 1H, J= 5.1 Hz); 13C NMR (D20) S 19.91, 20.29, 22.88, 27.80, 28.46, 45.88, 47.28, 52.97, 58.23, 58.77, 114.47, 126.02, 127.00, 131.50, 140.22, 141.00,147.99, 149.62,149.98.
ES-MS m/z 362 (M+H). Anal. Calcd. for C22H27N5=3HBr=2H20Ø2C4H100: C, 41.80; H, 5.54;
N, 10.69;
Br, 36.59. Found: C, 41.66; H, 5.45; N, 10.65; Br, 36.93.

Example 6 (~N- Q\~NH
N
N , NH

COMPOUND 6: Preparation of (1H-Benzimidazol-2-ylmethyl)-piperidin-4-ylmethyl-(5,6,7,8-tetrahydro-quinolin-8-yl -amine (hydrobromide salt) Preparation of 1-(tert-butoxycarbonyl)-piperidine-4-carboxaldehyde [01261 To a solution of ethyl isonipecotate (0.750 g, 4.77 mmol) in THE (24 mL) was added water (1 mL) followed by di-tert-butyl dicarbonate (1.09 g, 5.00 mmol) and the resultant mixture was stirred at room temperature for one hour. The mixture was diluted with ethyl acetate (50 mL) and the organic phase was washed with brine (3 x 20 mL), dried (MgSO4), and concentrated to provide 1.20 g (98%) of 1-(tert-butoxycarbonyl)-4-(carboethoxy)-piperidine as. a colorless oil.

[01271 To a cold (-78 C), stirred solution of the oil from above (1.20 g, 4.67 mmol) in dry THE (46 mL) was added diisobutylaluminum hydride (1.0 M in THF, 15 mL, 15 mmol).
After 30 minutes, the reaction mixture was warmed to room temperature and stirred for an additional 20 minutes. Saturated aqueous NH4C1(5 mL) was added and the resultant white slurry was stirred at room temperature for 45 minutes. Solid MgSO4 (5= g) was, added and the mixture was filtered through Florisil The column was washed with ethyl acetate (200 mL).
The combined eluant was concentrated under reduced pressure to provide 1.01 g (97%) of 1-(tert-butoxycarbonyl)-4-(hydroxymethyl)-piperidine as a white solid.
[01281 To a solution of the above alcohol (0.437 g, 2.03 mmol) in CH2C12 (10 mL), at room temperature, was added sequentially 3 A molecular sieves (1.07 g), N-methylmorpholine N-oxide (0.365 g, 3.11 mmol), and tetrapropylammonium perruthenate (70 mg, 0.20 mmol). After 1 hour, the mixture was filtered through a short column of silica gel and the cake was washed with ethyl acetate. The solvent was removed from the filtrate under reduced pressure. Purification of the crude material by column chromatography on silica gel (4:1 hexanes - ethyl acetate}provided 90 mg (20%) of 1-(tert-butoxycarbonyl)-piperidine-4-carboxaldehyde as a colorless oil. 1H NMR (CDC13). 8 1.46 (s, 9H), 1.51-1.62 (m, 2H), 1.85-1.93 (m, 2H), 2.37-2.46 (m, 1H), 2.88-2.97 (m, 2H), 3.94-4.00 (m, 2H), 9.66 (s, 1H).
[01291 Using General Procedure B: Reaction of 1-(test-butoxycarbonyl)-piperidine-4-carboxaldehyde (0.090 g, 0.42 mmol) and (1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-&-yl)-amine (0.110 g, 0.40 mmol) with NaBH(OAc)3 (0.223g, 1.05 mmol) in CH2C12 (5 mL) for 20 h followed by purification of the crude material by column chromatography on silica gel (50:1:1 CH2C12-CH3OH-NH4OH) provided 0.120 g (63%) of an off-white solid.
[0130] Using General Procedure D: Conversion of the off-white solid (120 mg) to the hydrobromide salt with simultaneous removal of the BOC-protecting group, followed by re-precipitation of the intermediate solid from methanol/ether, gave COMPOUND 6 (98 mg) as a white solid. 1H NMR (D20) 6 1.13-1.28 (m, 2H), 1.80-2.36 (m, 8H), 2.81-3.00 (m, 5H), 3.35-3.43 (m, 2H), 4.38 (d, 1H, J=16.5 Hz), 4.46 (d, 1H, J= 16.5 Hz), 4.52 (dd, 1H, J=
10.5, 6.0 Hz), 7.59-7.65 (m, 2H), 7.78-7.85 (m, 2H), 7.89 (dd, 1H, J= 7.8, 6.0 Hz), 8.37 (d, 1H, J= 8.1 Hz), 8.67 (d, 1H, J= 5.7 Hz); 13C NMR (D20) 8 17.72, 18.24, 24.98 (2 carbons), 25.71, 29.64, 41.94, 42.05, 45.79, 54.96, 57.53, 112.25, 124.08, 125.04, 128.97, 137.47, 139.09, 146.24, 148.75 (2 carbons); ES-MS m/z 376 (M+H). Anal. Calcd. for 3.1 HBr = 1.8 H2O: C, 41.93; H, 5.46; N, 10.63; Br, 37.60. Found: C, 42.07; H, 5.55; N, 10.28; Br, 37.43.

Example 7 N )-- P
N

\ONH
N NH

COMPOUND 7: (1H-Benzimidazol-2-ylmethyl)-piperidin-4-yl-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine (hydrobromide salt) Preparation of 4-(5,6,7,8-Tetrahydro-quinolin-8-ylamino)-piperidin-1-carboxylic acid tent-butyl ester:

)N-N

\N~
boc [0131] Using General Procedure B: Reaction of Boc-4-piperidone (641 mg, 3.22 mmol 5,6,7,8-Tetrahydro-quinolin-8-ylamine (476 mg, 3.22 mmol), sodium triacetoxyborohydride (1.36 g, 6.44 mmol) and acetic acid (0.25 mL) in THE (25 mL) at room temperature under N2.
for 20 min afforded the title compound (1.05 g, 98%) as a yellow oil.

[0132] The 4-(5,6,7,8-Tetrahydro-quinolin-8-ylamino)-piperidine-l-carboxylic acid tert-butyl ester (240 mg, 0.72 mmol), 2-Chloromethyl-benzimidazole-l-carboxylic acid text-butyl ester (212 mg, 0.79 mmol), DIPEA (0.20 mL, 1.58 mmol), and KI (6 mg, 0.036 mmol) were heated to 60 C in CH3CN (7 mL) overnight under N2. The reaction mixture was concentrated in vacuo, diluted with ethyl acetate, washed with NH4Cl (aq), NaCl (aq), and dried (MgS04). Evaporation of the solvent and purification of the residue by flash chromatography on silica gel (CH2C12-MeOH-NH4OH 98:1:1) afforded the title compound (331 mg, 82%) as a white foam.

[0133] Using General Procedure D: Conversion of the foam from above (100 mg, 0.18 mmol) to the hydrobromide salt using an acetic acid/HBr solution, followed by re-precipitation of the salt from diethyl ether gave COMPOUND 7 as a white solid.

(CD3OD) mixture of isomers S 1.94 - 2.15 (m, 3H), 2.19 - 2.26 (m, 2H), 2.41-2.51 (m, 2H), 2.60 - 2.65 (m, 1H), 3.03 - 3.14 (m, 4H), 3.18 - 3.28 (m, 1H), 3.41 -3.52 (m, 2H), 4.61 (d, 2H, J = 3.9 Hz), 4.67 - 4.72 (m, 1 H), 7.5 8 - 7.63 (m, 2H), 7.86 - 7.94 (in, 3H), 8.3 7 (d, 1H, J= 8.1 Hz), 8.91 (d, 1H, J= 5.7 Hz); 13C NMR (CD30D) mixture of isomers 6 25.71, 29.19, 31.67, 32.47, 33.30, 48.62, 48.76, 48.93, 60.93, 63.27, 118.96, 130.51, 131.51, 136.12, 144.91, 145.36, 152.51, 156.45, 156.63; ES-MS m/z 362.3 (M+H); Anal. Calcd.
For (C22H27N5)=3.0(HBr)=1.8 (H20)=0.4(C4H10O): C, 42.54; H, 5.69; N, 10.51; Br, 35.98.
Found C, C, 42.61; H, 5.47; N, 10.46; Br, 35.93 Example 8 f N

N n HN N H

COMPOUND 8: Preparation of (1H-benzimidazol-2-ylmethyl)-piperidin-3-yl-(5,6 7 tetrahydroquinolin-8-ylamine (hydrobromide salt) Preparation of tert-butyl 3-hydroxy- l -pip eridinecarboxylate:

[0134] To a 0 C solution of 3-hydroxypiperidine (2.12 g, 21.0 mmol) in EtOH
(20 mL) was added NEt3 (5.6 mL, 40.2 mmol), followed by a solution of (Boc)20 (5.03 g, 23.0 mmol) in EtOH (20 mL). The reaction stirred at room temperature for one hour, and then the solvent was evaporated under reduced pressure. The residue was dissolved in EtOAc (50 mL) and washed with 10% citric acid (50 mL), water (50 mL) and brine (50 mL). The organic solution was dried (MgSO4), filtered and evaporated under reduced pressure to afford the crude product as a white solid (3.55 g, 17.6 mmol, 84%). 1H NMR (CDC13) 6 1.45 (s, 9H), 1.48-1.52 (m, 2H), 1.72-1.78 (m, 1H), 1.84-1.94 (m, 1H), 2.12 (br. s, 1H), 3.01-3.12 (m, 2H), 3.46-3.59 (m, 1H), 3.65-3.78 (m, 2H).

Preparation of tent-butyl 3-oxo-l-piiperidinecarbox ly ate:
[0135] To a 0 C solution of the alcohol (2.01 g, 10.0 mmol) in CH2C12 (50 mL) was added crushed 3A molecular sieves (5.26 g), 4-methylmorpholine-N-oxide (1.76 g, 15.0 mmol) and tetrapropylammonium perruthenate (357 mg, 1.02 mmol). The resulting black solution was stirred at 0 C for 20 minutes, then at room temperature for a further one hour. The mixture was filtered through a plug of silica, rinsed with EtOAc and the concentrated filtrate was purified by flash chromatography on silica gel (EtOAc/hexane, 1:1) to afford the ketone as a yellow liquid (1.49 g, 7.48 mmol, 75%). 1H NMR
(CDC13) 61.46 (s, 9H), 1.98 (ddd, 2H, J=12.3, 6.5, 6.0 Hz), 2.47 (t, 2H, J= 6.5 Hz), 3.58 (t, 2H, J= 6.0 Hz), 4.00 (s, 2H).

Preparation of test-butyl 3-(5,6,7,8-tetrahydroquinolin-8-ylamino)-piperidine-l-carbox lyate:

[0136] To a solution of 8-amino-5,6,7,8-tetrahydroquinoline (1.00 g, 6.75 mmol) in MeOH (30 mL) was added a solution of the ketone (1.40 g, 7.03 mmol) in MeOH
(20 mL).
The reaction stirred at room temperature for 16 hours. NaBH4 (848 mg, 22.4 mmol) was added and the mixture stirred for a further 45 minutes. The solvent was evaporated under reduced pressure, and the residue was taken up into CH2C12 (50 mL) and washed with saturated aqueous NaHCO3 (10 mL) and brine (10 mL). The organic solution was dried (MgSO4), filtered and evaporated under reduced pressure. Purification by flash column chromatography on silica gel (CH2Cl2/MeOH/NH4OH, 9:1:0.5) gave a brown oil which, following a second purification (CH2C12/MeOH, 97:3) afforded the amine as a yellow oil (638 mg, 1.92 mmol, 28%). 1H NMR (CDC13) S 1.22-1.40 (m, 2H), 1.47 (s, 9H), 1.65-1.81 (in, 3H), 1.91-2.04 (m, 2H), 2.11-2.25 (m, 2H), 2.44-2.65 (m, 1H), 2.65-2.90 (in, 4H), 3.88-4.05 (m, 2H), 4.05-4.31 (in, 1H), 7.06 (dd, 1H, J= 7.7, 4.7 Hz), 7.36 (d, 1H, J= 7.8 Hz), 8.37 (d, IH, J= 4.3 Hz).

Preparation of COMPOUND 8:
[0137] A mixture of this amine (247 mg, 0.75 mmol), tent-butyl 2-chloromethyl-benzimidazole-1-carboxylate (238 mg, 0.89 mmol), DIPEA (0.20 mL, 1.2 mmol} and KI (14 mg, 0.08 mmol) in CH3CN (4 mL) was heated at 60 C for 20 hours. After cooling, the reaction was diluted with saturated aqueous NaHCO3 (10 mL) and extracted with CH2C12 (25 mL x 3). The organic solution was dried (MgSO4), filtered and evaporated under reduced pressure. The resulting dark red oil was purified by flash column chromatography on silica gel (CH2C12/MeOH, 9:1) giving an orange foam. A second purification (CH2C12/MeOH, 19:1) gave the tertiary, amine as an orange solid (83 mg, 20%).
[0138] This material was stirred in TFA (1.5 mL) at room temperature for 2 hours, and then the excess solvent was evaporated under reduced pressure. The residue was taken up into CH2C12 (20 mL) and washed with saturated aqueous NaHCO3 (10 mL). The aqueous solution was extracted with CH2Cl2 (20 mL x 2) and the combined organic extracts were dried (MgSO4), filtered and concentrated under reduced pressure. Purification by flash column chromatography on silica gel (CH2Cl2/MeOH/NH4OH, 89:10:1) gave an approximately 2:1 mixture of diastereomers of the free amine as a yellow foam (21 mg, 0.06 mmol, 41 %).
[0139] To a solution of this material (20 mg, 0.055 mmol) in glacial HOAc (1 mL) was added a saturated HBr in HOAc solution (0.5 mL). The reaction stirred at room temperature for 40 minutes. Et2O (2 mL) was added, the suspension was stirred and the solvent was decanted. The precipitate was washed with Et2O (1 mL x 5), then dried under reduced pressure giving COMPOUND 8 as a yellow solid (26 mg, 0.038 mmol, 70%). 1H NMR
(D20) S 1.61-1.94 (m, 3H), 1.98-2.11 (in, 1H), 2.11-2.17 (m, 2H), 2.17-2.49 (m, 1H), 2.80-2.92 (m, 1H), 2.93-3.01 (m, 2H), 3.09-3.25 (m, 2H), 3.31-3.40 (m, 1H), 3.82-3.90 (m, 1H), 4.43 (d, 1H, J= 16.5 Hz), 4.55 (d, 1H, J= 16.5 Hz), 4.55-4.65 (m, 1H), 7.53-7.60 (m, 2H), 7.67-7.77 (m, 3H), 8.20 (d, 0.67H, J = 7.8 Hz), 8.23 (d, 0.33H, J = 7.8 Hz), 8.51 (d, 0.67H, J

= 5.7 Hz), 8.55 (d, 0.33H, J= 5.7 Hz). 13C NMR (D20) 6 20.5 and 20.6, 21.9 and 22.1, 24.2 and 24.5, 26.8 and 27.5, 28.0, 43.2, 44.0, 46.2 and 47.0, 58.5 and 59.2, 114.4, 125.8, 126.8, 131.7, 139.5, 140.5 and 141.6, 147.7 and 147.8, 150.6 and 151.2. ES-MS m/z 362 (M+H).
Anal. Calcd. for C22H27N5.3.1HBr=1.8H20Ø3C4H100: C, 41.78; H, 5.55; N, 10.50; Br, 37.14.
Found: C, 41.48; H, 5.44; N, 10.44; Br, 37.50.

Example 9 N
N

~ J
HN N H

COMPOUND 9: Preparation of (1H-benzimidazol-2-ylmethyl)-piiperidin-3-yl-5,6,7,8-tetrahydroquinolin-8-yl)amine (hydrobromide salt) [0140] The free base was prepared by N-alkylation and TFA deprotection, as described previously (see COMPOUND 8). The crude material was purified by flash column chromatography on silica gel (CH2C12/MeOH/NH40H, 9:1:0.1) giving 18 mg of a single diastereomer (0.05 mmol, 5%) as a brown foam, along with 51 mg of the mixture of diastereomers (0.14 mmol, 14%) as a yellow foam.
[0141] The single diastereomer (18 mg, 0.05 mmol) was dissolved into HOAc (1 mL) and saturated HBr in HOAc (0.5 mL) was added. The solution stirred at room temperature for 40 minutes. Et2O (2 mL) was added, the mixture was stirred and the solvent was decanted. The precipitate was washed with Et2O (1 mL x 5) and dried under reduced pressure at 90 C, giving the diastereomer COMPOUND 9 as a yellow powder (22 mg, 0.03 mmol, 67%). 1H NMR (D20) 8 1.57-1.74 (in, 1H), 1.75-1.90 (m, 2H), 2.03-2.12 (m, 1H), 2.12-2.24 (m, 2H), 2.31-2.47 (m, 2H), 2.80-2.92 (m, 1H), 2.92-3.00 (m, 2H), 3.06-3.20 (m, 2H), 3.29-3.38 (m, 1H), 3.47-3.57 (in, 1H), 4.43-4.53 (m, 1H), 4.48 (d, 1H, J= 16.4 Hz), 4.57 (d, 1H, J= 16.4 Hz), 7.51-7.58 (in, 2H), 7.68-7.76 (in, 3H), 8.20 (d, 1H, J= 7.5 Hz), 8.53 (d, 1H; J= 5.7 Hz). 13C NMR (D20) 8 20.5, 21.9, 24.2, 26.8, 27.5, 43.4, 43.9, 47.0, 55.5, 59.2, 114.4, 125.8, 126.6, 132.0, 139.7, 140.5, 147.6, 150.9, 151.1. ES-MS m/z 362 (M+H). Anal. Calcd. for C22H27N5.3.0HBr-1.8 H2OØ3C4H100: C, 42.29; H, 5.60;
N, 10.63;
Br, 36.38. Found: C, 42.27; H, 5.60; N, 10.62; Br, 36.42.

Example 10 (~N- N---NH2 NH
N

COMPOUND 10: Preparation of Nl-(1H-Benzimidazol-2- lm ethyl)- NI-(5 6 7 8-tetrahydro-guinolin-8-yl)-ethane-1 2-diamine (hydrobromide salt) [0142] Using General Procedure B: Reaction of N-(tert-butoxycarbonyl)-2-amino-acetaldehyde (0.112 g, 0.71 mmol) and (1-tert-butoxycarbonyl-lH-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine (0.189 g, 0.50 mmol) with NaBH(OAc)3 (0.215g, 1.01 mmol) in CH2Cl2. (5 mL) for 18 h followed by purification of the crude material by radial chromatography on silica gel (2 mm plate, 100:1:1 CH2C12-CH3OH-NH4OH) provided a white solid (0.167 g, 64%).

[0143] Using General Procedure D: Conversion of the white solid (167 mg) to the hydrobromide salt with simultaneous removal of the BOC-protecting groups, followed by re-precipitation of the intermediate solid from methanol/ether, gave COMPOUND 10 (173 mg) as a white solid. 1H NMR (D20) 8 1.75-1.89 (m, 1H), 1.98-2.11 (m, 1H), 2.15-2.22 (m, 1H), 2.38-2.43 (m, 1H), 2.91-3.02 (m, 3H), 3.16-3.31 (m, 3H), 4.40 (d, 1H, J= 16.5 Hz), 4.52-4.67 (m, 2H), 7.58-7.63 (m, 2H), 7.76-7.84 (m, 3H), 8.32 (d, 1H, J= 7.8 Hz), 8.59 (d, IH, J=
5.4 Hz); 13C NMR (D20) 8 20.30, 20.44, 27.68, 37.75, 47.12, 49.11, 60.07, 114.40, 126.08, 127.11,131.17,139.78,140.92,148.23,150.09,150.17; ES-MS m/z 322 (M+H). Anal.
Calcd. for C19H23N5.3.0 HBr = 1.1 H20: C, 39.08; H, 4.87; N, 11.99; Br, 41.05.
Found: C, 39.19; H, 4.98; N, 11.76; Br, 40.89.

Exam l~ e 11 ~N- Q NO2 H N
N
N
COMPOUND 11: Preparation of Nl-(1H-Benzimidazol-2- lymethyl)-N2-(5-nitro-pyridin-2-yl)-N'-(5,6,7,8-tetrah dro-quinolin-8-yl)-ethane-l,2-diamine (hydrobromide salt) [0144] Using General Procedure B: To a solution of 6,7-dihydro-5H-quinolin-8-one (294 mg, 2 mmol) in MeOH (6 mL) was added 2-(2-aminoethylamino)-5-nitropyridine (368 mg, 2.02 mmol) and the resultant solution was stirred at room temperature for 3 hours. Solid NaBH4 (168 mg, 4.44 mmol) was added to the solution and the mixture was stirred at room temperature for an additional 45 minutes. The resultant crude yellow foam (639 mg) was used without further purification in the next step.
[0145] Using the General procedure for N-alkylation: To a solution of the material from above (639 mg), potassium iodide (5 mg, 0.030 mmol) and N,N-diisopropylethylamine (0.70 mL, 4.0 mmol) in CH3CN (10 mL) was added N-(tert-butoxycarbonyl- 2-chloromethylbenzimidazole (prepared as described by An, H., et al., Tetrahedron (1998) 54:3999-4012) (527 mg, 1.98 mmol) and the reaction stirred at 60 C for 6.5 h.
Purification of the crude brown foam by flash chromatography on silica gel (99:1 CH2C12/MeOH then 98:2) gave the alkylated product, 2-{[[2-(5-Nitro-pyridin-2-ylamino)-ethyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-methyl}-benzimidazole-l-carboxylic acid tert-butyl ester, (645 mg, 60%) as a yellow foam.
[0146] Using General Procedure D: Conversion of the free base from above (84 mg, 0.16 mmol) to the hydrobromide salt, followed by re-precipitation of the intermediate solid from methanol/ether, gave COMPOUND 11 (87 mg, 78%) as a yellow solid. 1H NMR (D20) 1.81-1.88 (m, 1H), 2.06-2.17 (m, 2H), 2.38-2.43 (m, 1H), 2.88-2.96 (m, 1H), 3.01-3.03 (m, 2H), 3.14-3.21 (m, 1H), 3.39-3.57 (m, 2H), 4.37 (d, 1H, J=16.8 Hz), 4.57 (d, 1H, J= 16.8 Hz), 4.61-4.66 (m, 1H), 6.49 (d, 1H, J= 9.6 Hz), 7.42 (dd, 2H, J= 6, 3 Hz), 7.57 (dd, 2H, J=
6, 3 Hz), 7.86-7.93 (m, 2H), 8.33 (br s, 1H), 8.37 (d, 1H, J= 7.8 Hz), 8.70 (d, 1H, J= 6.6 Hz); 13C NMR (D20) 8 20.41, 20.79, 27.80, 41.02, 49.30, 50.55, 62.07, 110.03, 110.77, 114.22, 126.02, 126.66, 130.60, 133.75, 135.36, 139.77, 140.95, 143.67, 148.28, 150.42, 151.28, 179.57; ES-MS m/z 444 (M+H). Anal. Calcd. for C24H25N702 =2.9 HBr =
2.4 H2O:
C, 39.96; H, 4.57; N, 13.59; Br, 32.12. Found: C, 40.17; H, 4.47; N, 13.20;
Br, 32.03.
Example 12 N
C
HN XNO
N N

COMPOUND 12: Preparation of (1H-benzimidazol-2-ylmethyl)-(2-imidazol-1-yl-ethyl)-(5,6,7,8-tetrah dy ro-quinolin-8-y1 -amine.

Preparation of toluene-4-sulfonic acid 2-tert-butoxycarbonylamino-eth l ester.

N x oJ
s [01471 Tosyl chloride (1.50 g, 7.87 mmol) was added to a solution of (2-hydroxy-ethyl)-carbamic acid tert-butyl ester (0.84 g, 5.2 mmol) and Et3N (1.23 mL, 8.82 mmol) in CH2Cl2 (26 mL), and the solution was stirred at room temperature for 17 h. The solution was washed with H2O (15 mL), and the aqueous phase was extracted with CH2C12 (10 mL). The combined organic phases were dried (MgSO4) and concentrated in vacuo.
Purification of the crude material by column chromatography on silica gel (20% EtOAc/hexanes) gave yellow crystals (1.29 g, 79%). 1H NMR (CDC13) 6 1.41 (s, 9H), 2.45 (s, 3H), 3.38 (m, 2H), 4.07 (m, 2H), 4.82 (br s, 1H), 7.35 (d, 2H, J= 8.1 Hz), 7.79 (d, 2H, J= 8.1 Hz).

(2-Imidazol-1-yl-ethyl)-carbamic acid text-butyl ester.
IOI
HNxO
X
N~
N-' [0148] A solution of imidazole (253 mg, 3.72 mmol) in DMF (2 mL) was added to a suspension of NaH (60% in mineral oil, 164 mg, 4.10 mmol) in DMF (8 mL), and the mixture was stirred at room temperature for 45 minutes. A solution of toluene-4-sulfonic acid 2-tent-butoxycarbonylamino-ethyl ester (1.29 g, 4.09 mmol) in DMF (6 mL) was added, and the mixture was stirred at room temperature for 16 h then concentrated in vacuo. The residue was partitioned between H2O (25 mL) and EtOAc (25 mL), and the aqueous phase was extracted with EtOAc (25 mL). The combined organic phases were dried (MgSO4) and concentrated in vacuo. Purification of the crude material by column chromatography on silica gel (200:5:1-100:5:1 CH2CI2/MeOH/NH40H) gave a colourless oil (224 mg, 29%). 1H
NMR (CDC13) 8 1.44 (s, 9H), 3.43 (m, 2H), 4.08 (m, 2H), 4.64 (br s, 1H), 6.92 (s, 1H), 7.09 (s, 1H), 7.46 (s, 1H).

(2-Imidazol-1-yl-ethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine.
CN-~Q
HNN

[0149] A solution of (2-imidazol-1-yl-ethyl)-carbamic acid tent-butyl ester (224 mg, 1.06 mmol) in 1:1 TFA/CH2C12 (4 mL) was stirred at room temperature for 1 h then concentrated in vacuo. The residue was dissolved in 1 N NaOH(aq) (10 mL) then saturated with sodium chloride and extracted with CHC13 (5 x 15 mL).. The combined organic extracts were dried (MgSO4) and concentrated in vacuo to give a yellow oil (55 mg).
[0150] Using General Procedure B: To a stirred solution of the amine from above (55 mg), 6,7-dihydro-5H-quinolin-8-one (73 mg, 0.50 mmol), and AcOH (0.030 mL, 0.52 mmol) in THE (5 mL) was added NaBH(OAc)3 (315 mg, 1.49 mmol) and the mixture was stirred at room temperature for 2 h. The crude material was dissolved in saturated HBr/AcOH (2 mL) and stirred at room temperature for 15 minutes. The solution was made basic with 10 N NaOH(aq) and extracted with CH2C12 (3 x 15 mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo. Purification of the crude material by column chromatography on silica gel (200:5:1 CH2C12/MeOH/NH4OH) gave a yellow oil (92 mg, 77%). 1H NMR (CDC13) 8 1.73 (m, 2H), 1.91-2.13 (m, 2H), 2.76 (m, 2H), 3.12 (m, 2H), 3.78 (m, 1H), 4.11 (m, 2H), 7.01 (s, 1H), 7.08 (m, 2H), 7.38 (d, 1H, J= 7.5 Hz), 7.56 (s, 1H), 8.37 (d, 1H, J= 3.9 Hz).

2- f [(2-Imidazol-l-yl-eth 11)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-methyl benzimidazole-l-carboxylic acid tert-butyl ester.

CN~
N

N N

[0151] A mixture of (2-imidazol-1-yl-ethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine (92 mg, 0.37 mmol), 2-chloromethyl-benzimidazole-l-carboxylic acid tert-butyl ester (101 mg, 0.379 mmol), potassium iodide (3 mg, 0.02 mmol), and N,N-diisopropylethylamine (0.10 mL, 0.57 mmol) in acetonitrile (4 mL) was heated at 60 C for 15 h. Saturated NaHCO3(aq) (15 mL) was added, and the mixture was extracted with CH2C12 (3 x 15 mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo. Purification of the crude material by column chromatography on silica gel (250:5:1 CH2C12/MeOHNH4OH) gave a yellow oil (21 mg, 12%). 1H NMR (CDC13) 8 1.45 (m, 1H), 1.66 (m, 10H), 1.91 (m, 2H), 2.69 (m, 2H), 2.92 (m, 1H), 3.18 (in, 1H), 3.67 (m, 2H), 4.20 (dd, 1H, J= 10, 5.6 Hz), 4.67 (d, 1H, J= 15 Hz), 4.80 (d, 1H, J= 15 Hz), 6.74 (s, 1H), 6.90 (s, 1H), 7.01 (dd, 1H, J= 7.7, 4.7 Hz), 7.33 (m, 4H), 7.73 (m, 1H), 7.86 (m, 1H), 8.38 (d, 1H, J= 3.3 Hz).

(1H-Benzimidazol-2-yhethyl)-(2-imidazol-1-yl-ethyl)-(5,6,7,8-tetrah dquinolin-8-yl)-amine (COMPOUND 12).
[0152] A solution of 2-{[(2-imidazol-1-yl-ethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-methyl}-benzimidazole-1-carboxylic acid tert-butyl ester (21 mg, 0.044 mmol) in 3:1 TFA/CH2Cl2 (4 mL) was stirred at room temperature for 30 minutes then concentrated in vacuo. The residue was partitioned between CH2C12 (20 mL) and 1 N NaOH(aq) (10 mL), and the aqueous phase was extracted with CH2C12 (10 mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo to afford COMPOUND 12 as a yellow foam (15 mg, 83%). 1H NMR (CDC13) S 1.73 (m, 2H), 1.99 (m, 1H), 2.20 (m, 1H), 2.69-2.88 (m, 2H), 2.92-3.08 (m, 2H), 3.82-3.98 (m, 2H), 4.04 (d, 1H, J= 17 Hz), 4.09 (m, 1H), 4.19 (d, 1H, J=17 Hz), 6.70 (s, 1H), 6.93 (s, 1H), 7.18 (m, 3H), 7.42 (m, 2H), 7.57 (br s, 2H), 8.51 (d, 1H, J= 3.9 Hz); 13C NMR (CDC13) 6 21.55, 25.06, 29.36, 46.03, 50.34, 52.23, 62.59, 119.32, 122.26, 122.82, 129.55, 134.97, 137.93, 147.26, 155.42, 156.77. ES-MS
m/z 373 (M+H). Anal. Calcd. for C22H24N6=0.2CH2C12=0.8CH40: C, 66.55; H, 6.70; N, 20.25.
Found: C, 66.64; H, 6.40; N, 20.06.

Example 13 CN HN-N

HN N

COMPOUND 13: Preparation of (1H-benzimidazol-2-ylmethyl)-[3-(1H-imidazol-2-yl)_ propyll-(5,6,7,8-tetrahdy ro-quinolin-8-yl)-amine.

Preparation of 1-trityl-1H-imidazole-2-carbaldehyde.
H~-/N
0 N~

[0153] To a suspension of imidazole-2-carboxaldehyde (1.00 g, 10.4 mmol) in DMF (16 mL) was added N,N-diisopropylethylamine (4.0 mL, 23.0 mmol) followed by a solution of trityl chloride (3.19 g, 11.4 mmol) in DMF (10 mL), and the mixture was stirred at 30 C for 21 h. The mixture was concentrated in vacuo then dissolved in EtOAc (60 mL).
The solution was washed with saturated NaHCO3(aq) (2 x 30 mL) and brine (15 mL) then dried (MgSO4) and concentrated in vacuo. Purification of the crude material by column chromatography on silica gel (20% EtOAc/hexanes) gave a yellow solid (1.63 g, 46%). 1H
NMR (CDC13) b 7.03 (s, 1H), 7.12 (m, 6H), 7.32 (m, 1OH), 9.23 (s, 1H).
(E)-3-(1-Trityl-1H-imidazol-2-yl)-acrylic acid ethyl ester.

N O
\
[0154] Triethyl phosphonoacetate (1.24 mL, 6.25 mmol) was added dropwise to a suspension of sodium hydride (60% in mineral oil, 212 mg, 5.30 mmol) in DME (5 mL) and stirred at room temperature for 30 minutes. The solution was added to a suspension of 1-trityl-IH-imidazole-2-carbaldehyde (1.63 g, 4.82 mmol) in DME (7 mL), and the mixture was heated at reflux for 15 minutes then stirred at 60 C for 1 hr. The reaction mixture was quenched with H2O (30 mL) and extracted with CH2C12 (3 x 15 mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo. Purification of the crude material by column chromatography on silica gel (25% EtOAc/hexanes) gave a yellow solid (1.32 g, 67%). 1H NMR (CDC13) 6 1.13 (t, 3H, J= 7.1 Hz), 4.00 (q, 2H, J= 7.1 Hz), 6.52 (d, 1H, J=
15 Hz), 6.70 (d, 1H, J= 15 Hz), 6.87 (d, 1H, J= 1.2 Hz), 7.13 (m, 7H), 7.33 (m, 9H).

3-(1 -Trityl- l H-imidazol-2-yl) -prop an- l -ol.
C
N OH

[0155] A solution of (E)-3-(1-trityl-1H-imidazol-2-yl)-acrylic acid ethyl ester (1.32 g, 3.23 mmol) in 4:1 McOH/EtOAc (20 mL) was stirred at room temperature with a suspension of 10% Pd/C (132 mg, 0.124 mmol) under hydrogen atmosphere (1 atm) for 20 h.
The catalyst was removed by filtration, and the filtrate was concentrated in vacuo to give yellow crystals (1.49 g).

[0156] To a solution of the crude ester from above (1.49 g) in THE (7 mL) was added LiAlH4 (1.0 M/THF, 7.0 mL, 7.0 mmol) at 0 C, and the mixture was stirred at room temperature for 1 h. Methanol (5 mL) was added followed by 1 N NaOH(aq) (40 mL), and the mixture was extracted with CH2C12 (2 x 25 mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo. 1H NMR (CDC13) S 1.37 (m, 2H), 2.09 (m, 2H), 3.51 (m, 2H), 6.68 (d, 1H, J= 1.5 Hz), 6.92 (d, 1H, J= 1.5 Hz), 7.13 (m, 6H), 7.33 (m, 9H).
3-(1-Trityl-1H-imidazol-2-yl)-propionaldehyde.

N

N

[01571 To a solution of 3-(1-trityl-1H-imidazol-2-yl)-propan-l-ol (201 mg, 0.545 mmol) in CH2C12 (6 mL) was added Dess-Martin periodinane (278 mg, 0.655 mmol) at room temperature. After stirring at room temperature for 1 h, the mixture was diluted with EtOAc (30 mL), washed with 1 N NaOH(aq) (2 x 10 mL) and brine (10 mL), then dried (MgSO4) and concentrated in vacuo to give a tan foam (178 mg, 89%). 1H NMR (CDC13) S
2.19 (m, 2H), 2.37 (m, 2H), 6.75 (d, 1H, J= 1.5 Hz), 6.93 (d, 1H, J= 1.5 Hz), 7.13 (m, 6H), 7.34 (m, 9H), 9.54 (s, 1H):

(1H-Benzimidazol-2-ylmethyl)-[3-(1H-imidazol-2-yl)-propel]-(5,6,7,8-tetrahydro-Quinolin-8-yl)-amine (COMPOUND 13).
[0158] Using General Procedure B: To a stirred solution of 2-[(5,6,7,8-tetrahydro-quinolin-8-ylamino)-methyl]-benzoimidazole-l-carboxylic acid tent-butyl ester (184 mg, 0.486 mmol) and 3-(1-trityl-1H-imidazol-2-yl)-propionaldehyde (178 mg, 0.486 mmol) in THE (5 mL) was added NaBH(OAc)3 (206 mg, 0.972 mmol), and the mixture was stirred at room temperature for 3.5 h. Purification of the crude material by column chromatography on silica gel (200:5:1 CH2C12/MeOH/NH4OH) afforded a yellow oil (168 mg) that was determined by 1H NMR to be a mixture of 2-({(5,6,7,8-tetrahydro-quinolin-8-yl)-[3-(1-trityl-1H-imidazol-2-yl)-propyl]-amino}-methyl)-benzimidazole-l-carboxylic acid tert-butyl ester and 3-(1-trityl-1H-imidazol-2-yl)-propan-l-ol and was used in the next step without further purification.
[0159] A solution of the crude amine from above (168 mg) in saturated HBr/AcOH
(3 mL) was stirred at room temperature for 1 h then basified with 10 N
NaOH(aq) and extracted with CH2C12 (3 x 10 mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo. Purification of the crude material by column chromatography on silica gel (300:5:1 CH2C12/MeOH/NH40H) afforded (1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-[3-(1-trityl-1H-imidazol-2-yl)-propyl]-amine as a yellow oil (101 mg, 33% over 2 steps).

[0160] To a solution of (1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-[3-(1-trityl-1H-imidazol-2-yl)-propyl]-amine (101 mg, 0.161 mmol) in CH2C12 (1.6 mL) was added triethylsilane (0.38 mL, 2.4 mmol) followed by TFA (1.9 mL, 25 mmol), and the solution was stirred at room temperature for 21 h then concentrated in vacuo.
The residue was dissolved in CH2C12 (15 mL) and washed with 1 N NaOH(aq), (10 mL). The aqueous phase was extracted with CH2C12 (2 x 10 mL), and the combined organic phases were dried (MgSO4) and concentrated in vacuo. Purification of the crude material by column chromatography on silica gel (150:5:1 CH2C12/MeOH/NH4OH) afforded COMPOUND 13 as a colourless foam (47 mg, 69%). 1H NMR (CDC13) 8 1.62-1.93 (m, 4H), 2.02 (m, 1H), 2.16 (m, 1H), 2.58-2.88 (m, 6H), 3.91 (d, 1H, J= 16 Hz), 3.98 (d, 1H, J= 16 Hz), 4.02 (m, 1H), 6.86 (s, 2H), 7.18 (m, 3H), 7.43 (d, 1H, J= 7.2 Hz), 7.55 (m, 2H), 8.55 (d, 1H, J= 3.6 Hz); 13C NMR (CDC13) 8 21.52, 23.71, 25.96, 26.67, 29.43, 49.21, 51.07, 62.23, 115.28, 120.75, 122.41, 122.81, 135.47, 138.23, 138.86, 146.68, 148.71, 155.28, 157.49. ES-MS m/z 387 (M+H). Anal. Calcd. for C23H26N6=0.21H20=0.36CH2C12: C, 66.67; H, 6.50; N, 19.97.
Found: C, 66.77; H, 6.65; N, 19.69.

Example 14 NHAc N N IT
H N
N
H
COMPOUND 14: Preparation ofN-(6-2-[(1H-Benzimidazol-2-ymethyl)-(5 6 7 8-tetrahydro-quinolin-8-yl)-amino}-ethylamino } -pyridin-3 -yl)-acetamide [0161] To a'solution of 2-{[[2-(5-Nitro-pyridin-2-ylamino)-ethyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-methyl}-benzimidazole-l-carboxylic acid tert-butyl ester (see COMPOUND 11) (316 mg, 0.58 mmol) in AcOH (4 mL) was added iron powder (172 mg, 3.08 mmol) and the reaction heated to reflux for 2 h. The mixture was cooled to room temperature, diluted with with water (5 mL) and extracted with CH2C12 (3 x 25 mL). The combined organic extracts were dried (Na2SO4), concentrated iii vacuo and purified by radial chromatography on silica gel (1 mm plate, 100:1:1 CH2C12/MeOH/NH4OH then 50:1:1) to give the desired product (96 mg, 30%) as a clear oil.
[0162] Using General Procedure D: Conversion of the free base (25 mg, 0.055 mmol) to the hydrobromide salt, followed by re-precipitation of the intermediate solid from methanol/ether, gave COMPOUND 14 (36 mg) as a white solid. 1H NMR (D20) 8 1.83-1.90 (m, 1H), 2.05-2.20 (m, 2H), 2.14 (s, 3H), 2.39-2.43 (m, 1H), 2.86-2.94 (m, 1H), 3.01-3.03 (m, 2H), 3.18-3.25 (m, 1H), 3.39-3.49 (m, 2H), 4.38 (d, 1H, J= 16.5 Hz), 4.58 (d, 1H, J= 16.5 Hz), 4.62-4.68 (m, 1H), 6.75 (d, 1H, J= 9.6 Hz), 7.47 (dd, 2H, J=
6, 3 Hz), 7.49 (s, 1H), 7.60 (dd, 2H, J= 6, 3 Hz), 7.83 (s, 1H), 7.89 (t, 1H, J= 6.6 Hz), 8.38 (d, 1H, J= 7.8 Hz), 8.71 (d, 1H, J= 6.6 Hz); 13C NMR (D20) 8 20.39, 20.84, 23.07, 27.83, 41.24, 49.13, 50.29, 62.01, 113.37, 114.24, 125.70, 125.82, 126.11, 126.96, 130.58, 138.24, 139.94, 141.08, 148.39, 149.47, 150.18, 151.32, 172.99; ES-MS m/z 456 (M+H). Anal.
Calcd. for C26H29N70.3.2 HBr = 2.4 H2O: C, 41.21; H, 4.92; N, 12.94; Br, 33.75. Found: C, 41.12;
H, 4.98; N, 12.77; Br, 34.06.

Example 15 N

/ NH
N
COMPOUND 15: Preparation ofNl-(1H-Benzimidazol-2-ylmethyl),-N'-(5,6,7,8-tetrahydro-guinolin-8-yl)-propane-1,3-diamine (hydrobromide salt) Preparation of N-(teat-butoxycarbonyl-3-amino-propionaldehyde:
[0163] To a solution of tent-butyl N-(3-hydroxypropyl)carbamate (0.177 g, 1.01 mmol} in CH2C12 (5 mL) was added Dess-Martin periodinane (0.545 g, 1.28 mmol) and the resultant mixture was stirred at room temperature for 2.5 hours. The mixture was diluted with ether (20 mL) and treated with 20% aqueous Na2S2O3 (5 mL) and saturated aqueous NaHC03 (5 mL). After 10 minutes the mixture became clear and colorless and the phases were separated. The aqueous phase was extracted with ether (3 x 10 mL). The combined organic extracts were washed sequentially with 20% aqueous Na2S2O3 (10 mL), saturated aqueous NaHCO3 (10 mL), and brine (10 mL), dried (MgSO4), and concentrated to provide 0.127 g (96%) of N-(tert-butoxycarbonyl)-3-amino-propionaldehyde as a colorless oil.

(CDC13) 8 1.43 (s, 9H), 2.71 (t, 2H, J= 6.0 Hz), 3.42 (m, 2H), 4.89 (br s, 1H), 9.81 (s, 1H).

[0164] Using General Procedure B: Reaction of N-(test-butoxycarbonyl)-2-amino-propionaldehyde (0.127 g, 0.73 mmol) and (1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine (0.152 g, 0.55 mmol) with NaBH(OAc)3 (0.262g, 1.24 mmol) in CH2C13 (5 mL) for 18 hours followed by purification of the crude material by radial chromatography on silica gel (2 mm plate, 50:1:1 CH2C12-CH3OH-NH4OH) provided 0.169 g of a yellow foam. The foam was dissolved in CH2C12 (2 mL) and treated with trifluoroacetic acid (1 mL). The resultant solution was stirred at room temperature for 2 hours then concentrated under reduced pressure. The residue was dissolved in CH2C12 (10 mL) and treated with NaOH (10 M, - 2 mL) until the aqueous phase was basic (pH 14).
The phases were separated and the aqueous phase was extracted with CH2C12 (3 x 5 mL). The combined organic extracts were dried (Na2SO4) and concentrated. Purification of the crude material by radial chromatography on silica gel (1 mm plate, 10:1:1 CH2C12-CH3OH-NH40H) provided 57 mg of a white foam.

[0165] Using General Procedure D: Conversion of the free base (57 mg)-to the hydrobromide salt, followed by re-precipitation of the intermediate solid from methanol/ether, gave COMPOUND 15 (75 mg) as a white solid. 1H NMR (D20) 8 1.77-2.09 (m, 4H), 2.18-2.22 (m, 1H), 2.38-2.42 (m, 1H), 2.60-2.70 (m, 1H), 2.87-2.97 (m, 3H), 3.01-3.04 (m, 2H), 4.42 (d, 1H, J= 16.8 Hz), 4.51-4.49 (m, 2H), 7.60-7.63 (m, 2H), 7.79-7.90 (m, 3H), 8.36 (d, 1H, J= 7.8 Hz), 8.65 (d, 1H, J= 5.7 Hz); 13C NMR (D20) 6 20.41(2 carbons), 26.38, 27.66, 37.69, 47.94, 49.13, 60.39, 114.32, 126.02, 126.98, 131.10, 139.50, 140.73,148.18,150.96,151.36; ES-MS nt/z 336 (M+H). Anal. Calcd. for C20H25N59 3.0 HBr = 1.6 H2O: C, 39.57; H, 5.18; N, 11.54; Br, 39.49. Found: C, 39.85; H, 5.10; N, 11.45;
Br, 39.15.

Example 16 cc N,,,,,-~H I / N IN

N NH

COMPOUND 16: Preparation of N'-(1H-Benzimidazol-2-ylmethyl)-N2-pyridin-2- 1l-N'-(5,6,7,8-tetrahydro-quinolin-8-yl)-ethane-1,2-diamine (hydrobromide salt) [0166] To a solution of N'-(1H-benzimidazol-2-ylmethyl)- N'-(5,6,7,8-tetrahydro-quinolin-8-yl)-ethane-1,2-diamine hydrobromide salt [COMPOUND 101 (98 mg, 0.168 mmol) in H2O (2 mL) was added NaOH (10 M, 2 mL). The resultant solution was extracted with CH2C12 (4 x 5 mL). The combined organic extracts were dried (Na2SO4) and concentrated and provided 53 mg of the free base. To a solution of the free base from above (53 mg, 0.165 mmol) in methanol (2 mL) was added pyridine-2-carboxaldehyde (20 L, 0.2 10 mmol) and the resultant solution was stirred at room temperature for 2 hours. NaBH4 (36 mg, 0.95 minol) was added and the mixture was stirred for 15 minutes. The mixture was concentrated and the residue was partitioned between CH2C12 (10'mL) and brine (5 mL). The phases were separated and the aqueous phase was extracted with CH2C12 (3 x 5 mL). The combined organic extracts were dried (Na2SO4) and concentrated. Purification of the crude material by radial chromatography on silica gel (1 mm plate, 25:1:1 CH2C12-NH4OH) provided 34 mg (45%) of the free base of the title compound.
[0167] Using General Procedure D: Conversion of the free base (34 mg) to the hydrobromide salt, followed by re-precipitation of the intermediate solid from methanol/ether, gave COMPOUND 16 (57' mg) as a white solid. 1H NMR (D20) S
1.78-1.90 (m, 1H), 1.98-2.11 (m, 1H), 2.17-2.22 (m, 1H), 2.39-2.43 (m, 1H), 2.97-3.09 (m, 3H), 3.25-3.37 (m, 3H), 4.39 (d, 1H, J= 16.5 Hz), 4.47 (d, 2H, J= 2.4 Hz), 4.54-4.59 (m, 2H), 7.57-7.65 (m, 4H), 7.77-7.88 (m, 3H), 8.04 (dt, 1H, J= 1.5, 7.5 Hz), 8.35 (d, 1H, J= 7.8 Hz), 8.50 (d, 1H, J= 4.8 Hz), 8.61 (d, 1H, J= 5.4 Hz); 13C NMR (D20) 6 20.27, 20.54, 27.67, 45.45, 47.48, 48.12, 50.32, 60.32, 114.42, 125.85, 126.11, 126.19, 127.27, 130.98, 139.83, 141.03, 141.70, 147.87, 148.39 (2 carbons), 149.85, 150.06; ES-MS in/z 413 (M+H).

Anal. Calcd. for C25H28N6.4.1 HBr = 2.0 H20: C, 38.48; H, 4.66; N, 10.77; Br, 41.98.
Found: C, 38.69; H, 4.78; N, 10.60; Br, 41.70.

Example 17 N

N N H

COMPOUND 17: Preparation of N1-(1H-Benzimidazol-2- ly methyl)- NI-(5,6,7,8-tetrahydro-auinolin-8-yl)-butane-1,4-diamine (hydrobromide salt) [0168] To a solution of (1-text-butoxycarbonyl-lH-Benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine (0.169 g, 0.451 mmol) in CH3CN (5 mL) was added N,N-diisopropylethylamine (0.25 mL, 1.44 mmol) followed by 4-bromobuty_ronitrile (0.10 mL, 1.01 mmol). The resultant mixture was heated to 80 C for 5 d then cooled to room temperature. The mixture was concentrated and the residue was partitioned between CH2C12 (20 mL) and brine (10 mL). The phases were separated and the aqueous phase was extracted with CH2C12 (3 x 10 mL). The combined organic extracts were dried (Na2SO4) and concentrated. Purification of the crude material by column chromatography on silica gel (30:1:1 CH2C12-CH3OH-NH4OH) provided 108 mg (54%) of a yellow foam.
[0169] The intermediate from above (108 mg, 0.24 mmol) was dissolved in NH3 saturated methanol (4 mL), treated with Raney nickel (100 mg), and placed under 50 psi H2 on a Parr shaker, for 24 h. The mixture was filtered through Celite and the cake was washed with methanol. The eluant was concentrated under reduced pressure.
Purification of the crude material by radial chromatography on silica gel (1 mm plate, 20:1:1 NH4OH) provided 33 mg (39%) of the free base of the title compound as a white foam.
[0170] Using General Procedure D: Conversion of the white foam (33 mg) to the hydrobromide salt, followed by re-precipitation of the intermediate solid from methanol/ether, gave COMPOUND 17 (40 mg) as a white solid. 1H NMR (D20) 6 1.52 (br s, 4H), 1.74-1.88 (m, 1H), 1.95-2.08 (m, 1H), 2.15-2.21 (m, 1H), 2.34-2.39 (m, 1H),2.50-2.61 (m, 1H), 2.79-2.86 (m, 3H), 2.99-3.02 (m, 2H), 4.38 (d, 1H, J=16.8 Hz), 4.47-4.56 (m, 2H), 7.58-7.63 (m, 2H), 7.76-7.88 (in, 3H), 8.34 (d, 1H, J= 7.8 Hz), 8.62 (d, 1H, J= 5.7 Hz); 13C
NMR (D20) 8 20.42(2 carbons), 25.03, 25.42, 27.64, 39.50, 48.20, 51.71, 60.64, 114.26, 125.93,126.93,131.05,139.32,140.62,148.09,150.31,151.82; ES-MS m/z 350 (M+H).
Anal. Calcd. for C21H27N5.2.9 HBr = 2.2 H2O: C, 40.44; H, 5.54; N, 11.23; Br, 37.15.
Found: C, 40.38; H, 5.42; N, 10.85; Br, 37.42.

Example 18 QH

N NH xHCI

COMPOUND 18: Preparation of 1V'-(1H-benzimidazol-2-ylmethyl)-N'-(S)-5,6,7,8-tetrahydro -quinolin-8-yl-butane-1 4-diamine (hydrochloride salt).
Preparation of 4-phthalamido-butyraldehyde:
[01711 A solution of 4-amino-l-butanol (5.0 g, 56 mmol) and phthalic anhydride (8.3 g, 56 mmol) in 20% MeOH/CHC13 (140 mL) was stirred at reflux for 66 h. The mixture was cooled to room temperature and washed sequentially with water (3 x 75 mL) and 1N NaOH
(3 x 50 mL). The separated organic layer was dried (MgSO4), concentrated, and purified by flash chromatography (5 cm id., 120 g silica gel, eluted with 2% McOH/CH2C12) to give the desired alcohol as a white solid (4.21 g, 34%).
[01721 To a stirred slurry of TPAP (340 mg, 0.96 mmol), NMO (3.4 g, 29 mmol) and 3A
molecular sieves (10 g) in CH2C12 (100 mL) was added dropwise a solution of the alcohol from above (4.2 g, 19 mmol) in CH2C12 (50 mL) over 30 min. The black slurry was stirred under N2 for 30 min after the addition, concentrated in vacuo, and purified by flash chromatography (5 cm id., 80 g silica gel, eluted with EtOAc) to afford the pure title com-pound as a grey solid (3.30 g, 80%). 1H NMR (CDC13) 5 1.97-2.07 (m, 2H), 2.54 (t, 2H, J=
7.2 Hz), 3.74 (t, 2H, J= 6.8 Hz), 7.71-7.75 (m, 2H), 7.82-7.88 (m, 2H), 9.77 (s, 1H).
[01731 Using General Procedure B: 4-phthalamido-butyraldehyde from above (3.21 g, 14.8 mmol) was reacted with S-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine (2.40 g, 16.3 mmol) and NaBH(OAc)3 (9.54 g, 45.0 mmol) in dichloromethane (150 mL). Flash chromatography (5 cm id, 200 g silica gel, eluted with 5% MeOH/CH2C12) provided the pure 2 amine as a white foamy solid (2.48 g, 48%).
[0174] To a solution of the amine from above (2.5 g, 7.1 mmol) in acetonitrile (70 mL) was added diisopropylethylamine (1.9 mL, 10.7 mmol), 1-boc-2-chloromethylbenzimidazole (2.3 g, 8.6 mmol), and potassium iodide (115 mg, 0.70 mmol). The mixture was stirred under an N2 atmosphere at 60 C for 15 h, cooled to room temperature and concentrated in vacuo.
The residue was partitioned between chloroform (150 mL) and water (100 mL).
The separated organic layer was dried (MgSO4), concentrated, and purified by flash chromatography (5 cm id, 120 g silica gel, eluted with CH2C12 to remove unreacted chloride then 2% McOH/CH2C12 to remove desired product) to give the desired amine as a pale yellow foamy solid (3.50 g, 85%).
[0175] A solution of the amine from above (3.33 g, 5.7 mmol) in ethanol (30 mL) was treated with hydrazine monohydrate (1.80 g, 36 mmol), stirred for three hours.
The mixture was then concentrated in vacuo and purified by flash chromnatography (5 cm id., 80 g silica gel, eluted with 5% MeOH/CH2Cl2) to give the unprotected amine as a pale yellow foamy solid (1.70 g, 86%).
[0176] The amine from above (1.70 g, 4.86 mmol) was dissolved in glacial acetic acid (5 mL) and treated with HC1 saturated acetic acid (5 mL). The solution was allowed to stir at room temperature 5 min, then it was slowly dropped into diethyl ether (400 mL) with vigorous stirring. The resultant slurry was suction filtered through a glass fritted funnel and the filter cake was washed with diethyl ether (3 x 100 mL) and dried in a vacuum oven at 40 C for 16 h to give COMPOUND 18 as a white solid (2.34 g, 94%). 1H NMR (D20) &
1.46-1.63 (m, 4H), 1.70-1.87 (m, 1H), 1.97-2.07 (m, 1H), 2.10-2.21 (m, 1H), 2.28-2.38 (m, 1H), 2.55-2.65 (m, 1H), 2.81-2.90 (m, 3H), 2.91-3.00 (m, 2H), 4.30 (d, 1H, J=
16.3 Hz), 4.41 (d, lH, J= 16.3 Hz), 4.42-4.48 (m, 1H), 7.48-7.51 (m, 2H), 7.70-7.75 (m, 3H), 8.20 (d, 1H, J
= 8.2 Hz), 8.53 (d, 1H, J= 4.5 Hz); 13C NMR (D20) S 20.36, 20.43, 21.67, 24.99, 25.24, 27.60, 39.51, 48.29, 51.78, 60.54, 114.46 (2 carbons), 125.63, 126.10 (2 carbons), 132.53, 139.58, 140.16, 147.34, 151.41, 151.81. ES-MS nt/z 350 (M+H). Anal. Calcd. for C21H27N5.2.5HC1.2.0H20Ø6CH3COOH: C, 52.01; H, 7.06; N, 13.66; Cl,17.29.
Found: C, 52.15; H, 7.09; N, 13.40; Cl, 17.56.
[0177] The enantiomeric purity of COMPOUND 18 was determined to be 96.7% by chiral HPLC using the following conditions: Instrument: Hewlett Packard 1100 HPLC

(VWD1); Column: Chiralpak OD, 0.46 cm x 25 cm; Mobile Phases: A: 90:10 hexanes/isopropanol with 0.1%DEA, B: isopropanol; Isocratic: 90% A, 10%B;
Total Run Time: 20 min; Flow Rate: 0.5 mL/min; Temperature: 10 C; Detector: UV @ 270 nm;
Injection volume: 20 L.

[0178] Retention time of the S enantiomer =16.3 min.
[0179] Retention time of the R enantiomer = 21.9 min.
Example 19 N
N

N H-Br H-Br H-Br COMPOUND 19: Preparation of N1-(1-Methyl-lH-benzoimidazol-2- ly meth -N'-(5 6 tetrah d~ ro-quinolin-8-yl)-butane-1,4-diamine (hydrobromide salt).

[0180] 2-[4-(5,6,7,8-Tetrahydro-quinolin-8-ylamino)-butyl]-isoindole-1,3-dione was prepared following the procedure for COMPOUND 18. 2-{4-[(1-Methyl-lH-benzoimidazol-2-ylmethyl)-(5, 6, 7, 8-tetrahydro-quinolin-8-yl)-amino}-butyl} -isoindole-1,3 -dione was prepared following the general procedure for reductive aminations.
[0181] To a solution of 2-[4-(5,6,7,8-Tetrahydro-quinolin-8-ylamino)-butyl]-isoindole-1,3-dione (0.2Q11 g, 0.58 mmol) in dichloromethane (5.8 mL) was added 1-Methyl-lH-benoimidazole-2-carbaldehyde (0.1844 g, 1.15 mmol) and NaBH(OAc)3 (0.2462g, 1.16mmol), and was stirred at room temperature for four days. The organic phase was washed with NaHCO3 (2 x 10 mL), dried over Na2SO4, filtered, and concentrated.
Purification of the crude material by column chromatography on silica gel (47:2:1 CH2C12-McOH-NH4OH) provided 103 mg (36%) of 2-{4-[(1-Methyl-lH-benzoimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-butyl}-isoindole-l,3-dione. 1H NMR
(CDC13) S
1.30-1.44 (m, 2H), 1.48-1.63 (m, 3H), 1.84-1.96 (m, 2H), 2.03-2.07 (m, 1H), 2.54-2.81 (m, 4H), 3.51 (t, 2H, J= 7.2Hz), 3.95 (s, 3H), 3.99-4.06 (m, 2H), 4.19 (d, 1H, J=13.5Hz), 6.94-6.98 (m, 1H), 7.13-7.21 (m, 2H), 7.24-7.29 (m, 2H), 7.63-7.68 (m, 3H), 7.74-7.78 (m, 2H), 8.40 (d, 1H, J = 3.6Hz).

[0182] To a solution of 2-{4-[(1-Methyl-lH-benzoimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-butyl}-isoindole-l,3-dione (0.1030 g, 0.21 mmol) in ethanol (lmL) was added hydrazine monohydrate (0.51 mL, 10.5 mmol), and the reaction mixture was stirred at room temperature for 18 hours. The mixture was concentrated and purified first via column chromatography on silica gel (91:12:1 CH2C12-MeOH-NH40H) and then by radial chromatography on silica (18:1:1 CH2C12-MeOH-NH4OH) to yield 0:0246 g (32%) of Nl-(1-Methyl-lH-benzoimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-l,4-diamine. 1H NMR (CDC13) S 1.32-1.42 (m, 5H), 1.91-2.02 (m, 2H), 2.05-2.11 (m, 1H), 2.55 (t, 2H, J= 6.9Hz), 2.60-2.64 (m, 3H), 2.76-2.86 (m, 1H), 3.98 (s, 3H), 4.04-4.17 (m, 3H), 7.00-7.04 (m, 1H), 7.21-7.27 (m, 2H), 7.30-7.33 (m, 2H), 7.68-7.72 (m, 1H), 8.47 (d, 1H, J= 3.3Hz).
[0183] Following General Procedure D, Nl-(1-Methyl-lH-benzoimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine was salted out. To a solution of Nl-(1-Methyl-lH-benzoinmidazol-2-ylmethyl)N'-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine (0.0246 g, 0.068 mmol) in acetic acid (0.81nL) was added HBr/AcOH (1 mL), followed by the addition of diethyl ether (50 mL), which resulted in the precipitation of the salt. The ether was decanted off and the remaining solid was washed with diethyl ether (2 x 50 mL). Any, residual diethyl ether was removed by vacuum and methanol (1 mL) was added to the solid. Again, diethyl ether (50 mL) was added and the salt was washed with diethyl ether (3 x 50 mL) to give COMPOUND 19 (23 mg, 76%) as a white solid. 1H NMR
(D20) S
1.52-1.53 (m, 4H), 1.73-1.87 (m, 1H), 1.99-2.11 (m, 1H), 2.15-2.19 (m, 1H), 2.40-2.43 (m, 1H), 2.51-2.58 (m, 1H), 2.78-2.84 (m, 3H), 2.97-2.99 (m, 2H), 3.96 (s, 3H), 4.38 (d, 1H, J=
17.7 Hz), 4.48-4.54 (in, 1H), 4.59 (d, 1H, J= 17.7 Hz), 7.58-7.61 (m, 2H), 7.75-7.84 (m, 3H), 8.30 (d, 1H, J= 7.8 Hz), 8.58 (d, 1H, J= 5.4 Hz); 13C NMR (D20) 20.44 (2H}, 25.03, 25.44, 27.69, 31.52, 39.47, 47.70, 52.18, 60.88, 112.80, 114.22, 125.88, 126.73, 127.12, 130.08, 133.45, 139.32, 140.64, 148.09, 151.13, 151.68. ES-MS m/z 364 (M+H). Anal.
Calcd. for C22H29N5 3.2HBr 2.2H2O: C, 39.91; H, 5.57; N, 10.58; Br, 38.62. Found: C, 39.97; H, 5.44;
N, 10.37; Br, 38.49.

Exam lp e 20 N

HN NIN

5:r F

COMPOUND 20: Preparation of N1-[5-(4-Fluoro-phenyl)-1H-imidazol-2- lme h I -N1-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine.
[01841 2-[4-(5,6,7,8-Tetrahydro-quinolin-8-ylamino)-butyl]-isoindole-1,3-dione was prepared following the General Procedure B for reductive amination. To a solution of 5,6,7,8-Tetrahydro-quinolin-8-ylamine (1.0609 g, 7.1 mmol) and 4-(1,3-dioxo-1,3-dihydro-isoindol=-2-yl)-butyraldehyde (1.4079 g, 6.8 mmol) (prepared according to the procedure for COMPOUND 18) in methylene chloride (64 mL) was, added NaBH(OAc)3 (4.07 g, 19.2 mmol) and the reaction stirred at room temperature for two hours. The reaction was quenched with 1N NaOH (45 mL), extracted with methylene chloride (2 x 55 mL), dried (Na2SO4), filtered, and concentrated. Purification of the crude material by column chromatography on silica gel (40:1:1 CH2Cl2-MeOH-NH4OH) provided 1.16g (52%) of 2-[4-(5,6,7,8-Tetrahydro-quinolin-8-ylamino)-butyl]-isoindole-1,3-dione. 1H NMR
(CDC13) 6 1.57-1.66 (m, 3H), 1.69-1.84 (m, 4H), 1.93-2.03 (m, 1H), 2.07-2.13 (m, 1H), 2.69-2.86 (m, 4H), 3.70-3.77 (m, 3H), 7.03-7.07 (m, 1H), 7.35 (d, 1H, J= 7.2 Hz), 7.67-7.73 (m, 2H), 7.80-7.85 (m, 2H), 8.37 (d, 1H, J= 3 Hz).
[01851 To a solution of 4-(4-fluoro-phenyl)-1-(2-trimethylsilanyl-ethoxymethyl)-lH-imidazole-2-carbaldehyde (0.2301 g, 0.72 mmol) in methylene chloride (7.2 mL) was added 2-[4-(5,6,7,8-tetrahydro-quinolin-8-ylamino)-butyl]-isoindole-1,3-dione (0.3030 g, 0.87 mmol) and then NaBH(OAc)3 (0.3060 g, 1.44 mmol), and the reaction mixture was stirred at room temperature for four days. The reaction was quenched with saturated NaHCO3 (6 mL), extracted with CH2C12 (2 x 25 mL), dried (Na2SO4), filtered, and concentrated.
Purification of the crude material by column chromatography on silica gel (50:1:1 CH2C12-MeOH-NH4OH) provided 0.3125 g (66%) of 2-{4-[[5-(4-fluoro-phenyl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-ylmethyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-butyl} -isoindole-1,3-dione. 1H NMR (CDC13) S 0.82-0.87 (m, 2H), 1.25-1.37 (m, 2H), 1.48-1.69 (m, 10H), 1.88-2.08 (m, 3H), 2.56-2.82 (m, 4H), 3.38-3.44 (m, 2H), 3.53 (t, 2H, J= 7.2 Hz), 3.96 (s, 2H), 4.01-4.04 (m, 1H), 5.56 (d, 1H, 10.8 Hz), 5.79 (d, 1H, J= 10.5 Hz), 6.97-7.03 (m, 3H), 7.12 (s, 1H), 7.30 (d, 1H, J= 7.5 Hz), 7.61-7.70 (m, 4H), 7.75-7.79 (m, 211), 8.44 (d, 1H, J= 4.5 Hz).
[0186] To a solution of 2-{4-[[5-(4-Fluoro-phenyl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-ylmethyl]-(5,6,7,8 'tetrahydro-quinolin-8-yl)-amino]-butyl}-isoindole-1,3-dione (0.3125 g, 0.48 mmol) in ethanol (5 mL) was added hydrazine monohydrate (0.12 mL), and the reaction mixture was stirred at room temperature for 17 hours. The reaction mixture was concentrated, and purified via column chromatography on silica gel (20:1:1 CH2C12-MeOH-NH40H) to yield 0.1838g (73%) of N1-[5-(4-fluoro-phenyl)-1-(2-trimethylsilanyl-ethoxymethyl)- 1H-imidazol-2-ylmethyl]7 N1-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-l,4-diamine. 1H NMR (CDC13) S 0.85 (t, 2H, J=
8.1 Hz), 1.25-1.34 (m, 7H), 1.61-1.72 (m, 1H), 1.89-2.05 (m, 4H), 2.54-2.82 (m, 8H), 3.35-3.47 (m, 3H), 3.93 (s, 2H), 4.06 (t, 1H, J= 8.1 Hz), 5.53 (d, 2H, J= 10.5 Hz), 5.78 (d, 2H, J=10.8 Hz), 6.99-7.04 (m, 3H), 7.15 (s, 1H), 7.31 (d, 1H, J= 7.5 Hz), 7.66-7.70 (m, 2H), 8.47" (d, 1H, J= 3.6 Hz).
[0187] To a solution of N1-[5-(4-fluro-phenyl)-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazol-2-ylmethyl]- Nl-(5,6,7,8-tetrahydro-quinolin-8-1)-butane-1,4-diamine (0.1838. g, 0.35 mmol) in nethylene chloride (5 mL) was added TFA (5 mL), and was stirred in a room temperature for 3 days. The mixture was concentrated, dissolved in CH2C12, and neutralized with 1ON NaOH. The aqueous phase was extracted with CH2C12 (4 times), and the combined organic extracts were then washed with brine, dried (Na2SO4), filtered and concentrated. The crude material was purified by column chromatography on silica gel (15:1:1 CH2C12MeOH-NH40H) and then by radial chromatography on silica (15:1:1 CH2C12MeOH-NH40H) to give COMPOUND 20 (0.0421 G, 31%) as an orange oil. 1H
NMR (CDC13) S 1,25-1.43 (m,4H), 1.62-1.75 (m, 1H), 1.84-1.92 (m, 1H), 1.96-2.05 (m, 1H), 2.13-2.15 (m, 1H), 2.44-2.50 (m, 3H), 2.63-2.73 (m, 2H), 2.79-2.89 (m, 1H), 3.87 (s, 1H), 3.99-4.04 (m, 2H), 7.04 (t, 2H, J = 9Hz), 7.10-7.14 (m, 1H), 7.23 (s, 1H), 740 (d, 1H, J= 7.5 Hz), 7.65-7.70 (m, 2H), 8.50 (d, 1H, J= 4.2 Hz); 13C NMR (CDC13) 8 21.70, 23.02, 26.37, 29.57, 30.17, 41.44, 49.02, 50.72, 61.70, 115.83 (d, 2C, J= 14.34 Hz), 122.49, 126.43 (d, 2C, J= 5.18 Hz), 130.26, 135.01, 137.74, 147.14 (2C), 149.64, 157.77, 160.34, 163.58. ES-MS

m/z 394 (M+H). Anal. Calcd. For C23H28N5F=1.3CH2C12: C, 70.20; H, 7.17; N, 17.80.
Found: C, 58.09; H, 6.23; N, 13.59.

Example 21 Q-' H

N~ NH
COMPOUND 21: Preparation of N'-(lH-Benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl -N-benzyl-l,4-butanediamine (hydrobromide salt) [0188] To a solution ofN'-(l-(2-trimethylsilyl)-ethan-1yloxymethyl)-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-1,4-butanediamine (70 mg, 0.15 mmol) in methanol (4 mL) was added benzaldehyde (0.015 mL, 0.15 mmol). The mixture was stirred overnight at room temperature, then cooled to 0 C. Sodium borohydride (38 mg, 1.0 mmol) was then added, and the reaction was stirred for one hour, gradually warming to room temperature. The solution was then concentrated. The residue was taken up in dichloromethane and washed with 1N sodium hydroxide (3 mL), then dried over anhydrous sodium sulfate, concentrated and purified by chromatography on silica gel (10:1 dichloromethane:methanol) to afford N'-(l-(2-trimethylsilyl)-ethan-1yloxymethyl)-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-N-benzyl-1,4-butanediamine (39 mg, 49%). 1H NMR (CDC13) S 0.10(s, 9H), 0.80 (t, 2H, J= 7.0 Hz), 1.41 (m, 3H), 1.76-2.21 (m, 5H), 2.44 (in, 2H), 2.46-2.26 (m, 2H), 3.35 (t, 2H, J= 7.0 Hz), 3.67 (s, 2H), 4.06 (m, 1H), 4.08 (d, 1H, J=15.8 Hz), 4.22 (d, 1H, J= 15.8 Hz), 5.80 (d, 1H, J= 14.6 Hz), 6.02 (d, 1H, J
=14.6 Hz), 7.00 (m, 1H), 7.27 (m, 8H), 7.42 (in, 1H), 7.80 (m, 1H), 8.44 (d, 1H, J= 4.8 Hz).
[0189] as taken up in acetic acid (1 mL), to which a saturated solution of HBr in acetic acid (1 mL) was added. The mixture was then stirred, precipitated and isolated as per procedure D to yield COMPOUND 21 as a white crystalline solid (26 mg). 1H NMR

(D20). 8 1.52 (m, 4H), 1.88 (m, 1H), 2.01 (m, 1H), 2.08 (m, 1H), 2.31 (m, 1H), 2.44 (m, 1H), 2.88 (m, 1H), 3.00 (t, 2H, J= 6.9 Hz), 3.03 (m, 2H), 4.13 (s, 1H), 4.31 (d, 1H, J= 16.1 Hz), 4.47 (m, 1H), 4.49 (d, 1H, J= 16.1 Hz), 7.36 (m, 5H), 7.60 (m, 211), 7.77 (m, 2H), 7.83 (in, 1H), 8.26 (d, 1H, J= 7.8 Hz), 8.68 (d, 1H, J= 4.9 Hz). 13C NMR (D20) 8 20.41, 23.68, 25.45, 27.63, 46.86, 48.24, 51.34, 51.57, 60.63, 114.25, 125.93, 126.95, 129.66, 130.08, 130.17, 130.98, 139.30, 140.60, 148.10, 151,24, 151.77. ES-MS m/z 440 (M+H);
Anal.
Calcd. for (C28H33N5 x 3.1 HBr x 1.4 H20): C, 46.99; H, 5.48; N, 9.79; Br 34.61. Found: C, 47.00; H, 5.44; N, 9.54; Br, 34.57.

Exam lp e 22 CN~

~\H I
N N
\ H -Br HN N
H-Br H-Br H-Br COMPOUND 22: Preparation of N1-(1H-Benzimidazol-2-ylmethyl)-1V4-puridin-2- l v y_ methl-Nl-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine (hydrobromide salt).

[0190] Using General Procedure B (Two step reductive amination): Reaction of N1-(l-(2-(trimethylsilyl)ethoxymethyl)-1H-Benzimidazol-2-ylmethyl)-NI-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine (101 mg, 0.21 mmol) with pyridine-2-carboxaldehyde (30 L, 0.32 mmol) in CH3OH (4 mL) for 6 hours and with NaBH4 (35 mg, 0.92 mmol) for 40 minutes followed by purification of the crude material by radial chromatography on silica gel (1 mm plate, 20:1:1 CH2C12-CH3OH-NH4OH) provided 84 mg (70%)>of a colorless oil. The oil from above (84 mg, 0.15 mmol) was dissolved in 6 N HCl (2 mL), heated at 50 C for 4.5 hours then cooled to room temperature. The solution was treated with 10 N NaOH
(2 mL) and extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts were dried (Na2SO4) and concentrated. Purification of the crude material by radial chromatography on silica gel (1 mm plate, 10:1:1 CH2Cl2-CH3OH-NH4OH) provided 41 mg (63%) of the free base of the title compound as a colorless oil.
[0191] Using General Procedure D: Conversion of the oil from above (41 mg, 0.092 mmol) to the hydrobromide salt followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 22 (72 mg, 93%) as a white solid. 1H NMR (D20) 8 1.50-1.66 (m, 4H), 1.79-1.89 (m, 1H), 1.96-2.08 (m, 1H), 2.15-2.20 (m, 1H), 2.35-2.39 (m, 1H), 2.50-2.60 (m, 1H), 2.80-2.88 (m, 1H), 3.00-3.10 (m, 4H), 4.36-4.56 (m, 5H), 7.58-7.63 (m, 2H), 7.72-7.88 (m, 5H), 8.22 (dt, 1H, J= 1.5, 7.8 Hz), 8.35 (d, 1H, J= 8.1 Hz), 8.62 (d, 1H, J= 5.7 Hz), 8.66 (d, 1H, J= 5.4 Hz); 13C NMR (D20) 8 20.43(2 carbons), 23.77, 25.43, 27.65, 47.86, 48.23, 49.66, 51.64, 60.64, 114.26, 125.94, 126.42, 126.54, 126.95, 130.97, 139.33, 140.62, 143.16, 146.99, 148.09, 148.11, 151.23, 151.76. ES-MS m/z 441 (M+H).
Anal. Calcd. for C27H32N6.4.0HBr=3.7H20: C, 39.03; H, 5.26; N, 10.11; Br, 38.47. Found:
C, 39.04; H, 5.22; N, 10.04; Br, 38.52.

Exam lp e 23 NH
-(N y N H

COMPOUND 23: Preparation ofNl-(1H-Benzimidazol-2-ylmeth -1V4-(]H-indol-3-ylmethyl) N'-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1 4-diamine (free base).
[0192) To a solution of N'-(1-(2-(trimethylsilyl)ethoxymethyl)-1H-Benzimidazol-ylmethyl)-NI-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine (73 mg, 0.16 mmol) in CH2Cl2 (2 mL) was added trifluoroacetic acid (4 mL) and the resultant solution was stirred at room temperature overnight then concentrated under reduced pressure. The residue was dissolved in CH2Cl2 (10 mL) and water (5 mL) and treated with NaOH (10 M, - 2 mL) until the aqueous phase was basic (pH 14). The phases were separated and the aqueous phase was extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts were dried (Na2SO4) and concentrated. Purification of the crude material by radial chromatography on silica gel (1 mm plate, 15:1:1 CH2Cl2-CH3OH-NH4OH) provided 37 mg of N'-(1H-Benzimidazol-2-ylmethyl)N'-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine as a white foam.
[01931 Using General Procedure B (Two step reductive amination): Reaction of NI-(lH-Benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine (86 mg, 0.25 mmol) with indole-3-carboxaldehyde (55 mg, 0.38 mmol) in CH3OH (2.5 mL) overnight and with NaBH4 (27 mg, 0.71 mmol) for 30 minutes followed by purification of the crude material by radial chromatography on silica gel (1 mm plate, 50:1:1 CH2Cl2-NH4OH) provided 74 mg (60%) of COMPOUND 23 as a white solid. 'H NMR (CDC13) 6 1.38-1.52 (m, 4H), 1.64-1.73 (m, 1H), 1.83-1.95 (m, 1H), 2.00-2.05 (m, 1H), 2.15-2.21 (m, 1H), 2.49-2.56 (m, 3H), 2.67-2.89 (m, 3H), 3.88 (s, 2H), 3.96-4.10 (m, 3H), 7.03 (br s, 1H), 7.07-7.13 (m, 2H), 7.16-7.22 (m, 3H), 7.35 (dd, 1H, J= 7.8, 1.0 Hz), 7.40 (d, 1H, J= 7.8 Hz), 7.58-7.60 (m, 3H), 8.17 (br s, 1H), 8.55 (d, 1H, J= 4.5 Hz); 13C NMR
(CDC13) S 21.79, 23.58, 26.53, 27.64, 29.64, 44.94, 49.34, 49.88, 50.59, 61.83, 111.66, 114.88, 118.99, 119.72, 121.96, 122.29, 122.51, 123.13, 127.42, 135.05, 136.74, 137.72, 147.10, 156.87, 157.83. ES-MS m/z 479 (M+H). Anal. Calcd. for C30H34N6=1.3 H20: C, 71.77; H, 7.35; N, 16.74.

Found: C, 71.69; H, 7.14; N, 16.59.

Example 24 H
N
N
H H
N~" NH
H-Br H-Br H-Br COMPOUND 24: Preparation of (1H-Benzimidazol-2-ylmethyl)-(3-piperidin-2-yl-propyl)-(5 6 7 8-tetrahydro-quinolin-8 yl)-amine (hydrobromide salt).

[0194] A mixture of 3-(2-pyridyl)-1-propanol (0.75 mL, 5.83 mmol), Pt02 (60 mg, 0.26 mmol) and concentrated HCl (0.48 mL, 5.86 mmol) in ethanol (3.1 mL) was hydrogenated (50 psi) on a Parr shaker at room temperature for 20 hours. The mixture was filtered through celite and the cake was washed with methanol. The solvent was removed from the filtrate under reduced pressure and provided 1.34 g of a white slushy solid. The solid (1.34 g) was dissolved in THE (30 mL) and water (1 mL), treated with NN-diisopropylethylamine (2.0 mL, 11.42 mmol) and di-tert-butyl dicarbonate (2.16 g, 9.89 mmol) and the resultant mixture was stirred at room temperature overnight. The reaction mixture was diluted with water (30 mL) and extracted with EtOAc (3 x 60 mL). The combined organic extracts were washed with brine (2 x 20 mL), dried (Na2S04) and concentrated. Purification of the crude material by column chromatography on silica gel (2:1 hexanes-ethyl acetate) provided 1.38 g (97%
from 3-(2-pyridyl)-1-propanol) ofN-tent-butoxycarbonyl-3-piperidin-2-yl-propan-l-ol as a colorless oil. 1H NMR (CDC13) 6 1.40-2.04 (m, 20H), 2.75 (t, 1H, J= 12 Hz), 3.66-3.69 (m, 1H), 3.94-3.96 (m, 1H), 4.25 (br s, 1H).
[0195] To a solution ofN-tent-butoxycarbonyl-3-piperidin-2-yl-propan-l-ol (0.372 g, 1.53 mmol) in CH2C12 (7.5 inL), at room temperature, was added sequentially 3A
molecular sieves (0.814 g), N-methylmorpholine N-oxide (0.278 g, 2.37 mmol) and tetrapropylammonium perruthenate (56 mg, 0.16 mmol). After 90 minutes, the mixture was filtered through a short column of silica gel and the cake was washed with ethyl acetate. The solvent was removed from the filtrate under reduced pressure to provide 0.32 g (86%) of N-tert-butoxycarbonyl-3-piperidin-2-yl-propionaldehyde as a green oil which was used without further purification.
[0196] Using General Procedure B: Reaction of N-tert-butoxycarbonyl-3-piperidin-2-yl-propionaldehyde (0.32 g, 1.33 mmol) and (1H-Benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine (0.307 g, 1.10 mmol) with NaBH(OAc)3 (0.448g, 2.11 mmol) in CH2C12 (10 mL) for 16 hours followed by purification of the crude material by column chromatography on silica gel (30:1:1 CH2C12-CH3OH-NH4OH) provided 0.285 g of a yellow foam. The foam (0.285 g) was dissolved in THE (10 mL), treated with 3 N HCl (10 mL), and the resultant solution was stirred at room temperature for 75 minutes. The pH
of the solution was adjusted to -14 using 10 N NaOH (-4 mL). The solution was extracted with CH2C12 (4 x 30 mL) and the combined organic extracts were dried (Na2SO4) and concentrated.
Purification of the crude material by column chromatography on silica gel (25:1:1 CH2C12-CH3OH-NH4OH) provided 0.176 g (40%) of the free base of the title compound as white foam.
[0197] Using General Procedure D: Conversion of the foam from above (69 mg, 0.17 mmol) to the hydrobromide salt followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 24 (79 mg, 67%) as a white solid. NMR and HPLC
analysis indicated a-1:1 mixture of diastereomers. 1H NMR (D20) S 1.18-1.53 (m, 7H), 1.78-1.84 (m, 4H), 1.96-2.08 (m, 1H), 2.15-2.20 (m, 1H), 2.35-2.40 (m, 1H), 2.49-2.56 (m, 1H), 2.81-3.00 (m, SH), 3.28-3.32 (m, 1H), 4.35-4.56 (m, 3H), 7.59-7.62 (m, 2H), 7.79-7.89 (m, 3H), 8.34 (br d, 1H, J= 7.8 Hz), 8.63 (br d, 1H, J= 5.4 Hz); 13C NMR (D20) S 20.42(2 carbons), 21.82, 22.22, 24.03, 27.64, 28.23, 31.02 & 31.11, 45.11, 48.13 &
48.24, 51.76 &
51.88, 56.76 & 56.83, 60.59 & 60.71, 114.25, 125.94, 126.97, 130.99, 139.31, 140.65, 148.11, 151.26, 151.75. ES-MS na/z 404 (M+H). Anal. Calcd. for C25H33N5.3.OHBr =3.2H2O:
C, 42.66; H, 6.07; N, 9.95; Br, 34.05. Found: C, 42.47; H, 5.82; N, 9.78; Br, 34.43.

Example 25 ()N-PH
NH NH
N

COMPOUND 25: Preparation of 4-[(1H-Benzoimidazole-2-ylmeth )-(5 6 7 8-tetrahydro-guinolin-8-yll-aminol-but air ldehyde aminoguanidine h drazone hydrobromide salt) [0198] Using General Procedure B: To a stirred solution of 4-[(1H-Benzoimidazole-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-butyraldehyde (see for preparation) (0.2182 g, 0.63 mmol) and aminoguanadine hydrochloride (69 mg, 0.63 mmol) in dry MeOH (4 mL) was added AcOH (75 L, 1.26 mmol) and the mixture was stirred at room temperature for 3 h. The reaction was concentrated and the residue was partitioned between CH2C12 (20 mL) and saturated aqueous NaHCO3 (30 mL), the phases separated and the aqueous layer extracted with CH2Cl2 (2 x 15 mL). The combined organic extracts were dried (Na2SO4), filtered, and concentrated under reduced pressure. Purification of the crude material by radial chromatography on silica gel (1 mm plate, CH2C12/MeOH/NH4OH, 20:1:1 then 10:1:1) afforded the desired aminoguanidine hydrazone (69 mg, 30%) as a pale yellow foam.

[0199] Using General Procedure D: Conversion of the foam from above (69 mg, 0.17 mmol) to the hydrobromide salt followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 25 (93 mg, 76%) as a beige solid. 1H NMR (D20) 8 1.54-1.77 (m, 2H), 1.78-1.94 (m, 1H), 1.95-2.11 (m, 1H), 2.12-2.31 (m, 3H), 2.32-2.44 (m, 1H), 2.45-2.62 (m, 1H), 2.79-2.91 (m, 1H), 2.96-3.08 (m, 2H), 4.35 (d, 1H, J=
16.5 Hz), 4.50 (d, 1H, J= 16.5 Hz), 4.51-4.59 (m, 1H), 7.32 (t, 1H, J= 5.1 Hz), 7.58-7.64 (m, 2H), 7.77-7.81 (m, 2H), 7.88 (dd, 1H, J= 7.8, 5.7 Hz), 8.36 (d, 1H, J= 7.8 Hz), 8.65 (d, 1H, J= 9.6 Hz); 13C NMR (D20) 6 20.40, 23.75, 27.69, 29.09, 48.45, 50.79, 60.42, 114.20, 125.88, 126.99, 130.98, 139.35, 140.72, 148.06, 151.35, 151.79, 152.94. ES-MS m/z 405 (M+H).
Anal. Calcd. for C22H28N8=3.1HBr=1.4H20Ø4C4H100: C, 39.91; H, 5.38; N, 15.78; Br, 34.88. Found: C, 39.89; H, 5.29; N, 15.84; Br, 34.94.

Example 26 N
'I~f N N N NH

COMPOUND 26: Preparation of 1-N'-14-(1H-Benzimidazol-2-ylmethyl)-(5,6,7,8-tetrah d oguinolin-8-yl)-amino]-aminobutane-N,N-dimethylformamidine (hydrobromide salt) [0200] Using the procedure of L. Cai (Y. Han and L. Cai Tetrahedron Lett.
1997, 38(31), 5423-5426) a solution of 2-pyridinesulfonyl chloride (56 mg, 0.32 mmol) in DMF
(1 mL) was stirred for 10 minutes at room temperature. IV-(1H-Benzimidazol-2-ylmethyl)-IV-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-l,4-diamine (73 mg, 0.21 mmol) was then added, and the mixture was stirred at room temperature for 2 hours. The DMF was then removed in vacuo, and the residue was taken up in dichloromethane and washed sequentially with a saturated aqueous sodium carbonate solution, followed by distilled water. The organic fraction was then dried over anhydrous sodium sulfate and concentrated. The residue was then purified by silica gel flash chromatography to afford two products: 1-N'-[4-(1H-Benzimidazol-2-ylmethyl)-(5,6,7, 8-tetrahydroquinolin-8-yl)-amino]-aminobutane-N,N-dimethylformamidine (51 mg, 59%), and N-(IH-benzimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine N-(2-pyridinyl)-sulfonamide (31 mg, 29%).
The spectral data for the formaniidine is as follows: 1H NMR (CDC13) 8 1.38-1.44 (m, 4H), 1.68 (m, 1H), 2.00 (m, 111), 2.15 (m, 1H), 2.35 (m, 1H), 2.66-3.01 (m, 4H), 3.01 (s, 6H), 3.16 (t, 2H, J = 6.9 Hz), 4.05 (s, 2H), 4.12 (m, 1H), 7.18 (m, 2H), 7.46 (m, 1H), 7.58 (m, 2H), 8.53 (m, 1H). The sulfonamide showed an excessive broadening of resonances in the spectrum (in CDC13), so it was not characterized fully at this stage, and was instead taken directly to the salting reaction.

[0201] 1-N'-[4-(1H-Benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-aminobutane-N,N-dimethylformamidine (49 mg, 0.120 mmol) was taken up in acetic acid (1 mL), to which a saturated solution of HBr in acetic acid (1 mL) was added. The mixture was then stirred, precipitated and isolated as per procedure D to yield COMPOUND
26 as a white crystalline solid (52 mg). 1H NMR (D20). 8 1.39 (m, 4H), 1.85 (m, 1H), 2.01 (m, 1H), 2.15 (m, 1H), 2.36 (m, 1H), 2.53 (m, 1H), 2.78 (m, 1H), 2.85 (s, 3H), 3.00 (m, 2H), 3.07 (s, 3H), 3.25 (t, 2H, J= 6.9 Hz), 4.46 (d, 1H, J=16.8 Hz), 4.51 (m, 1H), 4.52 (d, 1H, J= 16.8 Hz), 7.60 (m, 2H), 7.65 (s, 1H), 7.80 (m, 2H), 7.87 (dd, lH, J= 7.8, 5.8 Hz), 8.35 (d, 1H, J=
7.8 Hz), 8.63 (d, 1H, J= 5.8 Hz). 13C NMR (D20) 8 22.89, 23.27, 27.81, 30.10, 38.38, 45.57, 49.52, 51.21, 54.51, 63.61, 116.70, 128.35, 129.43, 133.35, 141.73, 143.03, 150.53, 153.75, 154.54, 158.63. ES-MS m/z 405 (M+H); Anal. Calcd. for (C24H32N6 x 3.3 HBr x 1.8 H20):
C, 40.95; H, 5.57; N, 11.94; Br 37.46. Found: C, 40.77; H, 5.59; N, 11.78; Br, 37.72.

Example 27 QNH

HN X N

COMPOUND 27: Preparation ofN-{4-[(1H-benzoimidazol-2- l~yl)-(5,6 7 8-tetrah dquinolin-8-yl)-aminol-butyl)-guanidine (hydrobromide salt) [0202] A solution ofN1-(5,6,7,8-tetrahydro-quinolin-8-yl)-N1-[1-(2-trimethylsilanyl-ethoxymethyl)- 1H-benzoimidazol-2-ylmethyl] -butane- 1,4-diamine (170 mg, 0.35 mmol), 1-H-pyrazole-l-carboxamidine hydrochloride (51 mg, 0.35-mmol) and DIPEA (61 L, 0.35 mmol) in THE (0.2 mL) was stirred at room temperature for 3 hours. Ether (1 x 10 mL and 3 x 5 mL) was added and decanted. The resulting syrup was dried in vacuo to afford a white foam (150 mg) that was used in the next reaction without further purification.
[0203] A solution of the guanidine from above (150 mg) in 6N HC1(5 mL) was heated to 50 C for 4 hours. The reaction mixture was cooled to room temperature, H2O (5 mL) was added and the mixture was neutralized with NaHCO3 (s) and saturated with NaCl (s). The aqueous layer was extracted with CHC13 (3 x 50 mL). The combined organic extracts were dried (MgSO4), filtered and concentrated under reduced pressure. Purification by column chromatography on silica gel (CH2C12/MeOH/NH4OH, 20:2:1) afforded the desired guanidine as a light yellow foam (63 mg, 46% over 2 steps).

[0204] Using General Procedure D: Conversion of the foam from above to the hydrobromide salt afforded COMPOUND 27 as a light beige solid. 1H NMR (D20) 8 1.40 (br s, 4H), 1.81-1.90 (m, 1H), 1.98-2.10 (m, 2H), 2.34-2.38 (m, 1H), 2.48-2.54 (m, 1H), 2.74-2.83 (m, 1H), 2.99-3.03 (m, 4H), 4.44 (d, 1H, J= 10.8 Hz), 4.51-4.63 (m, 2H), 7.57-7.63 (m, 2H), 7.77-7.82 (m, 2H), 7.87 (dd, 1H, J= 7.8, 6.0 Hz), 8.35 (d, 1H, J= 8.1 Hz), 8.64 (d, 1H, J= 5.5 Hz); 13C NMR (D20) 8 20.45, 25.52, 26.10, 27.66, 41.01, 48.97, 51.89, 61.17, 114.27, 125.92, 126.92, 131.04, 139.29, 140.50, 148.04, 151.41, 152.03, 156.91. ES-MS/??/z392.3 (M+H). Anal. Calcd. for C22H29N7.3.1HBr=1.2H20Ø3C4H100: C, 40.61; H, 5.51;
N, 14.29;
Br, 36.10. Found: C, 40.92; H, 5.31; N, 14.28; Br, 35.70.

Example 28 ON
N

N N"'J . S,H INH
N -COMPOUND 28: Preparation ofN-(1H-benzimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-l,4-diamine-N-(2-pyridinyl)-sulfonamide (hydrobromide salt) [0205] N-(1H-benzimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine-N-(2-pyridinyl)-sulfonamide (from the above reaction, 31 mg, 0.063 mmol) was taken up in acetic acid (1 mL), to which a saturated solution of HBr in acetic acid (1 mL) was added. The mixture was then stirred, precipitated and isolated as per procedure D
to yield COMPOUND 28 as a white crystalline solid (52 mg). 1H NMR (D20) 5 1.30 (m, 4H), 1.81 (m, 1H), 1.91 (m, 1H), 2.05 (m, 1H), 2.31 (m, 1H), 2.43 (m, 1H), 2.79 (m, 1H), 2.83 (t, 2H, J= 6.9 Hz), 3.00 (m, 2H), 4.31 (d, 1H, J= 16.3 Hz), 4.49 (m, 1H), 4.51 (d, I H, J
= 16.3 Hz), 7.57 (m, 2H), 7.86 (m, 2H), 7.83- (m, 2H), 8.00 (t, 2H, J= 7.8 Hz), 8.32 (d, 1H, J
= 7.8 Hz), 8.56 (d, 1H, J= 4.9 Hz), 8.68 (d, 1H, J= 5.4 Hz). 13C NMR (D20) 8 20.43, 20.81, 24.95, 26.54, 27.64, 42.44, 48.80, 51.47, 60.94, 114.26, 122.86, 125.92, 126.91, 128.36, 130.97, 139.30, 140.08, 140.48, 140.06, 150.22, 151.40, 152.00. ES-MS na/z 491 (M+H);

Anal. Calcd. for (C26H30N602S x 3.1 HBr x 1.7 H2O x 0.9 HOAc): C, 40.42; H, 4.89; N, 10.17; Br 29.98. Found: C, 40.31; H, 4.98; N, 10.13; Br, 30.22.

Example 29 N N
H
HN N

COMPOUND 29: Preparation ofN-(1H-benzoimidazol-2-ylmethyl)-N'-pyrimidin-2-ylmethyl-N-(5 6 7 8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine(hydrobromide salt .

[02061 Pyrimidine-2-carbaldehyde was prepared as described for COMPOUND 68 using pyrimidine-2-carboxylic acid methyl ester (255 mg, 1.85 mmol), THE (18 mL), and LiAlH4 (1.0 M/THF, 0.55 mL, 0.55 mmol). The crude material (332 mg) was determined by. 1H
NMR to be a mixture of pyrimidine-2-carbaldehyde, pyrimidine-2-carboxylic acid methyl ester, and THE (1.0:12.6:6.0 respectively) and was used in the next step without further purification.
[0207] Using General Procedure B: To a solution of the crude aldehyde from above (332 mg) and N-(1H-benzoimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine (49 mg, 0:14 mmol) in THE (2 mL) was added NaBH(OAc)3 (89 mg, 0.42 mmol) and the mixture was stirred at room temperature for 1.5 h. The crude material was dissolved in saturated HBr/AcOH (2 mL) and stirred at room temperature for 5 minutes.
The solution was made basic with 10 N NaOH(aq) and extracted with CH2C12 (3 x 15 mL).
The combined organic extracts were dried (MgSO4) .and concentrated in vacuo.
Purification of the crude material by column chromatography on silica gel (200:5:1 CH2C12/MeOH/NH4OH) afforded a yellow oil (44 mg).
[02081 Using General Procedure D: Conversion of the oil from above (44 mg, 0.10 mmol) to the hydrobromide salt followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 29 (68 mg, 84%) as a colourless solid. 1H NMR
(D20) 6 1.64-1.93 (m, 5H), 2.07 (m, 1H), 2.22 (m, 1H), 2.42 (m, 1H), 2.61 (m, 1H), 2.89 (m, 1H), 3.04 (m, 2H), 3.15 (m, 2H), 4.41-4.61 (m, 5H), 7.53 (t, 1H, J= 5.1 Hz), 7.63 (m, 2H), 7.87 (m, 3H), 8.38 (d, 1H, J= 8.1 Hz), 8.67 (d, 1H, J= 5.7 Hz), 8.80 (d, 2H, J= 5.1 Hz); 13C
NMR (D20) 6 20.44, 23.80, 25.46, 27.66, 47.61, 48.30, 51.00, 51.68, 60.67, 114.27, 121.65, 125.94, 126.94, 130.95, 139.35, 140.62, 148.12, 151.24, 151.78, 158.37, 160.71. ES-MS m/z 442 (M+H). Anal. Calcd. for C2bH31N7=4.0HBr=3.2H20: C, 37.95; H, 5.07; N,
11.92; Br, 38.84. Found: C, 38.20; H, 5.04; N, 11.77; Br, 38.61.

Exam lp e 30 N
~ -Q
HN
N
H
HN X N

COMPOUND 30: Preparation ofN-(1H-benzoimidazol-2-ylmethyl)-N'-(1H-imidazol-2-y1)-N-(5,6,7, 8-tetrahydro-quinolin-8-yl)-butane-1,4-di amine.

[0209] To a partially dissolved solution of 2-aminoimidazole sulfate (200 mg, 1.51 mmol) in MeOH (2 mL) was added NaOH (s) (65 mg, 1.59 nunol) and the mixture was stirred at room temperature overnight. The mixture was diluted with CH2C12 (20 mL), dried (MgSO4) and filtered through Celite. The cake was washed with CH2C12/MeOH
(10:1) and the filtrate was concentrated under reduced pressure to afford a brown syrup (115 mg) that was used in the next reaction without further purification.
[0210] A solution of the amine from above (39 mg, 0.47 mmol) and 4-{[1-(tert-butyloxycarbonyl)-(1 H-benzimidazol-2-ylmethyl)]-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino}butyraldehyde (see COMPOUND 32 for preparation) (100 mg, 0.22 mmol) in MeOH
(1.5 mL) was stirred at 40 C for 3 days. NaBH4 (17 mg, 0.44 mmol) was added and the resultant mixture stirred for an additional 15 minutes. The reaction mixture was diluted with CH2C12, filtered through Celite and the cake was washed with CH2C12. The combined filtrate was concentrated under reduced pressure. Purification of the crude orange foam by column chromatography on silica gel (CH2C12/MeOH/NH4OH, 50:2:1) followed by radial chromatography on silica gel (lmm plate, EtOAc/MeOH/NH4OH, 100:3:1) afforded COMPOUND 30 (32 mg, 35%) as a light purple foam. 1H NMR (CDC13) 8 1.32-1.75 (m, 5H), 1.83-1.95 (m, 1H), 2.02-2.10 (m, 1H), 2.17-2.21 (m, 1H), 2.51-2.91 (m, 4H), 3.05-3.09 (m, 2H), 3.98-4.11 (m, 3H), 4.31 (br s, 1H), 6.61 (s, 2H), 7.12-7.16 (m, 1H), 7.18-7.23 (m, 2H), 7.43 (d, 1H, J= 7.2 Hz), 7.56 (br s, 2H), 8.52 (d, 1H, J= 3.3 Hz); 13C
NMR (CDC13) S
21.12, 23.92, 25.24, 27.29, 29.14, 43.55, 49.17, 50.22, 62.13, 114.93, 117.27, 121.89, 122.34, 134.91, 137.65, 146.48, 150.88, 156.09, 157.26. ES-MS in/z 416.3 (M+H). Anal.
Calcd. for C24H29N7Ø9H20=0.3C4H802: C, 66.06; H, 7.30; N, 21.40. Found: C, 66.12; H, 7.32; N, 21.34.

Exam lie 31 (N)-N

H N
N NH H

COMPOUND 31: Preparation ofN1-(1H-benzimidazol-2-ylmethyl)-1V4-(IH-indol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl) butane-1 4-diamine.

102111 A solution of indole-2-carboxaldehyde (prepared as described for COMPOUND 65) (31 mg, 0.21 mmol) and NI-(IH-benzimidazol-2-yhnethyl)-Nl-(5,6,7,8-tetrahydroquinolin-8-yl)-butane-l,4-diamine (see COMPOUND 17) (51 mg, 0.15 mmol) in MeOH (1.8 mL) was stirred at room temperature under nitrogen for 23 hours.
NaBH4 (14 mg, 0.37 mmol) was added, and the reaction stirred for a further 15 minutes before the solvent was evaporated under reduced pressure. The residue was dissolved into CH2C12 (25 mL) and was washed with saturated aqueous NaHCO3 (5 mL) and brine (5 mL). The organic solution was dried (MgSO4), filtered and evaporated under reduced pressure.
The yellow residue was purified by flash column chromatography on silica gel (CH2C12/MeOH/NH4OH, 19:1:0.1) giving COMPOUND 31 as a white solid (37 mg, 0.077 mmol, 53%). 1H NMR
(CDC13) b 1.35-1.49 (m, 4H), 1.60-1.76 (m, 1H), 1.81-1.96 (m, 1H), 1.96-2.08 (m, 1H), 2.11-2.22 (m, IH), 2.45 (t, 2H, J= 6.5 Hz), 2.50-2.60 (m, IH), 2.66-2.76 (m, 2H), 2.76-2.90 (m, 1H), 3.83 (s, 2H), 3.93-4.10 (m, 3H), 6.27 (s, 1H), 7.02-7.16 (m, 3H), 7.16-7.24 (m, 2H), 7.32 (d, 1H, J= 7.8 Hz), 7.41 (d, 1H, J= 7.8 Hz), 7.53 (d, 1H, J= 7.8 Hz), 7.55-7.62 (m, 2H), 8.56 (d, 1H, J= 3.6 Hz), 9.01 (br. s, 1H). 13C NMR (CDCl3) 6 21.6, 23.8, 26.2, 27.5, 29.6, 47.2, 48.9, 49.8, 50.8, 62.3, 100.6, 111.2, 119.8, 120.4, 121.7, 122.0, 122.6, 128.8, 135.1, 136.5, 137.8, 147.1, 156.9, 157.8. ES-MS in/z 479 (M+H). Anal. Calcd. for C3oH34N6Ø5CH2Cl2Ø2C4H10O: C, 70.15; H, 6.96; N, 15.68. Found: C, 70.16; H, 6.97; N, 15.73.

Example 32 (NN
HN N

COMPOUND 32: (1H-Benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroguinolin-8-yl)-(N,N-dimethyl-4-amino-but-1-yl)-amine (Hydrobromide salt) Preparation of [1-(tert-butylox ca~yl)-(1H-benzimidazol-2-ylmethyl)]-(5,6,7,8-tetrahydroquinolin-8-yl)-(4-hydroxy.-but-1-yl -amine:

~NQ
N~~OH
O

~O~N I"' N

[0212] To a stirred suspension of NaH (95%, 0.81 g, 33.8 mmol) in THE (68 mL) at room temperature was added 1,4-butanediol (3.0 mL, 33.9 mmol). After 1.5 hours, tert-butyldimethylsilyl chloride (5.14 g, 34.1 mmol) was added. After stirring for a further 2.5 hours, the reaction was diluted with diethyl ether (250 mL). The organic phase was washed with saturated aqueous NaHCO3 (2 x 75 mL) and brine (1 x 75 mL). The combined aqueous phases were extracted with ether (1 x 75 mL). The combined organic extracts were dried (Na2SO4), filtered and concentrated under reduced pressure to give a colourless liquid (6.40 g,92%).

[0213] To a stirred solution of oxalyl chloride (6.0 mL, 68.8 mmol) in CH2C12 (450 mL) at -78 C was added DMSO (6.5 mL, 91.6 mmol). After 2 hours, the alcohol from above (6.40 g, 31.3 mmol) was added as a solution in CH2C12 (90 mL). Triethylamine (32 mL, 230 minol) was added after 20 minutes, followed by removal of the ice bath. After 1 hour the reaction was washed with water (1 x 200 mL). The aqueous phase was extracted with CH2C12 (3 x 100 mL). The combined organic phase was washed with IN HCl (1 x 200 mL), saturated aqueous NaHCO3 (1 x 200 mL) and brine (1 x 200 mL). The organic phase was dried (Na2SO4), filtered and concentrated under reduced pressure to give 6.36 g of a yellow liquid (quantitative).
[0214] Using the General Procedure B: To a stirred solution of the aldehdye from above (3.085 g, 15.2 mmol) and (1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amine (3.67 g, 13.2 mmol) in CH2C12 (90 mL) was added NaBH(OAc)3 (6.33 g, 29.9 mmol) and the mixture stirred for 16 hours. The yellow foam obtained (8.06 g) was dissolved in THE (20 mL) and treated with 3N HC1 (80 mL). After 2 hours, the reaction was basified with saturated aqueous NaHCO3. The phases were separated, and the aqueous phase was extracted with diethyl ether (4 x 150 mL) and CH2C12 (2 x 150 mL). The organic phase was dried (Na2SO4), filtered and concentrated under reduced pressure to give an orange oil (4.44 g, 72 %).
[0215] To a stirred solution of the protected alcohol from above (5.01 g, 10.8 mmol) in THE (50 mL) at 0 C was added hydrogen fluoride-pyridine (-P5 mL, -175 mmol).
After 75 minutes, a further lmL of HF-pyridine was added. After a further 20 minutes, the pH of the solution was raised to pH 13 with IN NaOH followed by ION NaOH. The mixture was extracted with CH2C12 (5 x 40 mL). The organic phase was dried (Na2SO4), filtered and concentrated under reduced pressure to give a crude oil (4.22 g). Purification of this oil by column chromatography. (4 cm OD, 100 g silica, 30:1 CH2C12: CH3OH) afforded the deprotected alcohol as a yellow foam (2.92 g, 77 %).
[0216] To a stirred solution of the deprotected alcohol from above (2.92 g, 8.33 mmol) and diisopropylethyl amine (15 drops) in THE (40 mL) at 0 C was added di-tert-butyl di-carbonate (1.96 g, 8.98 mmol). After stirring for 17 hours (over which time the reaction warmed to room temperature), the reaction was concentrated under reduced pressure. The residue was dissolved in CH2C12 (100 mL) and washed with brine (3 x 50 mL).
The organic phase was dried (Na2SO4), filtered and concentrated under reduced pressure to afford the N-protected material as a crude yellow foam (3.79 g, quantitative). 1H NMR
(CDC13) 5 1.48-1.71 (m, 14H), 1.93-2.05 (m, 2H), 2.15-2.25 (m, 1H), 2.57-2.67 (m, 1H), 2.71-2.94 (m, 3H), 2.53-2.59 (m, 2H), 4.32 (dd, 1H, J= 9.7, 6.5 Hz), 4.49 (d, 1H, J=15.8 Hz), 4.61 (d, 1H, J= 15.8 Hz), 6.93 (dd, 1H, J= 7.7, 4.6 Hz), 7.20-7.30 (m, 3H), 7.68-7.72 (m, 1H), 7.78-7.83 (m, 1H), 8.33 (d, 1H, J= 3.7 Hz).

Preparation of 4- f [1-(tert-but lox c~yl)-(1H-benzimidazol-2- lmeth 1)1-(5 6 tetrahydro-duinolin-8-yl)-amino }butyraldehyde:

CN

O

O%N \ N

[0217] To a stirred solution of oxalyl chloride (4.5 mL, 9.0 mmol) in CH2C12 (40 mL) at -78 C was added DMSO (0.86 mL, 12.1 mmol). After 30 minutes [1-(tert-butyloxycarbonyl)-(1 H-b enzimidazol-2-ylmethyl)]-(5,6, 7, 8-tetrahy, droquinolin-8-yl)-(4-hydroxy-but-l-yl)-amine (3.66 g, 8.13 mmol) was added as a solution in CH2C12 (7.5 mL).
After a further 20 minutes, triethylamine (70 mL, 71.7 mmol) was added and the ice bath was removed. The reaction was stirred for a further 75 minutes then concentrated under reduced pressure. The residue was taken up in ethyl acetate and filtered through celite to give a crude yellow oil (3.88 g). Purification of this oil by column chromatography on silica gel (solvent = 35:1:1 CH2.C12: CH3OH: NH4OH) afforded the desired pure aldehyde (1.25 g, 39%). 1H
NMR (CDC13) S 1.52-1.72 (m, 13H), 1.74-1.88 (m, 1H), 1.90-2.00 (m, 1H), 2.06-2.17 (m, 1H), 2.36 (t, 2H, J= 6.6 Hz), 2.53-2.74 (m, 2H), 2.79-2.88 (m, 1H), 4.22 (dd, 1H, J= 9.7, 6.3 Hz), 4.48 (d, 1H, J= 15.4 Hz), 4.66 (d, 1H, J=15.2 Hz), 6.93 (dd, 1H, J= 7.6, 4.7 Hz), 7.19-7.28 (m, 4H), 7.65-7.70 (m, 1H), 7.73-7.82 (m, 1H),8.33 (d, 1H, J= 3.6 Hz), 9.56 (s, 1H).
[0218] Using the General Procedure B: To a stirred solution of 4-{[1-(tert- -butyloxycarbonyl)-(1 H-benzimidazol-2-ylmethyl)]-(5, 6,7, 8-tetrahydro-quinolin-g-yl)-amino}butyraldehyde (119 mg, 0.265 mmol) and dimethyl amine (2.OM in THF, 0.145 mL, 0.290 mmol) in THE (5 mL) was added NaBH(OAc)3 (84 mg, 0.396 mmol) and the mixture stirred for 17 hours. Purification of the crude orange oil (116 mg) by radial chromatography on silica gel (75:1:1 CH2C12: CH3OH: NH4OH) afforded the desired N-protected intermediate (69 mg, 55%).

[0219] Using the General Procedure D for simultaneous Deprotection and HBr salting:
Conversion of the N-protected material from above (69 mg) to the hydrobromide salt was afforded a white solid (80 mg). This solid was diluted with 10N NaOH (3 mL) and extracted with CH2C12 (5 x 3 mL). The organic phase was dried (Na2SO4), filtered and concentrated under reduced pressure. Purification of the yellow oil (40 mg) obtained by radial chromatography on silica gel (60:1:1 CH2C12: CH3OH: NH4OH) afforded the pure freebase as a colourless oil (19 mg, 35%) [0220] Using the General Procedure D: Conversion of the freebase from above (19 mg) to the hydrobromide salt gave COMPOUND 32 as a white solid (24 mg, 71 %). 1H
NMR
(D20) 8 1.46-1.64 (m, 4H), 1.77-1.90 (m, 1H), 1.95-2.09 (m, 1H), 2.13-2.23 (m, 1H), 2.33-242 (m, 1H), 2.51-2.62 (m, 1H), 2.74-2.89 (m, 7H) containing 2.81 (s, 6H), 2.96-3.03 (m, 4H), 4.39 (d, 1H, J=16.6 Hz), 4.48-4.58 (m, 2H) containing 4.53 (d, 1H, J =
17.1 Hz), 7.61 (dd, 2H, J= 6.2, 3.1 Hz), 7.81 (dd, 2H, J= 6.2, 3.2 Hz), 7.87 (dd, 1H, J= 6.7, 6.9 Hz), 8.35 (d, 1H, J= 7.9 Hz), 8.63 (d, 1H, J= 5.4 Hz). 13C NMR (D2O) 8 20.43 (2 carbons), 22.27, 25.33, 27.63, 43.02 (2 carbons), 48.23, 51.66, 57.62, 60.70, 114.25 (2 carbons), 125.93, 126.93 (2 carbons), 131.01, 139.31, 140.60, 148.10, 151.24, 151.76. ES-MS m/z 378 (M+H) Anal Calc. for C23H31N5 -3.OHBr -3.1H2O: C, 40.86; H, 5.99; N, 10.36; Br, 35.45. Found: C, 40.74; H, 5.91; N, 10.22; Br, 35.71.

Example 33 ~NQ

H
N-\N' HN "N

COMPOUND 33: (1H-Benzimidazol-2-ylmethyl)-(5 6 7 8-tetrahydroguinolin-8-yl)_(_ allyl-4-amino-but-1-yl)-amine [0221] 4-Bromo-butan-l-ol (1.30 mL, 11.8 mmol) was added dropwise to refluxing allylamine (2.05 g, 35.9 mmol) and the mixture was stirred at 65 C for 23 hours. The orange solution was diluted with l ON NaOH (15 mL) and diethyl ether (30 mL). The aqueous phase was subsequently extracted with ether (2 x 30 mL). The organic phase was dried (MgSO4), filtered and concentrated under reduced pressure to give a yellow oil (841 mg, 55%).
[0222] To a stirred solution of the secondary amine from above (841 mg, 6.51 mmol) in THE at 0 C was added di-tert-butyl di-carbonate (1.449 g, 6.64 mmol) and the reaction was stirred at 0 C for 2 hours. The reaction was concentrated under reduced pressure. The yellow oil (1.645 g) was purified by column chromatography (4 cm OD, 35 g silica, EtOAc) to afford the N-protected alcohol (1.246 g, 84 %).
[0223] To a suspension of the N-protected alcohol from above (236 mg, 1.03 mmol), NMO (187 mg, 1.59 mmol) and 3A molecular sieves (537 mg) in CH2C12 (5 mL) was added TPAP (37 mg, 0.106 mmol) and the mixture was stirred at room temperature for 2 hours.
The mixture was filtered through a silica gel plug with ethyl acetate. The filtrate was concentrated under reduced pressure. The yellow oil (197 mg) was purified by column chromatography (12 g silica, 10:1 hexanes: ethyl acetate) to give the N-protected aldehyde (112 mg, 48%).
[0224] Using the General Procedure B: To a stirred solution of the N-protected aldehyde from above (112 mg, 0.49 mmol) and [1-(tert-butyloxycarbonyl)-(lH-benzimidazol-ylmethyl)]-(5,6,7,8-tetrahydroquinolin-8-yl)-amine (187 mg, 0.49 mmol) in CH2C12 (5 mL) was added NaBH(OAc)3 (208 mg, .98 mmol) and the mixture was stirred for 17 hours.
Purification of the crude yellow oil (286 mg) by flash chromatography (12 g silica, 50:1:1 CH2C12: CH3OH: NH4OH) afforded the N-protected tertiary amine (172 mg, 59%).
[0225] Using the General Procedure D: the N-protected tertiary amine from above (172mg, 0.308 mmol) was converted to COMPOUND 33 as a white solid (145 mg, 70%).
1H NMR (D20) 5 1.53 (br s, 4H), 1.77-1.90 (m, 1H), 1.95-2.03 (m, 1H), 2.13-2.23 (m, 1H), 2.32-2.42 (m, 1H), 2.50-2.60 (m, 1H), 2.77-2.86 (m, 1H), 2.88-2.95 (m, 2H), 2.97-3.03 (m, 2H), 3.56 (d, 2H, J= 6.5 Hz), 4.38 (d, 1H, J=16.7 Hz), 4.47-4.56 (m, 2H) containing 4.53 (d, 1H, J= 17.0 Hz), 5.39 (s, 1H), 5.44 (d, 1H, J= 4.8 Hz), 5.74-5.89 (m, 1H), 7.60 (dd, 2H, J= 6.1, 3.0 Hz), 7.80 (dd, 2H, J= 6.4, 3.4 Hz), 7.86 (dd, 1H, J= 7.9, 5.8 Hz), 8.34 (d, 1H, J
= 7.9 Hz), 8.62 (d, 1H, J= 5.3 Hz). 13C NMR (D20) 6 19.81 (2 carbons), 20.42, 23.79, 25.47, 27.28, 27.63, 46.75, 48.23, 49.80, 51.65, 50.65, 114.25 (2 carbons), 124.01, 125.93, 126.94 (2 carbons), 127.70, 130.98, 139.31, 140.61, 148.10, 151.26, 151.78. ES-MS m/z 390 (M+H) Anal Calc. for C21H25N50.3.2HBr -1.9H2O: C, 38.41; H, 4.91; N, 10.67;
Br, 38.94.
Found: C, 38.53; H, 5.02; N, 10.42; Br, 38.79.

Example 34 ~N
H
HN NN

COMPOUND 34: (lH-Benzimidazol-2-ylmethyl)-(5 6 7 8-tetrahvdroquinolin-8-yl)-(N-methyl-4-amino-but-1-yl -amine [0226] To a stirred solution of 4-(methylamino)-butyric acid hydrochloride (303 mg, 1.97 mmol) and dioxane (2 mL) in saturated aqueous NaHCO3 (2 mL) was added added di-tert-butyl di-carbonate (523 mg, 2.40 mmol) and the mixture was stirred at 0 C for 20 minutes followed by stirring at room temperature for 22 hours. The reaction was concentrated under reduced pressure and the residue was diluted with water (20 mL). The aqueous phase was extracted with ethyl acetate (2 x 15 mL). The aqueous phase was treated with 5% w/v aqueous. citric acid until a pH of 4 was obtained. The aqueous phase was then again extracted with ethyl acetate (4 x 15 mL). The combined organic phase was dried (MgSO4), filtered and concentrated under reduced pressure to give a colourless oil (300 mg, 70%).
[0227] To a stirred solution of the N-protected acid from above (143 mg, 0.659 mmol) in THE (5 mL) was added BH3-THF (1.OM in THF, 2.5 mmol) and the mixture was stirred at 50 C for 64 hours. Dry CH3OH (5 mL) was added, and the mixture stirred at 70 C
for 1 hour.
The reaction was concentrated under reduced pressure. The crude yellow oil (148 mg) was purified by column chromatography (2cm OD, 20 g silica, 1:1 EtOAc: hexanes) to afford the N-protected alcohol (71 mg, 53%).

[0228] To a suspension of the N-protected alcohol from above (71 mg, 0.35 mmol), NMO (65 mg, 0.56 mmol) and 3A molecular sieves (186 mg) in CH2C12 (2.55 mL) was added TPAP (13 mg, 0.04 mmol) and the mixture was stirred at room temperature for 1 hour.
The mixture was filtered through a silica gel plug with ethyl acetate. The filtrate was concentrated under reduced pressure to give a yellow oil (46 mg, 65%).
[0229] Using the General Procedure B: To a stirred solution of the N-protected aldehyde from above (46 mg, 0.229 mmol) and [1-(tent-butyloxycarbonyl)-(1H-benzimidazol-ylmethyl)]-(5,6,7,8-tetrahydroquinolin-8-yl)-amine (89 mg, 0.229 mmol) in CH2C12 (2.55 mL) was added NaBH(OAc)3 (100 mg, 0.47 mmol) and the mixture was stirred for 19 hours.
Purification of the crude yellow oil (126 mg) by flash chromatography (12 g silica, 50:1:1 CH2C12: CH3OH: NH40H) afforded the N-protected tertiary amine (80 mg, 62%).
[0230] Using the General Procedure D: The N-protected tertiary amine from above (76mg, 0.135 mmol) was converted to COMPOUND 34 as a white solid (71 mg, 75%}.

NMR (D20) 8 1.54 (br s, 4H), 1.74-1.90 (m, 1H), 1.95-2.09 (m, 1H), 2.13-2.23 (m, 1H), 2.32-2.42 (m, 1H), 2.50-2.64 (m, 4H) containing 2.61 (s, 3H), 2.77-2.94 (m, 3H), 2.97-3.04 (m, 2H), 4.39 (d, 1H, J= 17.1 Hz), 4.47-4.60 (m, 2H) containing 4.53 (d, 1H, J=17.2 Hz), 7.60 (dd, 2H, J= 6.1, 3.0 Hz), 7.80 (dd, 2H, J= 6.1, 3.0 Hz), 7.86 (dd, 1H, J=
7.9, 6.2 Hz), 8.34 (d, 1H, J= 7.9 Hz), 8.62 (d, 1H, J= 5.0 Hz). 13C NMR (D20) S 20.42 (2 carbons), 23.69, 25.40, 27.64, 33.05, 48.23, 49.00, 51.68, 60.66, 114.25 (2 carbons), 125.93, 126.93 (2 carbons), 130.97, 139.31, 140.61, 148.10, 151.25, 151.77. ES-MS na/z 364 (M+H). Anal Calc. for C21H25N50.3.2HBr -1.9H20: C, 38.41; H, 4.91; N, 10.67; Br, 38.94.
Found: C, 38.53; H, 5.02; N, 10.42; Br, 38.79.

Example 35 ('N-N X N

HN N H

COMPOUND 35: Preparation of (1H-benzimidazol-2-ylmeth ltd)-f 3-(2H-pyrazol-3-yl)-propyll-(5,6,7,8-tetrahydro-quinolin-8-yl -amine (hydrobromide salt).
Preparation of (cyanomethyl)triphenylphosphonium bromide:
[0231] To a solution of PPh3 (1.57 g, 5.99 mmol) in Et20 (30 mL) was added BrCH2CN
(0.42 mL, 6.0 mmol). The reaction was stirred at reflux for 17 hours. The solvent was removed under reduced pressure, the residue was suction filtered from a small portion of ice-cold Et2O, and washed with a small amount of cold Et2O, giving the phosphonium salt as a white powder (1.05 g, 2.74 mmol, 46%). 1H NMR (CDC13) S 6.39 (d, 2H, J= 15.3 Hz), 7.69-7.76 (m, 6H), 7.82-7.87 (m, 3H), 7.96-8.03 (m, 6H).

Preparation of 3-(2H-p3razol-3-yl -acrylonitrile:
[0232] To a suspension of the phosphonium salt (900 mg, 2.35 mmol) in THE (10 mL) under nitrogen was added NaH (60 % in mineral oil, 99 mg, 2.5 mmol) in one portion. The suspension stirred at room temperature for 10 minutes, then pyrazole-3-carboxaldehyde (211 mg, 2.20 mmol) was added as a solid in one portion. The reaction was heated to reflux for 30 minutes, then cooled to room temperature and saturated aqueous NH4C1(10 mL) was added.
The mixture was extracted with CH2C12 (25 mL x 3) and the combined organic solution was dried (MgSO4), filtered and concentrated under reduced pressure. Purification by flash column chromatography on silica (EtOAc/hexane, 1:1) gave the alkene (white solid) as an approximately 1.5:1 mixture of the E:Z isomers (232 mg, 1.95 mmol, 89%).

[0233] Data for E-isomer: 1fI NMR (CDC13) 8 5.92 (d, 1H, J= 16.5 Hz), 6.54 (d, 1H, J=
2.4 Hz), 7.43 (d, 1H, J= 16.8 Hz), 7.60 (d, 1H, J= 2.4 Hz).

[0234] Data for Z -isomer: 1H NMR (CDC13) S 5.46 (d, 1H, J= 12.0 Hz), 6.98 (d, 1H, J=
2.4 Hz), 7.24 (d, 1H, J= 12.3 Hz), 7.66 (d, 1H, J= 2.4 Hz).

Preparation of 3-(2H-pyrazol-3-yl -propylamine:

[0235] The aõ6-unsaturated nitrile (mixture of isomers, 250 mg, 2.10 mmol) was hydrogenated (45 psi) over Raney-nickel in MeOH saturated with NH3 (15 mL) for 15.5 hours. The mixture was suction filtered through Celite and washed with MeOH.
The filtrate was concentrated under reduced pressure giving a brown oil. Purification by flash column chromatography on silica (CH2C12/MeOH/NH40H, 5.6:1:0.07) gave the saturated primary amine as a yellow oil (197 mg, 1.57 mmol, 75%). 1H NMR (CDC13) 6 1.82 (quint, 2H, J=
7'.1 Hz), 2.76 (apparent q, 4H, J= 6.8 Hz), 4.46 (br. s, 3H), 6.07 (d, 1H, J=
2.1 Hz), 7.47 (d, 1H, J= 1.8 Hz).

Preparation of [3-(2H-pyrazol-3-y1):propyll-(5,6,7,8-tetrahydro-quinolin-8-yl -amine:
[0236] A solution of the primary amine (190 mg, 1.52 mmol) and 8-oxo-5,6,7,8-tetrahydroquinoline (270 mg, 1.83. mmol) in MeOH (4 mL) was stirred at room temperature for 6 hours. NaBH4 (75 mg, 2.0 mmol) was added and the reaction was stirred for an additional 15 minutes, then the solvent was evaporated under reduced pressure.
The residue was taken up into CH2Cl2 (20 mL) and was washed with saturated aqueous NaHCO3 (5 mL) and brine (5 mL). The organic solution was dried (MgSO4), filtered and concentrated under reduced pressure. Purification by flash column chromatography on silica (CH2C12/MeOH/NH40H, 19:1:0.1, then MeOH) gave the secondary amine as a yellow oil (100 mg, 0.39 mmol, 26%). 1H NMR (CDC13) 6 1.67-1.87 (m, 2H), 1.90-2.03 (m, 3H), 2.11-2.23 (m, 1H), 2.67-2.89 (m, 6H), 3.84 (dd, 1H, J= 7.7, 5.3 Hz), 6.03 (d, 1H, J= 1.8 Hz), 7.09 (dd, 1H, J= 7.7, 4.7 Hz), 7.39 (d, 1H, J= 7.6 Hz), 7.41 (d, 1H, J= 1.8 Hz), 8.42 (d, 1H, J=
3.9 Hz).

Preparation of 2-{[[3-(2H-pyrazol-3-y1)::p opyll-(5 6 7 8-tetrahydro-quinolin-8-y1) amino].-methyll-benzimidazole-l-carboxylic acid tent-butyl ester:
[0237] A solution of the amine (100 mg, 0.39 mmol), tent-butyl 2-chloromethyl-benzimidazole-l-carboxylate (107 mg, 0.40 mmol), DIPEA (0.10 mL, 0.57 mmol) and KI
(approx. 10 mg) in CH3CN (2.5 mL) was heated to 60 C under nitrogen for 18.5 hours.
Once cooled to room temperature, saturated aqueous NaHCO3 (10 mL) was added and the mixture was extracted with CH2C12 (15 mL x 3). The combined organic solution was dried (MgSO4), filtered and concentrated under reduced pressure. Three attempts at purification by flash column chromatography on silica, the first eluted with CH2C12/MeOH/NH4OH, 19:1:0.1, the second eluted with CH2C12/MeOH/NH4OH, 49:1:0.25, gradually increased to 19:1:0.1, and the third eluted with CH2C12/MeOH/ NH4OH, 49:1:0.25, gave the tertiary amine as a white foam (70.6 mg, 0.15 mmol, 37%). 1H NMR (CDC13) 6 1.64 (s, 9H), 1.64-1.80 (m, 2H), 1.90-2.12 (m, 3H), 2.19-2.33 (m, 1H), 2.41-2.51 (m, 1H), 2.60-2.86 (m, 4H), 3.06-3.15 (m, 1H), 3.23-3.37 (m, 1H), 4.04 (dd, 1H, J= 10.4, 6.8 Hz), 4.19 (d, 1H, J=
15.0 Hz), 4.53 (d, 1H, J =15.0 Hz), 6.00 (d, 1H, J= 1.5 Hz), 6.72 (dd, 1H, J=
7.5, 4.8 Hz), 6.89 (d, 1H, J= 7.5 Hz), 7.14-7.29 (m, 2H), 7.45 (d, 1H, J=1.5Hz), 7.63 (dd, 1H, J= 7.9, 1.5 Hz), 7.73 (dd, 1H, J= 7.9, 1.5 Hz), 8.35 (d, 1H, J= 3.6 Hz).
Preparation of COMPOUND 35:

[0238] To a solution of the tertiary amine (30.8 mg, 0.063 mmol) in glacial HOAc (1.0 mL) was added a saturated solution of HBr in HOAc (0.5 mL). The mixture was stirred at room temperature for 1 hour, then was diluted with Et20 (5 mL). The solvent was decanted and the precipitate was washed with Et2O (1 mL x 5) and dried at 90 C under reduced pressure giving COMPOUND 35 as a yellow solid (35.5 mg, 0.049 nunol, 78%). 1H
NMR
(D20) S 1.68-2.00 (m, 4H), 2.07-2.19 (m, 1H), 2.27-2.49 (m, 2H), 2.66 (t, 1H, J= 7.4 Hz), 2.73-2.85 (m, 1H), 2.92-3.01 (m, 2H), 4.32 (d, 1H, J=16.8 Hz), 4.47 (d, 1H, J=
16.8 Hz), 4.49 (dd, 1H, J= 10.7, 5.9 Hz), 6.32 (d, 1H, J= 2.7 Hz), 7.54-7.61 (m, 2H), 7.71-7.79 (m, 3H), 7.83 (dd, 1H, J= 8.1, 5.4 Hz), 8.32 (d, 1H, J= 7.8 Hz), 8.59 (d, 1H, J=
5.7 Hz). 13C
NMR (D2O) 5 20.4, 20.5, 22.8, 27.1, 27.6, 48.1, 50.9, 60.5, 106.2, 114.2, 125.9, 127.0, 130.9, 134.4, 139.3, 140.7, 148.1, 149.0, 151.1, 151.5. ES-MS na/z 387 (M+H). Anal.
Calcd. for C23H26N6.3.3HBr=1.9H20Ø9C4H100: C, 40.85; H, 5.10; N, 11.53; Br, 36.16.
Found: C, 41.02; H, 5.05; N, 11.56; Br, 35.98.

Example 36 N`./--/NHZ
\= ~ NH
j COMPOUND 36: N'-(1H-imidazol-2-ylmethyl)-N'-(5,6,7,8-tetrah dy ro-quinolin-8-yl)-butane-l,4-diamine (hydrobromide salt) Preparation of 2-[4-(5,6,7,8-tetrahydro-quinolin-8-ylamino)-butyl]-isoindole-l,3-dione:
[0239] 4-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-butyraldehyde (617 mg, 2.84 minol), 6,7-dihydro-5H-quinolin-8-one (463 mg, 3.13 mmol), and sodium triacetoxyborohydride (1.81 g, 8.53 mmol) in CH2C12 (25 mL) were stirred at room temperature for 2 hours.
Then it was quenched with 1N NaOH (20 mL) and the mixture was washed with CH2_C12 (2 x 25 mL).
The organic layer was dried (MgSO4), filtered, concentrated, and dried in vacuo to afford a brown oil. Purification by flash column chromatography on silica gel using (5:95) afforded the product pure as a yellow oil (506 mg, 51%). 1H NMR (CDC13) 1.59-1.83 (m, 6H), 1.98-2.00 (m, 1H), 2.14-2.16 (m, 1H), 2.73-2.81 (m, 4H), 3.70-3.76 (m, 3H), 7.06 (dd, 1H, J= 6.0, 3.0 Hz), 7.36 (d, 1H, J= 6.0 Hz), 7.68-7.71 (m, 2H), 7.82-7.84 (m, 2H), 8.36 (d, 1H, J= 6.0 Hz).

Preparation ofN'-(1H-imidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-l,4-diamine:
[0240] The above amine (215 mg, 0.62 mmol), 2-imidazolecarboxaldehyde (118 mg, 1.23 mmol), and sodium cyanoborohydride (114 mg, 1.85 mmol) were stirred in methanol (5 mL) overnight. Then the reaction mixture was dissolved in CH2C12 (15 mL) and extracted with saturated NaHCO3 (3 x 10 mL). The aqueous layer was washed with CH2C12 (2 x 20 mL). Then the combined organic extracts were dried (MgS04), filtered, concentrated, and dried in vacuo to afford a yellow foam. Purification by radial chromatography on silica gel (2 mm plate, using NH40H/CH30H/CH2C12i 1:1:100 -> 1:3:100) afforded the product partially clean as a yellow foam (179 mg, 67%). 'H NMR (CDC13) S 1.36-1.41 (m, 3H), 1.55-1.63 (m, 3H), 2.00-2.04 (m, 2H), 2.52-2.76 (in, 4H), 3.46-3.79 (m, 2H), 3.83 (q, 2H, J=
18 Hz), 4.18(m, 1H), 3.96 (s, 1H), 7.03-7.10 (m, 1H), 7.05 (s, 1H), 7.45-7.49 (m, 1H), 7.67-7.71 (m, 2H), 7.79-7.81 (m, 2H), 8.48 (d, 3.0 Hz).

[0241] To a solution of the above amine (179 mg, 0.42 mmol) in ethanol (4 mL) was added hydrazine hydrate (0.12 mL, 2.49 mmol). The reaction mixture was stirred at room temperature for 3 days. Then the solvent was removed under reduced pressure and the residue was dissolved in CH2C12 and filtered. The filtrate was concentrated to dryness to afford a yellow oil. Purification by radial chromatography on silica gel (2 mm plate, using NH4OH/CH3OH/CH2C12; 1:5:100 -> 1:10:100) afforded the product as a yellow oil (66.1 mg, 53%). 1H NMR (CDC13) S 1.31-1.38 (m, 4H), 1.61-1.65 (m, 1H), 1.79-1.83 (m, 1H), 1.96-2.02 (m, 1H), 2.11-2.15 (m, 1H), 2.32-2.39 (m, 1H), 2.46-2.55 (m, 2H), 2.61-2.70 (m, 2H), 2.74-2.80 (m, 1H), 3.78 (q, 2H, J= 15.3 Hz), 3.95 (dd, 1H, J= 9.3, 6.3 Hz), 6.93 (s, 2H), 7.09 (dd, 1H, J= 7.7, 4.5 Hz), 7.39 (d, 1H, J= 7.5 Hz), 8.42 (d, 1H, J=
3.9 Hz).

Preparation of N'-(1H-imidazol-2-y ineLhyl)-N'-(5 6 7 8-tetrahydro-quinolin-8-yl)-butane-l,4-diamine (hydrobromide salt):

[0242] To a solution of the above amine (66 mg, 0.22 mmol) in acetic acid (1 mL) was added a hydrobromic acid saturated acetic acid (0.5 mL). The reaction mixture was stirred for 30 minutes and then diethyl ether was added until the precipitation of was afforded as an orange oil (22 mg, 33%). 1H NMR (D20) 6 1.47-1.50 (m, 4H), 1.81-1.94 (m, 2H), 2.12-2.16 (in, 1H), 2.25-2.29 (m, 1H), 2.46-2.50 (m, 1H), 2.71-2.75 (in, 1H), 2.84-2.86 (m, 2H), 2.97-3.00 (in, 2H), 4.19 (q, 2H, J=19.8 Hz), 4.33-4.38 (m, 1H), 7.40 (s, 2H), 7.83 (t, 1H, J= 6.3 Hz), 8.31 (d, 1H, J= 8.1 Hz), 8.55 (d, 1H, J= 6.0 Hz). 13C
NMR (D20) S 20.19, 20.41, 25.02, 25.29, 27.57, 39.53, 47.09, 49.29, 51.20, 60.10, 119.54, 125.82, 139.22, 140.45, 145.32, 147.96, 151.46. ES-MS m/z 300 [M+H]+. Anal. Calcd. for C17H25N5.3.6HBr=1.4H20Ø4C2H402: C, 33.41; H, 5.12; N, 10.84; Br, 44.76.
Found: C, 33.41; H, 5.12; N, 10.84; Br, 44.76.

Example 37 ~N

N

COMPOUND 37: Preparation of N1-(1H-Benzimidazol-2-ylmethyl)-N1-(6,7,8,9-tetrahydro-5H-cyclohepta[ blpyridin-9-yl)-butane-1 4-diamine.

N
C

Preparation of 6 7 8 9-Tetrahydro-5H-cyclohepta[blpyridin-9-ylamine.
[0243] To a stirred solution of 2,3-cycloheptenopyridine (42.94 g, 0.292 mol) in glacial acetic acid (160 mL} at room temperature was added 30% H202 (30 mL) and the resultant solution was heated to 70 C. After 6 hours, the reaction mixture was cooled to room temperature, additional H202 (30 mL) was added, and the solution was heated at overnight. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in CHC13 (200 mL) and treated with solid Na2CO3 (100 g). After 1 hour, the supernatant was decanted and the residue was washed with warm CHC13 (3 x 200 mL). The combined supernatants were filtered and concentrated to provide 60 g of 6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine 1-oxide as a yellow oil. 1H
NMR (CDC13) 81.63-1.73 (m, 4H), 1.82-1.91 (m, 2H), 2.77-2.83 (m, 2H), 3.36-3.42 (m, 2H), 6.94-7.05 (m, 2H), 8.17 (d, 1H, J= 6.1 Hz).
[0244] The N-oxide was dissolved in acetic anhydride (222 mL) and heated at 90 C
overnight. The mixture was cooled to room temperature and concentrated.
Distillation (Kugelrohr, bpl 10-140 C @ 1 Torr) of the resultant oil provided 53.26 g of acetic acid 6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-y.1 ester.
[0245] To a solution of acetic acid 6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl ester (53.26 g, 0.259 mol) in methanol (350 mL) was added K2C03 (72.98 g, mol) and the resultant mixture was stirred at room temperature overnight. The mixture was poured into water (350 mL) and extracted with CHC13(3 x 300 mL). The combined organic extracts were dried (Na2SO4), and concentrated to provide 41.70 g of 6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol.
[0246] To a stirred solution of 6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol (41.70 g, 0.255 mol) in CH2C12 (300 mL) at 0 C was added triethylamine (72 mL, 0.517 mol) followed by methanesulfonyl chloride (30 mL, 0.388 mol). The resultant mixture was stirred at room temperature over night. The mixture was poured into water (200 mL) and the phases were separated. The organic phase was washed with brine (2 x 150 mL), dried (Na2SO4), and concentrated to give 50.87 g of crude methanesulfonic acid 6,7,8,9-tetrahydro-cyclohepta[b]pyridin-9-yl ester.
[0247] This ester was dissolved in DMF (420 mL), treated with sodium azide (33.40 g, 0.514 mol), and heated at 60 C overnight. The mixture was cooled to room temperature and concentrated. The resultant slurry was poured into brine (500 mL) and extracted with ether (4 x 500 mL). The combined organic extracts were washed with brine (2 x 100 mL), dried (Na2SO4), and concentrated. The crude material was filtered (eluant CH2C12) through a short plug of silica gel to provide 23.18 g (42% from 2,3-cycloheptenopyridine) of 9-azido-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine as a red oil. 1H NMR (CDC13) 8 1.53-1.66 (in, 1H), 1.73-2.14 (in, 5H), 2.63-2.72 (m, 1H), 2.99-3.09 (m, 1H), 4.93 (dd, 1H, J=
7.8, 1.7 Hz), 7.13 (dd, 1H, J= 7.9, 4.8 Hz), 7.44 (d, 1H, J= 5.7 Hz), 8.39 (dd, 1H, J= 4.8, 1.9 Hz).
[0248] To a solution of the azide (23.18 g, 0.123 mol) in methanol (150 mL) was added Palladium, 10 wt.% on activated carbon (1.95 g) and the resultant mixture was hydrogenated at 40 psi on a Parr shaker. The mixture was vacuum filtered through celite and the cake was washed with methanol. The solvent was removed from the filtrate under reduced pressure and the oil obtained was distilled (Kugelrohr, bp 105-140 C @ 0.2 Torr) to provide 17.56 g (88 %) of 6,7,8,9-Tetrahydro-5H-cyclohepta[b]pyridin-9-ylamine as a pale yellow oil. 1H
NMR (CDC13) S 1.23-1.37 (m, 1H), 1.43-1.57 (in, 1H), 1.78-2.10 (m, 6H) including 2.04 (s, 2H), 2.71-2.85 (m, 2H), 4.19 (dd, 1H, J=10.0, 1.5), 7.05 (dd, 1H, J= 7.4, 4.9 Hz), 7.36 (d, 1H, J= 5.9 Hz), 8.38 (d, 1H, J= 4.9 Hz).
[0249] To a stirred solution of 6,7,8,9-Tetrahydro-5H-cyclohepta[b]pyridin-9-ylamine (0.235 g, 1.45 mmol) from above and NaBH(OAc)3 (0.461 g, 2.18 mmol) in anhydrous CH2C12 (8 mL) was added dropwise 4-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-butyraldehyde (0.263 g, 1.21 mmol) in anhydrous CH2C12 (4 mL). The resultant mixture was stirred at room temperature for 3 hours, diluted with CH2C12 (25 mL), and quenched with saturated aqueous NaHCO3 (15 mL). The two phases were stirred together for 1 hour and then separated. The organic phase was dried (Na2SO4), filtered, and concentrated under reduced pressure.
Purification of the crude material by flash column chromatography on silica gel (30:1 CH2C12/MeOH followed by 20:1 CH2C12/MeOH) provided 0.34 g (65 %) of the amine as a colourless oil.

[0250] To a stirred solution of 2-[4-(6,7,8,9-Tetrahydro-5H-cyclohepta[b]pyridin-9-ylamino)-butyl]-isoindole-1,3-dione from above (0.34 g, 0.94 mmol) in CH3CN (5 mL) was added NN-diisopropylethylamine (0.30 mL, 1.7 mmol), KI (7.8 mg, 0.047 mmol) and 1-(tert-butoxycarbonyl)-2-(chloromethyl)benzimidazole (0.302 g, 1.13 mmol). The resultant mixture was stirred at 60 C overnight, cooled, and concentrated under reduced pressure. The residue was partitioned between CH2C12 (25 mL) and saturated aqueous NaHCO3 (15 mL).
The aqueous phase was extracted with CH2C12 (2 x 10 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure. Purification of the crude material by flash column chromatography on silica gel (50:1 CH2C12/MeOH) afforded the desired alkylated amine (0.33 g, 60 %) as a white foam.

[0251] To a stirred solution of 2-{[[4-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-butyl]-(6,7, 8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)-amino]-methyl} -benzimidazole-1-carboxylic acid tent-butyl ester (0.33 g, 0.56 mmol) from above in EtOH (4 mL) was added anhydrous hydrazine (0.090 mL, 2.8 mmol) and the resultant mixture stirred at room temperature for 16 hours. The mixture was filtered and concentrated under reduced pressure.
Purification of the crude material by radial chromatography on silica gel (TLC
grade 2 mm plate, 50:1:1 CH2C12/MeOH/NH4OH followed by 40:1:1 CH2C12/MeOH/NH40H) afforded 0.13 g (62 %) of the free base of the title compound as a white foam. 1H NMR
(CDC13) 8 1.30-1.85 (m, 7H), 1.90-2.00 (m, 2H), 2.10-2.24 (m, 1H), 2.40-2.52 (m, 1H), 2.57-2.78 (m, 4H), 3.15-3.27 (m, 1H), 3.77-3.86 (m, 1H), 4.00 (d, 1H, J=18 Hz), 4.15 (t, 1H, J= 6 Hz), 7.16 (dd, 1H, J= 2.7, 7.5 Hz), 7.20-7.26 (m, 4H), 7.48 (dd, 1H, J= 1.5, 7.5 Hz), 7.56-7.69 (m, 2H), 8.48 (dd, 1H, J=1.5, 4.8 Hz); 13C NMR (CDC13) 6 25.04, 27.46, 27.85, 28.85, 31.63, 34.58, 42.25, 48.21, 51.26, 67.12, 122.18, 122.76, 138.74, 145.95, 163.11. ES-MS m/z 364 (M+H). Anal. Calcd. for C22H29N5=0.3CH2C12: C, 68.86; H, 7.67; N, 18.00.
Found: C, 68.99; H, 7.84; N, 17.63.

Exam lp e 38 i I

N
HN N

COMPOUND 38: Preparation of (1H-benzoimidazol-2-ylmethyl -[3-(1H-imidazol-4-yl)-propyl]-(5,6,7,8-tetrah d~ ro-quinolin-8-yl)-amine.

Preparation of 3-(1H-imidazol-4-yl)-propionic acid:
O
N OH
<
N
H
[0252] A suspension of urocanic acid (2.00 g, 14.5 mmol) in H2O (40 mL) was shaken at room temperature with a suspension of 10% Pd/C (200 mg, 0.19 mmol) under hydrogen atmosphere (30 psi) for 2 h. The catalyst was removed by filtration, and the filtrate was concentrated in vacuo to give a colourless solid (1.95 g, 96%). 1H NMR (D20) S
2.52 (t, 2H, J= 7.2 Hz),, 2.92 (t, 2H, J= 7.2 Hz), 7.16 (s, 1H), 8.49 (s, IH).
Preparation of 3-(1H-Imidazol-4-yl)-propionic acid methyl ester:
O

<N
N
H
[0253] A solution of 3-(1H-imidazol-4-yl)-propionic acid (1.95 g, 13.9 mmol) and H2S04 (catalytic) in MeOH (30 mL) was heated at reflux for 15 h, then concentrated in vacuo. The residue was dissolved in CH2C12 (40 mL) and washed with saturated NaHCO3(aq) (30 mL).
The aqueous phase was saturated with sodium chloride and extracted with EtOAc (4 x 25 mL). The combined organic phases were dried (MgSO4) and concentrated in vacuo to give a yellow oil (1.93 g, 90%). 1H NMR (CDC13) 8 2.68 (t, 2H, J= 7.2 Hz), 2.93 (t, 2H, J= 7.2 Hz), 3.69 (s, 3H), 6.81 (s, 1H), 7.55 (s, 1H).

Preparation of 4-(3-Hydroxy-propyl)-imidazole-l-carboxylic acid tert-butyl ester:
N OH
</
N
OA
O
[0254] To a solution of 3-(1H-imidazol-4-yl)-propionic acid methyl ester (1.92 g, 12.5 mmol) in THE (25 mL) was added LiAIH4 (1.0 M/THF, 12.5 mL, 12.5 mmol) at 0 C, and the mixture was stirred at 0 C for 15 minutes. To the mixture was added H2O
(0.50 mL) followed by 15% NaOH(aq) (0.50 mL) and H2O (1.5 mL). The mixture was allowed to warm to room temperature then filtered and concentrated in vacuo to give a colourless oil (930 mg).

[0255] To a solution of the crude alcohol from above (930 mg) in THE (25 mL) was added di-t-butyl dicarbonate (2.40 g, 11.0 mmol), and the solution was stirred at room temperature for 3 days. The solution was concentrated in vacuo, and the crude material was purified by column chromatography on silica gel (200:5:1 CH2C12/MeOH/NH4OH) to give colourless crystals (1.04 g, 37%). 1H NMR (CDC13) 8 1.61 (s, 9H), 1.89 (m, 2H), 2.69 (t, 2H, J= 6.9 Hz), 2.98 (t, 1H, J= 5.7 Hz), 3.73 (dd, 2H, J= 12, 5.7 Hz), 7.10 (s, 1H), 7.99 (s, 1H).

Preparation of 4-(3-Oxo-propyl)-imidazole-l-carboxylic acid tert-butyl ester:
N ~O
</
N
OA
O
[0256] To a solution of 4-(3-hydroxy-propyl)-imidazole-l-carboxylic acid tert-butyl ester (95 mg, 0.42 mmol) in CH2C12 (4 mL) was added Dess-Martin periodinane (214 mg, 0.505 mmol) at room temperature. After stirring at room temperature for 1 h, the mixture was diluted with EtOAc (20 mL), washed with 1 N NaOH(aq) (2 x 10 mL) and brine (10 mL), then dried (MgSO4) and concentrated in vacuo to give a colourless oil (86 mg, 91%). 1H
NMR (CDC13) 8 1.61 (s, 9H), 2.86 (m, 4H), 7.11 (s, 1H), 7.99 (s, 1H), 9.84 (s, 1H).
[0257] Using General Procedure B: To a stirred solution of 2-[(5,6,7,8-tetrahydro-quinolin-8-ylamino)-methyl]-benzoimidazole-l-carboxylic acid tert-butyl ester (145 mg, 0.383 mmol) and 4-(3-oxo-propyl)-imidazole-l-carboxylic acid tert-butyl ester (86 mg, 0.38 mmol) in THE (4 mL) was added NaBH(OAc)3 (244 mg, 1.15 mmol) and the mixture was stirred at room temperature for 16 h. Purification of the crude material by column chromatography on silica gel (200:5:1 CH2C12/MeOH/NH40H) afforded a colourless oil (39 mg, 17%). 1H NMR (CDC13) 6 1.64 (m, 20H), 1.92 (m, 2H), 2.14 (m, 1H), 2.44 (m, 2H), 2.60-2.92 (m, 5H), 4.26 (dd, 1H, J= 9.5, 5.9 Hz), 4.52 (d, 1H, J=16 Hz), 4.66 (d, 1H, J= 16 Hz), 6.85 (d, 1H, J= 0.9 Hz), 6.95 (dd, 1H, J= 7.5, 4.8 Hz), 7.27 (m, 3H), 7.69 (m, 1H), 7.80 (m, 1H), 7.88 (d, 1H, J= 1.2 Hz)-, 8.37 (dd, 1H, J= 4.5, 1.2 Hz).
[0258] A solution of 2-{[[3-(1-tert-butoxycarbonyl-1H-imidazol-4-yl)-propyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-methyl}-benzoimidazole-l-carboxylic acid tert-butyl ester (39 mg, 0.066 mmol) in 3:1 TFA/CH2C12 (4 mL) was stirred at room temperature for 30 minutes then concentrated in vacuo. The residue was partitioned between CH2C12 (15 mL) and 1 N NaOH(aq) (10 mL), and the aqueous phase was extracted with CH2C12 (15 mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo to afford COMPOUND 38 as a yellow foam (24 mg, 80%). 1H NMR (CDC13) 8 1.67 (m, 3H), 1.86 (m, 1H), 2.00 (m, 1H), 2.16 (m, 1H), 2.42-2.87 (m, 6H), 4.01 (m, 3H), 6.51 (s, 1H), 7.15 (m, 3H), 7.42 (m, 2H), 7.53 (m, 2H), 8.54 (d, 1H, J= 3.6 Hz); 13C NMR (CDC13) 8 21.66, 23.85, 24.01, 28.39, 29.50, 49.64, 50.78, 62.36, 115.22, 118.74, 122.23, 122.74, 134.47, 135.25, 135.58, 138.03, 139.02, 146.88, 156.37, 157.69. ES-MS m/z 387 (M+H). Anal.
Calcd. for C23H26N6=0.4CH2C12=0.9CH40: C, 64.96; H, 6.82; N, 18.70. Found: C, 65.13; H, 6.93; N, 18.91.

Example 39 N
NIII N
HN NN

K

COMPOUND 39: Preparation of (1H-benzoimidazol-2-ylmethyl)-(3-pyridin-2-vl-propyl)-(5 6 7 8-tetrahydro-guinolin-8-yl -amine (hydrobromide salt).

Preparation of 3-pyridin-2-l-propionaldehyde:
[0259] To a stirred suspension of 2-pyridinepropanol (1.00g, 7.29 mmol), NMO
(1.281 g, 10.94 mmol) and 3 A molecular sieves (3.645 g) in CH2C12 (37 mL) was added TPAP (256 mg, 0.73 mmol). The resulting black mixture was stirred at room temperature overnight.
The mixture was concentrated and filtered through a silica gel plug.
Purification by column chromatography on silica gel (EtOAc, 100%) afforded the desired aldehyde (111 mg, 11%) as a yellow syrup. 1H NMR (CDC13) 8 2.90-2.95 (m, 2H), 3.11 (t, 2H, J= 7.0 Hz), 7.09 (dd, 1H, J= 7.0, 4.8 Hz), 7.17 (d, 1H, J= 7.8 Hz), 7.54-7.63 (m, 1H), 8.48 (d, 1H, J= 4.2 Hz), 9.86 (s, 1H).
[0260] To a stirred solution of the aldehyde from above (67.6 mg, 0.50 mmol) and 2-[(5,6,7,8-tetrahydro-quinolin-8-ylamino)-methyl]-benzoimidazole-l-carboxylic acid tert-butyl ester (200 mg, 0.50 mmol) in THE (5 mL) was added NaBH(OAc)3 and the resultant mixture was stirred at room temperature for 3 days. The reaction mixture was concentrated under reduced pressure, diluted with CH2C12 (75 mL) and washed consecutively with H2O (5 mL), saturated aqueous NaHCO3 (7 mL), and saturated aqueous NaCl (7 mL). The aqueous layers were extracted with CH2C12 (20 mL) and the combined organic extracts were dried (MgSO4), filtered and concentrated under reduced pressure. Purification by column chromatography on silica gel (CH2C12/MeOHINH40H, 100:1:1) afforded the desired compound (172 mg) as an orange syrup which was used in the next reaction without further purification.
[0261] To a solution of the amine from above (172 mg, 0.35 mmol) in CH2C12 (2 ML) was added TFA (2 mL) and the resultant mixture was stirred overnight at room temperature.
The reaction mixture was concentrated under reduced pressure, the syrup was dissolved in a minimum amount of H2O and basified with 1N NaOH (pH 10). CHC13 (75 mL) was added, the phases were separated and the aqueous layer was extracted with CHC13 (2 x 75 mL). The combined organic extracts were dried (MgS04), filtered and concentrated under reduced pressure. Purification of the crude yellow syrup by column chromatography on silica gel (CH2C12/MeOH/NH40H, 100:1:1) followed by radial chromatography on silica gel (CH2C12/MeOH/NH4OH, 100:1:1) afforded the desired compound (97 mg, 70%) as a yellow syrup.

[0262] Using General Procedure D: Conversion of the yellow syrup from above to the hydrobromide salt afforded COMPOUND 39 as a white solid. 1H NMR (D20) S 1.82-2.06 (m, 4H), 2.14-2.19 (m, 1H), 2.35-2.38 (m, 1H), 2.51-2.61 (m, 1H), 2.85-3.01 (m, 5H), 4.36 (d, 1H, J= 16.8 Hz), 4.47-4.56 (m, 2H), 7.56-7.61 (m, 2H), 7.72-7.79 (m, 4H), 7.85 (dd, 1H, J= 7.8, 6.0 Hz), 8.30-8.35 (m, 2H), 8.48-8.51 (m, 1H), 8.62 (d, 1H, J= 4.8 Hz); 13C NMR
(D20) 8 20.41, 20.58, 27.61, 27.65, 30.85, 47.99, 51.00, 60.39, 114.31, 125.32, 126.00, 127.00, 127.36, 130.96, 139.44, 140.71, 141.08, 147.26, 148.16, 151.05, 151.41, 156.22. ES-MS fn/z 398.3 (M+H). Anal. Calcd. for C25H27N5.3.2HBr=1.2H20: C, 44.28; H, 4.85; N, 10.33; Br, 37.71. Found: C, 44.31; H, 5.06; N, 10.19; Br, 37.71.

Example 40 O
n NS

H OI
HN (N

COMPOUND 40: Preparation of N-{4-[(1H-benzoimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl -amino]-butyl}-benzenesulfonamide.

[0263] To a solution ofN1-(1H-benzoimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine (56 mg, 0.16 mmol) and DIPEA (33 L, 0.19 mmol) in CH2C12 (1.0 mL) cooled to 0 C was added PhSO2C1(45 L, 0.35 mmol). The resultant mixture was stirred overnight at room temperature. The mixture was concentrated under reduced pressure, diluted with CH2C12 (75 mL) and washed consecutively with H2O (5 mL), saturated aqueous NaHCO3 (7 mL) and saturated aqueous NaCl (7 mL). The aqueous layers were extracted with CH2C12 (20 mL) and the combined organic extracts were dried (MgSO4), filtered and concentrated under reduced pressure. The resultant disulfonamide (98 mg) was used without further purification in the next reaction.
[0264] The disulfonamide from above (98 mg, 0.16 mmol) was stirred in a saturated HBr (g) in AcOH solution (1.5 mL) for 3 hours. The mixture was concentrated in vacuo and a suspension of the resultant yellow syrup and powdered K2C03 (excess) in MeOH
was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure, diluted with CH2C12 and filtered through Celite. The cake was washed with CH2C12 and the combined filtrate was concentrated under reduced pressure. Purification of the crude yellow foam by column chromatography on silica gel (CH2C12/MeOH/NH4OH, 100:1:1) followed by radial chromatography on silica gel (CH2Cl2/MeOH/NH4OH, 100:1:1) afforded COMPOUND 40 (50 mg, 64% over 2 steps). 1H NMR (CDC13) S 1.42-1.46 (m, 3H), 1.61-1.75 (m, 1H), 1.81-1.99 (m, 1H), 2.00-2.09 (m, 1H), 2.14-2.21 (in, 1H), 2.46-2.55 (m, 1H), 2.67-2.90 (m, 6H), 3.91 (d, 1H, J= 16.2 Hz), 3.98-4.05 (m, 2H), 5.80 (br s, 1H), 7.12-7.21 (m, 3H), 7.39-7.44 (m, 3H), 7.48-7.57 (m, 3H), 7.75-7.79 (m, 2H), 8.53-8.55 (m, 1H);
13C NMR (CDC13) 6 21.21, 23.06, 25.25, 27.47, 29.10, 42.81, 49.38, 50.21, 61.41, 121.73, 122.29, 126.92, 128.97, 132.37, 134.72, 137.51, 140.22, 146.71, 155.65, 157.25. ES-MS m/z 490.3 (M+H). Anal. Calcd. for C27H31N502S=1.0H20: C, 63.88; H, 6.55; N, 13.80;
S, 6.32.
Found: C, 63.91; H, 6.32; N, 13.46; S, 6.33.

Example 41 N~C02H
HN,N

COMPOUND 41: Preparation of (2S)-2-Amino-5-[(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-pentanoic acid (hydrobromide salt).

[0265] To a solution of (2S)-5-amino-2-(tert-butoxycarbonylamino)-pentanoic acid tert-butyl ester (free base) (0.905 g, 3.11 mmol) in CH3OH (15 mL) was added 6,7-dihydro-5H-quinolin-8-one (0.504 g, 3.43 mmol) and the resultant solution was stirred at room temperature for 5 hours. Powdered NaBH4 (0.379 g, 9.98 mmol) was added, and the mixture was stirred at room temperature for 25 minutes then concentrated under reduced pressure.
The residue was dissolved in CH2C12 (100 mL) and brine (20 mL). The phases were separated and the aqueous phase was extracted with CH2C12 (3 x 20 mL). The combined organic extracts were dried (Na2S04) and concentrated. Purification of the crude material by column chromatography on silica gel (20:1 CH2C12-CH3OH) provided 0.700 g (54%) of (2S)-q(~

2-tert-butoxycarbonylamino-5-(5,6,7,8-tetrahydroquinolin-8-ylamino)-pentanoic acid tert-butyl ester as a yellow oil.
[0266] Using the General Procedure for N-alkylation: A solution of (2S)-2-(tert-butoxycarbonylamino)-5-(5,6,7,8-tetrahydroquinolin-8-ylamino)-pentanoic acid tent-butyl ester (0.700 g, 1.67 mmol), 1-(tert-butoxycarbonyl)-2-(chloromethyl)-benzimidazole (0.690 g, 2.59 mmol) and N,N-diisopropylethylamine (0.60 mL, 3.44 mmol) in CH3CN (16 mL) was heated at 60 C for 24 hours. Purification of the crude material by column chromatography on silica gel (50:1 CH2C12-MeOH) provided 0.830 g (77%) of 2-{[(4-tert-butoxycarbonyl-4-tert-butoxycarbonylamino-butyl)-(5,6,7, 8-tetrahydroquinolin-8-yl)-amino]-methyl}-benzoimidazole-1-carboxylic acid tent-butyl ester as a tan foam.
10267] General Procedure D: Conversion of 2-{[(4-tent-butoxycarbonyl-4-tert-butoxycarbonylamino-butyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-methyl} -benzoimidazole-l-carboxylic acid tert-butyl ester (139 mg) to the hydrobromide salt with simultaneous removal of the BOC-protecting groups and hydrolysis of the tert-butyl ester, followed by re-precipitation of the intermediate solid from methanol/ether, gave COMPOUND 41 (116 mg, 81%) as a tan solid (mixture of 2 diastereomers). 1H NMR
(D20) 8 1.54-1.84 (m, SH), 1.96-2.06 (m, 1H), 2.15-2.2.19 (m, 111), 2.34-2.38 (m, 1H), 2.53-2.60 (m, 1H), 2.80-2.87 (m, 1H), 2.99-3.01 (m, 2H), 3.82 (t, 1H, J=6.3 Hz), 4.38 (d, 1H, J=
16.8 Hz), 4.50-4.55 (m, 2H), 7.57-7.62 (m, 2H), 7.76-7.88 (in, 3H), 8.33 (br d, 1H, J= 5.1 Hz), 8.62 (br d, 1H, J= 6.0 Hz); 13C NMR (D20) & 20.32, 20.40, 23.87, 24.12, 27.63, 27.93, 28.04, 48.16, 51.34, 51.51, 53.41, 53.54, 60.48, 60.58, 114.24, 125.92, 126.92, 130.98, 139.36, 140.60, 148.08, 151.18, 151.61, 173.06; ES-MS m/z 394 (M+H). Anal.
Calcd. for C22H27N502.2.9HBr=2.1H20: C, 39.68; H, 5.16; N, 10.52; Br, 34.79. Found: C, 39.81; H, 5.19; N, 10.14; Br, 34.70.

Example 42 N A
NN
H
HN 'N

COMPOUND 42: Preparation of N1-(1H-Benzimidazol-2-teeth l)-1V4-cyclopropyl-N1-(5,6,7,8-tetrah d~ ro-quinolin-8-yl)-butane-1,4-diamine (HBr salt).

[02681 1,4-Butanediol (0.90 ml, 10.16 mmol) was added to a stirred suspension of NaH
(246 mg, 10.25 mmol) in THE (20 ml) at room temperature and stirred for 30 minutes.
Acetyl chloride (0.70 mL, 9.84 mmol) was then added to the thick white slurry.
Following 45 minutes of stirring, the solution was diluted with diethyl ether (30 mL) and 10 W/, %
K2C03 (a9). The phases were separated and the organic phase washed with 10%
K2C03 (1 x 15 mL) and brine (1 x 15 mL). The combined aqueous phase was extracted with diethyl ether (1 x 30 mL). The organic phase was dried (MgSO4) and concentrated to afford 933mg crude product as a colourless liquid. Purification by column chromatography. (25 g silica, 2:1.
hexanes: ethyl acetate) afforded 686 mg of acetic acid 4-hydroxy-butyl ester (51%). 1H
NMR (CDC13) 8 1.58-1.77 (m, 4H), 2.05 (s, 3H), 3.68 (t, 2H, J= 6.1 Hz), 4.10 (t, 2H, J=
6.4 Hz).
[02691 Tetrapropylammonium perruthenate (195 mg, 0.555 mmol) was added to a solution of the mono-protected diol from above (715 mg, 5.41 mmol), as well as crushed and dried 3A molecular sieves (2.71 g, 5.42 mmol) and NMO (953 mg, 8.13 mmol), in CH2Cl2 (27 mL) and the mixture stirred for 75 minutes. The suspension was filtered through a plug of silica with ethyl acetate to give 0.48 g of acetic acid 4-oxo-butyl ester as a colourless oil (68%). 1H NMR (CDC13) 8 1.98 (pent, 4H, J= 6.6 Hz), 2.05 (s, 3H), 2.55 (t, 2H, J= 7.4 Hz), 4.10 (t, 2H, J= 6.4 Hz), 9.80 (s,1H).
[02701 Using, General Procedure B: Reaction of cyclopropylamine (0.51 mL, 7.36 mmol) and the mono-protected aldehyde from above (480mg, 3.69 mmol) with NaBH(OAc)3 (1.573 g, 7.42 mmol) in CH2Cl2 (18 mL) for 19 hours provided a crude product.
Purification of the crude material by column chromatography on silica gel (20 g silica, 50:1 4 25:1 CH2Cl2:
CH3OH) provided 293 mg (46%) of acetic acid 4-cyclopropylamino-butyl ester. 1H
NMR
(CDC13) 8 0.29-0.45 (m, 4H), 1.49-1.71 (m, 4H), 2.04 (s, 3H), 2.07-2.14 (m, 1H), 2.70 (t, 2H, J= 6.9 Hz), 4.07 (t, 2H, J= 6.7 Hz).
[02711 Di-tert-butyl-dicarbonate (399 mg, 1.83 mmol) was added to a solution of the amine from above (293 mg, 1.71 mmol) in THE (8.5 mL) at room temperature and the solution was stirred for 75 minutes, after which time the solution was concentrated under reduced pressure. The residue was diluted with CH2Cl2 (30 mL) and brine (20 mL). The phases were separated and the organic phase was washed with brine (2 x 20 mL).
The combined aqueous phases were extracted with CH2Cl2 (2 x 20 mL). The combined organic phase was dried (Na2SO4) and concentrated under reduced pressure to give 622 mg colourless liquid containing acetic acid 4-(tert-butoxycarbonyl-cyclopropyl-amino)-butyl ester and excess di-tert-butyl-dicarbonate.
[0272] Potassium carbonate (2.53 g, 18.3 mmol) was added to a solution of the ester from above (622 mg, 1.71 mmol) in methanol (10 ml) at room temperature and the suspension was stirred for 80 minutes. The solution was then diluted with distilled water (20 mL). The mixture was extracted with CHC13 (4 x 20 mL). The organic phase was dried (Na2SO4) and concentrated to afford 399 mg (100% over two steps) crude cyclopropyl-(4-hydroxy-butyl)-carbamic acid tert-butyl ester as a colourless oil.
[0273] Tetrapropylammonium perruthenate (65 mg, 0.185 mmol) was added to a suspension of the alcohol from above (399 mg, 1.74 mmol), NMO (305 mg, 2.60 mmol) and 3A molecular sieves (861 mg, 1.72 mmol) in dry CH2C12 (8.5 mL) at room temperature and the mixture was stirred for 1 hour. The suspension was then filtered through silica gel with ethyl acetate. The filtrate was concentrated under reduced pressure to give 545 mg crude product. This crude material was purified by column chromatography (28 g silica, 10:1 -5:1 hexanes: ethyl acetate) to give 63 mg (16%) of pure cyclopropyl-(4-oxo-butyl)-carbamic acid tert-butyl ester and 434 mg impure material. 1H NMR (CDC13) 6 0.56-0.62 (m, 2H), 0.71-0.78 (m, 2H), 1.45 (s, 9H), 1.62 (s, 1H), 1.87 (pent, 2H, J= 7.3 Hz), 2.45 (t, 2H, J= 6.6 Hz), 3.24 (t, 2H, J= 7.2 Hz), 9.79 (s, 1H).
[0274] Using General Procedure B: To a stirred solution of the N-protected aldehyde from above (63 mg, 0.277 mmol) and [1-(tert-butyloxycarbonyl)-(1H-benzimidazol-ylmethyl)]-(5,6,7,8-tetrahydroquinolin-8-yl)-amine (103 mg, 0.273 mmol) in (2.5 mL) was added NaBH(OAc)3 (86 mg, 0.406 mmol) and the mixture was stirred for 19 hours. Purification of the crude yellow oil (165 mg) by radial chromatography (2 mm plate, 150:1:1 CH2C12: CH3OH: NH4OH) afforded 116 mg (72%) 2-{[[4-(tert-butoxycarbonyl-cyclopropyl-amino)-butyl]-(5,6,7, 8-tetrahydro-quinolin-8-yl)-amino]-methyl}-benzimidazole-1-carboxylic acid tert-butyl ester.
[0275] Using the General Procedure D: The double-protected tertiary amine from above (116 mg, 0.197 mmol) was converted to COMPOUND 42 as a white solid (99 mg, 70%). 1H
NMR (D20) S 0.76-0.79 (m, 4H), 1.54 (br s, 4H), 1.81-1.85 (m, 1H), 1.95-2.07 (m, 1H), 2.15-2.19 (m, 1H), 2.34-2.38 (m, 1H), 2.55-2.61 (m, 2H), 2.79-2.84 (m, 1H), 3.01 (br s, 4H), 4.38 (d, 1H, J= 17.4 Hz), 4.50-4.56 (m, 2H), 7.57-7.59 (m, 2H), 7.77-7.79 (m, 2H), 7.83 (t, 1H, J= 6.6 Hz), 8.33 (d, 1H, J= 7.8 Hz), 8.62 (d, 1H, J= 5.4 Hz). 13C NMR
(D20) 6 3.35, 20.45, 23.69, 25.57, 27.67, 30.32, 48.12, 48.32, 51.71, 60.70, 114.28, 125.95, 126.94, 130.97, 139.34, 140.62, 148.12, 151.26, 151.79. ES-MS m/z 390 (M+H). Anal Calc. for -3.4HBr -3.0H20: C, 40.11; H, 5.67; N, 9.74; Br, 37.80. Found: C, 40.33; H, 5.57; N, 9.60;
Br, 37.63.

Exam lp e 43 xHN N COMPOUND 43: Preparation of (cis-2-aminomethyl-cyclopropylmethyl)-(1H-benzimidazol-2-ylmethyl)-(5 6 7 8-tetrahydro-quinolin-8-yl -amine (hydrobromide salt .

Preparation of (cis-2-hyd roxymethyI-cyclopropyl)-methanol:

[0276] To a 0 C solution of dimethyl cis-1,2-cyclopropanedicarboxylate (3.03 g, 19.1 mmol) in THE (25 mL) under nitrogen was slowly added LiAIH4 (1.0 M in hexane, 25 mL). The resulting mixture was stirred at room temperature for 1.5 hours, then was quenched by the careful addition of H2O (1 mL), 15% NaOH (1 mL) and H2O (3 mL). The precipitate was removed by suction filtration, washing with EtOAc and the filtrate was concentrated under reduced pressure. Purification by flash column chromatography on silica (CH2C12/MeOH, 19:1) gave the diol as a colourless liquid (1.79 g, 17.5 mmol, 92%). 1H
NMR (CDC13) 8 0.21 (dd, 1H, J=10.5, 5.4 Hz), 0.80 (td, 1H, J= 8.3, 5.1 Hz), 1.24-1.38 (m, 2H), 3.16-3.29 (m, 4H), 4.02-4.14 (m, 2H).

Preparation of Lis-2-(teat-butyl-dimeth l-silanylox nethyl)-cyclopropyll-methanol:
[0277] To a 0 C suspension of NaH (60% in mineral oil, 733 mg, 18.3 mmol) in THE (25 mL) under nitrogen was added a solution of the diol (1.78 g, 17.4 mmol) in THE
(10 mL).
The mixture was stirred for 10 minutes, then t-BDMSCI (2.73 g, 18.1 mmol) was added at once as a solid. The reaction was stirred at room temperature for 25 minutes, then saturated aqueous NaHCO3 (35 mL) was added, the layers were separated and the aqueous solution was extracted with CH2C12 (25 mL x 2). The combined organic solution was dried (Na2SO4), filtered and concentrated under reduced pressure. Purification by flash column chromatography on silica (hexane/EtOAc, 4:1) gave the silane as a pale yellow liquid (3.12 g, 14.4 mmol, 83%). 1H NMR (CDC13) 5 0.09 (s, 3H), 0.11 (s, 3H), 0.19 (dd, 1H, J=10.5, 4.5 Hz), 0.76 (td, 1H, J= 7.5, 6.0 Hz), 0.91 (s, 9H), 1.17-1.29 (in, 1H), 1.30-1.43 (m, 1H), 3.19-3.32 (m, 3H), 3.96 (td, 1 H, J =11.5, 5.3 Hz), 4.14 (dd, 1 H, J =11.7, 5.4 Hz).

Preparation of ter t-butyl-(cis-2-chloromethyl-cyclopropylmethoxy)-dimethyl-silane:
[0278] To a solution of the alcohol (3.11 g, 14.4 mmol)- and NEt3 (3.0 mL, 21.5 mmol) in CH2C12 (45 mL) under nitrogen was added MsCI (1.65 mL, 21.3 mmol). The reaction was heated at reflux for 17 hours. Once cooled to room temperature, saturated aqueous NaHCO3 (45 mL) was added, the layers were separated and the aqueous solution was extracted with CH2C12 (25 mL). The combined organic solution was dried (MgSO4), filtered and concentrated under reduced pressure. Purification by flash column chromatography on silica (hexane/EtOAc, 9:1) gave the chloride as a light yellow liquid (1.52 g, 6.46 mmol, 45%). 1H
NMR (CDC13) S 0.06 (s, 3H), 0.07 (s, 3H), 0.40 (dd, 1H, J=10.5, 4.6 Hz), 0.84-0.93 (m, 10H), 1.23-1.42 (m, 2H), 3.57-3.72 (m, 3H), 3.81 (dd, 1H, J=11.6, 5.7 Hz).

Preparation of N-(cis-2-hydroxymmethyl-cyclopropylmethyI -phthalimide:
[0279] A mixture of the chloride (1.51 g, 6.43 mmol) and potassium phthalimide (1.31 g, 7.07 mmol) in DMF (25 mL) was heated to 80 C for 3.5 hours. Once cooled to room temperature, H2O (25 mL) was added and the mixture was extracted with CH2C12 (25 mL x 3). The combined organic solution was dried (MgSO4)', filtered and concentrated under reduced pressure giving the crude phthalimide as a yellow oil.
[0280] To a solution of this material in THE (15 mL) was added a 1M HCI
solution (15 mL) and the reaction was stirred at room temperature for 30 minutes. The THE was evaporated under reduced pressure and the aqueous solution was extracted with (25 mL x 3). The organic solution was dried (Na2SO4), filtered and concentrated under reduced pressure. Purification by flash column chromatography on silica (EtOAc/hexane, 1.5:1) gave the alcohol as a white solid (880 mg, 3.80 mmol, 59%). 1H NMR
(CDC13) S 0.18 (dd, 1H, J=12.5, 5.0 Hz), 0.79 (td, 1H, J= 8.8, 5.2 Hz), 1.18-1.34 (in, 2H), 2.93 (br. s, 1H), 3.50-3.60 (m, 2H), 3.92-4.01 (m, 2H), 7.71-7.75 (m, 2H), 7.83-7.87 (m, 2H).

Preparation of cis- f2-(phthalimidomethyl)-1-cycloprop. l methyl methanesulfonate:
[0281] To a 0 C solution of the alcohol (443 mg, 1.92 mmol) and NEt3 (0.40 mL, 2.9 mmol) in CH2C12 (7 mL) under nitrogen was added a solution of MsCI (0.22 mL, 2.8 mmol) in CH2C12 (0.8 mL). The reaction was stirred at 0 C for 15 minutes, then saturated aqueous NaHCO3 (10 mL) was added. The layers were separated and the aqueous solution was extracted with CH2C12 (15 mL x 2). The combined organic solution was dried (MgSO4), filtered and concentrated under reduced pressure. Purification by flash column chromatography on silica (EtOAc/hexane, 1:1) gave the mesylate as a white solid (513 mg, 1.66 mmol, 86%). 1H NMR (CDC13) S 0.52 (dd, 1H, J=11.4, 5.7 Hz), 1.89 (td, 1H, J= 8.4, 5.4 Hz), 1.32-1.45 (m, 1H), 1.53-1.66 (m, 1H), 3.01 (s, 3H), 3.71 (dd, 1H, J=
14.4, 7.8 Hz), 3.79 (dd, 1H, J= 14.4, 7.8 Hz), 4.23 (dd, 1H, J= 11.0, 8.9 Hz), 4.57 (dd, 1H, J=11.1, 6.9 Hz), 7.70-7.75 (m, 2H), 7.83-7.88 (m, 2H).

Preparation of (cis-2-aminomethyl-cyclopropylmethyl)-(1H-benzimidazol-2-ylmeth l)-(5,6,7,8-tetrah dquinolin-8-yl)-amine:

[0282] A solution of the mesylate (371 mg, 1.20 mmol), (1-tent-butoxycarbonyl-lH-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine (379 mg, 1.00 mmol), DIPEA (0.26 mL, 1.5 mmol) and KI (19 mg, 0.11 mmol) in CH3CN (7 mL) was heated to 60 C under nitrogen for 19 hours. Once cooled, saturated aqueous NaHCO3 (10 mL) was added and,the mixture was extracted with CH2C12 (25 mL x 3). The combined organic solution was dried (MgSO4), filtered and concentrated under reduced pressure.
Purification by flash column chromatography on silica (CH2C12/MeOH/ NH4OH, 19:1:0.1) gave the tertiary amine (yellow foam) as an approximately 3:1 mixture of diastereomers (432 mg, 73%).

[0283] This material (420 mg, 0.71 mmol) and hydrazine monohydrate (0.35 mL, 7.2 mmol) in EtOH (9 mL) was heated at reflux under nitrogen for 1 hour. Once cooled, the solvent was evaporated under reduced pressure. The residue was taken up into saturated aqueous NaHCO3 (10 mL) and extracted with CH2C12 (25 mL x 3). The combined organic solution was dried (MgSO4), filtered and concentrated under reduced pressure.
Purification by flash column chromatography on silica (CH2C12/MeOH/NH4OH, 19:1:0.1, followed by 9:1:0.05) gave the fully deprotected amine as a white foam (147 mg, 0.41 mmol, 58%). 1H
NMR (CDC13) S -0.15-0.02 (m, 1H), 0.49-0.59 (m, 1H), 0.72-0.92 (m, 2H), 1.64-1.81 (m, 1H), 1.86-1.98 (m, 1H), 1.99-2.11 (m, 2H), 2.15-2.32 (m, 2H), 2.47-2.61 (m, 1H), 2.66-2.90 (m, 3H), 2'96-3.13 (m, 1H), 3.89 (2 x d, 0.3H, J=15.1 Hz), 4.06 (s, 0.7 H), 4.13 (dd, 0.7 H, J
=10.1, 5.9 Hz), 4.40 (2 x d, 0.3H, J= 6.2 Hz), 7.02-7.09 (m, 1H), 7.15-7.20 (m, 2H), 7.37 (d, 1H, J= 7.5 Hz), 7.52-7.62 (m, 2H), 8.51 (d, 1H, J= 3.3 Hz).

Preparation of COMPOUND 43:
[0284] To a solution of the amine (75 mg, 0.21 mmol) in glacial HOAc (1.0 mL) was added a saturated solution of HBr in HOAc (0.5 mL). The solution was stirred at room temperature for 25 minutes, then Et20 (5 mL) was added. The precipitate was washed with Et2O (1 mL x 5) and dried at 90 C under reduced pressure giving COMPOUND 43 as a yellow solid (131 mg, 0.19 mmol, 91%). 1H NMR (MeOH-d4) 8 0.23-0.32 (m, 0.7H), 0.36-0.45 (m, 0.3H), 0.51-0.69 (m, 1H), 1.01-1.20 (m, 1H), 1.33-1.57 (m, 1H), 1.87-2.04 (m, 1H), 2.06-2.31 (m, 2H), 2.37-2.60 (m, 1H), 2.63-2.88 (m, 2H), 2.99-3.27 (m, 4H), 4.52-4.83 (m, 3H), 7.57-7.67 (m, 2H), 7.86-8.02 (m, 3H), 8.38-8.46 (m, 1H), 8.87-8.95 (m, 1H). 13C NMR
(D20) 6 10.0 and 10.9, 12.4 and 13.6, 15.5, 20.4 and 20.6, 20.7, 27.7, 39.8, 48.6, 51.7 and 52.6, 61.3 and 62.0, 114.2, 125.9, 126.9, 130.9, 139.3 and 139.4, 140.5 and 140.6, 148.1, 151.0 and 151.2, 151.9 and 152.6. ES-MS nz/z 362 (M+H). Anal. Calcd. for C22H27N5.3.2HBr=2.4H20Ø3C4H10O: C, 40.63; H, 5.58; N, 10.21; Br, 37.28.
Found: C, 40.61; H, 5.45; N, 10.10; Br, 37.19.

Example 44 N -,..~NH2 NNH CIH
j CIH
CIH
COMPOUND 44: Preparation of (trans-2-aminomethyl-cyclopropylmethyl)-(1H--benz-imidazol-2-ylmetylh)-(S)-5,6,7,8-tetrah droquinlin-8-yl-amine (hydrochloride salt).
Preparation of trans-1,2-cyclopropanedimethanol:
[0285] To a solution of diethyl trans-1,2-cyclopropanedicarboxylate (14.9 g, 80 mmol) in THE (50 mL), cooled to 0 C under nitrogen, was added dropwise a 1.0 M solution of LAH in THE (107 mL, 107 mmol). The resultant mixture was heated at reflux for 2 hours, then cooled to room temperature and stirred for 16 h. The crude mixture was cooled to 0 C and carefully quenched by the slow addition of deionized water (4 mL), followed by 15% NaOH
solution (4 mL), and more deionized water (12 mL). The mixture was stirred at room temperature for 20 min. The thick slurry was diluted with diethyl ether (100 mL), dried over MgSO4, filtered through a glass sintered funnel, and concentrated in vacuo to afford the title compound as a colorless oil (6.30 g, 78%). 1H NMR (CDC13) S 0.43 (t, 2H, J=
6.8 Hz), 0.96-1.07 (m, 2H), 3.05 (dd, 2H, J= 11.4, 8.7 Hz), 3.13 (br. s, 2H), 3.83 (dd, 2H, J=11.4, 4.7 Hz).

Preparation of trans- l -hydroxymethyl-2-(tert-butyl-dimethyl-silanyloxymethyl)-cyclopropaneMcDougal P. G., et al J Or g. Chem. (1986) 51:3388-3390):
[0286] To a cooled (0 C) stirred solution of trans-1,2-cyclopropanedimethanol (2.0 g, 20, nunol) in THE (40 mL) was slowly added NaH (60% dispersion in oil, 0.80 g, 20 mmol).
Stirring was continued at 0 C for 10 min. tert-Butyldimethylchlorosilane (3.0 g, 20 mmol) was added. The thick white slurry was allowed to warm to room temperature and stirring was continued for 10 min. The resultant mixture was poured into diethyl ether (400 mL) and washed with 10% K2C03 (100 mL) then washed again with brine (100 mL). The separated organic layer was dried over Na2SO4 and concentrated. The crude material was purified by flash column chromatography (5 cm id., 100 g silica gel, eluted with 5:1 hexanes/ethyl acetate) to give the mono-protected desired product as a clear oil (2.8 g, 65%). 1H NMR
(CDC13) S 0.05 (s, 6H), 0.41-0.53 (m, 2H), 0.89 (s, 9H), 0.89-1.04 (m, 211), 1.41 (t, 1H, J=
5.8 Hz), 3.41-3.50 (m, 3H), 3.60 (dd, 1H, J=11.2, 5.8 Hz).

Preparation of trans-N- f [2-(hydroxymethyl)cycloprropyllmethyl}phthalimide=
[0287] To a stirred solution of trans-l-hydroxymethyl-2-(tent-butyl-dimethyl-silanyloxymethyl)-cyclopropane (4.7 g, 22 mmol) and triethylamine (9.2 mL, 65 mmol) in CH2Cl2 (75 mL) was added dropwise methanesulfonyl chloride (3.7 mL, 48 mmol).
The mixture was heated at reflux for 16 h, then allowed to cool to room temperature. Deionized water (50 mL) was added to the red solution and the layers were separated. The organic layer was washed with brine (50 mL), dried over MgSO4, and concentrated to a red oil. The crude material was purified by flash column chromatography (5 cm id., 140 g silica gel, eluted with 5% EtOAc/hexanes) to give the chloride as a yellow oil (4.0 g, 78%).
[0288] The chloride from above (4.0 g, 17 mmol) and potassium phthalimide (4.8 g, 26 mmol) were stirred in anhydrous DMF (115 mL) at 100 C, under a nitrogen atmosphere, for 3 h. The mixture was concentrated to remove DMF. The resultant residue was diluted with CH2C12 (200 mL), washed with brine (50 mL), dried over MgSO4, and concentrated in vacuo. The crude material was purified by flash chromatography (5 cm id., 160 g silica gel, eluted with 10:1 hexanes/ethyl acetate) to provide the phthalimide as a pale yellow oil (5.4 g, 92%).
[0289] The phthalimide from above (5.3 g, 15 mmol) was stirred in a mixture of THE (40 mL) and IN HCl (40 mL) for 1.5 h. The THE was removed in vacuo and the solution was extracted with CH2C12 (3 x 50 mL). The separated organic layers were combined, dried over MgSO4, and concentrated. The crude material was purified by flash column chromatography.
(5 cm id., 120 g silica gel, 1:1 hexanes/ethyl acetate) to afford the pure title compound as a white solid (3.5 g, 97%). 1H NMR (CDC13) S 0.50 (ddd, 1H, J= 8.4, 5.1, 5.1 Hz), 0.66 (ddd, 1H, J= 8.4, 5.1, 5.1 Hz), 1.13-1.25 (m, 2H), 1.50 (br. s, 1H), 3.33-3.43 (m, 1H), 3.45-3.53 (m, 1H), 3.60 (dd, 2H, J = 6.9, 5.1 Hz), 7.69-7.74 (m, 2H), 7.82-7.86 (m, 2H).

Preparation of 2-[(trans-2-phthalimidomethyl-ccyclopropylmethyl)-(S)-(5,6,7,8-tetrahydro-quinolin-8-yl)-aminomethyl]-benzimidazole-l-carboxylic acid tert-butyl ester:
[0290] To a 0 C solution of trans-N-{[2-(hydroxymethyl)cyclopropyl]methyl}
phthalimide (3.4 g, 15 mmol) and triethylamine (8.4 mL, 60 mmol) in CH2C12 (50 mL) was added dropwise methanesulfonyl chloride (2.9 mL, 37 mmol). The mixture was heated at reflux for 18 h, cooled to room temperature and washed with deionized water (100 mL), followed by saturated NaHCO3 (100 mL), and finally washed with brine (100 mL).
The separated organic layer was dried over MgSO4 and concentrated to a tan solid.
The crude solid was purified by flash column chromatography (5 cm id., 100 g silica gel, eluted with 9:1 hexanes/ethyl acetate) to give the chloride as an off-white solid (3.2 g, 85%).
[0291] Sodium iodide (12 g, 80 mmol) was added to a solution of the chloride from above (2.0 g, 8.0 mmol) in acetone (40 mL). The mixture was stirred vigorously at reflux for 68 h, then cooled to room temperature and concentrated. The residue was partitioned between deionized water (100 mL) and CH2C12 (100 mL). The separated organic layer was dried over MgSO4 and concentrated to an orange solid (3.2 g). This material was used without further purification.
[0292] A solution of the iodide from above (2.7 g, 8.0 mmol), (1-tert-butoxycarbonyl-1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine (2.9 g, 7.6 mmol) and DIPEA (2.1 mL, 12 mmol) in CH3CN (40 mL) was heated at 60 C, under nitrogen, for 15.5 hours. Once cooled to room temperature, the mixture was concentrated, saturated aqueous NaHCO3 (100 mL) was added and the aqueous layer was extracted with CHC13 (3 x 100 mL).
The combined organic portions were dried (MgSO4), filtered and concentrated under reduced pressure giving a brown foam. Purification by flash column chromatography on silica (5 cm id., 170 g silica gel, eluted with 2% McOH/CH2CI2) followed by a second column chromatography purification of the product containing material (5 cm id., 150 g silica gel, eluted with 5% NH40H/EtOAc) gave a 1:1 mixture of two diastereomers of the title compound as a pale yellow foam (2.7 g, 59%). 1H NMR (CDC13) 8 0.17-0.27 (m, 1H), 0.42-0.51 (m, 1H), 0.89-1.11 (m, 2H), 1.69 and 1.70 (2 x s, 9H)., 1.79-2.02 (m, 3H), 2.08-2.20 (m, 1H), 2.52-2.83 (m, 4H), 3.16 (dd, 0.5H, J=14.2, 7.7 Hz), 3.34 (dd, 0.5H, J=14.2, 7.7 Hz), 3.50-3.58 (m, 1H), 4.24-4.34 (m, 1H), 4.40-4.52 (m, 1H), 4.62 (d, 1H, J= 16.5 Hz),,6.88-6.94 (m, 1H), 7.18-7.29 (m, 4H), 7.57-7.64 (m, 2H), 7.67-7.76 (m, 2H), 7.78-783 (m, 1H), 8.28-8.33 (m, 1H).

Preparation of (trans-2-aminomethyl-cyclopropylmethyl -(1H-benz-imidazol-2-ly methyl)(S)-5,6,7,8-tetrahydroquinlin-8-yl-amine:
[0293] A solution of 2-[(trans-2-phthalimidomethyl-cyclopropy.lmethyl)-(S)-(5,6,7,8-tetrahydro-quinolin-8-yl)-aminomethyl]-benzimidazole-l-carboxylic acid tert-butyl ester (3.5 g, 5.9 mmol) and hydrazine hydrate (1.76 mL, 35 mmol) in EtOH (27 mL) was stirred at room temperature under nitrogen for 2 h. The white slurry was diluted with diethyl ether, filtered, and the filtrate was concentrated. The crude material was purified by flash column chromatography (5 cm id., 80 g silica gel, eluted with 2% NH40H/2%MeOH/CH2C12) to afford the pure title compound as a pale yellow foamy solid (1.8 g, 83%). 1H
NMR (CDC13) 8 0.15-0.31 (m, 2H), 0.58-0.74 (m, 2H), 1.59-1.76 (m, 1H), 1.79-1.92 (m, 1H), 1.96-2.07 (m, 1H), 2.15-2.91 (m, 7H), 4.06-4.16 (m, 2H), 4.21 (2 x d, 1H, J= 14.6 Hz), 7.10-7.22 (m, 3H), 7.41 (d, 1H, J= 7.5 Hz), 7.54-7.62 (m, 2H), 8.57 (d, 1H, J= 4.5 Hz).

Preparation of (trans-2-aminomethyl-cycloprop lmethyl)-(1H-benz-imidazol-2-ylmethyl)-(S)-5,6,7,8-tetrahydroquinlin-8-yl-amine (hydrochloride salt) (COMPOUND 44):
[0294] A stirred solution of (trans-2-aminomethyl-cyclopropylmethyl)-(1H-benz-imidazol-2-ylmethyl)-(S)-5,6,7,8-tetrahydroquinlin-8-yl-amine (1.7 g, 4.8 mmol) in glacial acetic acid (10 mL) was treated with a saturated solution of HC1(g) in glacial acetic acid (10 mL). The resultant solution was added dropwise to diethyl ether (300 mL) with vigorous stirring. Once the addition was complete, the white precipitate was allowed to settle and the clear liquid was decanted. The solid was washed repeatedly with ether (4 x 300 mL), decanting each time. The solid was then collected on a sintered glass funnel, rinsed with diethyl ether (3 x 50 mL), and dried in a vacuum oven at 40 C for 60 h to afford COMPOUND 44 as a white solid (2.1 g, 88%, 1:1 mixture of diastereomers). 1H
NMR
(D20) 8 0.11-0.18 (m, 0.5H), 0.30-0.41 (m, 1H), 0.44-0.50 (m, 0.5H), 0.69-0.87 (m, 2H), 1.71-1.86 (m, 1H), 1.91-2.52 (m, 5H), 2.70 (ddd, 1H, J= 27.0, 13.2, 6.0 Hz), 2.90-2.99 (m, 3H), 4.33-4.61 (m, 3H), 7.51-7.55 (m, 2H), 7.72-7.83 (m, 3H), 8.26 (t, 1H, J=
7.6 Hz), 8.59 (t, 1H, J= 7.6 Hz); 13C NMR (D20) 6 10.12, 11.19, 13.71, 15.45, 16.88, 17.04, 20.42, 20.56, 20.63, 27.62, 43.20, 43.31, 48.93, 49.64, 55.43, 55.73, 61.58, 61.89, 114.38, 125.71, 126.38, 126.43, 131.75, 132.04, 139.54, 140.30, 147.54, 147.64, 151.27, 152.28. ES-MS
ni/z 362 (M+H). Anal. Calcd. for C22H27N5=2.9HC1=1.7H20: C, 53.08; H, 6.74; N, 14.07;
Cl, 20.65.
Found: C, 52.91; H, 6.90; N, 14.20; Cl, 20.90.
[0295] The enantiomeric purity of COMPOUND 44 was determined to be 100% by chiral HPLC using the following conditions: Instrument: Hewlett Packard 1100 HPLC
(VWD1); Column: ChiralCel OD, 0.46 cm x 25 cm; Mobile Phases: A = 90:10 hexanes/reagent alcohol with 0.1%DEA, B = hexanes; Isocratic: 50% A, 50%B;
Total Run Time: 30 min; Flow Rate: 1.0 mL/min; Temperature: 40 C; Detector: UV @ 270 nm;
Injection volume: 20 L.
[0296] Retention time of the S enantiomer 13.0 min.
[0297] Retention time of the R enantiomer =16.7 min.
Exam lp e 45 N

HN N

COMPOUND 45: Preparation ofN'-(1H-benzimidazol-2-ylmethyl)-3-methyl-3-phenyl-N'-(5 6 7 8-tetrahydro-quinolin-8-yl)-butane-1 4-diamine CHO
Preparation of 2-methyl-2-phenyl-pent-4-enal (prepared as described byCiganek, E
Read, J M = Calabrese, J C J Org- Cliem 1995, 60, 5795-5802):
[0298] A solution of 2-phenylpropionaldehyde (9.90 mL, 74.5 mmol), allyl alcohol (20.4 mL, 300 mmol) andp-toluene sulfonic acid (0.8560 g, 4.5 mmol) in benzene (37 mL) was heated to reflux for 19 hours and a Dean-Stark trap was used to collect the water formed.
The mixture was cooled to room temperature and saturated aqueous NaHCO. (5 mL) and H2O (5 mL) were added. The phases were separated and the organic layer was washed a second time with saturated aqueous NaHCO3 (5 mL) and H2O (5 mL). The organic layer was dried (MgSO4) and concentrated under reduced pressure. A solution of the resultant yellow residue inp-xylene (150 mL) was heated to reflux for 24 hours. The solution was cooled to room temperature and concentrated under reduced pressure. The resultant aldehyde (13.0 g) was used in the next reaction without further purification.

Preparation of acetic acid 2-methyl-2-phenyl-pent-4-en .1 ester:
[0299] To a solution of 2-methyl-2-phenyl-pent-4-enal (1.23 g, 7.02 mmol) in ethanol (20 mL) was added sodium borohydride (0.80 g, 21.15 mmol) and the resultant suspension was stirred at room temperature for 3 days. The mixture was concentrated under reduced pressure, diluted in saturated NaHCO3 (10 mL), and extracted with chloroform (5 x 25 mL).
The combined organic extracts were dried (Na2SO4), filtered, concentrated, and dried in vacuo to afford a yellow oil (1.04 g), which was used without further purification in the next step.
[0300] To a solution of the crude alcohol from above (360 mg, 2.03 mmol), 4-dimethylaminopyridine (24.4 mg, 0.20 mmol) and triethylamine (340 L, 2.44 mmol) in CH2C12 (10 mL) was added acetic anhydride (230 L) and the resultant mixture was stirred at room temperature overnight. Then the mixture was quenched with saturated NaHCO3 (30 mL) and the phases were separated. The aqueous layer was washed with CH2C12 (2 x 20 mL). Then the combined organic extracts were washed with saturated NaHCO3 (2 x 30 mL), dried (MgSO4), filtered, concentrated, and dried in vacuo to afford a yellow oil. Purification by column chromatography on silica gel (CH3OH/CH2C12, 1:9) afforded the title compound (400 mg, 70% over 2 steps). 1H NMR (CDC13) S 1.36 (s, 3H), 2.01 (s, 3H), 2.45 (qd, 2H, J=
29.1, 16.2, 7.1 Hz), 4.19 (q, 2H, J=11.1, 7.8 Hz), 4.97-5.05 (m, 2H), 5.48-5.54 (m, 1H), 7.21-7.44 (m, 5H).

Preparation of acetic acid 2-methyl-5-oxo-2-phen j-pentyl ester:
[0301] To a solution of the acetate from above (400 mg, 1.82 mmol) and 4-methylmorpholine N-oxide (427 mg, 3.65 mmol) in CH2C12 (10 mL) was added osmium tetraoxide (2.5% in t-butanol) (680 gL, 0.06 mmol) and the mixture was stirred at room temperature overnight. Then the mixture was diluted with ethyl acetate and filtered through a layer of celite. The filtrate was concentrated under reduced pressure and was dried in vacuo to afford an orange oil. Partial purification by column chromatography on silica gel (CH3OH/NH4OH/CH2C12, 4:1:95) followed by radial chromatography on silica gel (2 mm plate, CH3OH/CH2C12, 0:100 then 2:98) afforded the diol (198 mg) as a yellow oil, which was used without further purification in the next step.
[0302] To a solution of the crude diol from above (198 mg, 0.82 mmol) in THE
(5 mL) and H2O (1 mL) was added sodium periodate (351 mg, 1.64 mmol) and the mixture was stirred for 2 hours at room temperature. The mixture was diluted with CH2C12 (15 rnL) and washed with saturated NaCl (15 mL). The aqueous layer was washed with CH2C12 (15 mL).
Then the combined organic extracts were dried (MgSO4), filtered, concentrated, and dried in vacuo to cleanly afford the product as a pale yellow oil (146 mg, 36% over 2 steps). 1H
NMR (CDC13) S 1.53 (s, 3H), 2.03 (s, 3H), 2.81 (ABqd, 2H, J= 49.2, 15.9, 2.7 Hz), 3.75 (t, 1H, J= 6.3 Hz), 4.23 (ABq, 2H, J= 20.4, 11.1 Hz), 7.24-7.34 (m, 4H), 7.38 (d, 1H, J= 3.0 Hz), 9.54 (t, 1H, J= 3.0 Hz).

Preparation of 4-1lH-benzoimidazol-2-ylmethyl)-(5.6.7.8-tetrahydro-quinolin-8-yl)-aminol-2-meth phenyl-butan-l -ol:
[0303] To a solution of the 2-[(5,6,7,8-tetrahydro-quinolin-8-ylamino)-methyl]-benzimidazole-1-carboxylic acid tent-butyl ester (299 mg, 0.79 mmol) and the above aldehyde (146 mg, 0.66 mmol) in CH2C12 (4 mL) was added sodium triacetoxyborohydride (251 mg, 1.18 mmol) and the mixture was stirred at room temperature for 3 days. The mixture was diluted with CH2C12 (10 mL) and was extracted with NaOH (iN, 2 x 10 mL) and brine (2 x 10 mL). The organic layer was dried (Na2SO4), filtered, concentrated, and dried in vacuo to afford a dark yellow oil. Partial purification by two attempts of radial chromatography on silica gel (2 mm plate, CH3OH/NH4OH/CH2C12, 0:1:99 then 3:1:96), and (2 mm plate, NH4OH/CH2C12, 0:100 then 1:99) afforded the compound as a yellow oil (198 mg), which was used without further purification [0304] To a solution of the crude amine from above (198 mg, 0.34 mmol) in methanol (3.5 mL) was added potassium carbonate (84 mg, 0.61 mmol) and the mixture was stirred at room temperature for 1 hour. Then the solvent was removed under reduced pressure and dissolved in CH2C12. The mixture was filtered to remove the inorganic salt and the filtrate was concentrated and dried in vacuo to afford a yellow oil. Purification by radial chromatography on silica gel (1 mm plate, CH3OH/NH4OH/CH2C12, 1:1:98 then 3:1:96) to afford the product as a pale yellow foam (85 mg, 24% over 2 steps). 1H NMR
(CDC13) S 1.20 and 1.26 (s, total 3H), 1.65-1.68 (m, 2H), 1.93-2.01 (m, 3H), 2.13-2.16 (m, 1H), 2.53-2.74 (m, 3H), 3.53-3.76 (m, 2H), 3.91-4.01 (m, 3H), 7.00-7.09 (m, 3H), 7.17-7.19 (m, 3H), 7.26-7.29 (m, 2H), 7.41 (t, 2H, J= 7.8Hz), 7.64-7.67 (br in, 1H), 8.43 and 8.47 (d, total 1H, J
3.5 Hz).
[0305] To a solution of the above alcohol (80 mg, 0.15 mmol) in CH2C12 (1.5 mL) was added Dess-Martin reagent (75 mg, 0.18 mmol) and the mixture was stirred at room temperature for 20 minutes. Saturated NaHCO3 (1 mL) and aqueous sodium dithionite (20%, 1 mL) was added to the mixture and stirred until the layers clarified. The mixture was diluted with CH2C12 (5 mL) and the phases were separated. The aqueous layer was washed with CH2C12 (3 x 10 mL). Then the combined organic extracts were dried (Na2SO4), filtered, concentrated, and dried in vacuo to afford a yellow foam (91 mg), which was used without further purification.

Preparation of N'-(1H-benzimidazol-2-ylmethyl)-3-methyl-3-phenyl=N'-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane- l ,4-diamine [0306] To a solution of the crude aldehyde from above (90 mg, 0.17 mmol) in methanol (1.5 mL) was added hydroxyamine hydrochloride salt (23 mg, 0.33 mmol) and the mixture was stirred at room temperature for 40 minutes. The mixture was concentrated under reduced pressure and the residue was dissolved in CH2C12 (5 mL). The mixture was basified to pH 9 with saturated NaHCO3 and the phases were separated. The aqueous layer was extracted with CH2C12 (2 x 10 mL). Then the combined organic extracts were dried (Na2SO4), filtered, concentrated, and dried in vacuo to afford a pale yellow foam (72 mg), which was used without further purification.

[0307] To a solution of the crude oxime from above (285 mg, 0.63 mmol) in methanol (20 mL) was added a slurry of Raney-nickel in water (approximately 30 mg). The mixture was purged with ammonium gas and then hydrogenated overnight at 35 psi. Then the mixture was filtered through a layer of celite and the filtrate was concentrated and dried in vacuo to afford a yellow oil. Purification by three attempts at radial chromatography on silica gel (2 mm plate, CH3OH/NH4OH/CH2Cl2, 0:1:99 then 1:1:98), (2 mm plate, CH3OH/NH4OH/CH2C12, 1:1:98 then 3:1:96), (1 mm plate, CH3OH/NH4OH/CH2C12, 1:1:98 then 2:1:97) to afford the minor spot, COMPOUND 45 as a yellow foam (16 mg, 4%
over 3 steps). 1H NMR (CDC13) S 1.21 and 1.25 (s, total 3H), 1.62-2.05 (m, 6H), 2.25-2.80 (m, 7H), 3.48 (q, 1H, J= 6.9 Hz), 3.89-4.15 (m, 3H), 7.00-7.26 (m, 8H), 7.36-7.38 (m, 1H), 7.58 (br s, .
2H), 8.58 (br m, 1H). 13C NMR (CDC13) S 21.70, 23.07, 23.71, 29.36, 30.09, 38.19, 38.57, 46.76, 49.87; 49.96, 62.02, 62.20, 122.10, 122.44, 126.34, 126.49, 126.56, 128.68, 128.97, 134.87, 137.63, 147.11, 147.20. ES-MS m/z 440 [M+H]+. Anal. Calcd. for C28H33N5=0.2CH2C12=0.6C4H100: C, 73.35; H, 7.93; N, 13.98. Found: C, 72.97; H, 7.87;
N, 13.78.

Example 46 N H R R' N NHZ x 3 HBr N" NH
7 R=H, R'=Ph or \ / B R=Ph, R'=H

COMPOUND 46(R), COMPOUND 46(S): Preparation of (1H-benzimidazol-2-ylmethyl)-(5 6 7 8-tetrahydro-quinolin-8-yl)-(1-phenyl-l-aminobut-4-yl -amine (hydrobromide salt), [0308] NOTE: Synthesis of COMPOUND 46(R) is listed below, proceeding from (R)-(N-t-butoxycarbonyl)-2-phenylglycinol. The synthesis of COMPOUND 46(S) proceeds identically from the (S)-isomer.

[0309] A solution of DMSO (2.13 mL, 30 mmol) in dichloromethane (100 mL) was chilled under nitrogen to -60 C. To this stirred solution, oxalyl chloride (15 mL of a 2.0 M
solution in dichloromethane, 30 mmol) was added over five minutes. The mixture was stirred at -60 C for ten minutes, then a solution of (R)-(N-t-butoxycarbonyl)-2-phenylglycinol (5.3 g, 20 mmol) in dichloromethane (40 mL) was added over ten minutes. The mixture was stirred at -60 C for 20 minutes, then triethylamine (8.35 mL, 60 mmol) was added. The mixture was stirred gradually warming to room temperature, over 60 minutes. A
saturated aqueous solution of ammonium chloride (75 mL) was then added. The aqueous and organic layers were separated, and the aqueous layer was washed twice with dichloromethane. The combined organic fractions were then dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford (R)-(N-t-butoxycarbonyl)-2-phenylglycinal as an unstable yellow oil, which was used immediately without further purification in the next reaction (assuming 100% conversion). 1H NMR (CDC13) & 1.43 (s, 9H), 5.31 (m, 1H), 5.75 (br s, 1H
(NH)), 7.30-7.41 (m, 5H), 9.55 (s, 1H).
[0310] The aldehyde was dissolved in benzene (150 mL), and methyl (triphenylphoshporanylidene) acetate (6.96 g, 20 mmol) was added. The mixture was then stirred at room temperature overnight. The suspension was then concentrated in vacuo and loaded directly onto a silica gel column (1:1 hexanes:ethyl acetate). The product (E)-methyl 4-[(t-butoxycarbonyl)-amino]-4-phenylbut-2-enoate was collected as a colourless oil in a yield of 3.17 g (52%). s, 9H), 3.71 (s, 3H), 4.95 (m, 1H), 5.56 (br s, 1H
(NH)), 5.96 (dd, 1H, J =15.2, 2.9 Hz), 7.05 (dd, 1H, J = 15.2, 4.1 Hz), 7.27-7.49 (m, 5H).
[0311] To a solution of methyl 4-[(t-butoxycarbonyl)-amino]-4-phenylbut-2-enoate (3.17 g) in methanol (100 mL) was added palladium on carbon (250 mg (10% by wt.
Pd)). The mixture was then placed under 50 psig hydrogen gas, and was shaken on a Parr hydrogenator for 2 hours. The mixture was then filtered through celite, concentrated in vacuo and purified by silica gel flash chromatography (3:1 hexanes:ethyl acetate) to afford methyl 4-[(t-butoxycarbonyl)-amino]-4-phenylbutanoate as a pale yellow oil in a yield of 2.61 g (82%).
1H NMR (CDC13) 5 1.45 (s, 9H), 2.07 (m, 2H), 2.36 (m, 2H), 3.69 (s, 3H), 4.59 (m, 1H), 5.15 (br s, 1H (NH)), 7.21-7.34 (m, 5H).
[0312] To a 0 C solution of methyl 4-[(t-butoxycarbonyl)-amino]-4-phenylbutanoate (293 mg, 1.0 mmol) in dichloromethane (25 mL) was added Dibal-H (3 mL of a 1.0 M
solution in dichloromethane, 3.0 mmol). The mixture was then stirred at 0 C for 2 hours.
before being quenched with a saturated aqueous sodium potassium tartrate solution (10 mL).
The biphasic mixture was then rapidly stirred for approximately 45 minutes, until the aqueous and organic layers clarified. The aqueous and organic layers were then separated and the aqueous layer was extracted twice with dichloromethane. The combined organic fractions were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford a pale yellow residue, which was purified by silica gel flash chromatography (1:1 hexanes:ethyl acetate) to afford 4-[(t-butoxycarbonyl)-amino]-4-phenylbutanol as a colourless oil in a yield of 138 mg (52%).
1H NMR (CDC13) 8 1.43 (s, 9H), 1.45 (m, 2H), 1.56 (m 2H), 2.71 (br s, 1H
(OH)), 3.54 (t, 2H, J= 6.9 Hz), 4.56 (m, 1H), 5.22 (br s, 1H (NH)), 7.16-7.26 (m, 5H).
[03131 To a 0 C solution of 4-[(t-butoxycarbonyl)-amino]-4-phenylbutanol (133 mg, 0.5 mmol) in dichloromethane (8 mL) was added triethylamine (0.140 mL, 1.0 mmol), followed by methanesulfonylchloride (0.057 mL, 0.75 mmol). The solution was then stirred at 0 C for 15 minutes before being quenched with an aqueous ammonium chloride solution (2 ML).
The aqueous and organic layers were then separated, the aqueous layer extracted twice with dichloromethane, and the combined organic fractions were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford 4-[(t-butoxycarbonyl)-amino]-4-phenylbutanol mesylate as a yellow oil, which was used immediately in the next reaction without further purification. 1H NMR (CDC13) 81.43 (s, 9H), 1.67-2.00 (m, 4H), 2.95 (s, 3H), 4.18 (t, 2H, J= 7.1 Hz), 4.20 (m, 1H), 4.92 (br s, 1H (NH)), 7.21-7.33 (m, 5H).
[0314] To a solution of the mesylate (0.5 mmol, assumed 100% conversion from the previous step) in dimethylformamide (5 mL) was added sodium azide (130 mg, 2 mmol).
The mixture was then heated to 70 C for 2 hours under nitrogen. After cooling, the reaction was diluted with 40 mL ethyl acetate, and extracted repeatedly with distilled water. The organic fraction was then dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by silica gel flash chromatography (1:1 hexanes:ethyl acetate) to afford 4-[(t-butoxycarbonyl)-amino]-4-phenylbutyl azide in a yield of 100 mg (69% from alcohol). 1H NMR (CDC13) 6 1.38 (s, 9H), 1.47-1.61 (m, 2H), 1.78 (m, 2H), 3.25 (t, 2H, J= 6.8 Hz), 4.58 (m, 1H), 4.97 (m, 1H (NH)), 7.20-7.33 (m, 5H).
[03151 To a solution of the azide (100 mg, 0.34 mmol) in methanol (20 mL) was added Lindlar's catalyst (5% Pd on CaCO3, poisoned with lead (15 mg)). The mixture was then placed under 1 atmosphere Hz and was stirred overnight. The mixture was then filtered through celite, concentrated in vacuo and purified by silica gel flash chromatography. (15%
methanol, 1%NH4OH in dichloromethane) to afford 4-amino-l-phenyl-l-(t-butoxycarbonyl)-amine in a yield of 65 mg (72%). 'H NMR (CDC13) 8 1.40 (s, 9H), 1.77 (m, 2H), 2.29 (m, 2H), 2.70 (t, 2H, J= 7.8 Hz), 4.58 (m, 1H), 5.11 (m, 1H (NH)), 7.20-7.33 (m, 5H).
[0316] To a solution of 5,6,7,8-tetrahydroquinolin-8-one (40 mg, 0.271 mmol) and 4-amino-l-phenyl-l-(t-butoxycarbonyl)-amine (65 mg, 0.246 mmol) in dichloromethane (8 mL) was added sodium triacetoxyborohydride (115 mg, 0.542 mmol). The reaction was then stirred overnight at room temperature. A saturated sodium carbonate solution (5 mL) was added, and the aqueous and organic layers were then separated. The aqueous layer was extracted twice with dichloromethane and the combined organic fractions were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by silica gel flash chromatography to yield and 4-[(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-1-phenyl-1-(t-butoxycarbonyl)-amine in a yield of 65 mg (61%). 1H NMR (CDC13) 8 1.40 (s, 9H), 1.61-1.85 (m, 6H), 1.94 (m, 1H), 2.04 (m, 1H), 2.74 (m, 4H), 3.78 (m, 1H), 4.91 (m, 1H), 5.35 (m, 1H (NH7)), 7.07 (dd, 1H, J= 8.1, 4.9 Hz), 7.24-7.28 (m, 5H), 7.36 (d, 1H, J=
8.1 Hz), 8.36 (d, 1H, J= 4.9 Hz). - fix I.H.
[0317] To a solution of (N-t-butoxycarbonyl)-2-chloromethylbenzimidazole (53 mg, 0.20 mmol), 4-[(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-1-phenyl-l-(t-butoxycarbonyl)-amine (65 mg, 0.165 mmol) and diisopropylethylamine (0.043 mL, 0.25 mmol) in acetonitrile (5 mL) were stirred at 70 C for 16 hours. After cooling, the mixture was diluted with dichloromethane (20 mL) and washed with a saturated sodium bicarbonate solution (5 mL).
The aqueous and organic layers were then separated, and the aqueous layer was extracted twice with dichloromethane. The combined organic fractions were then dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel flash chromatography to afford N-[(t-butoxycarbonyl)-benzimidazol-2-ylmethyl)]-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-phenyl-1-aminobut-4-yl)-(t-butoxycarbonyl)-amine as a pale foam in a yield of 73 mg (71%). 'H NMR (CDC13) 8 1.40 (s, 9H), 1.63 (s, 9H), 1.71-2.11 (m, 8H), 2.58-2.79 (m, 4H), 4.16 (dd, 1H, J= 10.9, 8.1 Hz), 4.43 (in, 3H), 5.05 (m, 1H (NH)), 6.96 (m, 1H), 7.15-7.31 (m, 8H), 7.75 (m, 1H), 7.83 (m, 1H), 8.30 (m, 1H).
[0318] Using General Procedure D: Conversion of the foam from above (72 mg, 0.117 mmol) to the hydrobromide salt followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 46(R) (58 mg, 70%) as a beige solid. 1H NMR
(D20) 6 0.83 (m, 1H), 1.84 (m, 5H), 2.06-2.20 (m, 2H), 2.30-2.55 (m, 2H), 2.90 (m, 2H), 4.05 (m, 1H), 4.22 (d, 1H, J= 15.8 Hz), 4.45 (m, 1H), 4.48 (d, 1H, J= 15.8 Hz), 7.07-7.18 (m, 5H), 7.62 (m, 2H), 7.73 (m, 2H), 7.87 (dd, 1H, J= 13.2, 5.7 Hz), 8.28 and 8.31 (d, 1H
total, J= 5.7 Hz (each doublet from a diastereomer)), 8.54 (d, 1H, J= 5-.4 Hz); 13C NMR
(D20) 6 20.59, 25.10, 25.23, 27.59, 30.46, 30.56, 49.59, 55.04, 55.50, 61.15, 61.98, 114.29, 125.92, 126.94, 127.28, 127.39, 129.47, 129.61, 129.84, 129.92, 130.82, 139.07; 139.23, 140.41, 148.13, 151.72. ES-MS m/z 426 (M+H). Anal. Calcd. for C27H31N5=3.0HBr=2.6H20:
C, 45.35; H, 5.52; N, 9.79; Br, 33.52. Found: C, 45.72; H, 5.34; N, 9.43; Br, 33.34.
[0319] COMPOUND 46(S) was prepared using the same procedure described above from 73 mg (0.117 mmol) of N-[(t-butoxycarbonyl)-benzimidazol-2-ylmethyl)]-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-phenyl- l -aminobut-4-yl)-(t-butoxycarbonyl)-amine to afford 49 mg (58%) of the hydrobromide salt as a white solid. 'H, 13C and MS data identical to that for COMPOUND 46(R). Anal. Calcd. for C27H31N5=3.0HBr=2.7H20: C, 45.23; H, 5.54; N, 9.77; Br, 33.43. Found: C, 45.52; H, 5.49; N, 9.39; Br, 33.45.

Example 47 ~N' QH
XN\ I NH2 N NH OH

COMPOUND 47: Preparation of (1H-benzimidazol-2-ylmeth(5,6,7,8-tetrahydro-guinolin- 8-vl)-(1-aminobutan-3-of-4-yl)-amine.

[0320] To a solution of 3-buten-l-ol (10 g, 138 mmol) in dichloromethane (150 mL) was added acetic anhydride (13 mL, 138 mmol) and 4-dimethylaminopyridine (244 mg, 2 mmol).
The mixture was then stirred at room temperature for 8 hours. The reaction mixture was then poured into a saturated aqueous sodium bicarbonate solution (100 mL). After separation of the aqueous and organic layers, the aqueous layer was extracted twice with 100 mL portions of dichloromethane. The combined organic fractions were then dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to afford 3-buten-1-yl acetate as a colourless oil in a yield of 12.9 g (82%). 1H NMR (CDC13) 8 2.04 (s, 3H), 2.38 (in, 2H), 4.11 (t, 3H, J= 7.1 Hz), 5.04 (d, 1H, J= 9.1 Hz), 5.08 (d, 1H, J=15.3 Hz), 5.77 (m, 1H).
[0321] To a solution of 3-buten-l-yl acetate (5.7 g, 50 mmol) in dichloromethane (200 n1L) was added ira-chloroperoxybenzoic acid (12.9 g, 75 mmol). The reaction was then stirred at room temperature for 3 hours. The reaction mixture was then filtered through celite and concentrated in vacuo. The residue was purified by silica gel flash chromatography (4:1 hexanes:ethyl acetate) to yield 3,4-epoxybutan-1-yl acetate as a colourless oil in a yield of 3.8 g (58%). 1H NMR (CDC13) 6 1.78-1.88 (m, 2H), 2.03 (s, 3H), 2.47 (m, 1H), 2.75 (m, 1H), 2.99 (m, I H), 4.18 (t, I H, J= 6.6 Hz).
[0322] To a solution of 3,4-epoxybytan-1-yl acetate (3.9 g, 29 mmol) in DMF
(50 mL) was added potassium phthalimide (6.47 g, 35 mmol). The stirred mixture was then heated to 90 C for 16 hours. After cooling, the mixture was diluted with ethyl acetate (200 mL) and extracted repeatedly with water. The organic fraction was then dried over anhydrous sodium sulfate, filtered and concentrated in. vacuo. The residue was purified by silica gel flash chromatography (1:1 hexanes:ethyl acetate) to afford N-(3-hydroxybutan-4-yl-l-acetate)-phthalimide as a pale yellow oil in a yield of 1.65g (20%). 1H NMR (CDC13) 5 1.69-1.88 (m, 2H), 2.04 (s, 3H), 2.90 (m, 1H (OH)), 3.79 (d, 2H, J= 5.7 Hz), 4.03 (m, 1H), 4.21-4.31 (m, 2H), 7.70 (m, 2H), 7.83 (m, 2H). MS m/z 300 (M+Na).
[0323] To a solution of afford N-(3-hydroxybutan-4-yl-l-acetate)-phthalimide (554 mg, 2.0 mmol) in acetonitrile (15 mL) was added imidazole (150 mg, 2.2 mmol) and t-butyldimethylsilyl chloride (310 mg, 2.05 mmol). The mixture was then stirred overnight at room temperature. Dichloromethane (50 mL) was then added to the reaction, and the mixture was extracted with a saturated ammonium chloride solution. The organic layer was then dried over anhydrous sodium sulfate, filtered and concentrated to leave a yellow oily residue which was purified by silica gel flash chromatography (3:1 hexanes:ethyl acetate) to afford N-(3-t-butyldimethylsiloxybutan-4-yl-l-acetate)-phthalimide in a yield of 570 mg (73%). 1H
NMR (CDC13) 5 -0.04 (s, 3H), -0.01 (s, 3H), 0.84 (s, 9H), 1.78 (m, 2H), 3.68 (dd, 1H, J= 8.1, 6.5 Hz), 3.73 (dd, 1H, J= 8.1, 6.2 Hz), 4.15 (m, 3H), 7.71 (m, 2H), 7.85 (m, 2H).
[0324] To a stirred -78 C solution of afford N-(3-t-butyldimethylsiloxybutan-4-yl-l-acetate)-phthalimide (670 mg, 1.71 mmol) in THE (20 mL) was added DIBAL-H (5.1 mL of a 1.OM solution in hexanes, 5.1 mmol). The reaction was stirred at -78 C for 45 minutes, then a saturated solution of ammonium chloride (5 mL) was added. The mixture was allowed to warm to room temperature, then ethyl acetate (20 mL) and IN HCl (2 mL) were added.
The mixture was then shaken in a reparatory funnel to speed the clarification of the layers, then the organic and aqueous layers were separated. The aqueous layer was extracted twice with ethyl acetate, then the combined organic fractions were separated and the aqueous layer was extracted twice with ethyl acetate. The combined organic fractions were then dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by silica gel flash chromatography (1:1 hexanes:ethyl acetate) to afford N-(3-t-butyldimethylsiloxybutan-1-ol-4-yl)-phthalimide as a colourless oil in a yield of 465 mg (78%). 1H NMR (CDC13) 6 -0.02 (s, 3H), 0.09 (s, 3H), 0.86 (s, 9H), 1.71-1.82 (m, 2H), 2.11 (m, 1H (OIL)), 3.76 (m, 4H), 4.28 (m, 1H), 7.73 (m, 2H), 7.85 (m, 2H).
[0325] To a solution ofN-(3-t-butyldimethylsiloxybutan-l-ol-4-yl)-phthalimide (160 mg, 0.4 mmol) in dichloromethane (10 mL) was added Dess-Martin Periodinane (212 mg, 0.5 mmol). The mixture was then stirred at room temperature for 30 minutes. A 5%
solution of sodium thiosulfate (10 mL) and a saturated sodium bicarbonate solution (10 mL) was added along with another 20 mL of dichloromethane. The mixture was then stirred rapidly for 20 minutes, and the aqueous and organic layers were separated. The aqueous layer was extracted twice with dichloromethane, and the combined organic fractions were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford N-(3-t-butyldimethylsiloxybutan- 1-al-4-yl)-phthalimide as a yellow oil, which was used immediately in the next reaction without further purification. 1H NMR (CDC13) 6 -0.02 (s, 3H), 0.05 (s, 3H), 0.81 (s, 9H), 2.61 (m, 211), 3.74 (m, 2H), 4.51 (m, 1H), 7.71 (m, 2H), 7.85 (m, 2H), 9.81 (m, 1H).
[0326] To a solution ofN-(3-t-butyldimethylsiloxybutan-l-al-4-yl)-phthalimide (0.4 mmol) in dichloromethane (15 mL) was added (5,6,7,8-tetrahydroquinolin-8-yl)-[(N-t-butoxycarbonyl)-benzimidazol-2-yl)methyl]-amine (151 mg, 0.4 mmol). The mixture was stirred at room temperature for 30 minutes, then sodium triacetoxyborohydride (170 mg, 0.8 mmol) was added, and the reaction was allowed to stir for 16 hours. A
saturated sodium bicarbonate solution (10 mL) was added, and the aqueous and organic layers were separated.
The aqueous layer was then extracted twice with dichloromethane, and the combined organic fractions were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was then purified by silica gel flash chromatography (3% methanol in dichloromethane) to afford [(N-t-butoxycarbonyl)-benzimidazol-2-ylmethyljl-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-(N-phthalimidyl)-butan-3-(t-butyldimethylsiloxy)-4-yl)-amine as a pale yellow foam in a yield of 224 mg (79%). 1H NMR (CDC13) 6 -0.25 (s, 3H), -0.23 (s, 3H), 0.69 (s, 9H), 1.44-1.63 (m, 411), 1.68 (s, 9H), 2.00 (m, 2H), 2.16 (m, 1H), 2.65-2.74 (m, 3H), 3.48-3.62 (m, 2H); 3.94 (m, 1H), 4.23 (m, 111), 4.44 (d, 1H, J = 15.3 Hz), 4.72 (m, 1H, J
=15.3 Hz), 6.95 (m, 1H), 7.20 (m, 3H), 7.67 (m, 3H), 7.77 (m, 3H), 8.44 (m, 1H).
[0327] To a solution of [(N-t-butoxycarbonyl)-benzimidazol-2-ylmethyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-(N-phthalimidyl)-butan-3-(t-butyldimethylsiloxy)-4-yl)-amine (170 mg, 0.24 mmol) in THE (8 mL) was added 1N HCl (2 mL). The mixture was then heated to 50 C for 2 hours. After cooling, dichloromethane (50 mL) was added, and the mixture was shaken with a saturated sodium bicarbonate solution (20 mL). After separation of the aqueous and organic layers, the aqueous layer was extracted twice with dichloromethane. The combined organic fractions were then dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford a foamy residue, which was purified by silica gel flash chromatography (5% methanol in dichloromethane) to afford (1-H-benzimidazol-2-ylmethyl)-(5,6,7, 8-tetrahydro-quinolin-8-yl)-(l-(N-phthalimidyl)-butan-3-of-4-yl)-amine as a white foam in a yield of 73 mg (49%). 1H NMR
(CDC13) 61.50-1.59 (m, 2H), 1.70-2.07 (m, 5H), 2.21 (m, 1H), 2.75-3.00 (m, 4H), 3.78-3.94 (m, 2H), 4.00-4.22 (m, 2H), 7.04 (m, 1H), 7.16 (m, 2H), 7.24 (d, 1H, J = 5.8 Hz), 7.68 (br s, 1H (NH)), 7.71 (m, 3H), 7.81 (m, 3H), 8.21 and 8.42 (d, total of 1H, J= 4.9, 5.1 Hz respectively).
[03281 To a solution of (1-H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-(N-phthalimidyl)-butan-3-ol-4-yl)-amine (73 mg, 0.147 mmol) in denatured ethanol (5 mL) was added hydrazine hydrate (0.07 mL, 1.5 mmol). The mixture was then heated to reflux for 60 minutes. After cooling, the reaction was concentrated in vacuo, taken up in dichloromethane (20 mL) and washed with an aqueous sodium carbonate solution (5 mL').
The aqueous layer was then extracted twice with dichloromethane, and the combined organic fractions were dried over anhydrous sodium sulfate, filtered and concentrated to afford a foamy residue which was purified by silica gel flash chromatography (10%
methanol, 0:5.%
ammonium hydroxide in dichloromethane) to afford (1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-aminobutan-3-of-4-yl)-amine (COMPOUND 47 -diastereomeric mixture) as a white foam in a yield of 22 mg (41%). 1H NMR
(CDC13) 6 1.35 (m, 1H), 1.70-1.82 (m, 2H), 2.06 (m, 1H), 2.26 (m, 1H), 2.54-2.99 (m, 5H), 3.57 and 3.84 (m, total of 1H), 3.94 (d, 1H, J =15.3 Hz), 4.01 (m, 1H), 4.13 (s, 1H), 4.13 (d, 1H, J = 15.3 Hz), 7.14-7.21 (m, 3H), 7.42 (d, 1H, J = 7.5 Hz), 7.57 (m, 2H), 8.46 and 8.56 (d, total of 1H, J=
3.6, 3.6 Hz respectively); 13C NMR (CDC13) 8 21.57, 22.25, 29.33, 31.52, 32.30, 46.46, 47.69, 48.69, 49.91, 62.15, 62.67, 70.1 1, 74.23, 122.33, 122.67, 122.99, 135.61, 138.21, 146.93, 147.29, 141.15, 154.89. ES-MS m/z 366 (M+H). Anal. Calcd. for C21H27N500Ø4CH2Cl2: C, 64.35; H, 7.01; N, 17.53. Found: C, 64.16; H, 7.20;
N, 17.22.

Example 48 QqH H
X N- f NH2 N
NH F

COMPOUND 48: Preparation of (1H-benzimidazol-2-ylmethy) (5,6,7,8-tetrahydro=
quinolin-8-vl)-(1-amino-3-fluoro-butan-4-yl)-amine.
[03291 To a 0 C solution of (1-H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-(l-(N-phthalimidyl)-butan-3-of-4-yl)-amine (81 mg, 0.163 mmol (preparation described above)) in dichloromethane (5 mL) in a polyethylene test tube under a nitrogen atmosphere was added diethylaminosulfur trifluoride (0.065 mL, 0.5 mmol). The mixture was stirred, gradually warming to room temperature for 2 hours. The mixture was then poured into a saturated sodium bicarbonate solution (10 mL). The aqueous and organic layers were then separated, and the aqueous layer was extracted twice with dichloromethane. The combined organic fractions were then dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by silica gel flash chromatography (5%
methanol in dichloromethane) to afford (1-H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-(N- phthalimidyl)-3-fluoro-butan-4-yl)-amine as a white foam in a yield of 55 mg (67%). 1H NMR (CDC13) 8 1.69 (m, 2H), 1.86-2.04 (m, 4H), 2.75-2.88 (m, 4H), 3.99 (m, 1H), 4.02-4.20 (m, 4H), 5.01 and 5.08 (m, total of 1H), 7.13 (m, 4H), 7.26 (m, 1H), 7.59-7.73 (m, 4H), 7.89 (m, 1H), 8.78 (m, 1H).
[03301 To a solution of (1-H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-(N-phthalimidyl)-3-fluoro-butan-4-yl)-amine (55 mg, 0.110 mmol) in denatured ethanol (5 mL) was added hydrazine hydrate (0.07 mL, 1.5 mmol). The mixture was then heated to reflux for 60 minutes. After cooling, the reaction was concentrated in vacuo, taken up in dichloromethane (20 mL) and washed with an aqueous sodium carbonate solution (5 mL). The aqueous layer was then extracted twice with dichloromethane, and the combined organic fractions were dried over anhydrous sodium sulfate, filtered and concentrated to afford a foamy residue which was purified by silica gel flash chromatography (10%
methanol, 0.5% ammonium hydroxide in dichloromethane) to afford (1H-benzimidazol-2-ylmethyl)-(5,6,7, 8-tetrahydro-quinolin-8-yl)-(1-amino-3-fluorobutan-4-yl)-amine (COMPOUND 48 - diastereomeric mixture) as a white foam in a yield of 16 mg (40%). 1H
NMR (CDC13),6 1.73 (m, 2H), 1.91-2.04 (m, 2H), 2.23 (m, 111), 2.61-2.86 (m, 6H), 4.00 (d, 1H, J = 16.5 Hz), 4.05 (s, 1H), 4.07 (m, 1H), 4.15 (m, 1H), 4.17 (d, 1H, J =
16.5 Hz), 4.47 and 4.53 (m, total of 1H), 7.14-7.22 (m, 4H), 7.42 (d, 1H, J = 8.1 Hz), 7.57 (m, 1H), 7.58 (br s, 1H (NH), 8.58 (d, 1H, J= 4.5 Hz); 13C NMR (CDC13) 6 21.73 and 23.83 (d, total of 1C, Jc-F = 23 Hz), 29.30, 29.54, 30.73, 39.09, 45.92 and 46.60 (total of 1C), 47.35, 50.10 and 62.23 (d, total of 1C, Jc_F = 27 Hz), 92.65 and 95.11 (d, total of 1H, Jc_F = 167 Hz), 115.38, 122.08, 122.73, 129.19, 131.29, 135.07, 137.82, 137.98, 146.99, 147.11, 156.49, 157.65. ES-MS m/z 368 (M+H). Anal. Calcd. for C21H26N5F=0.1CH2C12Ø2C6H12: C, 68.19; H, 7.34;
N, 17.83.
Found: C. 67.82; H, 7.14; N, 17.66.

Example 49 cc '--, NH2 HN N

COMPOUND 49: Preparation of 13-(1-amino-cyclopropyl)-propyll-(1H-benzimidazol-ly methyl)-(5,6,7,8-tetrahydro-quinolin-8-yl-amine (hydrobromide salt).
Preparation of 1 -tent-butox _c~ylamino-cyclopropanecarboxylic acid ethyl ester (Wentland, M. P., et al., J. Med. Chem. (1988) 31:1694-1697.):
[03311 To a suspension of 1-aminocyclopropanecarboxylic acid (998 mg, 9.87 mmol) in EtOH (25 mL), cooled to 0 C, was added SOC12 (2.0 mL, 27 mmol) dropwise over minutes. The resulting solution was heated at reflux under nitrogen for 2 hours, then was evaporated under reduced pressure, giving the ester as a light brown oil.
[03321 This material was dissolved into EtOAc (25 mL) and a solution of KHCO3 (1.51 g, 15.1 mmol) in H2O (9 mL) was added dropwise. The resulting solution was cooled to 0 C and a solution of Boc2O (2.97 g, 13.6 mmol) in EtOAc (10 mL) was added.
The reaction was stirred at room temperature for 16 hours, the layers were separated and the aqueous solution was extracted with EtOAc (25 mL). The combined organic solution was dried (MgSO4), filtered and concentrated under reduced pressure. Purification by flash column chromatography on silica (EtOAc/hexane, 1:3) gave the protected amine as light brown solid (1.27 g, 5.54 mmol, 56%). 'H NMR (CDC13) 81.08-1.18 (m, 2H), 1.23 (t, 3H, J
= 7.2 Hz), 1.44 (s, 9H), 1.46-1.53 (m, 2H), 4.14 (q, 2H, J= 7.2 Hz), 5.13 (br.
s, 1H).

Preparation of (1-hydroxymethyl-cyclopropyl)-carbamic acid tert-butyl ester:
[0333] To a solution of the ester (1.18 g, 5.15 mL) in THE (10 mL) under nitrogen was added a solution of LiBH4 (200 mg, 9.2 mmol) in THE (10 mL) dropwise over 10 minutes.
The reaction was stirred at room temperature for 17.5 hours, then was cooled to 0 C. A
solution of 50% HOAc was added dropwise until the evolution of gas had ceased (approx. 8 mL). The resulting white suspension was diluted with H2O (15 mL) and was extracted with Et2O (30 mL). The organic solution was washed with 15% aqueous NaHCO3 (15 mL) and brine (15 mL), then dried (Na2SO4), filtered and concentrated under reduced pressure.
Purification by flash column chromatography on silica (EtOAc/hexane, 1:1) gave the alcohol as a white solid (592 mg, 3.16 mmol, 61 %).2 'H NMR (CDC13) 8 0.81 (s, 4H), 1.43 (s, 9H), 3.52 (br. s, 1H), 3.58 (s, 2H), 5.12 (br. s, 1H).

Preparation of (1-formyl-cyclopropyl)-carbamic acid tert-butyl ester:
[0334] To a solution of the alcohol (389 mg, 2.08 mmol) in CH2C12 (11 mL), cooled:1o 0 C, was added crushed, dried 3A molecular sieves (1.05 g), NMO (382 mg, 3.26 mmol) and TPAP (76 mg, 0.22 mmol). The black mixture was stirred at 0 C for 30 minutes and at room temperature for a further 30 minutes. The mixture was diluted with EtOAc (20 mL) and flushed through a short silica column, rinsing with EtOAc. The product containing material was concentrated under reduced pressure giving the aldehyde as a white solid (345 mg, 1.86 mmol, 90%). 'H NMR (CDC13) 8 1.27-1.37 (m, 2H), 1.40-1.52 (m, 2H), 1.46 (s, 9H), 5.22 (br. s, 1H), 9.16 (s, 1H).

Preparation of (E)-3-(1-tert-butoxycarbonylamino-c .clopropyl)-acrylic acid ethyl ester:
[0335] Triethyl phosphonoacetate (0.62 mL, 3.13 mmol) was added dropwise to a suspension of 60% NaH in mineral oil (120 mg, 3.00 mmol) in THE (5 mL). The resulting solution was stirred at room temperature for 10 minutes, then cooled to 0 C
for the dropwise addition of a solution of the aldehyde (463 mg, 2.50 mmol) in THE (5 mL). The reaction was stirred at 0 C for 15 minutes, then heated to reflux for 1 hour. Once cooled to room temperature, saturated aqueous NH4Cl (10 mL) was added, the layers were separated and the aqueous solution was extracted with CH2C12 (10 mL x 2). The organic solution was dried (MgSO4), filtered and concentrated under reduced pressure. Purification by flash column chromatography on silica (EtOAc/hexane, 1:1) gave the unsaturated ester as a pale yellow solid (539 mg, 2.11 mmol, 84%). 1H NMR (CDC13) 6 1.11-1.18 (m, 2H), 1.24-1.29 (m, 5H), 1.44 (s, 9H), 4.17 (q, 2H, J= 7.1 Hz), 5.02 (br. s, 1H), 5.84 (d, 1H, J=15.3 Hz), 6.47 (d, 1H, J= 15.6 Hz).

Preparation of 3-(1-tert-butoxycarbonylamino-c yclopropyl)-propionic acid ethyl ester:
[0336] A solution of the unsaturated ester (495 mg, 1.94 minol) in EtOAc (10 mL) was hydrogenated (H2 balloon) over 10% PdJC (25 mg, 0.023 mmol) at room temperature for 3 hours. The mixture was suction filtered through Celite, washing with EtOAc and evaporation of the filtrate under reduced pressure gave the saturated ester as a colourless oil (500 mg, 1.94 mmol, 100%). 1H NMR (CDC13) 6 0.61-0.65 (m, 1H), 0.73-0.78 (m, 1H), 0.91 (t, 2H, J= 7.4 Hz), 1.25 (td, 3H, J= 7.1, 1.4 Hz), 1.43 (s, 9H), 1.78-1.90 (m, 2H), 2.36 (t, 1H, J= 7.7 Hz), 2.44 (t, 1H, J= 7.5 Hz), 4.12 (q, 2H, J= 7.1 Hz).

Preparation of [1-(3-hydroxy-propyl)-cyclopropyl]-carbamic acid tert-butyl ester:
[0337] LiBH4 (70 mg, 3.2 mmol) was added to a solution of the ester (500 mg, 1.94 mmol} in THE (8 mL). The reaction was stirred at room temperature under nitrogen for 18 hours, then was quenched by the dropwise addition of 50% aqueous HOAc until the evolution of gas had ceased (approx. 2 mL). The suspension was diluted with H2O (10 mL) and extracted with Et20 (15 mL). The organic solution was washed with saturated aqueous NaHCO3 (10 mL) and brine (10 mL), dried (Na2SO4), filtered and concentrated under reduced pressure. Purification by flash column chromatography on silica (hexane/EtOAc, 2:1; increased to 1:1) gave the alcohol as a colourless oil (164 mg, 0.77 mmol, 40%). 1H
NMR (CDC13) 6 0.55-0.62 (m, 2H), 0.69-0.75 (m, 2H), 1.40 (s, 9H), 1.52-1.72 (m, 4H), 2.10 (br. s, 1H), 3.64 (t, 2H, J= 6.3 Hz), 4.96 (br. s, 1H).

Preparation of 11-[3-(5 6,7 8-tetrahydro-quinolin-8-ylamino)-propyll-cyclopropyl}-carbamic acid tert-butyl ester:
[0338] To a solution of the alcohol (160 mg, 0.74 mmol) in CH2C12 (4 mL), cooled to 0 C, was added crushed, dried 3A molecular sieves (374 mg), NMO (125 mg, 1.07 mmol) and TPAP (26 mg, 0.07 mmol). The reaction was stirred at 0 C for 25 minutes, then at room temperature for a further 15 minutes. The reaction was diluted with EtOAc (8 mL) and the mixture was flushed through a short silica column, eluting with EtOAc. Removal of the solvent under reduced pressure gave the aldehyde as a pale yellow oil (123 mg, 78%).
[0339] A solution of this material (120 mg, 0.56 mmol) and 8-amino-5,6,7,8-tetrahydroquinoline (90 mg, 0.61 mmol) in MeOH (1.51nL) was stirred at room temperature under nitrogen for 17 hours. NaBH4 (35 mg, 0.93 mmol) was added and the reaction was stirred for a further 15 minutes. The solvent was evaporated under reduced pressure, the residue was taken up into CH2C12 (20 mL) and was washed with saturated aqueous NaHCO3 (5 mL) and brine (5 mL). The organic solution was dried (MgSO4), filtered and concentrated under reduced pressure. Purification by. flash column chromatography on silica (CH2C12/MeOH/NH4OH, 19:1:0.1) gave the secondary amine as an orange oil (51 mg, 0.15 mmol, 26%). 1H NMR (CDC13) S 0.57-0.63 (m, 2H), 0.69-0.76 (m, 2H), 1.42 (s, 9H), 1.56-1.80 (m, SH), 1.80-2.06 (m, 3H), 2.09-2.20 (m, 1H), 2.68-2.87 (m, 4H), 3.77 (t, 1H, J=
6.3 Hz), 5.16 (br. s, 1H), 7.06 (dd, 1H, J= 7.7, 4.7 Hz), 7.37 (d, 1H, J= 7.5 Hz), 8.38 (d, 1H, J= 4.2 Hz).

Preparation of 2-{[[3-(1-tert-butox .carbonylamino-cyclopro-pyl)-propyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-methyll-benzimidazole-l-carboxylic acid tert-butyl ester:
[0340] A solution of the secondary amine (51 mg, 0.147 mmol), tert-butyl 2-chloro-methylbenzimidazole-l-carboxylate (47 mg, 0.18 mmol), DIPEA (0.04 mL, 0.2 mmol) and KI (5 mg, 0.03 mmol) in CH3CN (0.8 mL) was stirred at 60 C under nitrogen for 18 hours.
Once cooled to room temperature, saturated aqueous NaHCO3 (5 mL) was added and the mixture was extracted with CH2C12 (10 mL x 3). The combined organic solution was dried (MgSO4), filtered and concentrated under reduced pressure. Purification by flash column chromatography on silica (CH2C12/MeOH/NH4OH, 19:1:0.1) gave the tertiary amine as a pale orange foam (60 mg, 0.104 nimol, 71%). 1H NMR (CDC13) 8 0.30-0.46 (m, 2H), 0.48-0.63 (m, 2H), 1.29-1.50 (in, 11H), 1.60-1.76 (m, 12H), 1.79-1.90 (m, 1H), 1.95-2.05 (m, 1H), 2.08-2.19 (m, 1H), 2.59-2.70 (m, 2H), 2.72-2.87 (m, 2H), 4.26 (dd, 1H, J= 9.5, 6.514z), 4.50 (d, 1H, J= 15.6 Hz), 4.63 (d, 1H, J= 15.0 Hz), 5.10 (br. s, 1H), 6.98 (dd, I
H, J= 7.7, 4.7 Hz), 7.26-7.32 (m, 3H), 7.72 (dd, 1H, J= 6.2, 3.2 Hz), 7.83 (dd, 1H, J= 6.0, 3.0 Hz), 8.37 (d, 1H, J= 3.0 Hz).

Preparation of COMPOUND 49:

[0341] To a solution of the tertiary amine (57.6 mg, 0.100 mmol) in glacial HOAc (1.0 mL) was added a saturated solution of HBr in HOAc (0.5 mL). The reaction was stirred at room temperature for one hour and Et20 (5 mL) was added. The resulting sticky solid was washed with Et2O (1 mL x 2), then crushed with a spatula while under Et2O (-2 mL). The resulting precipitate was washed with Et2O (1 mL x 2), then dried under reduced pressure affording COMPOUND 49 as an orange powder (65.7 mg, 0.091 mmol, 91%). 1H NMR
(D20) 6 0.63-0.68 (m, 2H), 0.81-0.86 (m, 2H), 1.46-1.67 (m, 4H), 1.76-1.90 (m, 1H), 1.93-2.06 (m, I H), 2.12-2.22 (m, 111), 2.31-2.41 (m, 1H), 2.48-2.58 (m, I H), 2.77-2.87 (m, 1H), 2.96-3.02 (m, 2H), 4.39 (d, 1H, J=16.8 Hz), 4.47-4.56 (m, 2H), 7.59 (dd, 2H, J= 6.2, 3.2 Hz), 7.79 (dd, 2H, J= 6.2, 3.2 Hz), 7.85 (dd, 1H, J= 7.8, 6.0 Hz), 8.33 (d, 1H, J= 7.8 Hz), 8.62 (d, 1H, J= 5.4 Hz). 13C NMR (D20) S 9.6, 20.4, 24.3, 27.6, 31.8, 34.3, 48.0, 51.8, 60.5, 114.3, 125.9, 126.9, 131.0, 139.3, 140.6, 148.1, 151.2, 151.7. ES-MS fn/z 376 (M+H). Anal.
Calcd. for C23H29N5.3.1HBr=1.5C2H4O2Ø2H2O: C, 43.37; H, 5.39; N, 9.73; Br, 34.40.
Found: C. 43.26; H, 5.67; N, 9.64; Br, 34.68.

Example 50 CN

HN N

COMPOUND 50: (1H-Benzimidazol-2-h)l)-(5 6 7 8-tetrah ydroquinolin-8-y.l)-(5-amino-pent-l-y1 -amine (Hydrobromide salt) [0342] To a stirred solution of [1-(2-(trimethylsilyl)ethoxymethyl)-(1H-benzimidazol-2-ylmethyl)]-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine (188 mg, 0.455 mmol) and diisopropylethyl amine (0.26 ml< 1.49 mmol) in CH3CN was added 5-bromovaleronitrile (0.12 mL, 1.03 mmol). The mixture was heated at 80 C for 47 hours, after which time the reaction was cooled to room temperature. After removal of volatiles under reduced pressure, the residue was dissolved in CH2Cl2 (20 mL). The solution was washed with brine (3 x 15 mL). The aqueous phase was extracted with CH2Cl2 (1 x 15 mL). The combined organic phases were dried (Na2SO4), filtered and concentrated under reduced pressure to give a crude orange oil (306 mg). Purification of this oil by column chromatography (1.75 cm OD, 14 g silica, 40:1 CH2C12: CH3OH) afforded the purified tertiary amine (110 mg, 50%).
[0343] The amine from above (110 mg) was dissolved in ammonia saturated CH3OH
(12 mL) and treated with Raney-Nickel (410 mg). The mixture was shaken on a Parr hydrogenator at 50 psi H2 for 20 hours, after which time the mixture was filtered through celite and concentrated to give a crude yellow-orange oil (124 mg).
[0344] The amine from above (124 mg) was dissolved in 4N HCl (2 mL) and heated to 50 C for 6 hours. The mixture was then cooled to room temperature and basified with 1ON
NaOH (final pH > 13). This aqueous phase was extracted with CH2Cl2 (4 x 10 mL). The organic phase was then dried (Na2SO4), filtered and concentrated to give a crude brown foam (83 mg). Purification of this foam by radial chromatography on silica gel (40:1:1 CH2Cl2:
CH3OH: NH4OH) afforded the pure freebase (38 mg, 46% over two steps).
[03451 Using the General Procedure D: Conversion of the freebase from above (38 mg) to the hydrobromide salt gave COMPOUND 50 as a white solid (53 mg, 76 %). 1H
NMR
(D20) 6 1.14-1.28 (m, 2H), 1.39-1.57 (m, 4H), 1.77-1.90 (m, 1H), 1.96-2.10 (m, 1H), 2.13-2.23 (m, 1H), 2.31-241 (m, 1H), 2.46-2.57 (m, 1H), 2.73-2.90 (m, 3H), 2.96-3.03 (m, 2H), 4.38 (d, 1H, J=16.7 Hz), 4.47-4.57 (m, 2H), 7.60 (dd, 2H, J= 6.3, 3.3 Hz), 7.80 (dd, 2H, J=
6.2, 3.1 Hz), 7.86 (dd, 1H, J= 7.9, 6.0 Hz), 8.31 (d, 1H, J= 7.0 Hz), 8.62 (d, 1H, J= 4.7 Hz).
13C NMR (D20) 8 20.40, 23.88, 26.92, 27.63, 27.87, 39.68, 48.51, 52.09, 60.86, 114.26 (2 carbons), 125.85, 126.83 (2 carbons), 131.17, 139.29, 140.47, 147.92 (2 carbons), 151.48, 152.00. ES-MS to/z 364 (M+H) Anal Calc. for C22H29N5.3.1HBr -2.6H2O: C, 39.97;
H, 5.69; N, 10.59; Br, 37.46. Found: C, 39.96; H, 5.64; N, 10.62; Br, 37.36.

Exam lp e 51 HN N

COMPOUND 51: (1H-Benzimidazol-2-y lmethyl)-(5 6 7 8-tetrahydroquinolin-8-YI -(6-amino-hex-1-yl)-amine (Hydrobromide salt) Preparation of N-(tert-butoxycarbonyl)-6-amino-l-hexanal:

xI
0 NO~
H H

[0346] Di-tert-butyl-dicarbonate (1.155 g, 5.29 mmol) was added to a solution of 6-amino-1-hexanol (541 mg, 4.62 mmol) and diisopropylethyl amine (0.25 mL) in THE
(10 mL). The mixture was stirred at ambient temperature for 18 hours, after which time the volatile components were removed under reduced pressure. The residue was dissolved in CH2C12 (30 mL) and washed with brine (3 x 20 mL). The organic phase was dried (Na2SO4), filtered and removed on a rotovap to leave a crude yellow oil (1.090g).
[0347] Some of the above-obtained oil (220 mg, 1.01 mmol) was dissolved in CH2C12 (5 mL) and treated with Dess-Martin periodinane (455 mg, 1.07 mmol). After 2 hours, the reaction was diluted with diethyl ether (20 mL) and treated with 20% w/v Na2S2O3 (aq). The phases were separated after 10 minutes, and the aqueous phase was extraced with ether (3 x mL). The combined organic phase was washed with 20% w/v Na2S2O3 (1 x 12 mL), saturated aqueous NaHCO3 (1 x 12 mL) and brine (1 x 12 mL). The organic phase was dried (MgSO4), filtered and removed under reduced pressure to give a crude colourless oil (172 mg). This oil was purified by column chromatography (1.75 cm OD, 14 g silica, 4:1 hexanes:
ethyl acetate) to give 31 mg of desired intermediate (14%). 1H NMR (CDC13) d 1.29-1.50 (m,. 13H), 1.63 (pentet, 2H, J= 7.4 Hz), 2.42 (td, 2H, J= 7.2, 1.6 Hz), 3.06-3.12 (m, 2H), 4.57 (br s, 1H), 9.74 (s, 1H).

[0348] Using the General Procedure B: To a stirred solution of [ 1-(2-(trimethylsilyl)ethoxymethyl)-(1 H-benzimidazol-2-y. hnethyl)] -(5,6,7, 8-tetrahydro-quinolin-8-yl)-amine (62 mg, 0.150 mmol) and N-(tent-butoxycarbonyl)-6-amino-1-hexanal (31 mg, 0.144 mmol) in CH2C12 (2.5 mL) was added NaBH(OAc)3 (66 mg, 0.311 mmol) and the mixture stirred for 24 hours to afford a crude yellow oil (91 mg).
[03491 This oil (91 mg) was dissolved in 4N HCl (2 mL) and heated to 50 C.
After 4 hours the reaction was allowed to cool. The reaction was basified with l ON
NaOH (final pH
> 13) and the aqueous phase was extracted with CH2C12 (8 x 7 mL). The organic phase was dried (Na2SO4), filtered and removed on a rotovap to give 52 mg crude yellow oil freebase.
This oil was purified by radial chromatography on silica gel (40:1:1 CH2C12:
CH3OH:
NH4OH) to give 36 mg yellow film (66% yield over two steps).
[03501 Using the General Procedure D: conversion of the freebase from above (36 mg) to the hydrobromide salt gave COMPOUND 51 as a white solid (53 mg, 84 %).
[03511 1H NMR (D20) 81.13-1.23 (m, 4H), 1.31-1.56 (m, 4H), 1.75-1.90 (m, 1H), 1.96-2.10 (m, 1H), 2.13-2.23 (m, 1H), 2.31-241 (m, 1H), 2.44-2.55 (m, 1H), 2.71-2.81 (m, 1H), 2.85 (t, 2H, J= 7.8 Hz), 2.97-3.04 (m, 2H), 4.38 (d, 1H, J= 17.0 Hz), 4.45-4.59 (m, 2H), 7.61 (dd, 2H, J= 6.1, 3.1 Hz), 7.80 (dd, 2H, J-- 6.1, 3.0 Hz), 7.86 (dd, 1H, J= 7.7, 5.9 Hz), 8.34 (d, 1H, J= 8.3 Hz), 8.62 (d, 1H, J= 5.7 Hz). 13C NMR (D20) 8 20.39, 20.45, 25.81, 26.41, 27.07, 27.64, 28.14, 39.74, 48.67, 52.22, 60.95, 114.24 (2 carbons), 125.86, 126.88 (2 carbons), 131.01, 139.21, 140.49, 147.99, 151.55, 152.12. ES-MS na/z 378 (M+H) Anal Cale. for C23H31N5 =3.1HBr =1.9H2O: C, 41.69; H, 5.77; N, 10.57; Br, 37.38.
Found: C, 41.77;
H, 5.60; N, 10.60; Br, 37.36.

Example 52 H

COMPOUND 52: Preparation of Nl-(1H-Benzimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydro-quinolin-8-yl)-cyclohexane-cis-1 4-diamine (hydrobromide salt).
Preparation of 4-fN-(tert-butyloxycarbonyl )lamino-cyclohexanone:
[0352] A solution of trans-4-aminocyclohexanol hydrochloride (2.67 g, 1.14 mol) in 1 N
NaOH (40 mL) was washed with CHC13 (40 mL), CH2Cl2 (2 x 30 mL) and EtOAc (4 x mL). The combined organic extracts were dried (Na2SO4), filtered and concentrated in vacuo to afford the desired free base (0.43 g) as a white solid. To a suspension of trans-4-asninocyclohexanol (0.43 g, 4.09 mmol) in THE (20 mL) was added di-tert-butyl dicarbonate (0.89 g, 4.09 mmol) and the mixture stirred at room temperature for 2 hours.
The mixture was concentrated under reduced pressure and the resultant crude product was used without further purification in the next reaction.
[0353] To a suspension of the alcohol from above (-3.7 mmol) and powdered 3 A
molecular sieves (0.90 g) in CH2C12 (10 mL) was added 4-methylmorplioline N-oxide (0.696 g, 5.95 mmol) and tetrapropylammonium perruthenate (0.089 g, 0.25 mmol) and the mixture stirred overnight. The reaction was concentrated under reduced pressure and purified by column chromatography through a plug of silica gel (ethyl acetate/hexanes, 1:1) to afford the title compound (0.670 g, 84% over 2 steps) as a white solid. 1H NMR (CDC13) S
1.45 (br s, 9H), 1.64-1.73 (m, 2H), 2.21-2.27 (m, 2H), 2.37-2.44 (m, 4H), 3.89-3.95 (m, 1H), 4.50 (br s, 1H, NH).
[0354] Following General Procedure B: To a stirred solution of 8-amino-5,6,7,8-tetrahydroquinoline (195 mg, 1.32 mmol) and 4-[N-(test-butyloxycarbonyl)}amino-cyclohexanone (293 mg, 1.38 mmol) in dry THE (5 mL) was added NaBH(OAc)3 (392 mg, 1.85 mmol)' and the mixture stirred for 2 h at room temperature. The reaction was diluted with CH2C12 (20 mL) and saturated aqueous sodium bicarbonate (40 mL) and the aqueous phase was washed with CH2C12 (2 x 10 mL). The combined organic extracts were dried (Na2SO4), filtered and concentrated to afford the desired secondary amine as a mixture of diastereomers (520 mg). The diastereomers were separated and purified by column chromatography with silica gel (CH2C12/MeOH, 96:4) to give a top, less polar diastereomer (179 mg, 39%) and a lower, more polar one (107 mg, 23%), each as an orange oil.
[0355] Following the General Procedure for N-alkylation: To a stirred solution of the top, less polar diastereomer from above (179 mg, 0.52 mmol) in CH3CN (5 mL) was added N,N-diisopropylethylamine (0.18 mL, 1.04 mmol), KI (24 mg, 0.14 mmol) and 1-(tert-butoxycarbonyl)-2-(chloromethyl)benzimidazole (149 mg, 0.56 mmol). The mixture was stirred at 60 C for 4 h then cooled, diluted with CH2Cl2 (40 mL) and saturated aqueous sodium bicarbonate (30 mL). The aqueous phase was washed with CH2C12 (2 x 10 mL), dried (Na2SO4), filtered and concentrated. Purification of the resultant brown oil by column chromatography with silica gel (CH2C12/MeOH, 96:4) afforded the desired alkylated cis-1,4-diamine, N1-(1-tert-butoxycarbonyl-benzimidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydro-quinolin-8-yl)-cyclohexane-cis-1,4-diamine-4-carboxylic acid tert-butyl ester, (142 mg, 47%) as a yellow oil.

[0356] Using General Procedure D: Conversion of the oil from above (72 mg, 0.13 mmol) to the hydrobromide salt with simultaneous removal of the N-tert-butoxycarbonyl protecting group followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 52 (67 mg, 82%) as an orange solid. 1H NMR (D20) 8 1.66-1.81 (m, 4H), 1.85-2.08 (m, 4H), 2.11-2.18 (m, 3H), 2.42-2.47 (m, 1H), 2.81-2.85 (m, 1H), 3.00-3.02 (m, 2H), 3.53-3.55 (m, 1H), 4.45 (d, 1H, J=16.8 Hz), 4.57-4.63 (m, 1H), 4.60 (d, 1H, J=
16.8 Hz), 7.59 (dd, 2H, J= 6.3, 3.3 Hz), 7.76 (dd, 2H, J= 6.3, 3.3 Hz), 7.80 (dd, 1H, J= 7.8, 6.3 Hz), 8.28 (d, 1H, J= 7.8 Hz), 8.58 (d, 1H, J= 5.5 Hz); 13C NMR (D2O) 8 20.79, 23.38, 24.33, 25.64, 27.55, 27.70, 27.90, 43.83, 46.55, 58.06, 59.77, 114.25, 125.82, 127.02, 130.95, 139.12, 140.53, 147.99, 151.38, 152.14. ES-MS m/z 376 (M+H). Anal. Calcd. for C23H29N5=2.9HBr=2.5H20: C, 42.16; H, 5.68; N, 10.69; Br, 35.37. Found:. C, 42.55; H, 5.43;
N, 10.31; Br, 35.28.

Example 53 N
O CI
N NH H

COMPOUND 53: Preparation N-Ã4-cis-[(1H-Benzimidazol-2-ylmethyl)-(5,6,7,8-tetrah dquinolin-8-yl -amino]-cyclohexyll)-2-chloro-benzamide (hydrobromide salt [0357] A solution of the diprotected amine from above, N1-(1-tent-butoxycarbonyl-benzimidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydro-quinolin-8-yl)-cyclohexane-cis-1,4-diamine-4-carboxylic acid tent-butyl ester, (see COMPOUND 52) (70 mg, 0.12 mmol) in CH2C12/TFA (1:1, 2 mL) was stirred at room temperature for 1.5 h. The reaction was then concentrated and diluted with CH2C12 (15 mL) and 1 N NaOH (15 mL). The aqueous layer was washed with CH2C12 (2 x 10 mL) and the combined organic extracts were dried (Na2SO4), filtered and concentrated. To a solution of the resultant crude amine (32 mg) CH2C12 (3 mL) was added Et3N (0.045 mL, 0.32 mmol) and 2-chlorobenzoylchloride (0:030 mL, 0.24 mmol) and the mixture stirred overnight. The reaction was diluted with CH2C12 (10 mL) saturated aqueous sodium bicarbonate (10 mL). The aqueous layer was washed with CH2C12 (2 x 5 mL) and the combined organic extracts were dried (Na2SO4), filtered and concentrated. Purification of the crude foam by radial chromatography on silica gel gel (1 mm plate, 100:1:1 CH2C12/MeOH/NH40H) afforded the title amide (23 mg, 37% over steps) as a yellow foam.
[0358] Using General Procedure D: Conversion of the foam from above (23 mg, 0.045 mmol) to the hydrobromide salt followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 53 (27 mg, 83%) as a yellow solid. 1H NMR
(D20) 8 1.44-1.62 (m, 4H), 1.74-1.97 (m, 4H), 2.04-2.21 (m, 3H), 2.41-2.46 (m, 1H), 2.80-2.84 (m, 1H), 3.00-3.02 (m, 2H), 3.98-3.99 (m, 1H), 4.41 (d, 1H, J= 16.8 Hz}, 4.55-4.60 (m, 1H), 4.58 (d, 1H, J=16.8 Hz), 7.30-7.37 (m, 2H), 7.43-7.45 (m, 2H), 7.60 (dd, 2H, J= 6, 3 Hz), 7.75 (dd, 2H, J= 6, 3 Hz), 7.82 (dd, 1H, J= 7.8, 6 Hz), 8.31 (d, 1H, J= 8.1 Hz), 8.58 (d, 1H, J=
5.7 Hz); 13C NMR (D2O) 8 20.78, 23.87, 25.39, 27.11, 27.59, 28.54, 28.92, 44.11, 45.77, 59.89, 60.00, 114.24, 125.83, 127.07, 127.73, 128.61, 130.18, 130.88, 131.89, 135.36, 139.08, 140.55, 148.01, 151.94, 152.11, 170.46. ES-MS m/z 514 (M+H). Anal.
Calcd. for C30H32N5OC1.2.2HBr=1.9H20: C, 49.61; H, 5.27; N, 9.64; Br, 24.20. Found: C, 49.65; H, 5.22; N, 9.50; Br, 24.17.

Example 54 (N~- N/".

N NHQNHZ

COMPOUND 54: Preparation of N1-(1H-Benzimidazol-2-ylmethyll-N1-(5,6,7,8-tetrahydro-quinolin-8-yl)-cyclohexane-trans-1,4-diamine (hydrobromide salt) [0359] Following the General Procedure for N-alkylation: To a stirred solution of the bottom, more polar diastereomer from above (see COMPOUND 52) (107 mg, 0.31 mmol} in CH3CN (5 mL) was added N,N-diisopropylethylamine (0.11 mL, 0.63 mmol), KI (14 mg, 0.08 mmol) and 1-(tert-butoxycarbonyl)-2-(chloromethyl)benzimidazole (106 mg, 0.40 mmol) and the mixture was stirred at 60 C for 7 h. Purification of the resultant brown oil by column chromatography with silica gel (CH2C12/MeOH/NH4OH, 96:4:0 then 95:4:1) followed by radial chromatography on silica gel (I mm plate, (CH2C12/MeOH/NH4OH, 50:1:1) afforded the desired alkylated trans-1,4-diamine (44 mg, 25%) as a clear oil.
[0360] Using General Procedure D: Conversion of the foam from above (31 mg, 0.054 mmol) to the hydrobromide salt with simultaneous removal of the N- tent-butoxycarnoyl protecting group followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 54 (32 mg, 90%) as a white solid. 1H NMR (D20) 8 1.40-1.61 (m, 4H), 1.86-2.30 (m, 7H), 2.42-2.46 (m, 1H), 2.76-2.84 (m, 1H), 3.00-3.02 (m, 2H), 3.11-3.18 (m, 1H), 4.44 (d, 1H, J= 16.8 Hz), 4.52-4.57 (m, 1H), 4.57 (d, 1H, J= 16.8 Hz), 7.60 (dd, 2H, J
= 6, 3 Hz), 7.77 (dd, 2H, J= 6, 3 Hz), 7.81 (dd, 1H, J= 7.8, 6 Hz), 8.29 (d, 1H, J= 7.8 Hz), 8.58 (d, 1H, J= 5.7 Hz); 13C NMR (D20) 8 20.73, 24.05, 27.54, 27.62, 29.60, 29.74, 29.85, 44.06, 49.58, 58.80, 59.30, 114.25, 125.80, 126.97, 131.03, 139.10, 140.46, 147.96, 151.62, 152.09. ES-MS in/z 376 (M+H). Anal. Calcd. for C23H29N5=3.OHBr=2.1H2O: C, 42.11; H, 5.56; N, 10.67; Br, 36.54. Found: C, 42.24; H, 5.60; N, 10.51; Br, 36.50.

Example 55 \ SCI
~ H
N HCI
N

N NH NHS
!5 COMPOUND 55: Preparation ofNl-(lH-Benzimidazol-2-ylmethyl)-NI-(( -5 6 7 8-tetrahydro-guinolin-8-yl)-trans-cyclohexane-1 4-diamine (hydrochloride salt) [0361] To a solution of trans-4-aminocyclohexanol hydrochloride (10.0 g, 65.9 mmol) and triethylamine (18.4 mL, 132.0 mmol) in tetrahydrofuran (132 mL) was added di-tert-butyl dicarbonate (15.31 g, 70.1 mmol). The mixture was stirred at 25 C under nitrogen for 17 h at which time ethyl acetate (250 mL) was added. The solution was washed with water (2 x 100 mL), dried (Na2SO4) and concentrated to afford (4-hydroxy-cyclohexyl)-carbamic acid tert-butyl ester as a white solid (13.82 g, 97%). 1H NMR (CDC13) S 1.09-1.25 (m, 2H), 1.31-1.39 (m, 211), 1.44 (s, 9H), 1.94-2.03 (m, 4H), 3.42 (bs, 1H), 3.56-3.64 (m, 1H), 4.34 (bs, 1H).

[0362] To a solution of (4-hydroxy,-cyclohexyl)-carbamic acid tert-butyl ester (5.80g, 26.9 mmol) in dry methylene chloride (67 mL) was added in order activated 3A
molecular sieves (6.54 g), 4-methylmorpholine N-oxide (5.04 g, 43.0 mmol) and tetrapropylammonium perruthenate (380 mg, 1.08 mmol). The mixture was stirred at 25 C for 18 h under nitrogen then the mixture was concentrated. Purification by column chromatography on silica gel with hexane/ethyl acetate (1:1) afforded (4-oxo-cyclohexyl)-carbamic acid tert-butyl ester as a white solid (5.52 g, 96%). 1H NMR (CDC13) S 1.46 (s, 9H), 1.64-1.74 (m, 2H), 2.21-2.27 (m, 2H), 2.39-2.45 (m, 411), 3.97 (bs, 114), 4.40 (bs, 1H).

[0363] Acetic acid (2.9 mL, 50.7 mmol), (4-oxo-cyclohexyl)-carbamic acid tert-butyl ester (4.32 g, 20.2 mmol) and sodium triacetoxyborohydride (7.56 g, 35.7 mmol) were added to a solution of (S)-5,6,7,8-tetrahydro-quinolin-8-ylamine (2.86 g, 19.3 mmol) in tetrahydrofuran (78 mL) and the mixture was stirred at 25 C for 3.5 h. The mixture was diluted with methylene chloride (500 mL) and washed with saturated sodium bicarbonate (600 mL). The aqueous layer was extracted with methylene chloride (2 x 150 mL). The combine organic layers were dried (Na2SO4) and concentrated. The crude mixture of isomers was purified by column chromatography on silica gel with methanol/methylene chloride (4:96) to afford the trans-isomer [4-((S)-5,6,7,8-tetrahydro-quinolin-8-ylamino)-trans-cyclohexyl]-carbamic acid tert-butyl ester as a white solid (2.01 g, 30%). 1H NMR
(CDC13) S 1.06-1.39 (m, 4H), 1.69 (s, 9H), 1.65-1.80 (m, 2H), 1.90-2.14 (m, 5H), 2.16-2.25 (m, 1H), 2.29 (bs, 1H), 2.56-2.71 (m, 1H), 2.72-2.88 (m, 2H), 3.43 (bs, 1H), 3.92 (t, 1H, J=
6.3 Hz), 4.39 (bs, 1H), 7.04 (dd, 1H, J= 7.9, 4.5 Hz), 7.35 (d, 1H, J= 7.5 Hz), 8.38 (d, 1H, J
= 4.5 Hz).

[0364] The enantiomeric purity of [4-((S)-5,6,7,8-tetrahydro-quinolin-8-ylamino)-trans-cyclohexyl]-carbamic acid tert-butyl ester was determined to be 95% by chiral HPLC using the following conditions: Instrument: Hewlett Packard 1100 HPLC (VWD2);
Column:
ChiralPak AD, 2.1 cm x 100 cm; Mobile Phases: A = 90:10 hexanes/ isopropanol with 0.1%TFA, B = isopropanol; Isocratic: 90% A, 10%B; Total Run Time: 25 min; Flow Rate:
1.0 mL/min; Temperature: 10 C; Detector: UV @ 254 nm; Injection volume: 30 L.
[0365] Retention time of the S enantiomer = 5.3 min.
[0366] Retention time of the R enantiomer = 8.1 min.
[0367] To a suspension of [4-((S)-5,6,7,8-tetrahydro-quinolin-8-ylamino)-trans-cyclohexyl]-carbamic acid tert-butyl ester (1.95g, 5.64 mmol) in dry acetonitrile (60 mL) was added 2-chloromethyl-benzoimidazole-l-carboxylic acid tert-butyl ester (1.65g, 6.20 mmol), diisopropylethylamine (2.0 mL, 11.4 mmol) and potassium iodide (100 mg, 0.60 mmol} The mixture was warmed to 60 C and stirred for 2 days under nitrogen. The mixture was concentrated, dissolved in methylene chloride (80 mL) and washed with brine (50 mL). The aqueous layer was extracted with methylene chloride (3 x 50 mL). The combined organic layers were dried (Na2S04) and concentrated. The crude mixture was purified by column chromatography on silica gel (80 g) with methanol/methylene chloride (4:96) to afford 2-{ [(4-tert-butoxycarbonylamino-trans-cyclohexyl)-(5, 6,7, 8-tetrahydro-quinolin-8-yl)-amino]-methyl}-benzimidazole-l-carboxylic acid tert-butyl ester as a white solid (1.82 g, 56%). 1H
NMR (CDC13) 81.09 (bs, 2H), 1.43 (s, 9H), 1.68 (s, 9H), 1.83-2.14 (m, 6H), 2.47-2.63 (m, 1H), 2.65-2.79 (m, 1H), 2.79-2.95 (m, 1H), 3.32 (bs, 1H), 4.30 (bs, 2H), 4.46 (s, 2H), 6.75-6.89 (m, 1H), 7.00-7.13 (m, 1H)., 7.61-7.70 (m, 1H), 7.70-7.79 (m, 1H), 8.32 (bs, 1H).
[0368] 2-{[(4-tent-Butoxycarbonylamino-trans-cyclohexyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-methyl}-benzimidazole-l-carboxylic acid tert-butyl ester was dissolved in acetic acid (15 mL) and hydrogen chloride gas was bubbled through the solution for 10 min.

The mixture was stirred for an additional 1.75 h then diluted with acetic acid (15 mL). The acetic acid solution was added dropwise, over 40 min., to a rapidly stirred flask of diethyl ether (300 mL) where a white fluffy precipitate formed. The ether mixture was allowed to settle and decanted. The slurry was washed with ether (4 x 300 mL) and then the precipitate was collected on a glass frit and rinsed thoroughly with ether. The frit was placed into a vacuum oven (40 C) for 18 h to afford COMPOUND 55 as a beige solid (1.36 g, 79%). 1H
NMR (D20) 6 1.34-1.1.52 (m, 2H), 1.57 (dq, 2H, J=12.3, 2.4 Hz), 1.77-1.92 (m, 1H), 1.97-2.21 (m, 6H), 2.24-2.42 (m, 1H), 2.82 (tt, 1H, J= 11.6, 3.1 Hz), 3.09 (d, 2H, J= 3.9 Hz), 3.13 (tt, 1H, J= 11.7, 3.6 Hz), 4.35 (d, 1H, J= 16.5 Hz), 4.51 (m, 2H), 7.52-7.58 (m, 2H), 7.71-7.77 (m, 3H), 8.23 (d, 1H, J= 7.5 Hz), 8.54 (d, 1H, J= 4.8 Hz); 13C NMR (D20) 8 20.70, 24.04, 27.51, 27.62, 29.62, 29.67, 29.85, 44.05, 49.60, 58.74, 59.42, 114.30 (2C), 125.64, 126.63 (2C), 131.62, 139.11, 140.28, 147.65, 151.75, 152.19. ES-MS m/z 376 (M+H). Anal.
Calcd. for C23H29N5=3.OHC1=2.5H20=0.2Et2O: C 52.47, H 7.22, N 12.86, C119.52.
Found:
C 52.46, H 6.97, N 12.85, C119.56.

[0369] The enantiomeric purity of COMPOUND 55 was determined to be 97% by chiral HPLC using the following conditions: Instrument: Hewlett Packard 1100 HPLC
(VWD2);
Column: ChiralPak AD, 2.1 cm x 100 cm; Mobile Phases: A = 90:10 hexanes/
isopropanol with 0.1%DEA, B = isopropanol; Isocratic: 70% A, 30%B; Total Run Time: 20 min;
Flow Rate: 0.6 mL/min; Temperature: 5 C; Detector: UV @ 270 nm; Injection volume:
20 L.
[0370] Retention time of the S enantiomer =11.1 min.
[0371] Retention time of the R enantiomer = 8.8 min.
Exam 1pe56 N

-., N NH NH

COMPOUND 56: Preparation of N1-(1H-Benzimidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydro-quinolin-8-yl -N2-benzyl-cyclohexane-trans-1,4-diamine (hydrobromide salt) Preparation of NI-(1H-Benzimidazol-2-yhneth -N1-(5,6,7,8-tetrahydro-guinolin-8-yl)-cyclohexane-trans-1,4-diamine:

CN-)-N

Preparation of N-test-butoxycarbonyl-trans-1,4-cyclohexanediamine (Smith, J.;
Liras, J.L.; Schneider, S.E.; Anslyn, E J. Org. Chem. 1996, 61, 8811-8818):
[0372] To a solution of trans-1,4-cyclohexanediamine (8.01 g, 70.1 minol) in CHC13 (230 mL) was added a solution of di-test-butyl dicarbonate (7.67 g, 35.1 mmol) in CHC13 (50 mL) via syringe pump over a period of 6 hours. The resultant white suspension was stirred at room temperature for an additional 10 hours then concentrated in vacuo and diluted with CH2C12 (100 mL) and saturated aqueous Na2CO3 (100 mL). The layers were separated and the organic layer was washed saturated aqueous Na2CO3 (2 x 30mL). The combined organic phases were dried (Na2SO4), filtered and concentrated to give the title compound (5.30 g, 71 % based on Boc2O) as a white solid.
[0373] Following General Procedure for Reductive Amination B: To a stirred solution of 6,7-dihydro-5H-quinolin-8-one (3.04 g, 20.65 mmol) and N- test-butoxycarbonyl-trans-1,4-cyclohexanediamine (4.42 g, 20.65 mmol) in dry THE (100 mL) was added AcOH (3 mL) and NaBH(OAc)3 (5.69 g, 26.85 mmol) and the mixture stirred overnight at room temperature. Purification by column chromatography on silica gel (CH2C12/MeOH/NH4OH, 96:4:0 then 94:5:1) afforded the desired amine (3.79 g, 53%) as a white solid.
[0374] Following the general procedure for N-alkylation: To a stirred solution of the trans-1,4-diamine from above (3.79 g, 11.0 mmol) in CH3CN (55 mL) was added N
N-diisopropylethylamine (3.5 mL, 19.7 mmol), KI (91 mg, 0.55 mmol) and 1-(tert-butoxycarbonyl)-2-(chloromethyl)benzimidazole (2.93 g, 11.0 nunol) and the mixture was stirred at 60 C overnight. Purification of the resultant orange foam by column chromatography on silica gel (CH2C12/MeOH/NH40H, 96:4:0 then 94:5:1) afforded the desired alkylated amine (3.28 g, 52%) as a yellow foam.
[0375] The yellow foam from above (3.28 g, 5.70 mmol) oil was dissolved in CH2C12/TFA (1:1, 10 mL) and the mixture stirred at room temperature for 2.5 hours. The reaction was then concentrated and diluted with CH2C12 (80 mL) and 1 N NaOH
(75 mL).
The aqueous layer was washed with CH2C12 (2 x 50 mL) and the combined organic extracts were dried (Na2SO4), filtered and concentrated to afford the title compound (1.97 g, 92%) as a yellow foam. 1H NMR (CDC13) S 0.92-1.10 (m, 2H), 1.21-1.28 (m, 2H), 1.45-1.58 (m, 4H), 1.66-1.77 (m, 2H), 1.82-1.90 (m, 2H), 1.95-2.09 (m, 1H), 2.17-2.35 (m, 1H), 2.39-2.59 (m, 2H), 2.67-2.80 (m, 1H), 2.83-2.96 (m, 1H), 4.10, (dd, 1H, J= 9, 6 Hz), 4.19 (s, 2H), 7.14-7.21 (m, 4H), 7.43 (d, 1H, J= 6 Hz), 7.55-7.62 (br in, 2H), 8.60 (d, 1H, J= 6 Hz);

(CDC13) S 21.85, 27.32, 29.31, 29.84, 30.97, 45.61, 50.03, 56.58, 62.37, 110.77, 118.96, 121.36, 122.23, 134.74, 137.52, 146.34, 158.32, 158.60.
[0376] To a stirred solution of]V1-(1H-benzimidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydro-quinolin-8-yl)-cyclohexane-trans-1,4-diamine (140 mg, 0.37 mmol) in dry MeOH
(3 mL) was added benzaldehyde (0.038 mL, 0.37 mmol) and the solution stirred at room temperature for 3 h. The mixture was concentrated in vacuo, analyzed by 1H NMR and redissolved in MeOH (3 mL) and CH2C12 (0.8 mL). To this solution was added sodium borohydride (28 mg, 0.74 mmol) and the mixture stirred for 2 h at room temperature. (see General Procedure B). Purification of the crude material by radial chromatography on silica gel (1 mm plate, CH2C12/MeOH/NH4OH, gradient elution from 100:1:1 to 20:1:1) afforded the free amine (119 mg, 69%) as a clear oil.
[0377] Using General Procedure D: Conversion of the oil from above (119 mg, 0.26 mmol) to the hydrobromide salt followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 56 (149 mg, 79%) as a white solid. 1H NMR
(D20) S 1.44-1.60 (m, 4H), 1.79-1.93 (m, 1H), 2.00-2.11 (in, 1H), 2.14-2.32 (m, 5H), 2.40-2.44 (m, 1H), 2.77-2.85 (m, 1H), 2.98-3.01 (m, 211), 3.12-3.20 (m, 1H), 4.21 (s, 2H), 4.42 (d, 1H, J=
16.8 Hz), 4.52-4.56 (m, 1H), 4.55 (d, 1H, J=16.8 Hz), 7.41-7.47 (m, 5H), 7.59 (dd, 2H, J=
6, 3Hz), 7.76 (dd, 2H, J= 6, 3 Hz), 7.79 (dd, 1H, J= 8.1, 6.3 Hz), 8.28 (d, 1H, J= 7.5 Hz), 8.57 (d, 1H, J= 5.5 Hz); "C NMR (D20) S 20.72, 24.03, 27.54, 27.61, 28.08, 28.35, 29.71, 44.01, 48.93, 56.04, 58.79, 59.32, 114.24, 125.80, 126.95, 129.72, 130.04, 131.06, 131.31, 139.10, 140.46, 147.95, 151.56, 152.03. ES-MS m/z 466 (M+H). Anal. Calcd. for C3oH35N5=3.OHBr=2.0H2O: C, 48.41; H, 5.69; N, 9.41; Br, 32.20. Found: C, 48.65; H, 5.92;
N, 9.32; Br, 31.97.

Exam lpe57 ~Q BrH
N
BrH
N

""
N f5' NH~ H
BrH

COMPOUND 57: Preparation ofN1-(1H-Benzimidazol-2-ulmethyl)-IV4-butyl-N1-(5 6 7 tetrahydro-quinolin-8-yl)-cyclohexane-trans-1,4-diamine (hydrobromide salt).
Preparation of N-tert-butoxycarbonyl-trans-1 4-cyclohexanediamine (Smith, J., et al J. Org. Chem. (1996) 61:8811-8818).

[0378] To a solution of trans-1,4-cyclohexanediamine (8.01 g, 70.1 mmol) in CHC13 (230 mL) was added a solution of di-tert-butyl dicarbonate (7.67 g, 35.1 mmol) in CHC13 (50 mL) via syringe pump over a period of 6 hours. The resultant white suspension was stirred at room temperature for an additional 10 hours then concentrated under reduced pressure and diluted with CH2C12 (100 mL) and saturated aqueous Na2CO3 (100 mL). The layers were separated and the organic layer was washed with saturated aqueous Na2CO3 (2 x 30 mL).
The combined organic phases were dried (Na2SO4), filtered, and concentrated to give the desired compound (5.30 g, 71% based on Boc2O) as a white solid.

Preparation ofN1-(1H-Benzimidazol-2-ylmethyl)-N1-(5 6 7 8-tetrahydro-quinolin-yl)-cyclohexane-trans-1,4-diamine [0379] Following, General Procedure B: To a stirred solution of 6,7-dihydro-5H-quinolin-8-one (3.04 g, 20.65 mmol) and N-tert-butoxycarbonyl-trans-1,4-cyclohexanediamine (4.42 g, 20.65 mmol) in dry THE (100 mL) was added AcOH (3 mL) and NaBH(OAc)3. (5.69 g, 26.85 nunol) and the mixture stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure, diluted with CH2C12 (100 mL) and saturated aqueous sodium bicarbonate (100 mL), and the aqueous phase was extracted with CH2C12 (3 x 75 mL). The combined organic extracts were dried (Na2SO4), filtered, and concentrated. Purification by column chromatography on silica gel (CH2C12/MeOH/NH4OH, 96:4:0 then 94:5:1) afforded the desired amine (3.79 g, 53%) as a white solid.
[0380] Following the general procedure for N-alkylation: To a stirred solution of [4-(5,6,7,8-Tetrahydro-quinolin-8-ylamino)-trans-cyclohexyl]-carbamic acid tert-butyl ester from above (3.79 g, 11.0 mmol) in CH3CN (55 mL) was added N,N-diisopropylethylamine (3.5 mL, 19.7 mmol~, KI (91 mg, 0.55 mmol) and 1-(tent-butoxycarbonyl)-2-(chloromethyl)benzimidazole (2.93 g, 11.0 mmol). The mixture was stirred at 60 C
overnight, cooled, concentrated, diluted with CH2C12 (100 mL) and saturated aqueous sodium bicarbonate (75 mL). The aqueous phase was washed with CH2C12 (2 x 50 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure. Purification of the resultant orange foam by column chromatography on silica gel (CH2CI2/MeOH/NH4OH, 96:4:0 then 94:5:1) afforded the desired alkylated amine (3.28 g, 52%) as a yellow foam.
[0381] The yellow foam from above (3.28 g, 5.70 mmol) was dissolved in (1:1, 10 mL) and the mixture stirred at room temperature for 2.5 hours. The reaction was then concentrated and diluted with CH2C12 (80 mL) and 1 N NaOH (75 mL). The aqueous layer was washed with CH2C12 (2 x 50 mL) and the combined organic extracts were dried (Na2SO4), filtered, and concentrated to afford N1-(1H-benzimidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydro-quinolin-8-yl)-cyclohexane-trans-1,4-diamine (1.97 g, 92%) as a yellow foam. 1H
NMR (CDC13) 8 0.92-1.10 (m, 2H), 1.21-1.28 (m, 2H), 1.45-1.58 (m, 4H), 1.66-1.77 (m, 2H), 1.82-1.90 (m, 2H), 1.95-2.09 (m, 1H), 2.17-2.35 (m, 1H), 2.39-2.59 (m, 2H), 2.67-2.80 (m, 1H), 2.83-2.96 (m, 1H), 4.10 (dd, 1H, J= 9,6 Hz), 4.19 (s, 2H), 7.14-7.21 (m, 4H), 7.43 (d, 1H, J= 6 Hz), 7.55-7.62 (br in, 2H), 8.60 (d, 1H, J= 6 Hz); 13C NMR (CDC13) 8 21.85, 27.32, 29.31, 29.84, 30.97, 45.61, 50.03, 56.58, 62.37, 110.77, 118.96, 121.36, 122.23, 134.74, 137.52, 146.34, 158.32, 158.60.
[0382] To a stirred solution ofN1-(1H-benzimidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydro-quinolin-8-yl)-cyclohexane-trans-1,4-diamine (0.0753 g, 0.20 mmol) in anhydrous MeOH (2 mL) was added freshly distilled butyraldehyde (22 L, 0.24 mmol). The resultant mixture was stirred at room temperature for 0.5 h and concentrated under reduced pressure. The residue was redissolved in anhydrous MeOH (2 mL) and NaBH4 (15 mg, 0.40 mmol) was added. The resultant mixture was stirred at room temperature for 22 hours. The mixture was concentrated and the residue was partitioned between CH2C12 (20 mL) and saturated aqueous sodium bicarbonate (30 mL). The phases were separated and the aqueous phase was extracted with CH2C12 (2 x 15 mL). The combined organic extracts were dried (Na2SO4), filtered, and concentrated under reduced pressure. Purification of the crude material by radial chromatography on silica gel (TLC grade 1 mm plate, 100:1:1 CH2C12/CH3OH/NH4OH
followed by 50:1:1 CH2C12/CH3OHINH4OH) provided 23 mg (30%) of the free base of the title compound as a pale yellow oil. Using General Procedure D: Conversion of the foam from above (23 mg, 0.05 mmol) to the hydrobromide salt followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 57 (73 mg, quantitative) as a white solid. 1H NMR (D2O) 8 0.88 (t, 3H, J= 7.5 Hz), 1.26-1.47 (m, 4H), 1.48-1.65 (m, 4H), 1.79-1.92 (m, 1H), 1.93-2.34 (br in, 7H), 2.35-2.47 (m, 1H), 2.75-2.88 (m, 1H), 2.95-3.14 (m, 5H), 4.42 (d, 1H, J= 16.8 Hz), 4.49-4.55 (m, 1H), 4.56 (d, 1H, J= 16.5 Hz), 7.54-7.63 (m, 2H), 7.72-7.84 (m, 3H), 8.28 (d, 1H, J= 7.5 Hz), 8.56 (d, 1H, J= 5.4 Hz); 13C
NMR (D20) 613.17, 19.61, 20.71, 24.03, 27.53, 27.59, 28.09, 28.20, 28.34, 29.69, 44.00, 45.15, 56.08, 58.78, 59.39, 114.24, 125.79, 126.96, 131.06, 139.10, 140.46, 147.942, 151.58, 152.05. ES-MS m/z 432 (M+H). Anal. Calcd. for C2?H37N5.3.OHBr=2.1H2O: C, 45.54; H, 6.26;
N, 9.83;
Br, 33.66. Found: C, 45.62; H, 6.07; N, 9.66; Br, 33.51.

Exam lpe58 GNQ
N

)0"' N-N NH

COMPOUND 58: Preparation ofN1-(1H-Benzimidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydro-quinolin-8-yl)-N2,N2-dimethyl-ccyclohexane-trans-1,4-diamine (hydrobromide salt) [03831 To a stirred solution of]V1-(1H-benzimidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydro-quinolin-8-yl)-cyclohexane-trans-1,4-diamine (157 mg, 0.42 mmol) in dry MeOH
(3 mL) was added paraformaldehyde (powder) (17 mg, 0.57 mmol) and the solution stirred at room temperature for 3 h. The mixture was concentrated in vacuo, analyzed by 1H NMR
and redissolved in MeOH (2.5 mL) and CH2C12 (1 mL). To this solution was added sodium borohydride (32 mg, 0.83 mmol) and the mixture stirred for 1.5 h at room temperature (see General Procedure A and B). Purification of the crude material by radial chromatography on silica gel gel (1 mm plate, CH2C12/MeOH/NH4OH, gradient elution from 50:1:1 to 10:1:1) afforded the dimethylated and monomethylated free amines (138 mg) as an inseparable yellow foam mixture. Repurification and separation of the two amines by column chromatography on basic alumina (CH2C12/MeOH, 98:2 then 95:5) afforded the dimethylated product (44 mg, 26%) and the monomethylated free amine (21 mg, 13%), both as clear oils.
[0384] Using General Procedure D: Conversion of the dimethylated amine from above (44 mg, 0.11 mmol) to the hydrobromide salt followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 58 (72 mg, 97%) as a white solid. 1H
NMR
(D20) 61.46-1.65 (m, 4H), 1.79-1.93 (m, 1H), 2.05-2.21 (m, 5H), 2.31-2.53 (m, 2H), 2.75-2.82 (m, 1H), 2.77 (s, 6H), 2.99-3.01 (m, 2H), 3.15-3.22 (m, 1H), 4.43 (d, 1H, J= 16.8 Hz), 4.50-4.55 (m, 1H), 4.56 (d, 1H, J= 16.8 Hz), 7.58 (dd, 2H, J= 6, 3 Hz), 7.76 (dd, 2H, J= 6, 3 Hz), 7.80 (dd, 1H, J= 7.8, 6 Hz), 8.28 (d, 1H, J= 7.8 Hz), 8.57 (d, 1H, J=
5.1 Hz);' 13C
NMR (D2O) 6 20.71, 23.97, 25.62, 25.82, 27.55, 27.76, 29.81, 40.05, 44.03, 58.87, 59.26, 64.33, 114.24, 125.82, 127.01, 130.98, 139.12, 140.48, 148.00, 151.53, 151.97.
ES-MS nt/z 404 (M+H). Anal. Calcd. for C25H33N5.3.OHBr=2.OH2O: C, 44.01; H, 5.91; N, 10.26; Br, 35.13. Found: C, 44.14; H, 6.02; N, 10.01; Br, 34.98.

Example 59 CN
Q
N
X", ""*0"' N NH NH

COMPOUND 59: Preparation ofN1-(1H-Benzimidazol-2-ylmethyl)-N1-(5,6,7 8-tetrah~dro-quinolin-8-yl)-N2-methyl-cyclohexane-trans-1,4-diamine (hydrobromide salt) [0385] Using General Procedure D: Conversion of the monomethylated amine from above (see COMPOUND 58) (21 mg, 0.054 mmol) to the hydrobromide salt followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 59 (25 mg, 71%) as a white solid. 1H NMR (D20) 8 1.31-1.43 (m, 2H), 1.51-1.63 (m, 2H), 1.78-1.93 (m, 1H), 1.99-2.31 (m, 6H), 2.40-2.44 (m, 1H), 2.63 (s, 3H), 2.75-2.87 (m, 1H), 2.98-3.01 (m, 3H), 4.42 (d, 1H, J= 16.8 Hz), 4.51-4.55 (m, 1H), 4.55 (d, 1H, J= 16.8 Hz), 7.59 (dd, 2H, J

= 6, 3Hz), 7.75 (dd, 2H, J= 6, 3 Hz), 7.79 (dd, 1H, J= 7.8, 6 Hz), 8.28 (d, 1H, J= 8.1 Hz), 8.56 (d, 1H, J= 5.4 Hz); 13C NMR (D2O}8 20.71, 24.01, 27.54, 27.85, 28.09, 29.63, 30.36, 44.00, 57.11, 58.81, 59.40,114.24,125.78,126-94,131.09,139.10,140.45,147.93,151.59, 152.05. ES-MS m/z 390 (M+H). Anal. Calcd. for C24H31N5.2.9HBr=3.0H20: C, 42.50; H, 5.93; N, 10.33; Br, 34.17. Found: C, 42.48; H, 5.65; N, 10.12; Br, 34.31.

Exam lp e 60 CNP

N "10 NH

COMPOUND 60: Preparation ofN-{4-trans-T(1H-Benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-uinolin-8-yl)-amino]-cyclohexyl}-guanidine (hydrobromide salt) [0386] To a solution ofN1-(1H-benzimidazol-2-ylmethyl) N1-(5,6,7,8-tetrahydro-quinolin-8-yl)-N2-benzyl-cyclohexane-trans-1,4-diamine (174 mg, 0.46 mmol) in dry THE
(1.5 mL) was added N. N'-bis-(tent-butoxycarbonyl)-1H-pyrazole-l-carboxamidine (Tetrahedron Lett. (1993) 34:3389) and the resultant mixture was stirred at room temperature for 26 hours. The reaction was concentrated and purified by radial chromatography on silica gel (2 mm plate, CH2C12/MeOHNH40H, gradient elution from 50:1:1 to 5:1:1) to afford the desired guanidine (51 mg, 18%) as a clear oil.
[0387] Using General Procedure D: Conversion of the oil from above (51 mg, 0.083 mmol) to the hydrobromide salt followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 60 (50 mg, 85%) as a white solid. 1H NMR
(D20) 8 1.22-1.34 (m, 2H), 1.49-1.60 (m, 2H), 1.79-2.21 (m, 8H), 2.40-2.44 (m, 1H), 2.70-2.78 (m, 1H), 2.98-3.01 (m, 2H), 3.24-3.32 (m, 1H), 4.42 (d, 1H, J= 16.8 Hz), 4.50-4.55 (m, 1H), 4.56 (d, 1H, J= 16.8 Hz), 7.59 (dd, 2H, J= 6, 3Hz), 7.76 (dd, 2H, J= 6, 3 Hz), 7.80 (dd, 1H, J=
7.8, 6 Hz), 8.28 (d, 1H, J= 7.8 Hz), 8.57 (d, 1H, J= 5.4 Hz); 13C NMR (D20) 8 20.75, 24.04, 27.55, 28.14, 30.36, 31.23, 31.51, 44.11, 50.20, 58.86, 59.67, 114.23, 125.78, 126.98, 130.97, 139.05, 140.45, 147.94, 151.73, 152.23, 156.22. ES-MS m/z 418 (M+H). Anal.
Calcd. for C24H31N7.3.OHBr=2.OH20=0.2C4H100: C, 41.78; H, 5.68; N, 13.75; Br, 33.62.
Found: C, 41.74; H, 5.63; N, 13.62; Br, 33.65.

Example 61 N
N "'0""1 N
\\NH H NH

COMPOUND 61: Preparation ofN1-(1H-Benzimidazol-2-ylmethyl)-N4-(JH-indol-3-ylmethylM-(5,6,7,8-tetrahydro-quinolin-8-yl)-cyclohexane-trans-1,4-diamine (free base l [0388] General procedure B (Two step reductive amination}: To a solution of N1 -(1H-benzimidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydro-quinolin-8-yl)-cyclohexane-trans-1,4-diamine (104 mg, 0.28 mmol) in CH3OH (5 mL) was added indole-3-carboxaldehyde (52 mg, 0.36 mmol) and the resultant solution was stirred at room temperature overnight. NaBH4 (26 mg, 0.68 mg) was added and the mixture was stirred for an additional 15 minutes. The mixture was concentrated under reduced pressure and the residue was partitioned between CH2C12 (20 mL) and saturated aqueous NaHCO3 (5 mL).
The phases were separated and the aqueous phase was extracted with CH2C12 (3 x 5 mL).
The combined organic extracts were dried (Na2SO4) and concentrated.
Purification of the crude material by radial chromatography on silica gel (1 mm plate, 50:1:1 NH4OH) provided 105 mg of COMPOUND 61 as a white foam. 1H NMR (CDC13) 8 0.93-1.30,(m, 3H), 1.47-2.02 (m, 9H), 2.20-2.25 (m, 1H), 2.50-2.51 (m, 2H), 2.65-2.76 (m, 1H), 2.83-2.94 (m, 1H), 3.93 (s, 2H), 4.10 (dd, 1H, J= 5.7, 10.2 Hz), 4.20 (s, 2H), 7.07-7.12 (m, 2H), 7.15-7.21 (m, 4H), 7.34 (d, 1H, J= 7.8 Hz), 7.42-7.49 (m, 2H), 7.59 (d, 1H, J= 7.8 Hz), 7.66-7.69 (m, 1H), 8.23 (br s, 111), 8.34 (br s, 1H), 8.60 (d, 1H, J= 3.6 Hz); 13C NMR
(CDC13) 8 22.22, 27.63, 29.71, 30.34, 31.43, 33.00, 33.14, 42.46, 46.01, 56.15, 57.61, 62.78, 111.30, 111.65, 115.35, 119.00 (2 carbons), 119.78, 121.59, 121.88, 122.40, 122.60, 122.78, 127.31, 134.03, 135.12, 136.78, 137.87, 145.03, 146.74, 158.77, 159.11. ES-MS
m/z 505 (M+H). Anal. Calcd. for C32H36N6=0.5 H20Ø5CH2C12: C, 70.19; H, 6.89; N, 15.11. Found:
C, 69.94; H, 6.81; N, 15.15.

Exam lp e 62 CN) N
N N
N NH H

H-Br H-Br H-Br H-Br COMPOUND 62: Preparation ofN1-(1H-Benzimidazol-2-ylmethyl)-1V4-(pyridin-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-quinolin-8-yl)-cyclohexane-trans-1,4-diamine (hydrobromide salt).

[03891 Using General Procedure B (Two step reductive amination): Reaction of Nl-(1H-benzimidazol-2-ylmethyl)-N1-(5, 6,7, 8-tetrahydro-quinolin-8-yl)-cyclohexane-trans-1,4-diamine (98 mg, 0.26 mmol) with pyridine-2-carboxaldehyde (30 L, 0.32 mmol) in CH3OH
(5 mL) for 2.5 hours and with NaBH4 (27 mg, 0.71 mmol) for 15 minutes followed by purification of the crude material by radial chromatography on silica gel (1 mm plate, 50:1:1 CH2C12-CH3OH-NH4OH) provided 79 mg (65%) of the free base of the title compound as a colorless oil.

[0390] Using General Procedure D: Conversion of the oil from above (79 mg, 0.17 mmol) to the hydrobromide salt followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 62 (126 mg, 85%) as a white solid. 1H NMR
(D20) 81.45-1.63 (m, 4H), 1.79-1.93 (m, 1H), 2.02-2.45 (m, 7H), 2.79-2.86 (m, 1H), 2.99-3.01 (m, 2H), 3.25-3.33 (m, 1H), 4.41-4.60 (m, 5H), 7.56-7.61 (m, 2H), 7.75-7.82 (m, 5H), 8.22-8.30 (m, 2H), 8.57 (d, 1H, J= 5.1 Hz), 8.69 (d, 1H, J= 4.5 Hz); 13C NMR (D20) 8 20.71, 24.03, 27.55 (2 carbons), 28.06, 28.31, 29.67, 43.99, 47.18, 57.04, 58.78, 59.21, 114.22, 125.83, 126.41, 126.60, 127.03, 130.91, 139.10, 140.51, 143.47, 146.81, 148.02, 148.03, 151.48, 151.97. ES-MS m/z 467 (M+H). Anal. Calcd. for C29H34N6=4.2HBr=3.7H20: C, 39.89; H, 5.26; N, 9.63; Br, 38.44. Found: C, 39.95; H, 5.19; N, 9.61; Br, 38.45.

Exam lp e 63 N--Q'-N
N N NH

COMPOUND 63: Preparation of 1-N'-(trans-4-(lH-Benzimidazol-2- lmeh 1)-(5,6,7,8-Y
tetrahydroquinolin-8-yl)-amino]-cyclohexanyl-N,N-dimethylformamidine (hydrobromide salt) [0391] Using the procedure of Cai, L., et al., Tetrahedron Lett. (1997) 38:5423-5426) a solution of 2-pyridinesulfonyl chloride (71 mg, 0.40 mmol) in DMF (1 mL) was stirred for 10 minutes at room temperature. N-(1H-Benzimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydro-quinolin-8-yl)-cyclohexane-trans-1,4-diamine (100 mg, 0.267 mmol) was then added, and the mixture was stirred at room temperature for 2 hours. The DMF was then removed in vacuo, and the residue was taken up in dichloromethane and washed sequentially with a saturated aqueous sodium carbonate solution, followed by distilled water. The organic fraction was then dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel flash chromatography to afford two products: 1-N'-[trans-4-(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-cyclohexanyl-N,N-dimethylformamidine (52 mg (45%)), and N-(lH-benzimidazol-2-ylmethyl)-N-(5,6,7,8.-tetrahydro-quinolin-8-yl)-cyclohexane-trans-1,4-diamine-N-(2-pyridinyl)-sulfonamide (41 mg, 29%). The spectral data for the formamidine is as follows: 1H NMR (CDC13) 8 1.41 (m, 2H), 1.56 (m, 2H), 1.67 (m, 2H), 1.79-1.91 (m, 3H), 2.21 (m, 1H), 2.51 (m, 1H), 2.74-2.81 (m, 3H), 2.83 (s, 6H), 4.06 (dd, 1H, J= 8.1, 5.4 Hz), 4.17 (s, 2H), 7.16 (m, 5H), 7,41 (d, 1H, J= 8.1 Hz), 7.44 (br s, 1H
(NH)), 7.68 (br s, 1H), 8.58 (d, 1H, J= 4.8 Hz). The sulfonamide showed an excessive broadening of resonances in the 1H NMR spectrum (in CDC13), so it was not characterized fully at this stage, and was instead taken directly to the salting reaction.

[0392] 1-N'-[trans-4-(1H-Benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-cyclohexanyl-N,N-dimethylformamidine (52 mg, 0.120 mmol) was taken up in acetic acid (1 mL), to which a saturated solution of HBr in acetic acid (1 mL) was added. The mixture was then stirred, precipitated and isolated as per procedure D to yield COMPOUND 63 as a white crystalline (36 mg). 1H NMR (D20). 8 1.45 (m, 414), 1.82-2.20 (m, 7H), 2.42(m, 1H), 3.74 (dd, 1H, J= 10.5, 11.1 Hz), 2.94 (s, 3H), 2.99 (m, 2H), 3.16 (s, 3H), 3.33 (m, 1H), 4.41 (d, 1H, J= 15.3 Hz), 4.52 (d, 1H, J=15.3 Hz), 4.54 (m, 1H), 7.58 (m, 2H), 7.75 (m, 2H), 7.77 (s, 1H), 7.80 (dd, 1H, J= 8.1, 5.7 Hz), 8.28 (d, 1H, J= 8.1 Hz), 8.56 (d, 1H, J= 5.7 Hz). 13C NMR (D20) 8 20.73, 24.04, 27.54, 28.10, 30.34, 32.07, 32.32, 36.05, 43.21, 44.11, 56.62, 58.79, 59.36, 114.21, 125.78, 126.99, 130.92, 139.03, 140.45, 147.99, 151.68, 152.19, 155.22. ES-MS m/z 431 (M+H); Anal. Calcd. for (C26H34N6 x 2.9 HBr x 2.7 H20): C, 43.74; H, 5.97; N, 11.77; Br 32.46. Found: C, 43.81; H, 5.70; N, 11.44;
Br, 32.39.

Example 64 ,N
N OSO I
H N NH

COMPOUND 64: Preparation ofN-(1H-benzimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydro-quinolin-8-yf --cyclohexane-trans-1 4-diamine-N (2-pyridinyl)-sulfonamide [0393] N-(1H-Benzimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydro-quinolin-8-y.1)-cyclohexane-trans-1,4-diamine-N-(2-pyridinyl)-sulfonamide (from the above reaction, 41 mg, 0.079 mmol) was taken up in acetic acid (1 mL), to which a saturated solution of HBr in acetic acid (1 mL) was added. The mixture was then stirred, precipitated and isolated as per procedure D to yield COMPOUND 64 as a white crystalline solid (52 mg). 1H
NMR
(D20) 8 1.20-2.16 (series of m, 9H), 2.38 (m, 1H), 2.60 (m, 1H), 2.82 (m, 1H), 2.98 (m, 2H), 3.10 (m, 1H), 3.62 (m, 1H), 4.46 (d, 1H, J = 15.3 Hz), 4.49 (m, 1H), 4,51 (d, 1H, J = 15.3 Hz), 7.56 (m, 2H), 7.73 (m, 3H), 7.94 (m, 1H), 8.06 (m, 1H), 8.26 (m, 1H), 8.56 (m, 2H). 13C
NMR (D20) 6 20.70, 27.51, 28.25, 30.44, 32.47, 44.04, 49.31, 52.58, 58.81, 59.48, 114.18, 122.92, 125.74, 126.97, 128.47, 130.87, 138.98, 140.25, 140.38, 147.90, 150.28, 151.72, 152.19. ES-MS m/z 517 (M+H); Anal. Calcd. for (C28H32N602S x 2.6 HBr x 3.3 H20): C, 42.76; H, 5.28; N, 10.69; Br 26.42. Found: C, 42.86; H, 5.07; N, 10.32; Br, 26.77.

Example 65 N NH N
H
COMPOUND 65: Preparation of Nl-(1H-benzimidazol-2-ylmethyl)-1V4-(1H-indol-2-ylmethyl)-M-(5, 6,7, 8-tetrahydroquinohn-8-yl)-cylcohexane-1,4-diamine.
Preparation of 2-hydroxymethylindole:
[0394] To a solution of indole-2-carboxylic acid (485 mg, 3.01 mmol) in THE
(20 mL), cooled to 0 C under nitrogen, was added a suspension of LiAIH4 (248 mg, 6.2 mmol) in THE
(6 mL). The resultant green suspension was stirred at room temperature for 4 hours. The reaction was quenched by slow addition of an 80% aqueous MeOH solution (1.0 mL) and the solvent was evaporated under reduced pressure. The residue was suspended in MeOH and filtered through Celite, rinsing with MeOH. Concentration of the filtrate under reduced pressure gave a yellow oil. Purification by flash column chromatography on silica (MeOH/CH2C12, 19:1 then 9:1) gave the alcohol as a beige solid (357 mg, 2.43 mmol, 81 %).
1H NMR (CDC13) 61.85 (t, 1H, J= 6.0 Hz), 4.83 (d, 2H, J= 6.0 Hz), 6.42 (d, 1H, J=1.5 Hz), 7.11 (td, 1H, J= 6.9, 1.5 Hz), 7.20 (td, 1H, J= 6.9, 1.5 Hz), 7.35 (dd, 1H, J= 6.9, 1.5 Hz), 7.59 (d, 1H, J= 6.9 Hz), 8.33 (br s., 1H).

Preparation of indole-2-carboxaldehyde:
[0395] To a solution of the alcohol (341 mg, 2.32 mmol) in CH2C12- (12 mL) was added activated Mn02 (2.40 g, 22.1 mmol). The suspension was stirred at room temperature for 2.5 hours, then was diluted with CH2C12 and suction filtered through Celite. The filtrate was concentrated under reduced pressure affording the crude aldehyde as an orange solid (288 mg, 1.98 mmol, 86%). 1H NMR (CDC13) 6 7.18 (td, 1H, J= 6.9, 1.5 Hz), 7.29 (d, 1H, J= 1.5 Hz), 7.37-7.50 (in, 2H), 7.76 (d, 1H, J= 6.9 Hz), 9.18 (br s., 1H), 9.86 (s, 1H).

Preparation of COMPOUND 65:

[03961 A solution of the aldehyde (74 mg, 0.51 mmol) and N1-(1H-benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydroquinolin-8-yl)-cylcohexane-1,4-diamine (189 mg, 0.50 mmol) in MeOH (5 mL) was stirred at room temperature under nitrogen for 20 hours.
NaBH4 (39 mg, 1.0 mmol) was added and the reaction was stirred for another 20 minutes.
The solvent was evaporated under reduced pressure, and the residue was dissolved into CH2C12 (50 mL) washing with saturated aqueous NaHCO3 (5 mL) and brine (5 mL).
The organic solution was dried (MgSO4), filtered and concentrated under reduced pressure.
Purification by flash column chromatography on silica (CH2Cl2/MeOH/NH4OH, 19:1:0.1) gave COMPOUND 65 as a light yellow solid (118 mg, 0.23 mmol, 47%). 111 NMR
(CDC13) S 0.88-1.13 (m, 2H), 1.16-1.29 (m, 1H), 1.39-1.52 (m, 1H), 1.63-1.73 (m, 1H), 1.80-2.04 (m, 6H), 2.19-2.23 (m, 1H), 2.33-2.41 (m, 1H), 2.44-2.52 (m, 1H), 2.67-2.74 (m, 1H), 2.81-2.94 (m, 1H), 3.91 (s, 2H), 4.09 (dd, 1H, J= 9.9, 5.9 Hz), 4.18 (s, 2H), 6.27 (s, 1H), 7.02-7.21 (m, 5H), 7.28 (d, 1H, J= 10.2 Hz), 7.43 (d, 1H, J= 7.8 Hz), 7.45-7.48 (m, 1H), 7.52 (d, 1H, J=
7.8 Hz), 7.66-7.69 (m, 1H), 8.60 (d, 1H, J= 4.2 Hz), 8.69 (br s., 1H). 13C NMR
(CDC13) S
21.8, 27.3, 29.3, 29.9, 31.0, 32.7, 32.9, 44.4, 45.7, 56.1, 57.2,-62.1, 99.6, 110.6, 110.9, 118.6, 119.5, 120.0, 121.2, 121.3, 121.5, 122.2, 128.5, 133.6, 134.7, 135.8, 137.4, 138.3, 144.6, 146.4, 158.4, 158.5. ES-MS m/z 505 (M+H). Anal. Calcd. for C32H36N6=CH2Cl2Ø1H2O: C, 67.07; H, 6.51; N, 14.22. Found: C, 67.34; H, 6.55; N, 14.23.

Exam lp e 66 N

N N
.

COMPOUND 66: Preparation of cis-(1H-benzimidazol-2-ylmethyl)-(4-morpholin-4-yl-cyclohexyl)-(5 ,6,7, 8-tetrahydro-quinolin-8-yl)-amine [0397] Cis-(4-morpholin-4-yl-cyclohexyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine was prepared as described for COMPOUND 67. 1H NMR (CDC13) 8 1.61-1.75 (m, 12H), 1.85-1.92 (m, 1H), 2.01-2.18 (m, 1H), 2.54 (t, 4H, J= 4.5 Hz), 2.76-2.81 (m, 2H), 2.92(br m, 1H), 3.74 (t, 4H, J= 4.5 Hz), 3.87-3.93 (m, 1H), 7.03-7.07 (m, 1H), 7.36 (d, 1H, J= 9.0 Hz), 8.39 (d, 1H, J= 6.0 Hz).
[0398] The above amine (69.0 mg, 0.22 mmol),, 2-chloromethyl-benzimidazole-l-carboxylic acid tert-butyl ester (70.0 mg, 0.26 mmol), N,N-diisopropylethylamine (50 L, 0.28 mmol), and potassium iodide (3.7 mg, 0.02 mmol) in CH3CN (1.5 mL) were stirred at 60 C overnight. The reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure. Purification of the crude material by radial chromatography on silica gel (1 mm plate, NH40H/MeOH/CH2C12, 1:1:98 then 1:2:97) afforded the desired compound (56.8 mg, 47%) as a pale yellow solid. 1H NMR
(CDC13) 8-1.30-1.34 (m, 2H), 1.45-1.66 (m, 11H), 1.88-2.01 (m, 4H), 2.05-2.16 (m, 4H), 2.40 (br m, 4H), 2.54 (t, 1H, J= 4.4 Hz), 2.59 (t, 1H, J= 3.9 Hz), 2.68-2.73 (m, 1H), 3.04-3.11 (m, 1H), 3.61-3.71 (m, 4H), 4.29 (dd, I H, J= 8.7, 5.7 Hz), 4.43 (s, 2H), 6.829 (dd, 1H, J= 7.5, 4.8 Hz), 7.07 (d, 1H, J= 6.9 Hz), 7.22-7.28 (m, 2H), 7.61-7.70 (m, 1H), 7.73-7.79 (m, 1H), 8.32 (dd, 1H, J= 4.8, 1.5 Hz).
[0399] To a solution of the above solid (56.8 mg, 0.10 mmol) in acetic acid (1 m-L) was added a solution of hydrobromic acid in acetic acid (0.5 mL) and the reaction mixture was stirred for. 1 hour. The diethyl ether was added until a precipitation of COMPOUND 67 was afforded as a pale yellow solid (49.1 mg, 62%). 1H NMR (D20) 8 1.75-1.89 (m, 6H), 2.12-2.36 (m, 8H), 2.98-3.99 (m, 4H), 3.11 (br m, 2H), 3.31 (br t, 2H), 3.64 (br m, 2H), 391 (m, 2H), 4.07 (br m, 2H), 7.565 (dd, 2H, J= 6.0, 3.2 Hz), 7.72-7.77 (m, 3H), 8.24 (d, 1H, J= 7.8 Hz), 8.52 (d, 1H, J= 6.0 Hz). 13C NMR (D20) 8 20.73, 23.37, 24.35, 24.46, 25.70, 27.50, 43.76, 50.48, 57.69, 59.40, 63.50, 63.78, 114.25, 125.73, 126.91, 131.23, 139.12, 140.44, 147.84, 151.29, 152.19. ES-MS m/z 446 [M+H]+. Anal. Calcd. for C27H35N5O=3.OHBr=2.OH2O: C, 44.83; H, 5.71; N, 9.68; Br, 33.14. Found: C, 44.88; H, 5.72; N, 9.49; Br, 33.13.

Example 67 N

O"/
N N N") COMPOUND 67: Preparation of trans-(1H-Benzimidazol-2- 1 y1L4-morpholin-4-1-cyclohexyl)-(5,6,7,8-tetrah dro-quinolin-8-yl)-amine (hydrobromide salt) Preparation of (4-morpholin-4-yl-cyclohex .lam)-carbamic acid tert-butyl ester:
[0400] To a solution of (4-oxo-cyclohexyl)-carbamic acid tert-butyl ester (426 mg, 2.00 mmol) and morpholine (175 L, 2.00 mmol) in CH2Cl2 (25 mL) and acetic acid (120 L) was added sodium triacetoxyborohydride (636 mg, 3.00 mmol) and the mixture was stirred at room temperature overnight. The mixture was concentrated under reduced pressure and diluted with saturated aqueous sodium carbonate (30 mL). The aqueous layer was washed with CH2Cl2 (4 x 20 mL), and the combined organic extracts were dried (MgSO4), filtered, and concentrated under reduced pressure. Purification by flash column chromatography on silica gel (MeOH/CH2Cl2, 1:9) afforded the title compound as a white solid (76.2 mg, 13%). 1H NMR (CDC13) 8 1.04-1.17 (m, 6H), 1.25-1.38 (m, 4H), 1.44 (s, 9H), 1.93 (d, 2H, J=12.0 Hz), 2.07 (d, 2H, J=12.0 Hz), 2.12-2.17 (m, 2H), 3.25-3.36 (br m, 1H), 4.35 (br m, 1H), 4.81 (br d, 1H).

Preparation of 4-morpholin-4-yl-cyclohexylamine:
[0401] To a solution of the acetamine from above (60.7 mg, 0.21 mmol) in CH2Cl2 (2 mL) was added trifluoroacetic acid (1 mL) and the mixture was stirred at room temperature for 1 hour. The solvent was removed under reduced pressure and the residue was taken up in NaOH (10 N) plus an equal volume of water. The aqueous layer was washed with CH2Cl2 (5 x 10 mL), and the combined organic extracts were dried (MgSO4), filtered, and concentrated under reduced pressure to afford the product as an off-white solid (33.5 mg, 85%). 1H NMR (CDC13) 8 1.08-1.27 (m, 4H), 1.39 (s, 2H), 1.88 (dd, 1H, J=10.5, 2.4 Hz), 2.16 (tt, 1H, J=11.3, 3.2 Hz), 2.53 (t, 4H, J= 4.7 Hz), 2.61 (tt, 4H, J=10.8, 3.6 Hz), 3.69 (t, 4H, J = 4.5 Hz).

Preparation of trans-(4-morpholin-4-yl-cyclohexyl)-(5,6,7,8-tetrahydro-quinolin-8-1 -amine:

[0402] The above amine (50.2 mg, 0.27 mmol) and 6,7-dihydro-5H-quinolin-8-one (40.1 mg, 0.27 mmol) in MeOH (2 mL) were stirred at room temperature overnight to form the imine. To the above solution was added sodium borohydride (20.6 mg, 0.544 mmol) and the mixture was stirred for an additional 2 hour. The solvent was removed under reduced pressure and to the residue was added CH2C12 and NaOH (0.5 N) until basic. The mixture was extracted with CH2C12 (3 x 15 mL), and the combined organic extracts were dried (MgSO4), filtered, and concentrated under reduced pressure. Purification by radial chromatography on silica gel (1 mm plate, CH2C12 then NH4OH/CH2C12, 1:99) afforded the desired amine (35.9 mg, 42%) as a yellow oil. 111 NMR (CDC13) 6 1.24-1.29 (m, 2H), 1.71-1.74 (m, 211),1.95-2.16 (m, 8H), 2.56 (t, 3H, J= 4.5 Hz), 2.75-2.79 (m, 211), 3.41 (s, 2H), 3.71 (t, 4H, J= 4.5 Hz), 3.92 (t, 1H, J= 6.0 Hz), 7.02-7.06 (m, 1H), 7.35 (d, 1H, J= 9.0 Hz), 8.37 (d, 1H, J= 3.0 Hz).

Preparation of trans-2-{[(4-morpholin-4-yl-ccyclohexyl)-(5 6 7 8-tetrahydro-quinolin-8-yl)-amino]-methyll-benzimidazole-l-carboxylic acid tent-butyl ester:
[0403] The above amine (35.9 mg, 0.11 mol), 2-chloromethyl-benzimidazole-l-carboxylic acid tent-butyl ester (36.7 mg, 0.14 mmol), N,N-diisopropylethylamine (25 L, 0.14 mmol), and potassium iodide (1.8 mg, 0.01 mmol) were stirred in CH3CN (1 mL) at 60 C overnight. The reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure. Purification of the crude material by, radial chromatography on silica gel (1 mm plate, CH2C12 then NH4OH/CH2C12, 1:99) afforded the desired compound (33.7 mg, 54%) as a yellow oil. 1H NMR (CDC13) 6 1.13-1.36 (m, 3H), 1.49-1.68 (m, 1111), 1.89-1.97 (m, 411), 2.02-2.14 (m, 411), 2.49-2.52 (m, 411), 2.59 (br t, 1H), 2.67-2.84 (m, 211), 3.68 (t, 411, J= 4.5 Hz), 4.24 (t, 1H, J= 6.0 Hz), 4.44 (d, 211, J= 6.0 Hz), 6.834 (dd, 1H, J= 7.5, 4.7 Hz), 7.08 (d, 111, J= 6.3 Hz), 7.22-7.25 (m, 211), 7.34-7.69 (m, 111), 7.71-7.78 (m, 111), 8.32 (dd, 1H, J= 4.5, 1.2 Hz).

Preparation of (S)-(1H-Benzimidazol-2-ylmethyl)-4-morpholin-4-yl-cyclohexyl)-(5 6 7 8-tetrahydro-quinolin-8-yl)-amine (hydrobromide salt):
[0404] To a solution of the above oil (33.7 mg, 0.062 mmol) in acetic acid (1.5 mL) was added a solution of hydrobromic acid in acetic acid (1 mL) and the reaction mixture was stirred for 1 hour. The diethyl ether was added until a precipitation of COMPOUND 67 was afforded as a pale yellow solid (28.9 mg, 63%). 1H NMR (D20) 81.48-1.61 (m, 4H), 1.82-1.88 (m, 2H), 2.07-2.39 (m, 6H), 2.75-2.81 (br t, 2H), 2.99 (br d, 2H, J=
4.5 Hz), 3.19 (t, 2H, J = 10.7 Hz), 3.44 (br d, 2H, J = 12.3 Hz), 3.76 (br td, 2H, J = 12.3 Hz), 4.09 (br d, 2H, J=11.7 Hz), 4.39-4.57 (m, 3H), 7.59 (dd, 2H, J= 6.3, 3.2 Hz), 7.74-7.77 (m, 3H), 8.27 (d, 1H, J= 7.8 Hz), 8.55 (d, 1H, J= 5.7 Hz). 13C NMR (D2O) 8 20.68, 23.95, 25.72, 25.93, 27.52, 27.80, 29.81, 43.97, 49.29, 58.82. 59.19, 64.38, 64.77, 114.23, 125.79,126.96, 131.07, 139.11, 140.45, 147.95, 151.53, 151.95. ES-MS m/z 446 [M+H]+, 468 [M+Na]+.
Anal.
Calcd. For C27H35N5O=3.OHBr=3.OH2O: C, 43.68; H, 5.97; N, 9.43; Br, 32.29.
Found: C, 43.72; H, 5.76; N, 9.25; Br, 32.06.

Example 68 i N
N,,, a HN N H N
NJ

COMPOUND 68: Preparation ofN-(1H-benzoimidazol-2-ylmethyl)-N'-pyrimidin-2-ylmeth 1-N- 5 6 7,8-tetrahydro-quinolin-8-yl )-transcyclohexane-l,4 diamine(hydrobromide salt).

Preparation of pyrimidine-2-carboxylic acid methyl ester:

cN',A 0 I ~N 1 [0405] To a saturated HC1(g)/MeOH solution (40 mL) was added a solution of 2-cyanopyrimidine (1.97 g, 18.7 nnnol) in MeOH (6 mL) at 0 C. The solution was stirred at room temperature for 30 minutes then poured into diethyl ether (200 mL) to give a colourless precipitate that was collected by filtration. The crude material was dissolved in H2O (50 mL), adjusted to pH 4 using saturated NaHCO3(aq) and 10% HC1(aq) then extracted with CHC13 (5 x 25 mL). The combined organic extracts were washed with saturated NaHCO3(aq) (25 mL) then dried (MgSO4) and concentrated in vacuo to give a colourless solid (1.49 g, 58%). 1H NMR (CDC13) S 4.08 (s, 3H), 7.51 (t, 1H, J= 5.1 Hz), 8.96 (d, 2H, J
= 5.1 Hz).
[0406] To a solution of pyrimidine-2-carboxylic acid methyl ester (243 mg, 1.76 mmol) in THE (17 mL) at -78 C was added LiAlH4 (1.0 M/THE, 0.47 mL, 0.47 mmol) over 30 minutes, and the solution was stirred at -78 C for 15 minutes. Acetic acid (0.25 mL, 4.4 mmol) was added dropwise, and the solution was allowed to warm to room temperature then concentrated in vacuo. The residue was dissolved in H2O (15 mL), adjusted to pH 4 using 10% HC1(aq) then extracted with CHCl3 (4 x 10 mL). The combined organic extracts were washed with saturated NaHCO3(aq) (20 mL) then dried (MgSO4) and concentrated in vacuo to give a yellow liquid (156 mg). The crude material was determined by 1H NMR
to be a mixture of pyrimidine-2-carbaldehyde, pyrimidine-2-carboxylic acid methyl ester, and THE
(1.0:1.7:7.7 respectively) and was used in the next step without further purification.
[0407] Using General Procedure B: To a solution of the crude aldehyde from above (156 mg) and N (1H-benzoimidazol-2 !ylmethyl)-N-(5,6,7,8-tetrahydro-quinolin-8-yl)-cyclohexane-trans-1,4-diamine (68 mg, 0.18 mmol) in THE (2 mL) was added NaBH(OAc)3 (114 mg, 0.538 mmol) and the mixture was stirred at room temperature for 1.5 h. The crude material was dissolved in saturated HBr/AcOH (2 mL) and stirred at room temperature for 5 minutes. The solution was made basic with 10 N NaOH(aq) and extracted with CH2C12 (3. x 15 mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo.
Purification of the crude material by column chromatography on silica gel (200:5:1 CH2C12/MeOH/NH4OH) afforded a colourless oil (50 mg).
[0408] Using General Procedure D: Conversion of the oil from above (50 mg, 0.11 mmol) to the hydrobromide salt followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 68 (78 mg, 85%) as a colourless solid. 1H
NMR
(D20) 6 1.58 (m, 4H), 1.89 (m, 1H), 2.03-2.45 (m, 7H), 2.84 (m, 1H), 3.00 (m, 2H), 3.30 (m, 1H), 4.42-4.60 (m, 5H), 7.50 (t, 1H, J= 5.1 Hz), 7.58 (m, 2H), 7.78 (m, 3H), 8.29 (d, 1H, J=
8.1 Hz), 8.58 (d, 1H, J= 5.7 Hz), 8.79 (d, 2H, J= 5.1 Hz); 13C NMR (D20) 8 20.73, 24.04, 27.56, 28.08, 28.33, 29.73, 44.05, 48.59, 56.44, 58.80, 59.26, 114.24, 121.65, 125.84, 127.02, 130.91, 139.12, 140.51, 148.03, 151.51, 152.00, 158.38, 160.98. ES-MS 771/z 468 (M+H).
Anal. Calcd. for C28H33N7.3.9HBr=3.2H20=0.2C4H1oO: C, 40.43; H, 5.34; N, 11.46; Br, 36.42. Found: C, 40.37; H, 5.05; N, 11.35; Br, 36.58.

Exg,mple 69 ~N
NH
N/" NH 2 COMPOUND 69: Preparation of N-(1H-Benzoimidazol-2- llmethyl)-1-methyl-N-(5,6,7,8-tetrahydro-quinolin-8-y1)-trans-cyclohexane-1 4-diamine (hydrobromide salt).
Preparation of trans-(4-Cyano-4-diallylamino-cyclohexyl)-carbamic acid tert-butyl ester:
[0409) To a stirred solution of (4-oxo-cyclohexyl)-carbamic acid tert-butyl ester (3.07 g, 14.4 mniol) and diallylamine (1.78 mL, 14.4 mmol) in anhydrous C1CH2CH2C1(25 nL) was added titanium (IV) isopropoxide (4.28 mL, 14.4 mmol) at 0 C. The reaction mixture was allowed to warm to room temperature and was stirred overnight. The mixture was then cooled to 0 C and diethylaluminum cyanide (1M in toluene, 17 ml, 17 mmol) was added with vigorous stirring. The reaction was allowed to warm to room temperature and stirred an additional 3.5 hours, after which are added CH2C12 (30 mL), EtOAc (40 mL), and celite (3 g).
The reaction mixture was cooled to 0 C, water (8 mL) was added slowly with vigorous stirring and, after an additional 5 minutes of stirring at room temperature, the excess water was quenched with Na2SO4. The final mixture was then filtered over celite, concentrated under reduced pressure, and subjected to flash chromatography over silica gel (Hexanes/EtOAc, 4:1) to afford the desired nitrile (3.11 g, 68 % over 2 steps) as a pale yellow oil. 1H NMR (CDC13) 5 1.44 (s, 9H), 1.53-1.59 (m, 3H), 1.78- 1.99 (m, 2H), 2.07 (d, 2H, J=
9 Hz), 2.28 (d, 2H, J= 12 Hz), 3.33 (t, 4H, J= 4.5 Hz), 3.37-3.55 (br in, 1H), 4.33-4.53 (br in, 1H), 5.12-5.24 (m, 4H), 5.82-5.94 (m, 2H).

Preparation of trans-(4-Diallylamino-4-methyl`cyclohexyl)-carbamic acid tert-butyl ester:
[0410] To a solution of the nitrile from above (3.11 g, 9.7 mmol) in anhydrous THE
(30 mL) at 0 C was added dropwise methylmagnesium bromide (3.0 Min Et2O, 10.0 mL, 29.2 mmol). After the addition, the reaction was allowed to warm to RT and stirred overnight. The reaction was then quenched with saturated aqueous NaHCO3 (50 mL), diluted with EtOAc (30 mL), and the layers separated. The aqueous layer was extracted with EtOAc (1 x 20 mL) and CH2C12 (1 x 20 mL). The combined organic extracts were dried (Na2SO4), filtered, and concentrated under reduced pressure to afford a crude mixture of the desired product (19%) and N-(4-Diallylamino-4-methyl-cyclohexyl)-acetamide (72%). The resultant crude, yellow oil (1.21 g) was used without further purification in the next step.

Preparation of trans-N,N-Diallyl-l-methyl-ccyclohexane-1,4-diamine:
[0411] To a stirred solution of the crude mixture from above in dry CH2C12 (4 mL) was added TFA (4 mL) and the reaction stirred at RT for 2.5 h. The reaction mixture was diluted with CH2C12 (30 mL) and concentrated under reduced pressure. The residue was diluted with CH2C12 (50 mL) and washed with 1N NaOH (1 x 40 mL) and the aqueous phase extracted with CH2C12 (2 x 25 mL). The combined organic extracts were dried (Na2SO4), filtered, and concentrated under reduced pressure to afford a yellow oil (0.840 g, 12 %
desired amine).
[0412] The byproduct from above, N-(4-diallylamino-4-methyl-cyclohexyl)-acetamide (0.1979- g, 0.79 mmol), was dissolved in 6N HCl (6 mL) and refluxed for 6 h.
The reaction was cooled to RT and made basic with l ON NaOH and extracted with CH2C12 (3 x 20 mL).
The combined organic extracts were dried (Na2SO4), filtered, and concentrated under reduced pressure to give the desired primary amine (0.1063 g, 65 %) as a yellow/green oil, which was used without further purification in the next reaction.

Preparation of 2-{[trans- 4-Amino-4-methyl-c cly ohexyl)-(5,6,7,8-tetrahydro-quinolin-8-yl -aminol-methyll-benzoimidazole-l-carboxylic acid tert-butyl ester:
[0413] Following General Procedure B: To a stirred solution of 6,7-dihydro-5H-quinolin-8-one (0.0895 g, 0.61 mmol) and the crude N,N-Diallyl-1-methyl-cyclohexane-1,4-diamine from above (0.1063 g, 0.51 mmol) in dry THE (5 mL) was added AcOH (5 drops) and NaBH(OAc)3 (0.1805 g, 0.85 mmol) and the mixture stirred overnight at room temperature. Purification by column chromatography on silica gel (CH2C12/MeOH/NH4OH, 96:4:0 then 95:4:1) afforded the desired amine (75.2 mg, 36 %) as a colourless oil.

[0414] Following the general procedure for N-alkylation: To a stirred solution of the combined amines from above (0.1842 g, 0.54 mmol) in CH3CN (4 mL) was added N,N-diisopropylethylamine (0.17 mL, 0.98 mmol), KI (4.5 mg, 0.027 mmol) and 1-(tert-butoxycarbonyl)-2-(chloromethyl)benzimidazole (0.1449 g, 0.54 mmol). The mixture was stirred at 60 C overnight. Purification of the resultant orange oil by column chromatography on silica gel (CH2C12/MeOH/NH40H, 96:4:0 then 89:10:1) afforded the desired alkylated amine (0.1364 g, 44%) as a orange foam.
[0415] To a stirred solution of the alkylated amine from above (0.1364 g, 0.24 mmol) in dry CH2C12 (4 mL) was added N,N-dimethylbarbituric acid (0.1869 g, 1.2 mmol) and tetrakis(triphenylphosphine)-palladium(0) (0.028 g, 0.024 mmol) and the mixture stirred at room temperature for 64 h. The reaction was diluted with CH2C12 (20 mL) and saturated aqueous NaHCO3 (30 mL). The phases were separated and the aqueous layer extracted with CH2C12 (2 x 20 mL). The combined organic extracts were dried (Na2SO4), filtered and concentrated under reduced pressure. Purification of the crude material by radial chromatography on silica gel (2 mm plate, CH2C12/MeOH/NH40H, 50:1:1 then 25:1:1) afforded the desired amine (28.9 mg, 25 %) and the monoallyl-protected amine (51.0 mg, 40 %).

Preparation of 2-{[trans-(4-text-Butoxycarbonylamino-4-methyl-c cl~ ohex 1)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-methyl)-benzoimidazole-l-carboxylic acid tent-but ly ester:
[0416] To a stirred solution of the desired primary amine (28.9 mg, 0.059 mmol) from above in dry THE (1.5 mL) was added di-tert-butyl dicarbonate (47 mg, 0.22 mmol) and the mixture stirred at room temperature overnight. The reaction was concentrated under reduced pressure and the residue was purified by radial chromatography on silica gel (1 mm plate, CH2C12/MeOH/NH40H, 100:1:1) to afford the protected amine (25 mg, 71%) as a colourless oil.
[0417] Using General Procedure D: Conversion of the oil from above (25 mg, 0.042 mmol) to the hydrobromide salt followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 69 (23 mg, 82%) as a white solid. 1H NMR (D20) S 1.29 (s, 3H), 1.56-1.78 (m, 4H), 1.79-2.04 (m, 4H), 2.07-2.27 (m, 3H), 2.38-2.48 (m, 1H), 2.77-2.83 (m, 1H), 2.99 (d, 2H, J= 5.4 Hz), 4.42 (d, IH, J= 16.5 Hz), 4.58 (d, 1H, J= 16.8 Hz), 4.54-4.61 (m, 1H), 7.56-7.61 (m, 2H), 7.72-7.81 (m, 3H), 8.27 (d, 1H, J=
7.8 Hz), 8.55 (d, 1H, J= 5.1 Hz); 13C NMR (D20) 6 20.71, 24.24, 26.56, 26.86, 27.50, 34.87, 35.05, 43.78, 53.48, 58.03, 59.84, 114.21, 125.76, 126.97, 131.05, 139.08, 140.46, 147.91, 151.38, 152.11.
ES-MS m/z 390 (M+H). Anal. Calcd. for C24H31N5.2.9HBr=3.1H2O: C, 42.39; H, 5.94; N, 10.30; Br, 34.08. Found: C, 42.30; H, 5.69; N, 10.11; Br, 34.18.

Example 70 CN!(?
N =,,o N B H

COMPOUND 70: Preparation ofNl-Ally-N-(1H-Benzoimidazol-2-ylmethyl)-l-methyl-N-(5,6 7 8-tetrahydro-guinolin-8-yl)-trans-cyclohexane-l,4-diamine (hydrobromide salt :

[0418] Repurification of the monoallyl-protected amine (51 mg, 0.10 mmol) from above by radial chromatography on silica gel (1 mm plate, CH2C12/MeOH/NH4OH, 100:1:1 then 50:1:1 then 25:1:1) afforded the monoallyl-protected amine (24.6 mg, 20 %) as an orange oil.
[0419] Using General Procedure D: Conversion of the oil from above (25 mg, 0.047 mmol) to the hydrobromide salt followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 70 (32 mg, 94%) as an off-white solid. 1H
NMR
(D20) 6 1.29 (s, 3H), 1.55-1.95 (br m, 7H), 2.01-2.22 (m, 6H), 2.38-2.45 (m, 1H), 2.77-2.86 (m, 1H), 2.97-3.02 (m, 2H), 3.65 (d, 2H, J= 6.9 Hz), 4.43 (d, 1H, J=16.8 Hz), 4.57 (d, 1H, J
= 16.8 Hz), 4.59-4.65 (m, 1H), 5.44 (d, 1H, J= 16.2 Hz), 5.48 (d, 1H, J= 23.1 Hz), 5.86-6.00 (m, 1H), 7.56-7.62 (m, 2H), 7.72-7.81 (m, 3H), 8.27 (d, 1H, J= 7.8 Hz), 8.55 (d, 1H, J= 5.4 Hz); 13C NMR (D2O) 8 14.52 (Et20), 20.70, 23.66, 24.11, 24.33, 26.08, 27.49, 33.48, 33.85, 43.72, 44.50, 66.47 (Et2O), 114.20, 123.96, 125.78, 127.03, 128.43, 130.95, 139.08, 140.51, 147.95, 151.28, 152.12. ES-MS m/z 430 (M+H). Anal. Calcd. for C27H35N5=3.OHBr=2.9H2O:
C, 44.76; H, 6.09; N, 9.67; Br, 33.08. Found: C, 45.00; H, 5.96; N, 9.61; Br, 32.72.

Example 71 CN

NH

COMPOUND 71: Preparation of N-(1H-Benzoimidazol-2-ylmethyl-1-phenyl-N-(5,6,7,8-tetrahydro-quinolin-8-yl)-trans-cyclohexane-1,4-diamine (hydrobromide salt).
Preparation of trans-(4-Cyano-4-diallylamino-c cly ohexyl)-carbamic acid ter't-butyl ester:
[0420] To a stirred solution of (4-Oxo-cyclohexyl)-carbamic acid tert-butyl ester (3.55 g, 16.6 mmol) and diallylamine (2.05 mL, 16.6 mmol) in anhydrous C1CH2CH2C1(30 mL) was added titanium(IV) isopropoxide (4.95 mL, 16.6 mmol) at 0 C. The reaction mixture was allowed to warm to room temperature and was stirred overnight. The mixture was then cooled to 0 C and diethylaluminum cyanide (1 M in toluene, 19.6 ml, 19.6 mmol) was added with vigorous stirring. The reaction was allowed to warm to room temperature and stirred an additional 5 h, after which were added CH2C12 (40 mL), EtOAc (40 mL), and celite (4 g).
The reaction mixture was cooled to 0 C, water (10 mL) was added slowly with vigorous stirring and, after an additional 5 minutes of stirring at room temperature, the excess water was quenched with Na2SO4. The final mixture was then filtered over celite, concentrated under reduced pressure, and subjected to flash chromatography over silica gel (Hexanes/EtOAc, 4:1) to afford the desired nitrile (2.62 g, 66 % over 2 steps) as a pale yellow oil. 1H NMR (CDC13) 8 1.44 (s, 911), 1.50-1.70 (m, 4H), 1.77- 1.99 (m, 2H), 2.07 (d, 2H, J=
9 Hz), 2.28 (d, 2H, J=12 Hz), 3.33 (t, 411, J= 6.0 Hz), 4.33-4.53 (br in, 1H), 5.11-5.24 (m, 4H), 5.82-5.95 (m, 2H).

Preparation of trans-(4-Diallylamino-4-phenyl-cyclohexyl)-carbamic acid tert-butyl ester:
[0421] To a solution of the nitrile from above (1.00 g, 3.1 mmol) in anhydrous THE
(16 mL) at 0 C was added dropwise phenylmagnesium bromide (3.0 M in Et2O, 3.1 mL, 9.4 mmol). After the addition, the reaction was allowed to warm to RT and stirred for 3 h. The reaction was then quenched with saturated aqueous NH4C1(40 mL), diluted with EtOAc (30 mL), and the layers separated. The aqueous layer was extracted with EtOAc (1 x 20 mL) and CH2C12 (1 x 20 mL). The combined organic extracts were dried (Na2SO4), filtered, and concentrated under reduced pressure. Purification by column chromatography on silica gel (Hexanes/EtOAc, 4:1) afforded both the desired product (0.2057g, 32 %) and N-(4-Diallylamino-4-phenyl-cyclohexyl)-benzamide (0.11 g, 17 %) as white solids.

Preparation of trans-NN-Diallyl-l-phenyl-cyclohexane-1,4-diamine:
[0422] To a stirred solution of the desired product (0.2057 g, 0.56 mmol) from above in dry CH2C12 (2 mL) was added TFA (2 mL) and the reaction stirred at RT for 4 h.
The reaction mixture was diluted with CH2C12 (15 mL) and concentrated under reduced pressure.
The residue was diluted with CH2C12 (20 mL) and washed with IN NaOH (1 x 30 mL) and the aqueous phase extracted with CH2C12 (2 x 20 mL). The combined organic extracts were dried (Na2SO4), filtered, and concentrated under reduced pressure to afford a yellow oil (0.1055g, 70 %). The resultant amine was used without further purification in the next reaction.
[0423] The byproduct from above, trans-N-(4-diallylamino-4-phenyl-cyclohexyl)-benzamide (0.4558 g, 1.22 mmol), was dissolved in a solution of H2O (2.5 mL), 6N HCl (3.5 mL) and THE (2 mL) and refluxed overnight. The reaction was cooled to RT, diluted with H2O (15 mL) and made basic with 1ON NaOH after which the aqueous solution was extracted with CH2C12 (3 x 20 mL). The combined organic extracts were dried (Na2SO4), filtered, and concentrated under reduced pressure. Purification by column chromatography on silica gel (CH2C12/MeOH/NH4OH, 96:4:0 then 89:10:1) afforded the desired primary amine (80 mg, 24 %) as a yellow oil.

Preparation of 2- { [trans-(4-Amino-4-phenyl-cyclohexyl)-(5,6,7,8-tetrahydro-quinolin-8-yl -amino]-methyl}-benzoimidazole-1-carboxylic acid tert-butyl ester:
[0424] Following General Procedure B (Stepwise Reductive Amination Using NaBH4):
To a stirred solution of 6,7-dihydro-5H-quinolin-8-one (0.099 g, 0.67 mmol) and N,N-diallyl-l-phenyl-cyclohexane-1,4-diamine (0.181 g, 0.48 mmol}in dry MeOH
(3 mL) was added NaBH4 (0.051 g, 1.3 mmol) after 2 h and the mixture stirred for an additional 2 h at room temperature. Purification by radial chromatography on silica gel (2 mm plate, CH2C12/MeOH/NH4OH, 100:1:1 then 75:1:1) afforded the desired amine (150 mg, 56 %) as a pale yellow oil.

[0425] Following the general procedure for N-alkylation: To a stirred solution of the amine from above (0.150 g, 0.37 mmol) in CH3CN (2 mL) was added N,N-diisopropylethylamine (0.12 mL, 0.67 mmol), KI (3 mg, 0.019 mmol) and 1-(tert-butoxycarbonyl)-2-(chloromethyl)benzimidazole (0.099 g, 0.37 mmol). The mixture was stirred at 60 C overnight. Purification of the resultant beige foam by radial chromatography on silica gel (2 mm plate, CH2C12/MeOH/NH4OH, 100:1:1 then 50:1:1) afforded the desired alkylated amine (0.149 g, 64%) as a yellow oil.
[04261 To a stirred solution of the alkylated amine (0.149 g, 0.24 mmol) from above in dry CH2C12 (2.5 mL) was added N,N-dimethylbarbituric acid (0.1841 g, 1.2 mmol) and Tetrakis(triphenylphosphine)-palladium(0) (0.068 g, 0.06 mmol) and the mixture stirred at room temperature for 64 h. The reaction was diluted with CH2C12 (20 mL) and saturated aqueous NaHCO3 (30 mL). The phases were separated and the aqueous layer extracted with CH2CI2 (2 x 20 mL). The combined organic extracts were dried (Na2S04), filtered and concentrated under reduced pressure. Purification of the crude material by radial chromatography on silica gel (2 mm plate, CH2C12/MeOH/NH4OH, 50:1:1 then 25:1:1 then 20:1:1) afforded the deprotected amine (28.9 mg, 25 %) and the monoallyl-protected amine (70.1.0 mg, 54 %, 90 % purity).

Preparation of 2-{[trans-(4-tert-Butox cy arbonylamino-4-phenyl-cyclohexyll)-(5,6,7,8-tetrahydro-quinolin-8-yl -amino],-methyl}-benzoimidazole-l-carboxylic acid tert-butyl ester:
[0427] To a stirred solution of the desired primary amine (28.9 mg, 0.13 mmol) from above in dry THE (2 mL) was added di-tert-butyl dicarbonate (42 mg, 0.19 mmol) and the mixture stirred at room temperature overnight. The reaction was concentrated under reduced pressure and the residue was purified by radial chromatography on silica gel (1 mm plate, CH2C12/MCOH/NH40H, 100:1:1 the 50:1:1) to afford the boc-protected amine (34 mg, 44 %) as a colourless oil.
[0428] Using General Procedure D: Conversion of the oil from above (24 mg, 0.037 mmol) to the hydrobromide salt followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 71 (24 mg, 85%) as a beige solid. 1H NMR
(D20) S 1.80-1.99 (m, 3H), 2.00-2.27 (m, 5H), 2.28-2.53 (m, 4H), 2.89-3.04 (m, 3H), 4.47 (d, 1H, J
= 16.8 Hz), 4.61 (d, 1H, J= 16.5 Hz), 4.60-4.68 (m, 1H), 7.40-7.53 (m, 5H), 7.55-7.61 (m, 2H), 7.71-7.81 (m, 3H), 8.26 (d, 1H, J= 7.2 Hz), 8.55 (d, 1H, J= 5.1 Hz); 13C
NMR (D20) S
20.74, 24.26, 24.54, 26.75, 27.53, 34.29, 34.46, 43.85, 57.40, 58.08, 59.61, 114.24, 125.12, 125.79, 126.97, 129.40, 129.64, 131.08, 139.14, 140.51, 140.91, 147.94, 151.34, 152.04. ES-MS m/z 452 (M+H). Anal. Calcd. for C29H33N5=2.7HBr=5.3H20: C, 45.50; H, 6.10;
N, 9.15;
Br, 28.18. Found: C, 45.43; H, 5.43; N, 8.93; Br, 28.23.

Example 73 N HBr I , HBr HBr N HBr No HBr N~. HBr ~/NHZ
HN ~N NH2 HN \'N

COMPOUND 73(R) and (S): Preparation of the two diastereomers of N1-(1H
Benzimidazol-2- l~yl)-Nl-(5,6,7,8-tetrahydro-quinolin-8-yl)-cyclohex-2-ene-trans-l,4-diamine [0429] Cis- 1 -acetoxy-4-chloro-2-cyclohexene was prepared from 1,3-cyclohexadiene following the procedure reported by Backvall, et al., J. Am. Clzem. Soc.
(1985) 107:3676-3686.
[0430] To a stirred solution of cis-1-acetoxy-4-chloro-2-cyclohexene (6.87 g, 39.4 mmol) in DMF (160 mL) was added sodium azide (5.29 g, 81.1 mmol) and the resultant mixture was stirred at room temperature for 2 hours. The reaction mixture was poured into brine (160 mL) and diluted with diethyl ether (300 mL) and water (80 mL). The phases were separated and the organic phase was washed with brine (5 x 50 mL). The organic phase was dried (MgS04), and concentrated to provide 6.13 g (85%) of trans-1-acetoxy-4-azido-2-cyclohexene as a pale red oil which was used without further purification.
[0431] A mixture of trans-1-acetoxy-4-azido-2-cyclohexene (6.13 g, 33.9 mmol), Lindlar's catalyst (1.18 g), and di-tent-butyl dicarbonate (11.35 g, 52.1 mmol) in methanol (170 mL) was hydrogenated under atmospheric pressure for 19 hours. The mixture was filtered through Celite( and the cake was washed with methanol. The filtrate was concentrated and the resultant oil was purified by column chromatography on silica gel (6:1 hexanes-ethyl acetate) and provided 6.70 g (77%) of trans- l-acetoxy,-4-(tert-butoxycarbonylamino)-2-cyclohexene as a white solid.

[0432] To a solution of trans-l-acetoxy-4-(tent-butoxycarbonylamino)-2-cyclohexene (6.70 g, 26.3 mmol) in methanol (130 mL) was added solid K2C03 (7.50 g, 54.4 mmol) and the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated and the residue was dissolved in CH2C12 (250 mL) and saturated aqueous NaHCO3 (100 mL). The phases were separated and the aqueous phase was extracted with CH2C12 (3 x 50 mL). The combined organic extracts were dried (Na2S04) and concentrated.
Purification of the crude material by column chromatography on silica gel (20:1 CH2C12-CH3OH) provided 3.38 g (60%) of trans- l-hydroxy-4-(tent-butoxycarbonylamino)-cyclohexene as a white solid. 'H NMR (CDC13) 6 1.44 (s, 9H), 1.52-1.57 (m, 1H), 2.05-2.14 (m, 3H), 4.20-4.26 (br s, 2H), 4.45 (br s .1H), 4.47-4.60 (m, 1H), 5.70 (d, 1H, J= 10.2 Hz), 5.81 (d, 1 H, J = 10.2 Hz);
[0433] To a mixture of trans- 1-hydroxy-4-(tert-butoxycarbonylamino)-2-cyclohexene (2.93 g, 13.8 mmol) in hexachloroacetone (70 mL) was added triphenylphosphine (7.51 g, 28.6 mmol) and the mixture was stirred at room temperature for 1 hour. The mixture was concentrated and the thus obtained oil was purified by column chromatography on silica gel (10:1 hexanes-ethyl acetate) and provided 1.98 g (62%) of cis- 1-(tent-butoxycarbonylamino)-4-chloro-2-cyclohexene as a yellow solid.
[0434] To a stirred solution of cis- 1-(tent-butoxycarbonylamino)-4-chloro-2-cyclohexene (1.85 g, 8.00 mmol) in DMF (40 mL) was added sodium azide (1.17 g, 18.0 mmol) and the resultant mixture was stirred at,. room temperature for 16 hours. The reaction mixture was poured into brine (40 mL) and diluted with ethyl acetate (120 mL) and water (20 mL). The phases were separated and the organic phase was washed with brine (4 x 25 mL).
The organic phase was dried (MgSO4), and concentrated. Purification of the crude material by column chromatography on silica gel (10:1 hexanes-ethyl acetate) provided 1.14 g (60%) of trans-l-azido-4-(tent-butoxycarbonylamino)-2-cyclohexene as a colorless oil.
[0435] To a solution of trans- l-azido-4-(tent-butoxycarbonylamino)-2-cyclohexene (1.14 g, 4.79 mmol) in THE (50 mL) and water (5 mL) was added triphenylphosphine (2.60 g, 10 mmol) and the mixture was stirred at room temperature for 20 hours. The mixture was concentrated and the thus obtained material was purified by column chromatography on silica gel (10:1:1 CH2C12-CH3OH-NH4OH) followed by radial chromatography on silica gel (2 mm plate, 100:1:1 CH2Cl2-CH3OH-NH4OH) and provided 0.32 g (31%) of trans-1-amino-4-(tert-butoxycarbonylamino)-2-cyclohexene as a colorless oil. 1H NMR (CDCl3) 6 1.44 (s, 9H), 1.50-1.92 (m, 2H), 1.99-2.10 (m, 2H), 3.32 (br s, 1H), 4.10-4.19 (m, 1H), 4.47-4.60 (m, 1H), 5.57-5.77 (m, 2H);
[0436] Using General Procedure B: Reaction of trans-l-amino-4-(tert-butoxycarbonylamino)-2-cyclohexene (0.222 g, 1.05 mmol) and 6,7-dihydro-5H-quinolin-8-one (0.304 g, 2.06 mmol) in THE (10 mL) with NaBH(OAc)3 (0.423 g, 2.00 mmol) for 4 hours followed by purification of the crude material by column chromatography on silica gel (25:1 CH2C12-CH3OH) provided 0.277 g (77%) of N1-(5,6,7,8-tetrahydro-quinolin-8-yl)-1V4-(tent-butoxycarbonyl)-cyclohex-2-ene-trans-1,4-diamine as a yellow foam.
[0437] Using the General Procedure for N-alkylation: A solution of N1-(5,6,7,8-tetrahydro-quinolin-8-yl)-1V4-(tent-butoxycarbonyl)-cyclohex-2-ene-trans-1,4-diamine (0.277 g, 0.81 mmol), 1-tent-(butoxycarbonyl)-2-(chloromethyl)benzimidazole (0.327 g, 1.22 mmol), catalytic potassium iodide (14 mg), and N,N-diisopropylethylamine (0.28 mL, 1.61 mmol) in CH3CN (8 mL) was heated at 60 C for 20 hours. Purification of the crude material by column chromatography on silica gel (20:1:1 CH2C12-MeOH-NH4OH) followed by radial chromatography on silica gel (1 mm plate, 100:1:1 CH2C12-MeOH-NH4OH) provided two diasteriomers of N1-(5,6,7,8-tetrahydro-quinolin-8-yl)-N1 -(1-tent-butoxycarbonyl-1H-Benzimidazol-2-ylmethyl)-1V4-(tent-butoxycarbonyl)-cyclohex-2-ene-trans-1,4-diamine, 129 mg (28%) of a white foam and 18 mg (4%) of a white solid.
[0438] General Procedure D: Conversion of the major diastereomer (100 mg) to the hydrobromide salt with simultaneous removal of the BOC-protecting groups, followed by re-precipitation of the intermediate solid from methanol/ether, gave COMPOUND
73(R) (103 mg, 88%) as a white solid. 1H NMR (D20) & 1.45-1.57 (m, 1H), 1.70-1.82 (m, 2H), 2.00-2.17 (m, 4H), 2.48-2.52 (m, 1H), 2.93 (br d, 2H, J= 5.1 Hz), 3.61-3.63 (m, 1H), 3.88-3.91 (m, 1H), 4.38-4.46 (m, 2H), 4.55 (d, 1H, J=16.8 Hz), 5.88 (br d, 1H, J=10.5 Hz), 6.25 (d, 1H, J= 10.5 Hz), 7.52-7.57 (m, 2H), 7.69-7.77 (m, 3H), 8.22 (d, 1H, J= 8.1 Hz), 8.55 (d, 1H, J= 5.1 Hz; 13C NMR (D20) 8 20.63, 23.56, 27.14, 27.30, 27.52, 42.75, 47.46, 56.83, 60.11, 114.17, 125.84, 127.00, 128.66,130.94, 133.97, 139.22, 140.59, 147.98, 151.38, 151.46; ES-MS m/z 374 (M+H). Anal. Calcd. for C23H27N5=3.OHBr=2.9H2O: C, 41.33; H, 5.40;
N, 10.48;
Br, 35.86. Found: C, 41.14; H, 5.15; N, 10.28; Br, 36.10.
[0439] General Procedure D: Conversion of the minor diastereomer (18 mg) to the hydrobromide salt with simultaneous removal of the BOC-protecting groups, followed by re-precipitation of the intermediate solid from methanol/ether, gave COMPOUND
73(S) (15 mg, 68%) as a white solid. 1H NMR (D20) 8 1.45-1.56 (m, 1H), 1.73-1.90 (m, 2H), 2.03-2.37 (m. 5H), 2.96(d, 2H, J= 4.8 Hz), 3.66-3.70 (m, 1H), 3.89-3.91 (m, 1H), 4.34-4.46 (m, 211), 4.52 (d, 1H, J= 16.2 Hz), 5.75 (d, 1H, J= 10.25 Hz), 6.05 (d, 1H, J=
10.2 Hz), 7.53-7.56 (m, 2H), 7.70 -7.76 (m, 3H), 8.22 (d, 1H, J= 7.8 Hz), 8.52 (d, 1H, J= 5.7 Hz); 13C
NMR (D20) S 20.56, 24.42, 25.14, 27.03, 27.40, 43.22, 47.65, 57.18, 58.39, 114.24, 125.76, 126.90, 128.40, 131.22, 135.51, 139.13, 140.42, 147.75, 150.87, 152.02; ES-MS
m/z 374 (M+H). Anal. Calcd. for C23H27N5=3.OHBr=3.1H20: C, 41.10; H, 5.43; N, 10.42;
Br, 35.67.
Found: C, 41.38; H, 5.09; N, 10.35; Br, 35.36.

Example 74 CN
~N
N ~ NH NH2 COMPOUND 74: Preparation of (Z)-N'-(1H-Benzimnidazol-2-ylmethyl-N'-(5 6 7 8-tetrahydro-quinolin-8-yl)-but-2-ene-1,4-diamine Preparation of ((Z)-4-Chloro-but-2-end)-carbamic acid tert-butyl ester:
CI

N O~
H

[04401 To a stirred suspension of (Z)-4-chloro-2-butenylamine hydrochloride (1.0 g, 7.0 mmol) in THE (35 mL) and water (0.2 mL) was added N,N-diisopropylethylamine (2.7 mL, 15.4 mmol) followed by di-tert-butyl dicarbonate (1.8 g, 8.4 mmol). The resultant solution was stirred for 3 h, at which time saturated aqueous sodium bicarbonate (20 mL) and diethyl ether (40 mL) were added. The phases were separated and the aqueous layer was extracted with Et2O (3 x 30 mL). The combined organic extracts were washed once with brine (20 mL), dried (MgS04), and concentrated in vacuo. Purification of the crude material by flash chromatography (silica gel, 4:1 hexane-EtOAc) afforded 1.3 g (90%) of the title compound as a white solid. 1H NMR (CDC13) 8 1.44 (s, 9H), 3.82 (t, 2H, J= 6 Hz), 4.12 (d, 2H, J= 9 Hz), 4.62 (br s, 1H), 5.60-5.70 (m, 1H), 5.72-5.77 (m, 1H).

[0441] Following the General Procedure for N-alkylation: To a solution of (1H-N-tert-butoxycarbonyl-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amine (200 mg,, 0.53 mmol) and ((Z)-4-chloro-but-2-enyl)-carbamic acid tert-butyl ester (130 mg, 0.64 mmol) in CH3CN (3 mL) were added N,N-diisopropylethylamine (138 L, 0.80 mmol) and KI (4.4 mg, 0.027 mmol) and the reaction stirred at 60 C for 18 h. The crude material was taken up in neat TFA (1 mL) and stirred 3 h. Saturated aqueous sodium bicarbonate (5 mL) was cautiously added, and the resulting mixture was extracted with CH2C12 (3 x 10 mL) then the combined organic extracts were dried (MgSO4), filtered and concentrated in vacuo.
Purification of the crude material by radial chromatography (1 mm plate, 50:1:1 CH2C12-McOH-NH40H) afforded the title compound (57 mg, 31%) as a white solid. 1H NMR
(CDC13) 8 1.68-1.72 (m, 111), 1.84-2.05 (m, 2H), 2.15-2.22 (m, 1H), 2.71 (dt, 1H, J=17, 5 Hz), 2.84 (ddd, 1H, J= 16, 10, 5 Hz), 3.15-3.26 (m, 3H), 3.38 (dd, 1H, J=14, 7 Hz), 3.97-4.12 (m, 3H), 5.46-5.54 (m, 2H), 7.13 (dd, 1H, J= 8, 5 Hz), 7.16-7.21 (m, 2H), 7.40 (dd, 1H, J= 7, 1 Hz), 7.57 (br s, 2H), 8.57 (dd, 1H, J= 5, 1 Hz); 13C NMR (CDC13) S
21.0,22.9; 28.9, 37.4,46.4,48.6, 60.5, 115.0,121.8,122.2,130.7,131.6,134.6,137.4,146.6,154.2,156.8.
ES-MS m/z 348 (M+H). Anal. Calcd. for C21H25N5Ø1CHCl3Ø8CH4O: C, 68.32; H, 7.41;
N, 18.19. Found: C, 68.60; H, 7.05; N, 17.82.

Exam lpe75 O
N N 0 L'~3 COMPOUND 75: Preparation of 2-{4-[(1H-benzoimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino].-(E)-but-2-enyl} -isoindole-1,3-dione.
CN~-p O
~N

N N O

Preparation of 2-{{[((Z)T4-(1 3-dioxo-1 3-dihydro-isoindol-2-yl)-but-2-enyll-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]methyl}-benzoimidazole-l-carboxylic acid tert-butyl ester:
[0442] Following the General Procedure for N-alkylation, (1H-N-tert-butoxycarbonyl-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amine (293 mg, 0.77 mmol) and (E)-N-(4-bromo-2-butenyl)phthalimide (prepared as described by Norman, M. H., et al., J. Med. Chem. (1996) 39:149-157) (260 mg, 0.93 mmol) were converted into the corresponding alkylation product using the following quantities of reagents and solvents:
diisopropylethylamine (202 L, 1.16 mmol), CH3CN (4 mL). The reaction time in this case was 18 h, while the reaction temperature was 40 C. The resulting crude material was purified by flash chromatography (silica gel, 20:2:1 CH2C12-MeOH-NH4OH) to provide 360 mg (81%) of 2-{[[(2)-4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-but-2-enyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-methyl}-benzoimidazole-l-carboxylic acid tert-butyl ester. 1H NMR
(CDC13) & 1.67 (s, 9H), 1.68-1.70 (m, 111), 1.79-1.91 (m, 1H), 1.93-2.04 (m, 1H), 2.14-2.19 (m, 1H), 2.59-2.79 (m, 2H), 3.33-3.48 (m, 2H), 4.00 (d, 2H, J= 6 Hz), 4.25 (dd, 1H, J= 10, 6 Hz), 4.42 (d, 1H, J=16 Hz), 4.60 (d, 1H, J=16 Hz), 5.29-5.57 (m, 1H), 5.65-5.74 (m, 1H), 6.95 (dd, 1H, J= 7, 5 Hz), 7.17-7.25 (m, 3H), 7.63-7.72 (m, 3H), 7.74-7.80 (m, 3H), 8.37 (d, 1H, J= 4 Hz).
[0443] 2-{[[(Z)-4-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-but-2-enyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-methyl}-benzoimidazole-l-carboxylic acid tert-butyl ester (150 mg, 0.26 mmol) was taken up in neat TFA (2 mL) and stirred 3 h. Saturated aqueous sodium bicarbonate (10 mL) was cautiously added, and the resulting mixture was extracted with CH2C12 (3 x 10 mL) then the combined organic extracts were dried (MgSO4), and concentrated in vacuo. Purification of the crude material thus obtained by radial chromatography (silica gel, 1 mm plate, 50:1:1 CH2C12-MeOH-NH4OH) afforded 102 mg (81%) of COMPOUND 75 as a white solid. 1H NMR (CDC13) 61.66-1.71 (m, 1H), 1.84-1.97 (m, 2H), 2.13-2.15 (m, 1H), 2.66-2.79 (m, 2H), 3.22-3.26 (m, 2H), 3.99-4.07 (m, 3H), 4.13-4.16 (m, 211), 5.67-5.71 (m, 2H), 7.10 (dd, 1H, J= 8, 5 Hz), 7.14-7.20 (m, 2H), 7.36 (dd, 1H, J= 8, 1 Hz), 7.43-7.62 (m, 2H), 7.64-7.69 (m, 2H), 7.74-7.79 (m, 2H), 8.56 (dd, 1H, J= 5, 1 Hz); 13C NMR (CDC13) 6 21.3, 24.0, 29.1, 39.1, 49.2, 52.0, 61.0, 110.9, 118.7, 121.6, 122.1, 123.2, 126.1, 132.0, 132.8, 133.9, 134.5, 137.2, 146.7, 156.3, 157.5, 167.8. ES-MS m/z 478 (M+H). Anal. Calcd. for C29H27N502Ø2CH2C12Ø3H20: C, 70.15;
H, 5.64; N, 14.01. Found: C, 70.40; H, 5.73; N, 13.90.

Exam lp e 76 CI
cIIIIIIIii = HHHCICI

N N

COMPOUND 76: Preparation of (Z)-N1-(1H-Benzimidazol-2-ylmethyl)-N1-5,6,7,8-tetrahydro-quinolin-8-yl-but-2-ene-1,4-diamine (hydrochloride salt) [0444] (Z)-4-Chloro-2-butenylamine hydrochloride (3.88 g, 27.3 mmol), water (1 mL) and diisopropylethylamine (9.6 mL, 55.1 mmol) were dissolved in tetrahydrofuran (140 mL) and stirred for 5 min. under nitrogen. Di-tert-butyl dicarbonate (15.31g, 70.1 mmol) was added and the mixture was stirred for an additional 4 h at 25 C. The mixture was concentrated and the residue dissolved in methylene chloride (100 mL) and washed with saturated sodium bicarbonate (80 mL). The aqueous layer was extracted with methylene chloride (2 x 50 mL). The combined organic layers were dried (MgS04) and concentrated to afford a brown oil which solidified on standing. Purification by column chromatography on silica gel afforded 6.4 g of a mixture of the desired product and di-tert-butyl dicarbonate.
Recrystallization from hot hexanes afforded (4-chloro-but-2-enyl)-carbamic acid tent-butyl ester (3.27 g, 50 %) as white crystals. 1H NMR (CDC13) 81.45 (s, 9H), 3.83 (t, 2H, J= 6.2 Hz), 4.12 (d, 2H, J= 7.4 Hz), 4.58 (bs, 1H), 5.58-5.68 (m, 1H), 5.71-5.81 (m, 1H).

[0445] (4-Chloro-but-2-enyl)-carbamic acid tent-butyl ester (1.81 g, 7.47 mmol), potassium iodide (59 mg, 0.36 mmol) and diisopropylethylamine (1.80 mL, 10.3 mmol) were added to a solution of 2-[(5,6,7,8-tetrahydroquinolin-8-ylamino)-methyl}-benzimidazole-l-carboxylic acid tert-butyl ester (2.57 g, 6.79 mmol)) in acetonitrile (70 mL) and warmed to 60 C and stirred for 17 h under nitrogen. The solvent was removed in vacuo.
The residue was dissolved in methylene chloride (100 mL) and washed with brine (100 mL).
The aqueous layer was extracted with methylene chloride (2 x 150 mL). The combined organic layers were dried (Na2SO4) and concentrated. The crude mixture was purified by column chromatography on silica gel (150 g) to afford 2-{[(S)-((Z)-4-tert-butoxycarbonylamino-but-2-enyl)-5,6,7,8-tetrahydro-quinolin-8-yl-amino]-methyl}-benzimidazole-l-carboxylic acid tert-butyl ester (5.99 g, 88%) as a white foamy solid. 'H NMR (CDC13) 8 1.43 (s, 9H), 1.72 (s, 9H), 1.95-2.08 (m, 4H), 2.09-2.20 (m, 1H), 2.61 (d, 1H, J=16.2 Hz), 3.28 (dd, 1H, J=
14.1, 5.4 Hz), 3.62 (dd, 1H, J=13.7, 7.2 Hz), 3.69-3.85 (m, 2H), 4.29 (dd, 1H, J= 9.2, 6.6 Hz), 4.42 (d, 1H, J=14.9 Hz), 4.48 (d, 1H, J=14.9 Hz), 5.43-5.63 (m, 211), 6.19 (s, 1H), 6.87 (dd, 1H, J= 7.5, 4.8 Hz), 7.17 (d, 1H, J= 7.7 Hz), 7.23-7.28 (m, 1H), 7.65-7.71 (m, 1H), 7.75-7.80 (m, 114), 8.34 (d, 1H, J= 4.4 Hz).
[0446] 2- { [(S)-((Z)-4-tert-Butoxycarbonylamino-but-2-enyl)-5,6,7,8-tetrahydro-quinolin-8-yl-amino]-methyl}-benzimidazole-1-carboxylic acid tert-butyl ester was dissolved in acetic acid (15 mL) and hydrogen chloride gas was bubbled through the solution for 10 min. The mixture was stirred for an additional 60 min. then diluted with acetic acid (15 mL). The acetic acid solution was added dropwise, over to a flask containing of diethyl ether (600 mL), stirred rapidly, where a white fluffy precipitate formed. The ether mixture was allowed to settle and decanted. The slurry was washed with ether (3 x 500 mL) and then the precipitate was collected on a glass frit and rinsed thoroughly with ether. The frit was placed into a vacuum oven (40 C) for 18 h to afford COMPOUND 76 as a light pink solid (2.20 g, 72%).
1H NMR (D20) 6 1.75-1.88 (m, 1H), 1.98-2.11 (m, 1H), 2.17-2.22 (m, 1H), 2.37-2.42 (m, 1H), 3.00 (dd, 2H, J= 7.8, 3.9 Hz), 3.25 (dd, 1H, J= 14.7,4.4 Hz), 3.58-3.65 (m, 3H), 4.4.32 (d, 1H, J=16.5 Hz), 4.46-4.55 (m, 2H), 5.43-5.53 (m, 114), 5.77-5.86 (m, 1H), 7.55-7.62 (m, 2H), 7.74-7.81 (m, 2H), 7.84 (dd, 1H, J= 7.9, 5.9 Hz), 8.33 (d, 1H, J= 7.8 Hz), 8.62 (d, 1H, J= 5.4 Hz); 13C NMR (D20) 20.35, 20.47, 27.61, 36.45, 48.00, 48.67, 60.52, 114.31 (2C), 124.75, 125.91, 126.81 (2C), 131.27, 132.58, 139.49, 140.64, 147.98, 150.92, 151.47. ES-MS
in/z 348 (M+H). Anal. Calcd. for C21H25N5=3.1HC1=2.5H20=0.3Et20: C 50.70, H
6.88, N
13.32, Cl 20.90. Found: C 50.81, H 6.89, N 13.45, C120.80.

[0447] The enantiomeric purity of COMPOUND 76 was determined to be 98% by chiral HPLC using the following conditions: Instrument: Hewlett Packard 1100 HPLC
(VWD2);
Column: ChiralPak AD, 4.6 cm x 25 cm; Mobile Phases: A = 90:10 hexanes/
reagent alcohol with 0.1 %DEA, B = reagent alcohol; Isocratic: 90% A, 10%B; Total Run Time: 40 min;
Flow Rate: 0.5 mL/min; Temperature: 40 C; Detector: UV @ 270 nm; Injection volume:

L.
[0448] Retention time of the S enantiomer = 21.4 min.
[0449] Retention time of the R enantiomer = 14.3 min.
Example 77 NN
N N

COMPOUND 77: Preparation of N1-(1H-benzoimidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydro-quinolin- 8-yl)-(E)-but-2-ene-1, 4-di amine.

[0450] 2-{[[(Z)-4-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-but-2-enyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-methyl}-benzoimidazole-l-carboxylic acid tert-butyl ester (prepared as described for COMPOUND 75) (200 mg, 0.35 mmol) was taken up in EtOH (3 mL) and hydrazine monohydrate (0.5 mL, 10 mmol) was added. The resulting mixture was heated to reflux for 18 h, at which point saturated aqueous sodium bicarbonate (15 mL) was added, and the resulting mixture was extracted with CH2C12 (3 x 20 mL) then the combined organic extracts were dried (MgSO4), and concentrated in vacuo. Purification of the crude material thus obtained by radial chromatography (silica gel, 1 mm plate, 50:1:1 CH2C12-MeOH-NH4OH) afforded 53 mg (44%) of COMPOUND 77 as a white solid. 1H NMR (CDC13) &
1.47-1.71 (m, 3H), 1.89-2.08 (m, 2H), 2.18-2.20 (m, 1H), 2.74-2.83 (m, 2H), 3.13 (d, 2H, J=
6 Hz), 3.25-3.27 (m, 2H), 4.06-4.10 (m, 3H), 5.46 (dt, 1H, J= 15, 6 Hz), 5.71 (dt, 1H, J= 15, 6 Hz), 7.12-7.21 (m, 3H), 7.41 (d, 1H, J= 8 Hz), 7.50-7.58 (m, 2H), 8.60 (dd, 1H, J= 5, 1 Hz); 13C N MR (CDC13) 8 21.3, 23.6, 29.2, 43.1, 48.8, 52.5, 61.3, 114.3, 121.5, 122.1, 128.5, 133.4, 134.6, 137.3, 146.7, 156.4, 157.5. ES-MS m/z 348 (M+H). Anal. Calcd.
for C21H25N5Ø2CH2C12Ø9CH40: C, 67.49; H, 7.43; N, 17.81. Found: C, 67.59; H, 7.31; N, 17.46.

Exam lp e 78 N
N j NH2 HN N

COMPOUND 78: Preparation ofN1-(1H-benzimidazol-2-ylmethyl)-N1-(5,6,7,8-tetrah c~dro-quinolin-8-yl)-but-2-yne-1,4-diamine.

Preparation of (4-chlorobut-2-yny)carbamic acid tert-butyl ester:
[0451] To a stirred mixture of 1-amino-4-chloro-2-butyne hydrochloride (1.12 g, 8.01 mmol) and Boc2O (2.12 g, 9.71 mmol) in a solution of THE (40 mL) and H2O
(15 drops) was added DIPEA (3.1 mL, 17.8 mmol). The resultant solution was stirred at room temperature for 4.5 hours. Saturated aqueous NaHCO3 (20 mL) was added, the layers were separated and the aqueous solution was extracted with Et2O (25 mL x 2). The combined organic extracts were dried (Na2SO4), filtered and concentrated under reduced pressure.
Purification by flash column chromatography on silica gel (hexane/EtOAc, 7:3) gave the Boc-protected amine as an off-white solid (1.38 g, 6.79 mmol, 85%). 1H NMR
(CDC13) 8 1.44 (s, 9H), 3.97 (d, 2H, J= 4.5 Hz), 4.13 (t, 2H, J= 2.1 Hz), 4.74 (br. s, 1H).

Preparation of 2-{[(4-tert-butoxycarbonylamino-2-butynyl)-(5,6,7,8-tetrahydroquinolin-8-yl -amino].-meths f -benzimidazole-l-carboxylic acid tert-but .lam [0452] A solution of the chloride from above (182 mg, 0.89 mmol), (1-terAt-butoxycarbonyl-1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine (285 mg, 0.75 mmol), DIPEA (0.20 mL, 1.2 mmol) and catalytic KI (8 mg, 0.05 mmol) in CH3CN
was heated at 60 C for 17 hours. Saturated aqueous NaHCO3 (10 mL) was added and the mixture was extracted with CH2Cl2 (25 mL x 3). The organic solution was dried (MgSO4), filtered and evaporated under reduced pressure. Purification by flash column chromatography on silica (CH2C12/MeOH/NH4OH, 9:1:0.1) gave the tertiary amine as a pale brown foam (374 mg, 0.69 mmol, 91%). 1H NMR (CDC13) 61.43 (s, 9H), 1.67 (s, 9H), 1.97-2.14 (m, 4H), 2.61-2.73 (m, 1H), 2.75-2.88 (m, 1H), 3.61-3.80 (m, 4H), 4.31 (dd, 1H, J= 7.8, 5.6 Hz), 4.45 (d, 1H, J= 15.9 Hz), 4.54 (d, 1H, J= 15.9 Hz), 4.63 (br. s, 1H), 7.01 (dd, 1H, J
= 7.5, 4.8 Hz), 7.27-7.34 (m, 3H), 7.72 (dd, 1H, J= 6.0, 3.0 Hz), 7.83 (dd, 1H, J= 6.0, 3.3 Hz), 8.39 (d, 1H, J= 3.3 Hz).

Preparation of COMPOUND 78:
[0453] The di-Boc protected amine (365 mg, 0.67 mmol) was stirred in TFA (6 mL) at room temperature for 1.5 hours. Saturated aqueous NaHCO3 (approx. 100 mL) was added until the mixture was neutral and the aqueous solution was extracted with CH2C12 (50 mL
x 3). The organic solution was dried (Na2SO4), filtered and concentrated under reduced pressure. Purification by flash column chromatography on silica gel (CH2C12/
McOH/NH4OH, 19:1:0.1) gave COMPOUND 78 as a beige foam (90.4 mg, 0.26 mmol, 39%). 1H NMR (CDC13) 6 1.65-1.79 (m, 1H), 1.94-2.14 (m, 2H), 2.16-2.28 (m, 1H), 2.69-2.81 (m, 1H), 2.81-2.95 (m, 1H), 3.21 (s, 2H), 3.54 (d, 2H, J= 2.1 Hz), 4.04 (d, 1H, J= 16.2 Hz), 4.15 (d, 1H, J= 16.2 Hz), 7.14-7.23 (m, 3H), 7.45 (d, 1H, J= 7.5 Hz), 7.54-7.64 (m, 2H), 8.58 (d, 1H, J= 4.3 Hz). 13C NMR (CDC13) 6 21.1, 24.6, 29.3, 31.9, 41.0, 49.9, 61.6, 79.2, 85.8, 122.1, 122.8, 135.0, 137.9, 147.0, 155.5, 157.4. ES-MS m/z 346 (M+H). Anal.
Calcd. for C21H23N5Ø2CH2Cl2Ø1C4H100: C, 70.15; H, 6.65; N, 18.94. Found:
C, 69.97; H, 6.85; N, 18.96.

Example 79 (N) N\~~

HN N

COMPOUND 79: 3-Aminomethyl-N'-(1H-benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-quinolin-8-yl)-but-2-ene-1,4-diamine (hydrobromide salt).

Preparation of (3-tert-Butoxycarbonylamino-2-oxo-propel)-carbamic acid text-butyl ester [0454] To a suspension of 1,3-diamino-2-hydroxypropane (2.43 g, 0.027 mol) in THF/H20 (15:1, 80 mL) was added di-tent-butyl dicarbonate (11.77 g, 0.054 mol) and the reaction stirred for 2.5 h then concentrated in vacuo.
[0455] To a solution of oxalyl chloride in CH2C12 (2.0 M, 7.7 mL, 15.4 mmol) at -78 C
was added a solution of DMSO (1.7 ml, 24.0 mmol) in CH2C12 (12 mL) and the mixture allowed to stir for 30 min. at -78 C, after which the crude alcohol from above (2.86 g) in CH2C12 (10 ml) was added dropwise. Stirring was continued for 15 min. and then Et3N (5.0 ml, 35.9 mmol) was added dropwise. The cooling bath was removed, stirring was continued for 1.5 h, and the mixture was diluted with CH2C12 (20 ml) and water (30 mL).
The aqueous layer was extracted with CH2C12 (20 ml) and the combined organic extracts were washed with brine (30 mL), dried over Na2SO4 and concentrated. Evaporation of the solvent and purification of the residue by flash chromatography on silica gel, using 40%
ethyl acetate in CH2Cl2, gave the title compound (350 mg, 16% over 2 steps) as a beige solid.

(CDC13) 6 1.42 (s, 18H), 4.03 (br d, 4H, J= 6 Hz), 5.26 (br s, 2H).

Preparation of (4-teat-butoxycarbonylamino-3-(tent-butox ca~ylamino-methyl)-but-2-enoic acid ethyl ester:
[0456] To a solution of (3-teat-butoxycarbonylamino-2-oxo-propyl)-carbamic acid tert-butyl ester (310 mg, 1.08 mmol) in benzene (20 mL) was added (carbethoxymethylene)-triphenyl phosphorane (825 mg, 2.37 mmol) and the reaction mixture was stirred at 45 C
overnight. Then the mixture was cooled to room temperature and the solvent concentrated down. Purification by radical chromatography on silica gel (2 mm plate, using CH2C12) afforded the desired compound as a yellow oil (290 mg, 75%). 1H NMR (CDC13) S
1.26 (t, 3H, J= 9.0 Hz), 1.42 (s, 18H), 3.87 (d, 2H, J= 6.0 Hz), 4.09 (d, 2H, J= 6.0 Hz), 4.15 (q, 2H, J= 9.0 Hz), 5.34 (br s, 1H), 5.85 (s, 1H), 7.34 (s, 1H).

Preparation of [2-(tert-butoxycarbonylaminomethyl) 4=hydroxy-but-2-enyl]-carbamic acid tert-butyl ester:
[0457] To a solution of the above ester (290 mg, 0.81 mmol) in THE (10 mL) was added DIBAL (1.0 M in CH2C12) (2.4 mL, 2.42 mmol) at -78 C. The temperature was increased to room temperature after 40 minutes. After 1 hour, the reaction was quenched with Rochelle's salt (10 mL) and was stirred overnight. Then it was extracted with CH2C12 (3 x 10 mL). The combined organic extracts were dried (Na2SO4), filtered, concentrated, and dried in vacuo to afford a yellow oil. Purification by flash column chromatography on silica gel using 50%
hexanes/ethyl acetate afforded the desired product as a pale yellow oil (210 mg, 83%). 1H
NMR (CDC13) 8 1.42 (s, 10H), 1.85 (br t, 1H), 3.89 (d, 4H, J= 9.0 Hz), 4.15 (t, 2H, J= 7.5 Hz), 4.75 (br t, 1H), 5.55 (br s, 1H), 5.78 (t, 1H, J= 7.5 Hz).

Preparation of 2-{[[4-tert-butoxycarbonylamino-3-(tert-butoxycarbonylamino-methyl)-but-2-enyl]-(5,6,7,8-tetrahydro-quinolin-8- -amino]-meth)l}-benzimidazole-l-carboxylic acid tert-butyl ester:

[0458] To a solution of the above alcohol (107 mg, 0.34 mmol) and triethylamine (70 L, 0.41 mmol) in CH2C12 was added methanesulfonyl chloride (30 L, 0.41 mmol) at 0 C. After 20 minutes at that temperature, the reaction mixture was quenched with saturated NH4C1(10 mL). The organic layer was washed with saturated NH4C1(2 x 10 mL), dried (Na2SO4), filtered, concentrated, and dried in vacuo to afford a yellow oil (150 mg).
This was used without further purification. 'H NMR (CDC13) 8 1.43 (s, 18H), 3.02 (s, 3H), 3.76 (t, 4H, J=
6.0 Hz), 4.89 (d, 2H, J= 6.0 Hz), 4.9a (br s, 1H), 4.99 (br s, 1H), 5.64 (t, 1H, J= 6.0 Hz).
[0459] The above mesylate (150 mg, 0.43 mmol), 2-[(5,6,7,8-tetrahydro-quinolin-ylamino)-methyl]-benzimidazole-l-carboxylic acid tert-butyl ester (195 mg, 0.52 mmol), N,N-diisopropylethylamine (90 mL, 0.52 mmol), and potassium iodide (7 mg, 0.04 mmol) in CH3CN (10 mL) was stirred at 40 C for three days. Then the solvent was concentrated down and the residue was dissolved in CH2C12 (15 mL). The organic layer was extracted with saturated NaHCO3 (3 x 15 mL), dried (MgSO4), filtered, concentrated, and dried in vacuo to afford a yellow oil. Purification by four attempts at radial chromatography on silica gel (2mm plate, using CH3OH/NH4OH/CH2Cl2 (0:1:99 -> 4:1:95); 1 mm plate, using CH3OH/NH4OH/CH2C12 (0:1:99 -> 2:1:97); 1 mm plate, using ethyl acetate; 1 mm plate, using CH3OH/NH4OH/CH2C12 (1:1:100)) afforded the desired compound as a while foam (39 mg, 13%). 1H NMR (CDC13) 8 1.38 (s, 9H), 1.43 (s, 9H), 1.70 (s, 9H), 2.04-2.11 (m, 3H), 2.56 (d, 1H, J=16.2 Hz), 2.77 (br t, 1H), 3.22 (dd, 1H, J=13.7, 6.2 Hz), 3.39 (dd, 1H, J=
15.6, 5.4 Hz), 3.49-3.58 (m, 2H), 3.76 (dd, 1H, J= 14.1, 8.1 Hz), 3.96 (dd, 1H, J= 14.1, 4.2 Hz), 4.22 (t, 1H, J= 8.1 Hz), 4.39 (ABq, 2H, J= 38.4, 14.4 Hz), 5.20 (br in, I
H), 5.47 (br m, 1H), 6.72 (dd, 1H, J= 7.5, 4.8 Hz), 7.04 (d, 1H, J= 7.2 Hz), 7.20-7.25 (m, 3H), 7.54-7.62 (m, 2H), 7.69-7.72 (m, 1H), 8.25 (d, 1H, J= 3.9 Hz).

Preparation of 3 -aminomethyl-N-(1H-benzimidazol-2- 1~y1)-N'-(5,6,7,8-tetrahydro-quinolin-8-yl)-but-2-ene-1,4-diamine (hydrobromide salt):
[0460] To a solution of the above diamine (39 mg, 0.06 mmol) in acetic acid (1 mL) was added a hydrobromic acid saturated acetic acid (0.5 mL) and the reaction mixture was stirred for 20 minutes. Then diethyl ether was added until the precipitation of COMPOUND 79 was afforded as a pink solid (20 mg, 30%). 1H NMR (D20) 6 1.76-1.84 (m; 1H), 2.16-2.21 (m, 1H), 2.37-2.41 (m, 1H), 2.98 (br d, 2H, J= 5.1 Hz), 3.41 (dm, 1H, J= 15.0 Hz), 3.68-3.70 (m, 3H), 3.76-3.85 (m, 2H), 4.26-4.46 (m, 3H), 6.23 (dd, 1H, J=10.8, 4.2 Hz), 7.56-7.60 (m, 2H), 7.73-7.84 (m, 3H), 8.30 (d, 1H, J= 7.5 Hz), 8.59 (d, 1H), J= 6.0 Hz). 13C
NMR (D20) S 20.22, 20.30, 27.59, 37.12, 42.32, 46.68, 48.91, 59.19, 114.28, 126.03, 127.04, 128.73, 131.00, 136.26, 139.60, 140.88, 148.14, 150.51. ES-MS m/z 399 [M+H]+, 399 [M+Na]+.
Anal. Calcd. for C22H28N6.4.2HBr=2.2H20Ø6C4H100: C, 36.61; H, 5.36; N, 10.50; Br, 41.93. Found: C, 36.68; H, 5.08; N, 10.48; Br, 41.87.

Example 80 N
( 'Q

C N\>--/ N NH2 CN
H
HO
COMPOUND 80: Preparation of (E)-2-aminomethyl-4-[(1H-benzimidazol-2-yl-methyl)-(5 6,7,8-tetrahydroquinolin-8-y1)-amino]-but-2-en-l-ol [0461] To a solution of 3-amino-1,2 propanediol (7.75 g, 0.085 mmol) in THE
(430 mL) was added water (20 mL) followed by tent-butyl dicarbonate (19.60 g, 0.0898 mmol) in one portion. The solution was stirred at room temperature for 23 hours. The solvent was removed under reduced pressure and the residue was dissolved in EtOAc (100 mL) and saturated sodium carbonate (100 mL). The phases were separated and the aqueous phase was extracted with ethyl acetate (3 x7 5 mL). The combined organic extracts were dried over sodium sulfate, filtered, concentrated to give (1,2-dihydroxy-ethyl)-carbamic acid tert-butyl ester as a crude white solid (15 g, 92%).

[0462] To a solution of crude from above (494 mg, 2.6 mmol) in CH2Cl2 (13 mL) was added imidazole (236 mg, 3.5 mmol) followed by TBDMS-Cl (410 mg, 2.7 mmol) and the reaction was stirred at room temperature overnight. The reaction mixture was diluted with CH2Cl2 (40 mL) and saturated aqueous sodium bicarbonate (40 mL). The phases were separated and the aqueous layer was extracted with CH2Cl2 (3 x 30 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated.
Purification of the crude material by column chromatography (15g silica, 8:1 hexanes/ EtOAc) gave [2-(tert-butyl-dimethyl-silanyloxy)-1-hydroxy.-ethyl]-carbamic acid tert-butyl ester as a colorless oil (555 mg, 70%). 1H NMR (CDC13) 8: 4.96 (broad s, 1H), 3.74-3.71 (m, 1H), 3.67-3.62 (m, 1H), 3.56-3.50 (m, 1H), 1.44 (s, 9H), 0.90 (s, 9H), 0.07 (s, 6H).
[0463] To a solution of the above material (555 mg, 1.81 mmol) in CH2Cl2 (9 mL) was added NMO (324 mg, 2.77 mmol), followed by 3A molecular sieves (960mg) and TPAP (62 mg, 0.18 mmol). The green-black solution was stirred at room temperature for 2 hours. TLC
(2:1 hexane/EtOAc-stained in ninhydrin) monitored the reaction. The reaction mixture was filtered through a cake of silica gel and the cake was washed with ethyl acetate. The filtrate was concentrated to provide crude [2-(tert-butyl-dimethyl-silanyloxy,.)-acetyl]-carbamic acid tert-butyl ester as a yellow oil (458 mg, 83%).

Preparation of 3-tert-butoxycarbonylamino-4-(tert-butyl-dimethyl-silanyloxy -but-2-_ enoic acid ethyl ester [0464] To the ketone from above (458 mg, 1.51 mmol) in benzene (8 mL) was added (carbethoxymethylene) triphenyl phosphorane (815 mg, 2.35 mmol). The reaction mixture was heated to -40-45 C and stirred at this temperature overnight. The reaction mixture was then concentrated and the residue purified by column chromatography (25 g silica, 25:1 hexane/EtOAc) to give two yellow oils (cis/trans isomers) as major products (430 mg total, 76%). 1H NMR of trans-isomer (CDCl3) 8: 6.06 (s, 1H), 5.41 (broad s, 1H), 4.31 (s, 2H), '4.18 (q, 2H, J= 7.5 Hz), 3.94 (d, 2H, J = 7.0 Hz), 1.42 (s, 9H), 1.30 (t, 3H, J= 7.5 Hz), 0.92 (s, 9H), 0.07 (s, 6H). 1H NMR of cis-isomer (CDC13) 8: 5.78 (s, 1H), 4.87 (s, 2H), 4.14 (q, 2H, J = 7.5 Hz), 4.00 (d, 2H, J = 7.0 Hz), 1.45 (s, 9H), 1.27 (t, 3H, J = 7.5 Hz), 0.91 (s, 9H), 0.09 (s, 6H).
[04651 To a solution of Trans-3-tert-butoxycarbonylamino-4-(tert-butyl-dimethyl-silanyloxy)-but-2-enoic acid ethyl ester (0.66 g, 1.8 mmol) in dichloromethane (18 mL) added a solution of DIBAL-H (8.8 mL, 1.0 M in CH2C12, 8.8 nunol) at 0 C. The solution was allowed to stir for I h while warming to room temperature. Saturated potassium sodium tartrate solution (20 mL) was then added and the solution stirred for another hour. The phases were separated and the organic phase dried (MgSO4), filtered and concentrated under reduced pressure to give, after column chromatography (1:3 ethyl acetate/hexane), trans-[2-(tert-butyl-dimethyl-silanyloxymethyl)-4-hydroxy-but-2-enyl]-carbamic acid tert-butyl ester (0.255 g, 39%).
[0466] Methanesulfonyl chloride (65 L, 0.8 mmol) and triethylamine (0.15 mL, 1.0 mmol) was added to a solution of the above alcohol (0.23 g, 0.7 mmol) in dichloromethane (7.0 mL) at room temperature and stirred 0.5 hours. This gave, after aqueous work up, the crude allylic methanesulfonate (0.25 g, 80%) as a pale yellow crystalline solid.
[0467] Using General Procedure D from above, the above methanesulfonate (0.25 g, 0.7 mmol), (N-tert-butoxycarbonylbenzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amine (0.26 g, 0.70 mmol) and potassium iodide (6 mg, 35 gmol) were stirred at 60 C in acetonitrile (7.0 mL) and diisopropylethylamine (0.18 mL, 1.0 mmol)) for 16 hours to yield, after work-up and column chromatography (2.5:97.5 McOH/CH2C12), the desired alkylated E-regioisomer (0.200 g, 42%).
[0468] A solution of the above compound (0.20 g, 0.30 mmol) in THE (1.0 mL) was treated with TBAF (0.6 mL, 1.0 M in THF, 0.6 mmol) for 0.5 hours. This gave, after column chromatography (1:99 McOH/CH2C12), the di-boc-protected E-2-{[[3-(tert-butoxycarbonylaminomethyl)-4-hydroxy-but-2-enyl]-(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-methyl}-benzimidazole-l-carboxylic acid tent-butyl ester (60 mg, 38%).

(CDC13) 6 1.41 (s, 9H), 1.65 (br, IH), 1.69 (s, 9H), 2.11 (m, 3H), 2.60 (m, 1H), 2.77 (m, 1H), 3.27 (m, 1H), 3.60 (m, 1H), 3.88 (in, 3H), 4.07 (m, 1H), 4.23 (m, 1H), 4.29 (d, 1H, J=15.0 Hz), 4.46 (d, 1H, J= 15.0 Hz), 5.50 (m, 1H), 6.74 (m, 1H), 7.05 (d, 1H, J= 6.0 Hz), 7.24 (in, 2H), 7.59 (m, 1H), 7.70 (m, 2H), 8.26 (d, 1H, J= 3.0 Hz).
[0469] The above material (60 mg, 0.11 mmol) was then dissolved in neat TFA (1 mL) and stirred for 1 hour. CH2C12 (10 mL) and 15% aqueous NaOH was added until pH
=13.
The organic phase was separated and the aqueous phase was extracted with CH2C12 (2 x mL). The combined organic phases were then dried (MgSO4), filtered, and concentrated under reduced pressure to provide COMPOUND 80 free base as a pale yellow free flowing powder (14 mg, 10%). 1H NMR (CDC13) S 1.66 (br, 1H), 1.85 (m, 1H), 2.00 (br, 1H), 2.17 (br, 1H), 2.80 (m, 3H), 3.19 (m, 111), 3.30 (m, 1H), 3.36 (s, 2H), 3.90 (d, 1H, J= 15.0 Hz), 4.01 (d, 1H, J= 18.0 Hz), 4.10 (br, 3H), 5.64 (m, 1H), 7.09 (m, 1H), 7.15 (m, 2H), 7.40 (d, 1H, J= 9.0 Hz), 7.54 (br, 2H), 8.49 (d, 1H, J= 3.0 Hz); 13C NMR (CDC13) S
21.46, 23.21, 29.47, 39.86, 47.47, 49.46, 61.34, 67.08, 115.11 (3C), 122.165 (2C), 122.62, 126.31 (2C), 135.25, 137.97, 142.19, 147.02, 155.11, 157.26. ES-MS m/z 378 (M+H). Anal.
Calcd. for C22H27N50Ø7CH2C12: C, 62.40; H, 6.55; N, 16.03. Found: C, 62.70; H, 6.70;
N,. 15.97.

Example 81 N\\/-j OH
N
H

COMPOUND 81: Preparation of (Z)-2-aminomethyl-4-[(1H-benzimidazol-2-yl-methyl) (5 6 7 8-tetrahydroquinolin-8-yl)-amino]-but-2-en-l-ol [0470] To a solution of cis-3-tert-butoxycarbonylamino-4-(tert-butyl-dimethyl-silanyloxy)-but-2-enoic acid ethyl ester (0.49 g, 1.3 mmol) in dichloromethane (13 mL) was added a solution of DIBAL-H (6.5 mL, 1.0 M in CH2C12, 6.5 mmol) at 0 C. The solution was allowed to stir for 1 h while warming to room temperature. Saturated potassium sodium tartrate solution (15 mL) was then added and the solution stirred for another hour. The phases were separated and the organic phase dried (MgSO4), filtered and concentrated to give the crude cis-[2-(tent-butyl-dimethyl-silanyloxymethyl)-4-hydroxy-but-2-enyl]-carbamic acid tent-butyl ester (0.33 g, 77%).
[0471] Methanesulfonyl chloride (39 L, 0.42 mmol) and triethylamine (0.090 mL, 0.63 mmol) was added to a solution of the above alcohol (0.14 g, 0.42 mmol) in dichloromethane (4.2 mL) at room temperature and stirred 0.5 hours. This gave, after aqueous work up, the crude allylic methanesulfonate (0.14 g) which was used immmediately in the next reaction.
[0472] Using the general procedure for N-alkylation, the methanesulfonate (0.14 g, 0.42 mmol), (N-tent-butoxycarbonylbenzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amine (0.16 g, 0.42 mmol) and potassium iodide (3 mg, 21 mol) were stirred at 60 C in acetonitrile (4.2 mL) and diisopropylethylamine (0.11 mL, 0.63 mmol) ) for 16 hours to yield, after work-up and column chromatography (1:99 McOH/CH2C12), the desired alkylated Z-regioisomer (0.100 g, 34%).
[0473] A solution of the above compound (0.10 g, 0.16 mmol) in THE (2 mL) and HC1 (2 mL) was stirred for 1.5 hours. The solution was then cooled to 0 C and 15% aqueous sodium hydroxide was added until the pH = 12. The aqueous phase was then extracted with CH2C12. (3 x 15 mL) and the combined organic phases were dried (MgSO4), filtered and concentrated under reduced pressure. This gave, after radial chromatography (8:2.5:89.5 McOH/NH4OH/CH2C12), Z- {4-[(1H-benzimidazol-2-yl-methyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-2-hydroxymethyl-but-2-enyl}-carbamic acid tert-butyl ester (35 mg, 58%). 1H
NMR (CDC13) 8 1.40 (s, 9H), 1.77 (br, 1H), 1.97 (m, 1H), 2.10 (m, 311), 2.80 (m, 2H), 3.27 (m, 2H), 3.64 (br, 2H), 3.72 (d, 1H, J= 15.0 Hz), 3.92 (d, 1H, J= 15.0 Hz), 4.02 (s, 2H), 4.12 (m, 1H), 4.58 (m, NH), 7.18 (m, 3H), 7.50 (m, 2H), 7.68 (br, 1H), 8.52 (d, 1H, J= 3.0 Hz).
[0474] The above compound (35 mg, 0.07 mmol) was then dissolved in neat TFA (1 mL) and stirred for 1 hour. CH2C12 (10 mL) and 15% aqueous NaOH was added until pH
= 12.
The organic phase was separated and the aqueous phase was extracted with CH2C12 (2 x 5 mL). The combined organic phases were dried (MgS04), filtered, and concentrated under reduced pressure. This afforded, after radial chromatography (8:2.5:89.5 McOH/NH40H/CH2C12), COMPOUND 81 free base as a pale yellow free flowing powder (18 mg, 68%). 1H NMR (CDC13) 8 1.75 (br, 1H), 1.94 (m, 1H), 2.08 (br, 2H), 2.85 (m, 3H), 3.30 (m, 4H), 3.78 (d, 1H, J= 14.4 Hz), 3.95 (d, 1H, J= 15.6 Hz), 4.11 (d 2H), 4.15 (m, 1H), 5.48 (m, 1H), 7.19 (m, 3H), 7.46 (d, 1H, J= 7.2 Hz), 7.58 (br, 2H), 8.53 (d, 1H, J= 3.3 Hz);
13C NMR (CDC13) 8 20.88, 23.54, 29.20, 47.22, 47.74, 49.28, 59.50, 61.77, 115.24 (3C), 122.42 (2C), 122.82, 125.40 (2C), 135.27, 138.23, 143.73, 146.88, 155.01, 157.26. ES-MS
in/z 378 (M+H). Anal. Calcd. for C22H27N50=0.7CH2C12Ø2C6H12: C, 63.26; H, 6.84; N, 15.43. Found: C, 63.36; H, 6.79; N, 15.59.

Exam lpe82 N

H
N NH

COMPOUND 82: Preparation of N1-(1H-Benzimidazol-2- l~yl)-N1-(5 6 7 8-tetrahydro-guinolin-8-yl)-cyclohexane-trans-1,2-diamine (hydrobromide salt) Preparation of N-(2-nitrobenzenesulfonyl)-7-azabic clo[4 1 0}he tp ane (N-(2-nitrobenzenesulfonyl)-1,2-cyclohexeneaziridine):
Ns [0475] A solution of trans-2-aminocyclohexanol hydrochloride (1.185 g, 7.81 mmol} and 2-nitrobenzenesulfonyl chloride (1.73 g, 7.81 mmol) in CH2C12 (20 mL) was cooled in an ice bath under a nitrogen atmosphere while Et3N (2.40 mL, 17.2 mmol) was added.
The mixture was heated at reflux for 35 minutes, then concentrated in vacua. Water (100 mL) was added to the residue, and the mixture was extracted with EtOAc (100 mL). The organic extract was washed with brine (2 x 30 mL), then dried (MgSO4), filtered and concentrated in vacuo to give a green foam (2.32 g).

[0476] A solution of the foam from above and Et3N (1.3 mL, 9.3 mmol) in CH2C12 (15 mL) was stirred at -78 C under argon while methanesulfonyl chloride (0.66 mL, 8.5 mmol) was added. The mixture was stirred at -78 C for 10 minutes, then the cold bath was removed and stirring was continued at room temperature for 30 minutes and the solution was then concentrated in vacuo. Water (30 mL) and saturated NaHCO3(aq) (30 mL) were added to the residue, and the mixture was extracted with EtOAc (1 x 50 mL, 3 x 20 mL).
The combined organic extracts were dried (MgSO4) and concentrated in vacuo to give the crude mesylate as a light yellow solid (2.65 g).

[0477] The crude mesylate (2.65 g, 7.0 mmol) was stirred as a suspension in toluene (30 mL) at room temperature while a solution of 85% KOH (2.01 g, 35.9 mmol) in H2O
(12 mL) was added: The mixture was stirred for 40 minutes then diluted with EtOAc (50 mL) and brine (40 mL). The aqueous phase was separated and washed with EtOAc (1 x 40 mL) then dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by column chromatography on silica gel (25% EtOAc/hexanes) to give the desired aziridine as colorless crystals (1.54 g, 71% over 3 steps). 1H NMR (CDC13) 8 1.23-1.30 (m, 2H), 1.35-1.42 (m, 2H), 1.84-1.93 (m, 4H), 3.22 (dd, 2H, J= 6, 1 Hz), 7.72-7.76 (m, 3H), 8.18-8.20 (m, 1H).
[0478] A solution of N-(2-nitrobenzenesulfonyl)-1,2-cy. clohexeneaziridine from above (341 mg, 1.21 mmol), (1-tert-butoxycarbonyl-lH-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine (434 mg, 1.15 mmol) and Et3N (0.16 mL, 1.15 mmol) in THE (5 mL) was heated at 60 C under nitrogen atmosphere for 2.5 days. The solution was then cooled, concentrated and diluted with CH2C12 (40 mL) and saturated aqueous NaHCO3 (40 mL). The aqueous phase was extracted with CH2C12 (2 x 20 mL). The combined organic extracts were dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by column chromatography on silica gel (CH2C12/MeOH, 98:2 then 96:4) to give the desired alkylated product as a yellow foam (411 mg, 54%).
[0479] The foam from above (271 mg, 0.41 mmol) oil was dissolved in CH2C12/TFA
(1:1, 2 mL) and the mixture stirred overnight. The reaction was then concentrated and diluted with CH2C12 (30 mL) and 1 N NaOH (30 mL). The aqueous layer was washed with CH2C12 (2 x 10 mL) and the combined organic extracts were dried (Na2SO4), filtered and concentrated to afford the Boc-deprotected material as a yellow foam (159 mg, 69%).
[0480] Deprotection of the 2-nitrobenzenesulfonamide (nosyl) group: To a stirred solution of the nosyl-protected adduct from above (159 mg, 0.28. mmol) in dry (5 mL) was added benzenethiol (0.175 mL, 1.71 mmol) and powdered potassium carbonate (240 mg, 1.74 mmol) and the mixture was stirred at room temperature overnight.
The reaction mixture was concentrated in vacuo and partitioned between CH2C12 (15 mL) and water (15 mL). The aqueous layer was separated and extracted with CH2C12 (2 x 10 mL) and the combined organic phases were dried (Na2SO4), filtered and evaporated in vacuo to give the crude product as a yellow oil. Purification by column chromatography on basic alumina (CH2C12/MeOH, 100:0 followed by 95:5) afforded the desired amine (85 mg, 80%) as a yellow foam.
[0481] Using General Procedure D: Conversion of the foam from above (34 mg, 0.091 mmol) to the hydrobromide salt followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 82 (38 mg, 65%) as a white solid. 1H NMR
(D20) 6 1.36-1.46 (m, 2H), 1.59-1.91 (m, 5H), 2.22-2.32 (m, 3H), 2.35-2.45 (m, 2H), 2.81-2.84 (m, 2H), 3.21-3.28 (m, 1H), 3.44-3.56 (m, 1H), 4.33 (d, 1H, J=15.9 Hz), 4.42 (d, 1H, J= 15.9 Hz), 4.65 (t, 1H, J= 8.4 Hz), 7.23 (dd, 1H, J= 7.5, 6 Hz), 7.51 (dd, 2H, J=
6.3, 3.3 Hz), 7.59 (dd, 2H, J= 6.3, 3.3 Hz), 7.86 (d, 1H, J= 8.1 Hz), 8.11 (d, 1H, J= 5.5 Hz);
13C NMR (D2O) 6 19.35, 22.02, 22.46, 23.56, 26.46, 27.94, 29.94, 37.81, 50.82, 61.34, 66.88, 112.92, 123.83, 126.14, 129.54, 138.38, 139.34, 146.03, 148.26, 148.34. ES-MS m/z 376 (M+H).
Anal.
Calcd. for C23H29N5=2.9HBr=1.8H20: C, 42.99; H, 5.57; N, 10.90; Br, 36.06.
Found: C, 43.29; H, 5.55; N, 10.6Q; Br, 35.67.

Exam lpe83 CQ
H

N NH2 ~Ic N NH

COMPOUND 83: Preparation of N-(1H-benzimidazol-2- lvl)-N-(5,6,7,8-tetrahydro-quinolin-8-yl)-cyclohexane-1,3-diamine (hydrobromide salt) Preparation ofN-tent-butoxycarbon 1~yclohexanediamine (Smith, J., et al., J. Org. Chem. (1996) 61:8811-8818):

H2N H C NHBoc [04821 To a solution of 1,3-cyclohexanediamine (cis and trans) (1.00 g, 8.76 mmol) in CHC13 (20 mL) was added a; solution of di-tert-butyl dicarbonate (0.95 g, 4.35 mmol) in CHC13 (15 mL) via syringe pump over a period of 3 hours. The resultant white suspension was stirred at room temperature overnight then concentrated in vacuo and purified by column chromatography on silica gel (CH2C12/MeOH/NH4OH, 90:8:2) to afford the title compound (0.66 g, 35% based on starting diamine) as a clear oil.
[04831 Following General Procedure B: To a stirred solution of 6,7-dihydro-5H-quinolin-8-one (444 mg, 3.00 mmol) and N-tert-butoxycarbonyl-1,3-cyclohexariediamine (660 mg, 3.08 mmol) in dry THE (5 mL) was added AcOH (0.4 mL) and NaBH(OAc)3 (822 mg, 3.88 mmol) and the mixture stirred overnight at room temperature.
Purification by column chromatography on silica gel (CH2C12/MeOH, 96:4) afforded the desired amine (370 mg, 60%) as a mixture of inseparable diastereomers.
[0484] Following the general procedure for N-alkylation: To a stirred solution of the yellow foam from above (370 mg, 1.07 mmol) in CH3CN (5 inL) was added N,N-diisopropylethylamine (0.35 mL, 2.01 mmol), KI (30 mg, 0.18 mmol) and 1-(tert-butoxycarbonyl)-2-(chloromethyl)benzimidazole (343 mg, 1.29 mmol). The mixture was stirred at 60 C overnight. Purification of the resultant orange foam by column chromatography on silica gel (CH2C12/MeOH, 96:4 then 92:8) afforded the desired alkylated amine (430 mg, 70%) as a mixture of diastereomers.
[0485] Using General Procedure D: Conversion of the foam from above (96 mg, 0.17 mmol) to the hydrobromide salt with simultaneous removal of the N-tert-butoxycarbonyl protecting group followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 83 (96 mg, 88%) as an orange solid (mixture of diastereomers).

NMR (D20) 6 1.27-1.64 (m, 4H), 1.74-2.00 (m, 4H), 2.07-2.38 (m, 311), 2.40-2.44 (m, 1H), 2.84-2.90 (m, 1H), 2.98-3.01 (m, 2H), 3.15-3.20 (m, 1H), 4.43-4.62 (m, 3H), 7.60 (dd, 2H, J
= 6, 3 Hz), 7.76 (dd, 2H, J= 6, 3 Hz), 7.78-7.83 (m, 1H), 8.28 (br d, 1H, J=
7.8 Hz), 8.57-8.60 (m, 1H); 13C NMR (D2O) 619.58, 20.71, 22.37, 22.45, 24.23, 27.21, 27.51, 28.60, 29.16, 29.70, 30.54, 31.08, 31.75, 34.35, 36.21, 43.65, 48.61, 49.79, 54.46, 58.57, 58.70, 58.93, 114.23, 125.86, 127.05, 130.91, 139.16, 140.55, 148.03, 151.18, 151.26, 151.83. ES-MS m/z 376 (M+H). Anal. Calcd. for C23H29N5=3.0HBr=1.96H20: C, 42.34; H, 5.53;
N, 10.73; Br, 36.74. Found: C, 42.27; H, 5.59; N, 10.37; Br, 37.04.

Example 84 C;~-c nN~ NH2 N

COMPOUND 84: Preparation of 4-[(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-aminol-piperidine-l-carboxylic acid amide (hydrobromide salt) [0486] 4-Hydroxypiperidine (2.58 g, 25.5 mmol) was dissolved in THE (100 mL) and treated with di-tert-butyl dicarbonate (5.57 g, 25.5 mmol) and stirred for 40 minutes at room temperature. The solvent was removed under reduced pressure to afford 4-hydroxypiperidine- 1 -carboxylic acid tert-butyl ester as a light yellow oil that was used in the next reaction.
[0487] A solution of the above alcohol (0.79 g, 3.9 mmol) in CH2C12 (20 mL) was treated with molecular sieves (1.95 g), N-methylmorpholine oxide (0.69 g, 5.9 mmol), and TPAP
(0.14 g, 0.40 nimol). The mixture was stirred for 2 hours at room temperature and then filtered through a plug of silica gel, eluting with Et2O. The filtrate was then concentrated under reduced pressure to afford the desired 4-oxopiperidine- 1 -carboxylic acid tert-butyl ester (0.69 g, 89%). 1H NMR (CDC13) 81.49 (s, 9H), 2.44 (t, 4H, J= 7.0 Hz), 3.72 (t, 4H, J
= 7.0 Hz).
[0488] Using General Procedure B, 4-oxopiperidine-l-carboxylic acid tent-butyl ester (0.69 g, 3.4 mmol), (5,6,7,8-tetrahydroquinolin-8-yl)-amine (0.51 g, 3.4 mmol) and sodium triacetoxyborohydride (1.10 g, 5.2 mmol) were stirred at room temperature in dichloromethane (20 mL) for 16 hours to yield, after work-up and column chromatography with silica gel (5:0.5:94.5 McOH:NH4OH:CH2C12), 4-(5,6,7,8-tetrahydroquinolin-ylamino)-piperidine-l-carboxylic acid tert-butyl ester as a white solid (1.00 g, 87%).
[0489] To a solution of 4-(5,6,7,8-tetrahydroquinolin-8-ylamino)-piperidine-l-carboxylic acid tert-butyl ester (1.00 g, 3.0 mmol), 2-chloromethyl-benzimidazole-l-carboxylic acid tert-butyl ester (1.20 g, 4.5 mmol), and potassium iodide (25 mg, 0.15 mmol) in anhydrous acetonitrile (30 mL) was added diisopropylethylamine (1.05 mL, 6.0 mmol) and stirred at 40 C for 16 hours. The mixture was then concentrated under reduced pressure and the residue partitioned between dichloromethane (30 mL) and brine (25 mL). The organic phase was separated and the, aqueous phase was extracted with dichloromethane (2 x 25 mL). The combined organic phases were then dried (Na2SO4), filtered, and concentrated under reduced pressure to give a crude residue that was purified by column chromatography with silica gel (2:0.5:97.5 McOH:NH4OH:CH2C12). This afforded 2-{[(1-tert-butoxycarbonyl-piperidin-4-yl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-methyl}-benzimidazole-l-carboxylic acid tert-butyl ester as an light orange solid (0.50 g, 30%).

[0490] A solution of the above compound (0.50 g, 0.9 mmol) was dissolved in CH2C12 (2 mL) and treated with trifluoroacetic acid (2.5 mL) for 1 hour. CH2C12. (20 mL) was added and the solution was basified to pH > 9 with 15% aqueous NaOH solution (10 mL).
Brine (20 mL) was added to alleviate emulsification. The phases were then separated and the aqueous extracted with CH2C12 (2 x 40 mL). The combined organics were then dried (Na2S04) and concentrated under reduced pressure to give (1H-benzimidazol-2-ylmethyl)-piperidin-4-yl-(5,6,7,8-tetrahydroquinolin-8-yl)-amine (0.32 g, 100%). 1H NMR (CDC13): 8 1.35 (m, 1H), 1.50 -1.75 (m, 3H), 1.84 (m, 2H), 2.05 (br, 1H), 2.23 (br, 1H), 2.40 - 2.65 (m, 3H), 2.74 (m, 1H), 2.80 - 2.95 (m, 2H), 3.07 (m, 1H), 4.13 (m, 1H), 4.21 (s, 2H), 7.16 (m, 3H), 7.43 (d, 1H, J= 7.5 Hz), 7.44 (br, 1H), 7.67 (br, 1H), 8.59 (d, 1H, J= 4.5 Hz).
[0491] A solution of (1H-benzimidazol-2-ylmethyl)-piperidin-4-yl-(5,6,7,8-tetrahydroquinolin-8-yl)-amine (0.16 g, 0.43 mmol) in isopropanol (3 mL) was treated with trimethylsilylisocyanate (81 L, 0.60 mmol) at room temperature. The reaction was stirred 20 hours and concentrated under reduced pressure. This afforded, after column chromatography with silica gel (5:0.5:94.5 McOH:NH4OH:CH2C12), 4-[(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-piperidine-1-carboxylic acid amide (112 mg, 66%). 1H NMR (CDC13) 5 1.42 (m, 1H), 1.60 - 1.95 (m, 5H), 2.02 (br, 1H), 2.24 (br, 1H), 2.60 - 2.80 (m, 4H), 2.89 (m, 111), 3.70 (br, 1H), 4.03 (br, 1H), 4.15 (m, 3H), 4.39 (br, 2H, NH2), 7.18 (m, 3H), 7.45 (d, 1H, J= 7.5 Hz), 7.66 (br, 2H), 8.59 (d, 1H, J= 4.0 Hz).
[0492] Using General Procedure D: The above material (105 mg, 0.26 mmol) was converted to the hydrobromide salt to provide COMPOUND 84 (107 mg) as a white solid.
1H NMR (D20) 3 1.56 (dqt, 2H, J= 2.1, 12.0 Hz), 1.82 (br, 2H), 2.14 (br, 3H), 2.42 (br, 1H), 2.77 (br t, 2H, J = 12.3 Hz), 2.97 (br, 3H), 3.92 (br t, 2H, J = 17.1 Hz), 4.42 (d, 1 H, J = 16.8 Hz), 4.54 (m, 1H), 4.57 (d, 1H, J= 16.8 Hz), 7.59 (m, 2H), 7.75 (in, 2H), 7.79 (m, 1H), 8.28 (d, 1H, J= 8.1 Hz), 8.55 (d, 1H, J= 5.7 Hz). 13C NMR (D20) S 20.71, 23.89, 27.55, 29.45, 31.09, 43.98 (3C), 58.88, 58.97, 114.21 (2C), 125.83, 127.03 (2C), 130.90, 139.11, 140.49 (2C), 148.02, 151.55, 151.96, 160.13. ES-MS m/z 405 (M+H). Anal. Calcd. for C23H28N60.3.OHBr=1.3H2OØ3C4H10O: C, 41.95; H, 5.32; N, 12.13; Br, 34.60.
Found: C, 42.08; H, 5.30; N, 12.19; Br, 34.52.

Exam lUe85 C 'Q -N
N N
N\\"-~ ZNaN
H

COMPOUND 85: Preparation of (1H-benzimidazol-2-ylmethyl)-F2-(4-benzylamino-piperidin-1-yl)-ethyl]-(5,6,7,8-tetrahydroquinolin-8-yl)-amine (hydrobromide salt).
[0493] To a solution of N-Boc-piperidone (3.0 g, 15.1 mmol) in THE (76 inL) was added benzylamine (1.65 mL, 15.1 mmol), acetic acid (0.86 mL, 15.1 mmol) and sodium triacetoxyborohydride (4.8 g, 22.6 mmol). After stirring 2.5 hours the reaction mixture was concentrated under reduced pressure and CH2C12 (50 mL) and saturated aqueous NaHCO3 solution (50 mL) was added. The organic phase was separated, and the aqueous was extracted with CH2C12 (2 x 50 mL). The combined organic phases were then dried (MgSO4), filtered, and concentrated under reduced pressure to afford 4-benzylamino-piperidine-1-carboxylic acid tent-butyl ester (4.30 g, 98%).
[0494] The crude material from above (4.30 g, 14.8 mmol) and 2-nitrobenzenesulfonyl chloride (3.60 g, 16.3 mmol) were dissolved in CH2C12 (75 mL) and triethylamine (2.68 mL, 19.2 mmol) was added. The solution was stirred for 16 h and saturated aqueous NaHCO3 solution (70 mL) was added. The organic phase was separated, and the aqueous extracted with CH2C12 (50 mL). The combined organic phases were then dried (MgSO4), filtered, and concentrated under reduced pressure. This gave, after column chromatography (CH2C12), the desired nosyl-protected substrate (3.92 g, 56%).
[0495] A solution of the above material (3.92 g, 8.2 mmol) in 1:1 TFA/ CH2C12 (26 mL) was stirred for 0.5h and then concentrated under reduced pressure. CH2C12 (50 mL), saturated aqueous NaHCO3 solution (50 mL), and 15% aqueous NaOH (10 mL) was added until pH =
14. The organic phase was separated, and the aqueous was extracted with CH2C12 (30 mL).
The combined organic phases were then dried (MgSO4), filtered, and concentrated under reduced pressure. This afforded the desired unprotected cyclic amine (2.74 g, 89%).
[0496] To a solution of the cyclic amine (2.74 g, 7.3 mmol) in anhydrous acetonitrile (73 mL) was added 2-bromoethanol (0.52 mL, 7.3 mmol), and triethylamine (1.25 mL, 8.7 mmol). The reaction was stirred at 50 C for 16 hours, and saturated aqueous NaHCO3 i solution (50 mL) and ethyl acetate (50 mL) was added. After separating the organic phase and washing with brine (35 mL), the extracts were dried (MgSO4), filtered and concentrated under reduced pressure. This gave, after column chromatography (2:98 McOH/CH2C12), N-benzyl-N-[1-(2-hydroxy-ethyl)-piperidin-4-yl]-2-nitro-benzenesulfonamide as a colorless solid (1.62 g, 53%). 1H NMR (CDC13) 6 1.62-1.71 (m, 4H), 2.14 (dt, 2H, J =
12.0, 3.0 Hz), 2.47 (t, 2H, J= 6.0 Hz), 2.88 (br d, 2H, J= 12.0 Hz), 3.53 (t, 2H, J= 4.5 Hz), 3.92 (m, 1H), 4.54 (s, 2H), 7.21 (m, 3H), 7.30 (m, 2H), 7.47 (rn, 1H), 7.61 (d, 2H, J= 4.5 Hz), 7.77 (d, 1H, J"= 9.0 Hz).
[0497] Methanesulfonyl chloride (100 L, 1.2 mmol) and triethylamine (0.20 mL, 1.4 mmol) was added to a solution of the above alcohol (0.40 g, 0.95 mmol) in (3 mL) at 0 C and then allowed to warm to room temperature over 20 minutes.
This gave, after aqueous work up, the desired crude methanesulfonate (0.53 g, quant) as a white solid which was used immediately, in the next reaction.
[0498] Using the general procedure for N-alkylation, the crude methanesulfonate (0.47 g, 0.94 mmol) and (N-tert-butoxycarbonylbenzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amine (0.36 g, 0.94 mmol) was stirred at room temperature in acetonitrile (10 mL) and diisopropylethylamine (0.25 mL, 1.4 mmol) for 16 hours. This yielded, after work-up and column chromatography (5:95 MeOH/CH2C12), 2-{[{2-[4-(benzyl-2-nitrobenzenesulfonyl-amino)-piperidin-1-yl]-ethyl} -(5,6,7, 8-tertahydroquinolin-8-yl)-amino]-methyl}-benzimidazole-1-carboxylic acid tert-butyl ester as a colorless flaky solid (0.25 g, 34%).
[0499] To a solution of the above material (0.25 g, 0.32 mmol) and thiophenol (0.17 mL, 1.6 mmol) in anhydrous acetonitrile (2.0 mL) was added potassium carbonate (0.27 g, 1.9 mmol). The reaction was stirred for 5 h. CH2C12 (10 mL) was then added and the mixture was filtered through a celite pad and concentrated under reduced pressure.
This afforded, after column chromatography (5:95 McOH/CH2C12), the desired nosyl-deprotected product (0.75 g, 60%).
[0500] To a solution of the above material (75 mg, 0.15 mmol) in anhydrous THE
(1.5 mL) was added di-tert-butyldicarbonate (100 mg, 0.45 mmol). The solution was allowed to stir for 16 h and then concentrated under reduced pressure. This gave, after radial chromatography (1.5:1.5:97 McOH/NH40HCH2C12), the desired di-boc-protected product (42 mg, 40%). 1H NMR (CDC13) 6 1.32 (br s, 9H), 1.47 (br s, 5H), 1.67 (s, 9H), 1.77 (br s, 4H), 1.97 (m, 1H), 2.15 (m, 2H), 2.29 (m, 1H), 2.73 (m, 6H), 4.22 (m, 1H), 4.26 (br s, 2H), 4.53 (d, 1H, J=15.0 Hz), 4.73 (d, 1H, J= 15.0 Hz), 6.97 (m, 1H), 7.16 (in, 3H), 7.23 (m, 5H), 7.68 (m, 1H), 7.81 (m, 1H), 8.36 (d, 1H, J= 3.0 Hz).
[0501] Using General Procedure D: The above material (24 mg, 0.0345 mmol) was converted to the hydrobromide salt to provide COMPOUND 85 (26 mg) as a white solid. 1H
NMR (D20) 6 1.82 (br in, 1H), 1.97 (m, 3H), 2.17 (br in, 1H), 2.45 (m, 3H), 3.00-3.23 (br in, 5H), 3.38-3.75 (br in, 6H), 4.29 (s, 2H), 4.39 (d, 1H, J= 16.8 Hz), 4.50 (m, 1H), 4.56 (d, 1H, J=16.8 Hz), 7.47 (br s, 5H), 7.60 (in, 2H), 7.79 (m, 2H), 7.83 (t, 1H, J= 6.0 Hz), 8.32 (d, 1H, J= 7.8 Hz), 8.61 (d, 1H, J= 5.7 Hz), 13C NMR (D20) 6 20.29, 20.64, 26.15 (2C), 27.65, 46.41, 47.13, 49.13, 51.39 (2C), 51.91, 54.39, 60.07, 114.41 (2C), 126.16, 127.06 (2C), 129.82 (2C), 130.16 (2C), 130.26, 130.71, 131.30, 139.85 (2C), 140.96, 148.27, 149.95, 150.18. ES-MS in/z 495 (M+H). Anal. Calcd. for C31H38N6=4.2HBr=3.0H20: C, 42.05; H, 5.49; N, 9.49; Br, 37.51. Found: C, 42.13; H, 5.64; N, 9.16; Br, 37.53.

Example 86 :N
N\>--/ No- N H

H

COMPOUND 86: Preparation of f2-(4-amino-piperidin-l-yl -ethyl]-[(1H-benzimidazol-2-l~yl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amine (hydrobromide salt).

[0502] To a solution ofN-benzyl-N-[ 1-(2-hydroxy-ethyl)-piperidin-4-yl]-2-niitro-benzenesulfonamide (0.62 g, 1.5 mmol) and thiophenol (0.76 mL, 7.4 mmol) in anhydrous acetonitrile (9 mL) was added potassium carbonate (1.22 g, 8.8 mmol). The reaction was stirred for 16 h. The mixture was then filtered through a celite to give, after column chromatography (10:90 McOH/CH2C12), the desired nosyl-deprotected intermediate (0.30 g, 86%).
[0503] The above material (0.30 g, 1.3 mmol) was dissolved in anhydrous ethanol (15 mL) and the solution purged with nitrogen gas. 10% palladium on carbon (130 mg) was added and the reaction mixture was allowed to stir under a new atmosphere of hydrogen (1 atm) for 16 h. The mixture was then filtered through celite to afford a crude yellow residue of 2-(4-amino-piperidin-1-yl)-ethanol (0.20 g, quant.).

[0504] To a solution of the above material (0.20 g, 1.5 mmol) in anhydrous THE
(7.5 mL) was added di-tert-butyldicarbonate (0.37 g, 1.7 mmol). The solution was allowed to stir for 16 h and then concentrated under reduced pressure. This afforded, after column chromatography (5:95 McOH/CH2C12), the desired boc-protected amine (0.14 g, 37%). 1H
NMR (CDC13) b 1.42 (m, 2H), 1.44 (s, 9H), 1.92 (br d, 2H), 2.14 (br t, 2H), 2.50 (t, 2H, J=
6.0 Hz), 2.82 (br d, 2H), 3.45 (br, 1H), 3.57 (t, 2H, J= 6.0 Hz), 4.48 (br, NH).
[0505] Methanesulfonyl chloride (60 L, 0.7 mmol) and triethylamine (0.12 mL, 0.9 mmol) was added to a solution of the above material (0.14 g, 0.6 mmol) in CH2C12 (3 mL) at 0 C and then allowed to warm to room temperature over 20 minutes. This gave, after aqueous work up, the desired methanesulfonate (0.16 g) that was used immediately, in the next reaction without further purification.
[0506] Using the general procedure for N-alkylation, the crude methanesulfonate (0.16 g, 0.5 mmol) and (5,6,7,8-tetrahydroquinolin-8-yl)-[1-(2-trimethylsilanyl-ethoxymethyl)-1H-benzimidazol-2-ylmethyl]-amine (0.18 g, 0.44 mmol) was stirred at room temperature in acetonitrile (5 mL) and diisopropylethylamine (0.13 mL, 0.75 mmol) for 16 hours. This yielded, after work-up and column chromatography (5:95 MeOH/CH2C12), the desired alkylated product (27 mg, 12%).
[0507] The material from above (27 mg, 0.042 mmol) was dissolved in 6N HCl (1 mL) and stirred at 50 C for 3 h. 15% aqueous NaOH (2 mL) was added until pH =12, and the aqueous phase was concentrated under reduced pressure. This gave, after filtering from methanol and radial chromatography (5:1:94 McOH/NH40H/CH2C12) the desired SEM-deprotected free base (12 mg, 69%). 1H NMR (CDC13) 6 1.48 (m, 2H), 1.70 (m, 1H), 1.82 (m, 3H), 1.98 (m, 2H), 2.23 (m, 2H), 2.66-2.95 (m, 8H), 3.74 (s, 1H), 3.98 (d, 2H, J= 15.0 Hz), 4.13 (m, 1H), 7.13 (m, 1H), 7.19 (m, 2H), 7.40 (d, 1H, J= 9.0 Hz), 7.58 (m, 2H), 8.49 (d, 1H, J= 3.0 Hz).
[0508] Using General Procedure D: The material from above (12 mg, 0.030 mmol) was converted to the hydrobromide salt to provide COMPOUND 86 (14 mg) as a white solid. 1H
NMR (D20) S 1.85-2.05 (br in, 3H), 2.20-2.30 (br in, 3H), 2.47 (m, 1H), 3.00 (br in, 2H), 3.15 (br in, 2H), 3.34 (m, 1H), 3.44-3.63 (br in, 4H), 4.35 (d, 1H, J= 16.5 Hz), 4.47 (m, 1H), 4.53 (d, 1H, J= 16.5 Hz), 4.80-4.93 (br, 4H), 7.58 (m, 2H), 7.80 (m, 3H), 8.30 (d, 1H, J= 7.5 Hz), 8.58 (d, 1H, J= 5.7 Hz), 13C NMR (D20) S 20.30, 20.64, 27.29 (2C), 27.65, 45.53, 46.43, 47.14, 51.41 (2C), 54.36, 60.08, 114.44 (2C), 126.08, 126.90 (2C), 131.59, 139.88, 140.86 (2C), 148.10, 150.06, 150.30. ES-MS na/z 405 (M+H). Anal. Calcd. for C24H32N6=4.1HBr=3.3H20: C, 36.41; H, 5.42; N, 10.62; Br, 40.93. Found: C, 36.52; H, 5.49;
N, 10.26; Br, 40.94.

Example 87 m N HN
0: N\> /N~ NH2 N ~-1 H

COMPOUND 87: Preparation of 4-1(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-y4)-amino]-butyramidine (hydrobromide salt).

[0509] [N-(tert-Butoxycarbonyl)-benzimidazol-2-ylmethyl)]-(5,6,7,8-tetrahydroquinolin-8-yl)-(3-cyano-prop-1-yl)-amine (0.14 g, 0.30 mmol) was dissolved in anhydrous methanol (3 mL) and anhydrous diethyl ether (5 mL) was added. The solution was cooled to 0 C and hydrogen chloride gas was bubbled through the solution over 0.5 hour to saturation. The reaction was then allowed to stir at room temperature for 16 hours, after which the solvent was removed under reduced pressure. The residue was then washed with diethyl ether (3 x 20 mL) and dried in vacuo. This afforded the required 4-[(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-butyrimidic acid methyl ester (hydrochloride salt), which was used immediately in the next reaction.
[0510] The salt from above (0.30 mmol) was dissolved in a solution of ammonia in methanol (2 M, 3 mL, 1.5 mmol), and stirred for 16 hours. The solution was then concentrated under reduced pressure and purified by column chromatography, (10:1:89 McOH/NH4OH/CH2C12) to give the desired 4-[(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-butyramidine free base as a crystalline solid (42 mg, 38%, 2 steps). 1H NMR (CDC13) 61.50 (m, 1H), 1.73-1.95 (br in, 4H), 2.14 (m, 1H), 2.40-2.80 (br in, 6H), 3.91 (m, 1H), 3.95 (br d, 1H, J=15.0 Hz), 4.10 (br d, 1H, J= 15.0 Hz), 7.10 (br, 3H), 7.37 (d, 1H, J= 6.0 Hz), 7.55 (br, 2H), 8.44 (br, 1H), 8.87 (br, NH), 9.51 (br, NH).
[0511] Using General Procedure D: The material from above (42 mg, 0.11 mmol) was converted to the hydrobromide salt to provide COMPOUND 87 (28 mg). 1H NMR
(D20) 6 1.85 (br in, 3H), 1.95 (m, 1H), 2.17 (br in, 1H), 2.37 (t, 3H, J= 7.8 Hz), 2.56 (m, 1H), 2.86 (m, 1H), 3.00 (br, 2H), 4.37 (d, 1H, J= 16.8 Hz), 4.48 (m, 1H), 4.53 (d, 1H, J=16.8 Hz), 7.60 (m, 2H), 7.79 (m, 2H), 7.86 (t, 1H, J= 6.9 Hz), 8.34 (d, 1H, J= 7.8 Hz), 8.62 (d, 1H, J=
5.4 Hz); 13C NMR (D20) 6 20.37, 20.50, 25,60, 27.63, 30.11, 47.89, 50.91, 60.41, 114.27 (2C), 126.01, 127.02 (2C), 130.99, 139.43, 140.74 (2C), 148.20, 151.41, 152.06. ES-MS nt/z 363 (M+H). Anal. Calcd. for C21H26N6.3.1HBr=1.3H20Ø3C4H100: C, 40.17; H, 5.27; N, 12.66; Br, 37.32. Found: C, 40.09; H, 5.27; N, 12.62; Br, 37.31.

Example 88 (N) ~N H
'-"--,"NH2 HN N

COMPOUND 88: Preparation of N1-(1H-Benzimidazol-2- l~yl)-Nl-(R -5,6,7,8-tetrahydro-quinolin-8-yl-butane-1,4-diamine (crystal).

[0512] Solution A: To a solution of anhydrous zinc (II) chloride (70.80 g, 0.52 mol) in tetrahydrofuran (320 mL) at room temperature was added sodium borohydride (17.86 g, 0.47 mol) and the mixture stirred for 1 hour. The solution was then chilled to -20 C.
[0513] Solution B: To a solution of (R)-(5,6,7,8-tetrahydro-quinolin-8-yl)amine (70.0 g, 0.47 mol) and 4-(1,3-dioxo-1}3-dihydro-isoindol-2-yl)-butyraldehyde (102.59 g, 0.47 mol) in tetrahydrofuran (160 mL) at room temperature was added potassium carbonate (65.28 g, 0.47 mol) and the mixture stirred for 1 hour. The suspension was then filtered and chilled to -20 C. The cold filtrate was slowly added to Solution A via canula over 35 minutes. The resulting mixture was stirred at -20 C for 1 hour, until reaction was complete by NMR
aliquot. The reaction was then neutralized by the careful addition of 6N HCl until pH = 2-3, keeping the temperature below -7 C. The solution was then warmed to 22 C and basified with 13w/v% Na2C03(aq) until pH = 4. The tetrahydrofuran was removed under reduced pressure and the concentrate diluted with water (700 mL) and CH2Cl2 (530 mL).
The phases were separated and the organic phase washed with concentrated ammonium hydroxide (1 x 230 mL) and water (1 x 315 mL). The organic phase was then concentrated to 200-250 mL
and filtered through a conditioned silica gel pad (14 g). The silica gel was rinsed with CH2Cl2 (2 x 20 mL). The combined filtrate was concentrated to 100-150 mL and diluted with diisopropyl ether (1000 mL). The solution was concentrated to 300-350 mL
and chilled to -10 C, at which temperature the product began to precipitate. Mechanical stirring was continued for 45 minutes at -10 C, after which time the product was collected by filtration.
The product was washed with diisopropyl ether (100 mL) and dried under reduced pressure to give pure 2- {4-[(R)-(5,6,7,8-tetrahydro-quinolin-8-yl)amino]-butyl}-isoindole-1,3-dione (135.3 g, 82%). 1H NMR (300 MHz, CDC13, 8 ppm) 1.55-1.85 (m, 6H), 1.95-2.05 (m, 1H), 2.05-2.20 (m, 1H), 2.50 (b, 1H), 2.65-2.85 (m, 4H), 3.65-3.80 (m, 3H), 7.04 (dd, 1H, J= 4.5 & 7.5 Hz), 7.35 (d, 1H, J= 7.5 Hz), 7.65-7.75 (m, 2H), 7.75-7.85 (m, 2H), 8.36 (d, 1H, J=
4.5 Hz).

[0514] To a solution of 2-{4-[(R)-(5,6,7,8-tetrahydro-quinolin-8-yl)amino]-butyl}-isoindole-1,3-dione (135.3 g, 0.39 mol) and 2-chloromethyl-benzimidazole-l-carboxylic acid tert-butyl ester (103 g, 0.39 mol) in acetonitrile (780 mL) at room temperature was added diisopropylethylamine (101 mL, 0.58 mol) and potassium iodide (6.4 g, 0.04 mol) and the mixture heated to 50 C for 3 hours. The mixture was then concentrated under reduced pressure and redissolved in methyl t-butyl ether (500 mL) and water (500 mL).
The pH was adjusted to 2 with 6N HCl then the phases were separated. The aqueous layer was washed with methyl t-butyl ether (500 mL). The aqueous phase was stirred for 22 hours, adding 6N
HCl as needed to maintain pH = 2. The solution was basified to pH 10-11 with ION NaOH
and extracted with toluene (2 x 1.5 L). The organic phase was washed with 1N
NaOH (1 x 200 mL) and brine (1 x 200 mL). The organic phase was dried (Na2SO4), filtered and concentrated under reduced pressure to give 2-{4-[(R)-(1H-benzimidazol-2-ylmethyl)-5,6,7,8-tetrahydro-quinolin-8-yl-amino]-butyl}-isoindole-1,3-dione (209 g). 1H
NMR (300 MHz, CDC13, 8 ppm) 0.75-1.75 (series of in, 5H), 1.80-2.10 (2m, 2H), 2.15-2.25 (m, 1H), 2.55-2.90 (m, 4H), 3.52 (t, 2H, J= 7.0 Hz), 3.95-4.10 (m, 1H), 4.01 (d, 1H, J=
17.0 Hz), 4.11 (d, 1H, J= 17.0 Hz), 7.10-7.30 (m, 4H), 7.39 (d, 1H, J= 7.5 Hz), 7.50-7.55 (m, 1H), 7.60-7.70 (m, 2H), 7.70-7.80 (m, 2H), 8.60 (d, 1H, J= 3.5 Hz).
[0515] To a solution of 2-{4-[(R)-(1H-benzimidazol-2-ylmethyl)-5,6,7,8-tetrahydro-quinolin-8-yl-amino]-butyl}-isoindole-1,3-dione (209 g, max 0.39 mol) in methanol (2 L) at room temperature was added hydrazine hydrate (179 mL, 3.12 mol) and the mixture stirred for 16 hours. The solution was filtered and the filtrate concentrated. The residue was taken up in 1N HCl until pH = 2-3. The resulting suspension was filtered. The filtrate was basified to pH = 6 with 10 N NaOH and washed with CH2C12 (2 x 400 mL). The aqueous phase was further basified to pH = 12 with 1 ON NaOH and extracted with CH2C12 (3 x 1000 mL). The combined organic phase was concentrated under reduced pressure to about 1.4L.
Charcoal (48 g) was added and the suspension stirred for 1 hour. The charcoal was removed by filtration and the filtrate was filtered through a dry silica gel pad (140 g).
The silica was eluted with 20:1 CH2C12: MeOH until no more product could be seen by UV (1.0 L). The filtrate was washed with 0.1N NaOH (1 x 800 mL), dried (Na2SO4), filtered and concentrated under reduced pressure to give amorphous N1-(1H-benzimidazol-2-ylmethyl)-N1-(R)-5,6,7,8-tetrahydro-quinolin-8-yl-butane-l,4-diamine (99 g, 73% over two steps). 1H NMR
(300 MHz, CDC13, 8 ppm) 1.05-1.35 (m, 4H), 1.30-1.50 (m, 1H), 1.60-1.85 (2m, 2H), 1.90-2.05 (m, 1H), 2.25-2.70 (m, 6H), 3.75-4.00 (m, 3H), 6.90 (dd, 1H, J= 4.5 & 7.5 Hz), 6.95-7.05 (m, 2H), 7.15 (d, 1H, J= 7.5 Hz), 7.35-7.45 (m, 2H), 8.37 (d, 1H, J= 4.5 Hz).
[0516] Amorphous ]V'-(1H-Benzimidazol-2-ylmethyl)-N1-(R)-5,6,7,8-tetrahydro-quinolin-8-yl-butane-1,4-diamine (90.98 g, 0.260 mol) was diluted with ethyl acetate (730 ml, 0.125 g/mL) and heated with stirring until all solids had dissolved ('max = 62 C).
The solution was allowed to slowly cool to room temperature while stirring.
Stirring at room temperature was continued for 20 hours. The crystals were then collected on a buchner funnel under N2 atmosphere. The crystals were dried under reduced pressure, then ground with a mortar and pestle. The crystals were then dried in a vacuum oven (40 C, greater then 30" Hg) for two nights to give dryN1-(1H-benzimidazol-2-ylmethyl)-Nl-(R)-5,6,7,8-tetrahydro-quinolin-8-yl-butane-l,4-diamine crystals (69.52 g, 77%). 'H NMR
(CDC13) S
1.21-1.47 (m, 4H), 1.58-1.73 (m, 1H), 1.82-2.06 (m, 2H), 2.12-2.23 (m, 2H), 2.45-2.59 (m, 3H), 2.64-2.89 (m, 3H), 3.97-4.12 (m, 3H), 7.08-7.20 (m, 3H), 749 (d, 1H, J=
7.4 Hz), 7.53-7.60 (m, 2H), 8.57 (d, 1H, J= 4.2 Hz). 13C NMR (CDC13) S 21.15, 23.50, 25.78, 28.96, 30.96, 41.61, 49.23, 50.26, 61.62, 114.83, 121.22, 121.88, 134.28, 137.01, 146.42, 156.49, 157.39. Purity (HPLC) = 99.40 %. Enantiomeric Excess (HPLC) = 99.66 %.
Hydrazine (HPLC) = 4.7 ppm. ES-MS m/z 35& (M+H). Anal Calc. for C21H27N5: C, 72.17; H, 7.79; N, 20.04. Found: C, 71.82; H, 7.74; N, 19.74.

Example 89 cc IN~\NH2 HN ~N

COMPOUND 89: Preparation of N1-(4,5,6,7-tetrahydro-lH-benzoimidazol-2-yhnethyl)-Nl-(5 , 6, 7, 8-tetrahydro-quino lin- 8-yl)-butane-1 4-diamine.

[0517] To solution of 4,5,6,7-tetrahydro-lH-benzoimidazole (1.9992 g, 16.4 mmol) and triethylamine (4.60 mL, 32.8 mmol) in CH2Cl2 (20 mL) at 0 C was added dropwise a solution of dimethyl sulfamoyl chloride (1.76 mL, 16.4 mmol) in CH2Cl2 (10 mL). The reaction was warmed to room temperature and stirred for 3.5 hours. CH2Cl2 (80 mL) was added and the organic phase was washed with distilled water (1 x 80 mL). The aqueous washing was extracted with CH2Cl2 (2 x 40 mL), and the combined organic extracts were washed with brine (1 x 80 mL), dried (Na2SO4), and concentrated. Purification of the crude material by column chromatography, on silica gel (2:1 hexanes-EtOAc) provided 2.89 g (77%) of 4,5,6,7-tetrahydro-benzoimidazole-l-sulfonic acid dimethylamide as a white solid. 1H
NMR
(CDC13) 8 1.77-1.86 (m, 4H), 2.58-2.61 (m, 2H), 2.72 (t, 2H, J= 6 Hz), 2.87 (s, 6H), 7.77 (s, 1H).

[0518] 2-Formyl-4,5,6,7-tetrahydro-benzoimidazole-l-sulfonic acid dimethylamide was prepared following a modification of the procedure found in the Journal of Medicinal Chemistry (1997) 14:2205. To a solution of 4,5,6,7-tetrahydro-benzoimidazole-l-sulfonic acid dimethylamide (2.67 g, 11.6 mmol) in dry THE (100 mL) under argon at -78 C was added dropwise 2.5 M n-butyllithium in hexanes (7.0 mL, 17.5 mmol). The reaction was stirred at -78 C for 1 hour, then DMF (1.1 mL, 13.9 mmol) was added dropwise, and the reaction was warmed to room temperature and stirred for 2 hours. Saturated NH4C1(25 mL) was added, and the reaction mixture was concentrated, and then diluted with CH2Cl2 (500 mL) and distilled water (25 mL). The layers were separated and the aqueous phase was extracted with CH2Cl2 (2 x 100 mL). The combined organic extracts were washed with brine (1 x 100 mL), dried (Na2SO4), and concentrated. Purification of the crude material by column chromatography on silica gel (1:1 hexanes-EtOAc) provided 1.53 g (51%) of 2-formyl-4,5,6,7-tetrahydro-benzoimidazole-l-sulfonic acid dimethylamide as a yellow solid.
1H NMR (CDC13) S 1.82-1.86 (in, 4H), 2.66-2.68 (m, 2H), 2.86-2.88 (in, 2H), 2.96 (s, 6H), 9.99 (s, 1H).
[05191 To a solution of 2-formyl-4,5,6,7-tetrahydro-benzoimidazole-l-sulfonic acid dimethylamide (0.3991 g, 1.5 mmol) and 2-[4-(5,6,7,8-tetrahydro-quinolin-8-ylamino)-butyl]-isoindole-1,3-dione (0.4424 g, 1.3 mmol) in CH2C12 (13 mL) was added sodium triacetoxyborohydride (0.5539 g, 2.6 mmol), and the reaction stirred at room temperature for 22 hours. Saturated NaHCO3 (20 mL) was added and the aqueous phase was extracted with CH2C12 (2 x 100 mL), and the combined organic extracts were washed with brine (1 x 75 mL), dried (NaSO4), and concentrated. Purification of the crude material by column chromatography on silica gel (33:1:1 CH2C12-McOH-NH4OH) provided 0.4564 g (52%) of 2- {[[4-(1,3-dioxo-l ,3-dihydro-isoindol-2-yl)-butyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-methyl}-4,5,6,7-tetrahydro-benzoimidazole-l-sulfonic acid dimethylamide as a yellow foam. 1H NMR (CDC13) S 1.28 (t, 2H, J= 9 Hz), 1.49-1.52 (m, 2H), 1.74-1.81 (m, 6H), 1.91-2.00 (m, 1H), 2.11-2.20 (in, 1H), 2.50-2.73 (m, 7 H), 2.92 (s, 2H), 2.95 (s, 4H), 3.52-3.57 (m, 2H), 4.17-4.22 (m, 2H), 4.32-4.37 (in, 1H), 4.81 (s, 1H), 6.95-6.98 (in, 1H), 7.27-7.28 (in, 1H), 7.68-7.70 (m, 2H), 7.79-7.82 (m, 2H), 8.32 (d, 1H, J= 3 Hz).
[0520] 2-{[[4-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-butyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-methyl}-4,5,6,7-tetrahydro-benzoimidazole-l-sulfonic acid (0.4564 g, 0.77 mmol) and 2 N HC1(7.5 mL) were stirred at reflux for 23 hours. The reaction mixture was cooled to room temperature and 15% (w/v) aqueous NaOH (5 mL) was added. The aqueous layer was extracted with CH2C12 (3 x 150 mL), and the combined organic extracts were washed with brine (1 x 100 mL), dried (Na2SO4), and concentrated. 0.2466 g (64%) of the crude 2-{4-[(4,5,6,7-tetrahydro-lH-benzoimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-butyl}-isoindole-1,3-dione was isolated as a pale yellow foam. 1H
NMR
(CDC13) 6 1.37-1.39 (m, 2H), 1.79-1.88 (m, 10H), 1.98-2.11 (m, 2H), 2.51-2.63 (m, 8H), 3.50-3.52 (m, 1H), 3.66-3.86 (m, 2H), 3.97-3.99 (m, 1H), 7.02-7.11 (m, 2H), 7.37-7.40 (m, 2H), 7.68-7.71 (in, 1H), 7.80-7.82 (in, 1H), 8.44-8.46 (m, 1H).
[05211 To a solution of 2-{4-[(4,5,6,7-tetrahydro-1H-benzoimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-butyl}-isoindole-1,3-dione (0.2466 g, 0.51 mmol) in ethanol (5 mL) was added hydrazine hydrate (0.3 mL, 2.5 mmol), and stirred at room temperature for 18 hours. The reaction mixture was concentrated, and purification of the crude material by column chromatography on silica gel (20:1:1 CH2C12-MeOH-NH40H) provided 0.1031 g (58%) of COMPOUND 89 as a pale yellow solid. 1H NMR (CDC13) S
1.32-1.43 (m, 5H), 1.60-1.68 (m, 1H), 1.72-1.81 (m, 5H), 1.96-2.02 (m, 1H), 2.08-2.17 (m, 1H), 2.45-2.60 (m, 9H), 2.69-2.71 (m, 1H), 2.76-2.86 (m, 1H), 3.70-3.84 (m, 2H), 3.95-4.01 (m, 1H), 7.05-7.10 (m, 1H), 7.36 (d, 1H, J= 7.5 Hz), 8.44 (d, 1H, J= 3 Hz).

(CDCL3) 8 20.80, 22.38, 22.71, 23.07, 25.37, 28.77, 30.54, 41.23, 48.53, 49.81, 60.54, 121.36, 133.94, 136.52, 146.20, 146.32, 157.37. ES-MS m/z 354.5 (M+H). Anal.
Calcd. for (C21H31N5)0.7(H20)0.1(CH2C12): C, 67.65; H, 8.77; N, 18.69. Found: C, 67.46;
H, 8.80; N, 18.43.

Example 90 ~N- Nv v NHz N "~
NH
COMPOUND 90: Preparation ofNl-(1H-Benzimidazol-2-ylmethyl -2-methylene-N1-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine (hydrobromide salt).

[0522] To a cold (0 C), stirred solution of A1C13 (9.43 g, 70.7 mmol) in Et2O
(250 mL) was added powdered LiA1H4 (8.10 g, 213 mmol). After the resultant grey suspension was stirred for 40 minutes, a solution of dimethyl itaconate (8.49 g, 53.7 nunol) in Et2O (130 mL) was added dropwise, by cannula, over 30 minutes. The mixture was stirred for an additional 60 minutes, and then treated with saturated aqueous NH4C1(110 mL). The mixture was diluted with Et20 (500 mL) and filtered through filter paper. The filtrate was concentrated and provided 4.52 g of 2-methylene-butane-1,4-diol as a pale yellow oil. To a stirred solution of 2-methylene-butane-1,4-diol (4.52 g, 44.3 mmol) in CH2C12 (330 mL), at room temperature, was added triethylamine (10.0 mL, 71.7 mmol) followed by benzoic anhydride (7.53 g, 33.3 mmol). After 16 hours, the mixture was washed sequentially with 1.0 M HCl (2 x 35 mL), saturated aqueous NH4Cl (2 x 50 mL), and brine (2 x 50 mL), dried (Na2SO4), and concentrated. Purification of the crude material by column chromatography, on silica gel (2:1 hexanes-ethyl acetate) provided 3.57 g (32% from dimethyl itaconate) of an -5.5:1 mixture of benzoic acid 4-hydroxy-2-methylene-butyl ester and benzoic acid 3-hydroxymethyl-but-3-enyl ester.

[0523] To an -5.5:1 mixture of benzoic acid 4-hydroxy-2-methylene-butyl ester and benzoic acid 3-hydroxymethyl-but-3-enyl ester (3.57 g, 17.3 mmol) in CH2C12 (175 mL) was added Et3N (6.00 mL, 43.0 mmol) followed by methanesulfonyl chloride (2.40 mL, 31.0 mmol). The resultant mixture was stirred at room temperature for 15 hours. The mixture was washed with brine (3 x 50 mL), dried (Na2SO4), and concentrated. The resultant oil was dissolved in DMF (90 mL), treated with potassium phthalimide (6.38 g, 34.4 mmol), and the resultant mixture was heated at 80 C for 24 hours then cooled to room temperature. The mixture was diluted with ethyl acetate (200 mL), brine (90 mL), and water (45 mL) and the phases were separated. The organic phase was washed with brine (5 x 25 mL), dried (MgSO4), and concentrated. The crude material was purified by column chromatography on silica gel (4:1 hexanes-ethyl acetate) and provided 4.11 g (71%) of an -3:1 mixture of benzoic acid 4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-2-methylene-butyl ester and benzoic acid 3-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethyl)-but-3-enyl ester.

[0524] To an -3:1 mixture of benzoic acid 4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-2-methylene-butyl ester and benzoic acid 3-(1,3-dioxo-1,3-dihydro-isoindol-2-ylmethy_l)-but-3-enyl ester (4.11 g, 12.3 mmol) in methanol (123 mL) was added NaOH (1.21 g, 30.3 mmol) and the mixture was stirred at room temperature for 30 minutes. The mixture was diluted with ethyl acetate (250 mL) and saturated aqueous NaHCO3 (125 mL). The phases were separated and the aqueous phase was extracted with ethyl acetate (3 x 100 in-L). The combined organic extracts were washed with brine (3 x 30 mL), dried (MgSO4), and concentrated. Purification of the crude material by column chromatography on silica gel (2:1 hexanes-ethyl acetate) provided 0.83 g (29%) of 2-(3-Hydroxymethyl-but-3-enyl)-isoindole-1,3-dione as a white solid and 0.19 g (7%) of 2-(4-Hydroxy-2-methylene-butyl)-isoindole-1,3-dione as a white solid.

[0525] 2-(3-Hydroxymethyl-but-3-enyl)-isoindole-1,3-dione: 1H NMR (CDC13) 6 2.07 (br s, I H), 2.49 (t, 2H, J= 6.0 Hz), 3.91(t, 2H, J= 6.0 Hz), 4.18 (m, 2H), 4.79 (s, 1H), 5.01 (s, 1H), 7.70-7.73 (m, 2H), 7.81-7.85 (m, 2H); 13C NMR (CDC13) S 32.67, 37.04, 66.30, 113.60, 123.30, 132.00, 134.02, 145.30, 168.60; ES-MS fn/z 231 (M+H).
[0526] 2-(4-Hydroxy-2-methylene-butyl)-isoindole-1,3-dione: 1H NMR (CDC13) S
1.88 (br s, 111), 2.36 (t, 2H, J= 6.0 Hz); 3,83 (m, 2H), 4.29 (s, 2H), 4.99 (s, 1H), 5.02 (s, 1H), 7.72-7.77 (m, 2H), 7.84-7.88 (m, 2H); 13C NMR (CDC13) 6 37.64, 42.24, 61.21, 114.23, 123.84, 132.37, 134.53, 140.73, 168.57; ES-MS m/z 231 (M+H).
[0527] To a solution of 2-(3-Hydroxymethyl-but-3-enyl)-isoindole-1,3-dione (0.229 g, 0.99 mmol) in CH2C12 (10 mL) was added Et3N (0.28 mL, 2.01 mmol) followed by methanesulfonyl chloride (0.12 mL, 1.55 mmol). The resultant mixture was stirred at room temperature for 1 hour. The mixture was diluted with CH2C12 (40 mL), washed with brine (3 x 10 mL), dried (Na2SO4), and concentrated to provide 0.31 g (100%) of a yellow oil.
[0528] Using General N-alkylation Procedure: A solution of the oil from above (0.31 g), (1-tent-butoxycarbonyl-lH-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine (0.252 g, 0.67 mmol), KI (33 mg, 0.20 mmol), and N,N-diisopropylethylamine (0.35 mL, 2.00 mmol) in CH3CN (13 mL) was heated at 60 C for 21 hours. Purification of the crude material by column chromatography on silica gel (50:1:1 CH2C12 i CH3OH-NH4OH) provided 239 mg (60%) of 2-{[[4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-2-methylene-butyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-methyl}-benzimidazole-l-carboxylic acid tert-butyl ester as a beige foam.
[0529] To a solution of 2-{[[4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-2-methylene-butyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-methyl}-benzimidazole-l-carboxylic acid tert-butyl ester (0.239 g, 0.40 mmol) in ethanol (8 mL) was added hydrazine monohydrate (0.40 mL, 8.26 mmol) and the resultant mixture was stirred at room temperature overnight. The mixture was filtered through filter paper and concentrated. Purification of the crude material by column chromatography on silica gel (20:1:1 CH2C12-CH3OH-NH4OH) provided 86 mg (55%) of the free base of the title compound as a yellow oil.
[0530] Using General Procedure D: Conversion of the free base to the hydrobromide salt followed by, reprecipitation of the intermediate solid from methanol/ether gave COMPOUND 90 (97 mg, 69%) as a beige solid. 1H NMR (D2O) S 1.75-1.84 (m, 1H), 2.03-2.15 (m, 2H), 2.24-2.40 (m, 3H), 2.79-2.88 (m, 1H), 2.94-3.01 (m, 3H), 3.18 (d, 1H, J=13.8 Hz), 3.41 (d, 1H, J=13.8 Hz), 4.37 (d, 1H, J= 16.5 Hz), 4.48 (d, 1H, J= 16.5 Hz), 4.59-4.62 (m, 1H), 4.89 (s, 1H), 5.25 (s, 1H), 7.60-7.62 (m, 2H), 7.78-7.81 (m, 2H), 7.87-7.91 (m, 1H), 8.37 (br d, 1H, J= 7.8 Hz), 8.69 (br d, 1H, J= 5.4 Hz); 13C NMR (D20) S 20.06, 20.30, 27.82, 31.03, 37.47, 48.28, 57.13, 60.45, 114.26, 118.52, 126.12, 127.05, 130.93, 139.65, 139.79, 141.16, 148.31, 150.83, 151.36; ES-MS m/z 362 (M+H). Anal. Calcd. for C22H27N5.3.OHBr=2.2H2O: C, 41.04; H, 5.39; N, 10.88; Br, 37.23. Found: C, 40.99; H, 5.25;
N, 10.78; Br, 37.21.

Example 91 N

I N

N NH

COMPOUND 91: Preparation of [1-(2-Amino-ethyl)-cyclopropylmethyll-(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl-amine (hydrobromide salt).

[0531] To a cold (0 C), stirred solution of diethyl zinc (1.0 M in hexanes, 4.0 mL, 4.0 mmol) in CH2C12 (10 mL) was added neat C1CH2I (0.59 mL, 8.10 mmol) drop wise by syringe. After 30 minutes, a solution of 2-(3-Hydroxymethyl-but-3-enyl)-isoindole-1,3-dione (0.456 g, 1.97 mmol) in CH2C12 (6 mL) was added by cannula. After 60 minutes, the reaction mixture was treated with saturated aqueous NH4C1(20 mL), diluted with CH2Cl2 (20 mL), and warmed to room temperature. The phases were separated and the aqueous phase was extracted with CH2C12 (3 x 20 mL). The combined organic extracts were dried (Na2SO4) and concentrated. The crude material was purified by column chromatography on silica gel (1:1 hexanes-ethyl acetate) and provided 0.31 g (64%) of 1-[2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-cyclopropane-methanol as a white solid. 1H NMR (CDC13) S 0.31-0.34 (m, 2H), 0.38-0.43 (m, 2H), 1.75 (t, 2H, J= 6.9 Hz), 3.54 (s, 2H), 3.90(t, 2H, J= 6.6 Hz), 7.70-7.73 (m, 2H), 7.81-7.85 (m, 2H);
[0532] To a solution of 1-[2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethyll-cyclopropane-methanol (0.31 g, 1.26 mmol) in CH2C12 (6 mL) was added sequentially. 3A
molecular sieves (0.644 g), N-methylmorpholine N-oxide (0.223 g, 1.90 mmol), and tetrapropylammonium perruthenate (88 mg, 0.25 mmol). After 30 minutes, the mixture was filtered through silica gel and the cake was washed with ether. The solvent was removed from the filtrate under reduced pressure and provided 0.25 g (82%) of 1-[2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-cyclopropanecarboxaldehyde as a colorless oil.

[0533] Using General Procedure B: Reaction of (1-tert-butoxycarbonyl-lH-benzimidazol-2-yhnethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine (0.269 g, 0.70 mmol) and 1-[2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-cyclopropanecarboxaldehyde (0.25, 1.03 mmol) with NaBH(OAc)3 (0.433 g, 2.04 mmol) in CH2C12 (7 mL) for 6 hours followed by purification of the crude material by column chromatography on silica gel (50:1:1 CH2C12-CH3OH-NH4OH) followed by radial chromatography on silica gel (1 mm plate, 100:1:1 CH2C12- CH3OH -NH4OH) provided 0.125 g (29%) of 2-{[{1-[2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-cyclopropylmethyl} -(5,6,7, 8-tetrahydro-quinolin-8-yl)-amino]-methyl}-benzimidazole-l-carboxylic acid text-butyl ester as a white foam.
[0534] To a solution of 2-{[{1-[2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-ethyl]-cyclopropylmethyl} -(5, 6, 7, 8-tetrahydro-quinolin-8-yl)-amino]-methyl} -b enzimidazole- l -carboxylic acid tert-butyl ester (0.121 g, 0.20 mmol) in ethanol (4 mL) was added hydrazine monohydrate (0.20 mL, 4.12 mmol) and the resultant mixture was stirred at room temperature overnight. The mixture was filtered through filter paper and concentrated.
Purification of the crude material by column chromatography on silica gel (20:1:1 CH2C12-CH3OH-NH4OH) provided 39 mg (50%) of the free base of the title compound as a yellow oil.
[0535] Using General Procedure D: Conversion of the free base to the hydrobromide salt followed by reprecipitation of the intermediate solid from methanol/ether gave COMPOUND 91 (50 mg, 76%) as a white solid. 1H NMR (D2O) 6 0.31-0.41 (m, 3H), 0.52-0.58 (m, 1H), 1.34-1.45 (m, 1H), 1.75-1.98 (m, 1H), 2.02-2.20 (m, 3H),.2.27-2.33 (m, 1H), 2.44 (d, 1H, J=13.5 Hz), 2.81-2.91 (m, 3H), 2.98-3.01 (m, 2H), 4.39 (s, 2H), 4.69 (dd, 1H, J
= 6.3, 9.3 Hz), 7.60-7.63 (m, 2H), 7.79-7.90 (m, 3H), 8.36(br d, 1H, J= 7.8 Hz), 8.71 (br d, 1H, J= 5.7 Hz); 13C NMR (D20) S 9.00, 12.17, 15.30, 19.79, 20.30, 27.87, 31.06, 37.62, 48.20, 57.47, 59.82, 114.31, 126.04,127.00,131.20,139.66,141.14,148.20,151.16,151.31;
ES-MS m/z 376 (M+H). Anal. Calcd. for C23H29N5=3.0HBr=2.2H20: C, 41.99; H, 5.58; N, 10.65; Br, 37.44. Found: C, 42.03; H, 5.41; N, 10.62; Br, 36.42.

Example 92 \ I.

N' CHH NH2 N O~
NH

COMPOUND 92 Preparation of N1-(1H-Benzimidazol-2-ylmethyl)-3-methoxy-Nl-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine (hydrobromide salt) Preparation of 4-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-methoxy-butyraldehyde:
O
O\^~N

[05361 To a solution of 2-[4-(tent-butyl-dimethyl-silanyloxy)-2-hydroxy-butyl}-isoindole-1,3-dione (see Nl-(1H-benzimidazol-2-ylmethyl)-3,3-difluoro-Nl-(5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine example for preparation) (455 mg, 1.30 mmol) in neat MeI (2 mL) was added Ag20 (224 mg, 0.97 mmol) and the reaction stirred at 60 C for 2 days. The mixture was cooled, concentrated, diluted with CH2C12 (10 mL), and filtered through Celite, washing with Et2O (75 mL). The filtrate was concentrated and purified by column chromatography (3:1 hexanes/EtOAc) to afford the methylated product (291 mg, 62%) as a clear oil.
[0537] A solution of the TBS-protected alcohol from above (291 mg, 0.80 mmol) in THE/1 N HCl (1:1, 7 mL) was stirred for 3 h. The mixture was diluted with EtOAc (35 mL) and water (10 mL) and saturated aqueous ammonium chloride (10 mL). The phases were separated and the organic phase was washed with brine (1 x 25 mL), dried (Na2SO4) and concentrated to give the crude product (242 mg) as a clear oil which was used without further purification in the next reaction.
[05381 To a solution of the alcohol from above (242 mg) in CH2C12 (10 mL) was added 3A molecular sieves (265 mg), NMO (137 mg, 1.17 mmol) and TPAP (25 mg, 0.071 mmol) and the reaction stirred 1.5 h. The mixture was concentrated and purified by flash chromatography (EtOAc/hexanes, 1:2) to afford the title compound (95 mg, 48%
over 2 steps) as a clear solid. 1H NMR (CDC13) S 2.65-2.69 (m, 2H), 3.46 (s, 3H), 3.82 (t, 2H, J= 6 Hz), 4.02-4.08 (m, 1H), 7.74 (dd, 2H, J = 6, 3 Hz), 7.86 (dd, 2H, J = 6, 3 Hz), 9.78 (s, 1H).
[0539] Following General Procedure B: To a stirred solution (1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine (108 mg, 0.39 mmol) and 4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-3-methoxy-butyraldehyde (95 mg, 0.385 mmol) in dry CH2C12 (10 mL) was added NaBH(OAc)3 (125 mg, 0.59 mmol) and the mixture stirred for 2.5 h at room temperature. The resultant crude yellow foam (230 mg) was used without further purification in the next step.
[0540] To a solution of the phthalimide from above (0.38 mmol) in EtOH (3.5 mL) was added anhydrous hydrazine (0.06 mL, 1.89 mmol) and the mixture stirred overnight. The resultant white solid was filtered through filter paper, washing thoroughly with CH2C12 and the filtrate concentrated in vacuo. The crude product was purified by radial chromatography on silica gel (1 mm plate, CH2C12/MeOH/NH4OH, 50:1:1 then 25:1:1) to give the desired free amine (85 mg, 58% 2 steps) as a pale yellow oil.
[0541] Using General Procedure D: Conversion of the material from above (78 mg, 0.21 mmol) to the hydrobromide salt gave COMPOUND 92 (124 mg, 89%) as a yellow solid. 1H
NMR (D20) mixture of diastereomers S 1.81-1.86 (br in, 3H), 2.01-2.07 (m, 1H), 2.18-2.24 (m, 1H), 2.37-2.42 (m, 1H), 2.54-2.63 (m, 1H), 2.88-3.10 (m, 5H), 3.24 (s, 3H), 3.51-3.56 (m, 1H), 4.40 (d, 1H, J= 16.8 Hz), 4.50-4.58 (m, 2H), 7.60 (dd, 2H, J= 6.3, 3.3 Hz), 7.81 (dd, 2H, J= 6.3, 3.3 Hz), 7.88 (br t, 1H, J = 6.8 Hz), 8.36 (d, 1H, J= 8.1 Hz), 8.63-8.66 (m, 1H); 13C NMR (D20) mixture of diastereomers 8 20.43, 27.65, 29.90, 30.52, 42.10, 47.48, 48.01, 48.20, 57.04, 57.28, 60.47, 75.71, 75.92, 114.30, 126.02, 127.00, 131.01, 139.45, 140.69, 140.78, 148.21, 151.06, 151.51. ES-MS m/z 380 (M+H). Anal. Calcd. for C22H29N50.3.1HBr=1.5H20Ø3C4H10O: C, 41.00; H, 5.65; N, 10.3-1; Br, 36.45.
Found: C, 41.01; H, 5.62; N, 10.34; Br, 36.39.

Example 93 CN

Oc>jN NH2 N
H F F

COMPOUND 93: Preparation of N' -(1H-benzimidazol-2- lmethyl)-3,3-difluoro-N1-(5,6 7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine [0542] To a mixture of potassium phthalimide (310.39 g, 1.68 mol) in DMF (1.0 L) at 0 C was added allyl bromide (290.4 mL, 3.36 mol) from a dropping funnel over 30 minutes.
The reaction was then warmed to room temperature and allowed to stir for 5 days. The mixture was filtered to remove salts while washing the residue with ethyl acetate (1 L), and the filtrate concentrated under reduced pressure. The residue was then partitioned between saturated aqueous NaHCO3 (0.5 L) and CH2C12 (0.8 L) and the organic phase separated. The aqueous phase was extracted with CH2C12 (2 x 0.8 L), and the combined organic phases were dried (Na2SO4), filtered and concentrated under reduced pressure to give N-allylphthalimide as a white powder (294 g, 94%). 1H NMR (CDC13) 8 4.30 (d, 2H, J= 6.0 Hz), 5.22 (m, 2H), 5.88 (m, 1H), 7.73 (in, 2H), 7.85 (m, 2H).
[0543] A solution of paraformaldehyde (245 g) was heated to 70 C in a solution of H2SO4 (360 mL) and H2O (90 mL) using a hot water bath until the mixture became homogenous.
Solid N-allylphthalimide (133 g, 0.71 mol) was then added over 10 minutes, keeping the exotherm generated under control. The solution was then stirred at this temperature for an additional 0.5 hour and poured into ice water (1.5 L). The mixture was extracted with ethyl acetate (3 x 1 L), dried (MgS04), filtered and concentrated under reduced pressure. The crude solid was then purified through a silica gel plug (1 kg Si02) from CH2C12 as the eluent.
This afforded the desired 1,3-doxane-4-ylmethylphthalimide as a white solid (95 g, 54%}
[0544] 1,3-Dioxane-4-ylmethylphthalimide (95 g, 390 mmol) was dissolved in a saturated solution of hydrochloric acid in methanol (600 mL) and stirred for 2 days at 80 C.
The reaction was then cooled to room temperature, and the acid neutralised to pH 7 with solid NaHCO3. Ethyl acetate (1 L) was added and the mixture was filtered to remove salts. The filtrate was then concentrated under reduced pressure and dried overnight in vacuo. The crude was purified through a silica gel plug (1 kg silica) using 2:98 CH3OH:CH2C12 eluent to give the desired N-(2,4-dihydroxybutyl)phthalim.ide as a white solid (45 g, 50%). 1H NMR
(MeOD) 8 1.62 (m, 1H), 1.75 (m, 1H), 3.31 (s, 1H), 3.64 (m, 2H), 3.69 (d, 2H, J= 5.1 Hz), 4.06 (sept, 1H), 7.79 (m, 2H), 7.85 (m, 2H).
[0545] To a solution of N-(2,4-dihydroxybutyl)phthalimide (51 g, 217 mmol) in pyridine (725 mL) at 0 C was added acetic anhydride (20.5 mL, 217 mmol). The solution was stirred at 0 C for 4 hours and then concentrated on the rotary evaporator using a water bath temperature of 35 C. The crude residue was then purified through a silica gel plug (1 kg silica) with 0.5:99.5 CH3OH:CH2C12 eluent to give the desired product which was unfortunately contaminated with pyridine. CH2C12 (100 mL) was then added and the organic was washed with IN HCl (3 x 50 mL), saturated aqueous NH4C1(50 mL), and brine (50 mL).
The organic phase was then separated, dried (Na2SO4), filtered, and concentrated under reduced pressure to afford clean N-(4-acetoxy-2-hydroxybutyl)phthalimide as a white solid (10.2 g, 17%).
[05461 A solution ofN-(4-acetoxy-2-hydroxybutyl)phthalimide (10.2 g, 36.8 mmol) in CH2C12 (185 mL) at 0 C was treated with molecular sieves (18.4 g), N-methylmorpholine oxide (6.46 g, 55.2 mmol), and tetrapropylammonium perruthenate (1.29 g, 3.7 mmol). The mixture was allowed to warm to room temperature over 20 minutes and immediately filtered through silica (using 500 g Si02 in a coarse glass fritted funnel). The silica was washed with excess diethyl ether (2 L) and concentrated under reduced pressure to afford the desired N-(4-acetoxy-2-oxobutyl)phthalimide (9.22 g, 92%).
[0547] The above ketone (8.0 g, 29 mmol) was added as dry solid to neat DAST
(20 mL) at 0 C and then heated to 50 C for 40 hours. The homogenous solution was then cooled to 0 C, diluted with CH2C12 (75 mL), and quenched with excess brine (50 ml). The organic phase was separated and the aqueous phase extracted with CH2C12 (3 x 75 mL).
The combined organic phases were then dried (Na2SO4), filtered and concentrated under reduced pressure. The crude red solid was then purified by column chromatography on silica gel (1:4 ethyl acetate/hexane) to give the desired N-(4-acetoxy-2,2-difluorobutyl)phthalimide as a peach colored solid (3.84 g, 44%). 'H NMR (CDC13) 6 2.07 (s, 3H), 2.32 (tt, 2H, J=16.5, 6.0 Hz), 4.11 (t, 2H, J= 13.5 Hz), 4.35 (t, 2H, J= 7.5 Hz), 7.75 (m, 2H), 7.90 (m, 2H).
[0548] The above N-(4-acetoxy-2,2-difluorobutyl)phthalimide (3.84 g, 12.9 mmol) was dissolved in THE (65 mL) and cooled to -78 C. A solution of DIBAL-H (32.3 mL, 1.0 Min hexanes, 32.3 mmol) was added slowly and the solution allowed to stir 0.5 h.
Saturated aqueous NH4C1 solution (15 mL) was then added and the solution was warmed to room temperature. MgSO4 (15 g) and diethyl ether (200 mL) were added, and the mixture was filtered through celite, washing with excess 1:1 Et20/THF (1 L). The filtrate was then concentrated under reduced pressure and the crude material was purified by column chromatography on silica gel (1:2 EtOAc/hexanes) to give the desired N (2,2-difluoro-4-hydroxybutyl)phthalimide as a pale yellow solid (1.47 g, 45%). 1H NMR (CDC13) 6 1.97 (t, OH, J= 6.0 Hz), 2.22 (tt, 2H, J=16.5, 6.0 Hz), 3.95 (q, 2H, J= 6.0 Hz), 4.19 (t, 2H, J= 15 Hz), 7.75 (m, 2H), 7.90 (m, 2H).

[0549] Methanesulfonyl chloride (0.50 mL, 6.3 mmol) and triethylamine (1.20 mL, 8.6 mmol) was added to a solution of the above alcohol (1.47 g, 5.76 mmol) in (29 mL) at 0 C and allowed to warm to room temperature over 30 minutes. This gave, after aqueous work up, the desired crude methanesulfonate (1.84 g, 96%) as a fine, pale yellow powder that was used immediately in the next reaction.
[0550] A solution of the above crude methanesulfonate (1.84 g) in DMF (19 mL) was treated with sodium azide (1.87 g, 28.8 mmol) and heated to 80 C for 2 h. The reaction mixture was then concentrated and the residue partitioned between ethyl acetate (20 mL) and brine (15 mL). The organic phase was separated, washed with brine (3 x 15 mL), and dried over MgSO4. The mixture was then filtered and concentrated under reduced pressure to give the desired N-(4-azido-2,2-difluorobutyl)phthalimide (1.37 g, 85% 2 steps).
[0551] The material from above (1.37 g) was dissolved in anhydrous methanol (50 mL) and the reaction vessel purged with nitrogen. 10% palladium on carbon (275 mg) was added and the mixture stirred under an atmosphere of hydrogen (30 psi) for 16 hours.
The reaction mixture was then filtered through celite and purified by column chromatography with silica gel (2:98 methanol:dichloromethane) to afford N-(4-amino-2,2-difluorobutyl)phthalimide (0.71 g, 57%). 1H NMR (CDC13) 8 2.32 (tt, 2H, J= 16.5, 6.0 Hz), 3.02 (t, 2H, J=15.0 Hz), 3.94 (t, 2H, J= 7.5 Hz), 7.73 (m, 2H), 7.85 (m, 2H).
[0552] Using General Procedure B from above, N-(4-amino-2,2-difluorobutyl)phthalimide (0.28 g, 1.1 mmol), 6,7-dihydro-5H-quinolin-8-one (0.21 g, 1.4 mmol) and sodium triacetoxyborohydride (0.45 g, 2.2 mmol) were stirred at room temperature in dichloromethane (5.5 mL} for 16 hours to yield, after work-up and column chromatography (2:98 McOH:CH2C12),2-[2,2-difluoro-4-(5,6,7,8-tetrahydroquinolin-8-ylamino)-butyl]-isoindole-1,3-dione as a sticky oil (0.36 g, 85%).
[0553] To a solution of the above secondary amine (0.36 g, 0.93 mmol), N-(tert-butoxycarbonyl)-2-chloromethylbenzimidazole (0.25 g, 0.93 mmol), and potassium iodide (8 mg, 0.05 mmol) in anhydrous acetonitrile (9.3 mL) was added diisopropylethylamine (0.24 mL, 1.4 mmol) and stirred at 60 C for 16 hours. The mixture was then concentrated under reduced pressure and the residue partitioned between dichloromethane (20 mL) and brine (15 mL). The organic phase was separated and the aqueous phase was extracted with dichloromethane (2 x 15 mL). The combined organic phases were then dried (Na2SO4), filtered, and concentrated under reduced pressure to give a crude residue that was purified by column chromatography with silica gel (2:98 MeOH/CH2CI2). This afforded 2-{[[4-(1,3-dioxo-1,3-dihydroisoindol-2-yl)-3,3-difluorobutyl]-(5,6,7,8-tertahydroquinolin-8-yl)-amino]-methyl}-benzimidazole-1-carboxylic acid tert-butyl ester (0.24 g, 41%).
[0554] A solution of the above substrate (0.24 g, 0.39 mmol) in anhydrous ethanol (3.7 mL) was treated with hydrazine monohydrate (0.20 mL, 3.9 mmol) and stirred for 16 h.
The white mixture was then filtered, concentrated under reduced pressure, and purified by column chromatography with silica gel (5:0.5:94.5 methanol: ammonium hydroxide:dichloromethane) to afford N-(1H-benzimidazol-2-ylmethyl)-3,3-difluoro-N-(5.,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine as a light beige solid (87 mg, 66%). 1H
NMR (CDC13) 6 1.67 (m, 1H), 1.70-2.20 (m, 4H), 2.28 (m, 1H), 2.55-3.00 (m, 5H), 3.10 (m, 1H), 4.12 (m, 1H), 4.26 (s, 2H), 7.20 (m, 3H), 7.45 (d, 1H, J= 7.5 Hz), 7.59 (br, 2H), 8.61 (d, 1H, J= 3.9 Hz). 13C NMR (CDC13) 8 21.88, 24.85, 29.49, 35.88 (t, 1C, J= 20 Hz), 38.24 (t, 1C, J= 92 Hz), 51.74, 55.25 (t, 1C, J= 116 Hz), 62.99, 115.41 (br, 3C), 122.14 (2C), 122.92, 125.40,128.61, 135.29,137.93, 147.10, 155.75, 156.98. ES-MS m/z 385 (M+H).
Anal.
Calcd. for C21H25N5F2=0.2CH2C12: C, 63.27; H, 6.36; N, 17.40. Found: C, 63.27;
H, 6.60; N, 17.26.

Example 94 I -,-, C N , , > / N N

H F F

COMPOUND 94: Preparation ofN1-(1H-benzimidazol-2-ylmethyl)-2,2-difluoro-N1-(5,6,7,8-tetrahyydroquinolin-8-yl)-butane-1,4-diamine.
[0555] To a solution of N-(4-amino-2,2-difluorobutyl)phthalimide (0.33 g, 1.3 mmol) in anhydrous THE (7 mL) was added di-tert-butyldicarbonate (0.31 g, 1.4 mmol) and a drop of water. The solution was stirred 30 minutes and saturated aqueous ammonium chloride solution (25 mL) was added and the solution was extracted with ethyl acetate (2 x 30 mL).
The combined organic phases were then dried (MgSO4), filtered, and concentrated under reduced pressure. This afforded the crude boc-protected primary amine as yellow solid (0.42 g, 91%).

[0556] A solution of the above amine (0.42 g, 1.2 mmol) in anhydrous ethanol (12 mL) was treated with hydrazine monohydrate (0.57 mL, 12 mmol) and stirred for 16 h. The turbid white mixture was then filtered, concentrated under reduced pressure, and purified by column chromatography with silica gel (1:1:10 methanol: ammonium hydroxide:dichloromethane) to give (4-amino-3,3-difluorobutyl)-carbamic acid tert-butyl ester (0.21 g, 77%).

(CDC13) 8 1.30 (br, NH2), 1.45 (s, 9H), 2.01 (tt, 2H, J=16.5, 6.0 Hz), 2.95 (t, 2H, J= 6.0 Hz), 3.52 (td, 2H, J= 15.0, 7.0 Hz), 5.00 (br, NH).
[0557] Using General Procedure B from above, N-(4-amino-2,2-difluorobutyl)phthalimide (0.26 g, 1.2 mmol), 6,7-dihydro-5H-quinolin-8-one (0.22 g, 1.5 mmol) and sodium triacetoxyborohydride (0.49 g, 2.3 mmol) were stirred at room temperature in dichloromethane (5.5 mL) for 16 hours to yield, after work-up and column chromatography (1:99 McOH:CH2C12), [3,3-difluoro-4-(5.,6,7,8-tetrahydroquinolin-8-ylamino)-butyl].-carbamic acid tert-butyl ester as a sticky oil (0.37 g, 90%).
[0558] To a solution of the above secondary amine (0.37 g, 1.0 mmol), N-(tert-butoxycarbonyl)-2-chloromethylbenzimidazole (0.44 g, 1.7 mmol), and potassium iodide (9 mg, 0.05 mmol) in anhydrous acetonitrile (10.0 mL) was added diisopropylethylamine (0.36 mL, 2.1 mmol) and stirred at 60 C for 16 hours. The mixture was then concentrated under reduced pressure and the residue partitioned between dichloromethane (20 mL) and brine (15 mL). The organic phase was separated and the aqueous phase was extracted with dichloromethane (2 x 15 mL). The combined organic phases were then dried (Na2SO4), filtered, and concentrated under reduced pressure to give a crude residue that was purified by column chromatography with silica gel (2:98 McOH/CH2C12). This afforded 2-{[(4-tert-butoxycarbonylamino-2,2-difluorobutyl)-(5,6,7,8-terrahydroquinolin-8-yl)-amino]-methyl} -benzimidazole-l-carboxylic acid tert-butyl ester as a pale yellow solid (0.23 g, 41%).
[0559] A solution of the above material (0.23 g, 0.4 mmol) in neat TFA (4 mL) was stirred for 0.5 h. The solution was diluted with CH2C12 (20 mL), and 15%
aqueous NaOH
was added until pH > 10. The organic phase was separated, and the aqueous was extracted with CH2C12 (2 x 20 mL). The combined organic phases were then dried (Na2SO4), filtered, and concentrated under reduced pressure. This afforded, after radial chromatography (2:1:97 McOH:NH4OH:CH2C12), N-(1H-benzimidazol-2-ylmethyl)-2,2-difluoro-N-(5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine as a pale yellow flaky solid (0.11 g, 72%). 1H
NMR (CDC13) 8 1.69 (m, 1H), 1.85-2.10 (m, 4H), 2.23 (m, 1H), 2.70-2.97 (m, 6H), 4.03 (d, 1H, J= 17.1 Hz), 4.07 (m, 1H), 4.15 (d, 1H, J=16.8 Hz), 7.15-7.24 (m, 3H), 7.45 (d, 1H, J=

7.8 Hz), 7.58 (br, 2H), 8.57 (d, 1H, J= 3.9 Hz). 13C NMR (CDC13) 8 21.62, 24.35, 29.47, 34.03 (t, 1C, J= 93 Hz), 44.55 (t, 1C, J= 20 Hz), 47.26 (t, 1C, J= 112 Hz), 50.12, 62.87, 118 (br, 3C), 122.09 (2C), 122.80, 123.86, 127.06, 135.10, 137.99, 147.06, 156.27, 157.41. ES-MS m/z 385 (M+H). Anal. Calcd. for C21H25N5F2Ø2CH2C12: C, 63.27; H, 6.36; N, 17.40.
Found: C, 63.34; H, 6.68; N, 17.29.

Example 95 CN

(N>j \ NNH2 N C
H N-vOMe COMPOUND 95: Preparation of (1H-benzimidazol-2- ly methyl)-(5,6,7,8-tetrahydro-quinolin-&-yl)-(1-amino-2-(O-methyloxime)-butan-4-yl-amine.
[0560] To a solution of 3-buten-l-ol (10 g, 138 mmol) in dichloromethane (150 mL) was added acetic anhydride (13 mL, 138 mmol) and 4-dimethylaminopyridine (244 mg, 2 mmol).
The mixture was then stirred at room temperature for 8 hours. The reaction mixture was then poured into a saturated aqueous sodium bicarbonate solution (100 mL). After separation of the aqueous and organic layers, the aqueous layer was extracted twice with 100 mL portions of dichloromethane. The combined organic fractions were then dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to afford 3-buten-1-yl acetate as a colourless oil in a yield of 12.9 g (82%). 1H NMR (CDC13) 6 2.04 (s, 3H), 2.38 (m, 2H), 4.11 (t, 3H, J= 7.1 Hz), 5.04 (d, 1H, J= 9.1 Hz), 5.08 (d, 1H, J= 15.3 Hz), 5.77 (m, 1H).
[0561] To a solution of 3-buten-1-yl acetate (5.7 g, 50 mmol) in dichloromethane (200 mL) was added m-chloroperoxybenzoic acid (12.9 g, 75 mmol). The reaction was then stirred at room temperature for 3 hours. The reaction mixture was then filtered through celite and concentrated in vacuo. The residue was purified by silica gel flash chromatography. (4:1 hexanes:ethyl acetate) to yield 3,4-epoxybutan-l-yl acetate as a colourless oil in a yield of 3.8 g (58%). 1H NMR (CDC13) 81.78-1.88 (m, 2H), 2.03 (s, 3H), 2.47 (m, 1H), 2.75 (m, 1H), 2.99 (m, 1H), 4.18 (t, 1H, J= 6.6 Hz).

[0562] To a solution of 3,4-epoxybutan-1-yl acetate (3.9 g, 29 mmol) in DMF
(50 mL) was added potassium phthalimide (6.47 g, 35 mmol). The stirred mixture was then heated to 90 C for 16 hours. After cooling, the mixture was diluted with ethyl acetate (200 mL) and extracted repeatedly with water. The organic fraction was then dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by silica gel flash chromatography (1:1 hexanes: ethyl acetate) to afford N-(3-hydroxybutan-4-yl-1-acetate)-phthalimide as a pale yellow oil in a yield of 1.65g (20%). 1H NMR (CDC13) 8 1.69-1.88 (m, 2H), 2.04 (s, 3H), 2.90 (m, 1H (OR)), 3.79 (d, 2H, J= 5.7 Hz), 4.03 (m, 1H), 4.21-4.31 (m, 2H), 7.70 (m, 2H), 7.83 (m, 2H). MS m/z 300 (M+Na).
[0563] To a solution of afford N-(3-hydroxybutan-4-yl-l-acetate)-phthalimide (554 mg, 2.0 mmol) in acetonitrile (15 mL) was added imidazole (150 mg, 2.2 mmol) and t-butyldimethylsilyl chloride (310 mg, 2.05 mmol). The mixture was then stirred overnight at room temperature. Dichloromethane (50 mL) was then added to the reaction, and the mixture was extracted with a saturated ammonium chloride solution. The organic layer was then dried over anhydrous sodium sulfate, filtered and concentrated to leave a yellow oily residue which was purified by silica gel flash chromatography (3:1 hexanes:ethyl acetate) to afford N-(3-t-butyldimethylsiloxybutan-4-yl-l-acetate)-phthalimide in a yield of 570 mg (73%). 1H
NMR (CDC13) 8 -0.04 (s, 3H), -0.01 (s, 3H), 0.84 (s, 9H), 1.78 (m, 2H), 3.68 (dd, 1H, J= 8.1, 6.5 Hz), 3.73 (dd, 1H, J= 8.1, 6.2 Hz), 4.15 (m, 3H), 7.71 (m, 2H), 7.85 (m, 211).
[0564] To a stirred -78 C solution of afford N-(3-t-butyldimethylsiloxybutan-4-yl-1-acetate)-phthalimide (670 mg, 1:71 mmol) in THE (20 mL) was added DIBAL-H (5.1 mL of a 1.OM solution in hexanes, 5.1 mmol). The reaction was stirred at -78 C for 45 minutes, then a saturated solution of ammonium chloride (5 mL) was added. The mixture was allowed to warm to room temperature, then ethyl acetate (20 mL) and 1N HCl (2 mL) were added.
The mixture was then shaken in a separatory funnel to speed the clarification of the layers, then the organic and aqueous layers were separated. The aqueous layer was extracted twice with ethyl acetate, then the combined organic fractions were separated and the aqueous layer was extracted twice with ethyl acetate. The combined organic fractions were then dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was purified by silica gel flash chromatography (1:1 hexanes:ethyl acetate) to afford N-(3-t-butyldimethylsiloxybutan- 1-ol-4-yl)-phthalimide as a colourless oil in a yield of 465 mg (78%). 1H NMR (CDC13) 6 -0.02 (s, 3H), 0.09 (s, 3H), 0.86 (s, 911), 1.71-1.82 (m, 2H), 2.11 (m, 1H (OR)), 3.76 (m, 414), 4.28 (m, 1H), 7.73 (m, 2H), 7.85 (m, 2H).

[0565] To a solution ofN-(3-t-butyldimethylsiloxybutan-l-ol-4-yl)-phthalimide (160 mg, 0.4 mmol) in dichloromethane (10 mL) was added Dess-Martin Periodinane (212 mg, 0.5 mmol). The mixture was then stirred at room temperature for 30 minutes. A 5%
solution of sodium thiosulfate (10 mL) and a saturated sodium bicarbonate solution (10 mL) was added along with another 20 mL of dichloromethane. The mixture was then stirred rapidly for 20 minutes, and the aqueous and organic layers were separated. The aqueous layer was extracted twice with dichloromethane, and the combined organic fractions were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford N-(3-t-butyldimethylsiloxybutan- 1-al-4-yl)-phthalimide as a yellow oil, which was used immediately in the next reaction without further purification. 1H NMR (CDC13) 6 -0.02 (s, 3H), 0.05 (s, 3H), 0.81 (s, 9H), 2.61 (m, 2H), 3.74 (m, 2H), 4.51 (m, 1H), 7.71 (m, 2H), 7.85 (m, 2H), 9.81 (m, 1H).
[0566] To a solution ofN-(3-t-butyldimethylsiloxybutan-l-al-4-yl)-phthalimide (0.4 mmol) in dichloromethane (15 mL) was added (5,6,7,8-tetrahydroquinolin-8-yl)-[(N-t-butoxycarbonyl)-benzimidazol-2-yl)methyl]-amine (151 mg, 0.4 mmol). The mixture was stirred at room temperature for 30 minutes, then sodium triacetoxyborohydride (170 mg, 0.8 mmol) was added, and the reaction was allowed to stir for 16 hours. A
saturated sodium bicarbonate solution (10 mL) was added, and the aqueous and organic layers were separated.
The aqueous layer was then extracted twice with dichloromethane, and the combined organic fractions were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was then purified by silica gel flash chromatography (3% methanol in dichloromethane) to afford [(N-t-butoxycarbonyl)-benzimidazol-2-ylmethyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-(N-phthalimidyl)-butan-2-(t-butyldimethylsiloxy)-4-yl)-amine as a pale yellow foam in a yield of 224 mg (79%). 1H NMR (CDC13) 6 -0.25 (s, 3H), -0.23 (s, 3H), 0.69 (s, 9H), 1.44-1.63 (m, 411), 1.68 (s, 9H), 2.00 (m, 2H), 2.16 (m, 1H), 2.65-2.74 (m, 3H), 3.48-3.62 (m, 211), 3.94 (m, 1H), 4.23 (m, 1H), 4.44 (d, 1H, J = 15.3 Hz), 4.72 (m, 1H, J
=15.3 Hz), 6.95 (m, 1H), 7.20 (m, 3H), 7.67 (m, 3H), 7.77 (m, 3H), 8.44 (m, 1H).
[0567] To a solution of [(N-t-butoxycarbonyl)-benzimidazol-2-ylmethyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-(N-phthalimidyl)-butan-2-(t-butyldimethylsiloxy)-4-yl)-amine (170 mg, 0.24 mmol) in THE (8 mL) was added 1N HCl (2 mL). The mixture was then heated to 50 C for 2 hours. After cooling, dichloromethane (50 mL) was added, and the mixture was shaken with a saturated sodium bicarbonate solution (20 mL). After separation of the aqueous and organic layers, the aqueous layer was extracted twice with dichloromethane. The combined organic fractions were then dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford a foamy residue, which was purified by silica gel flash chromatography, (5% methanol in dichloromethane) to afford (1-H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-(N-phthalimidyl)-butan-2-of-4-yl)-amine as a white foam in a yield of 73 mg (49%). 1H NMR
(CDC13) 81.50-1.59 (m, 2H), 1.70-2.07 (m, 5H), 2.21 (m, 111), 2.75-3.00 (m, 4H), 3.78-3.94 (m, 2H), 4.00-4.22 (m, 2H), 7.04 (m, 1H), 7.16 (m, 2H), 7.24 (d, 1H, J = 5.8 Hz), 7.68 (br s, 1H (NH)), 7.71 (m, 3H), 7.81 (m, 3H), 8.21 and 8.42 (d, total of 1H, J= 4.9, 5.1 Hz respectively).
[0568] To a solution of (1-H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-(N-phthalimidyl)-butan-2-ol-4-yl)-amine (132 mg, 0.246 mmol) in dichloromethane (10 mL) was added Dess Martin Periodinane (145 mg, 0.344 mmol). The reaction mixture was then stirred for 60 minutes. A 5% Na2S2O3 / 5% NaHCO3 aqueous solution (10 mL) was then added, and the resulting mixture was stirred vigorously at room temperature for 20-minutes (until the aqueous and organic layers had clarified). The layers were then separated, and the aqueous layer was extracted twice with dichloromethane. The combined organic fractions were then dried over anhydrous sodium sulfate, filtered and concentrated, and the residue was purified by silica gel flash chromatography (5% methanol in dichloromethane) to give the desired product, (1-H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-(N-phthalimidyl)-butan-2-one-4-yl)-amine as a pale yellow foam in a yield of 109 mg (84%). 'H NMR (CDC13) 6 1.73 (m, 1H), 1.85 (m, 1H), 2.03 (m, 1H), 2.26 (m, 1H), 2.57-2.81 (m, 4H), 3.10 (in, 1H), 4.08 (s, 2H), 4.08 (m, 1H), 4.35 (d, 1H, J= 16.5 Hz), 4.63 (d, 1H, J= 16.5 Hz), 7.00 (m, 1H), 7.19 (m, 2H), 7.18 (m, 1H), 7.38 (br s, 1H
(NH)), 7.75 (m, 4H), 7.88 (m, 2H), 8.56 (in, 1H).
[0569] To a solution of (1-H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-(N-phthalimidyl)-butan-2-one-4-yl)-amine (58 mg, 0.117 mmol) in methanol (5 mL) was added hydroxylamine hydrochloride (83.5 mg, 1.0 mmol). The resulting solution was stirred at room temperature overnight. Aqueous sodium bicarbonate (5 mL of a saturated solution) was then added, dichloromethane (10 mL) was also added the aqueous and organic layers were separated and the aqueous layer was extracted twice with dichloromethane. The combined organic fractions were then dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel flash chromatography using a 5%
methanol in dichloromethane mixture as an eluent to afford (1-H-benzimidazol-2-ylmethyl)-(5, 6,7, 8-tetrahydro-quinolin-8-yl)-(1-(N-phthalimidyl)-butan-2-(O-methyloxime)-4-yl)-amine as a pale yellow foam in a yield of 29 mg (49%). 1H NMR (CDC13) 6 1.73-2.05 (series of in, 5H), 2.45 (t, 2H, J= 6.9 Hz), 2.87-2.98 (m, 4H), 3.16 and 3.79 (s, total of 3H), 4.01-4-12 (m, 3H), 4.26 and 4.30 (d, J= 16.7 and 16.9 Hz respectively, total of 1H), 4.47 and 4.85 (d, J=
16.7 and 16.9 Hz respectively, total of 1H), 7.13-7.17 (m, 2H), 7.25 (m, 2H), 7.22 (m, 1H), 7.60 (br s, 1H (NH)), 7.75 (m, 4H), 7.87 (in, 2H), 8.38 and 8.44 (m, total of 1H).
[0570] To a solution of (1-H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-(N-phthalimidyl)-butan-2-(O-methyloxime)-4-yl)-amine (29 mg, 0.055 mmol) in denatured ethanol (5 mL) was added hydrazine hydrate (0.07 mL, 1.5 mmol). The mixture was then heated to 60 C for 60 minutes. After cooling, the reaction was concentrated in vacuo, taken up in dichloromethane (20 mL) and washed with an aqueous sodium carbonate solution (5 mL). The aqueous layer was then extracted twice with dichloromethane, and the combined organic fractions were dried over anhydrous sodium sulfate, filtered and concentrated to afford a foamy residue which was purified by silica gel flash chromatography (10% methanol, 0.5% ammonium hydroxide in dichloromethane) to afford (1H-benzimidazol-2-ylmethyl)-(5, 6, 7, 8-tetrahydro-quinolin-8-yl)-(1-amino-2-(O-methyloxime)-butan-4-yl)-amine (COMPOUND 95 - diastereomeric mixture) as a white foam in a yield of mg. 1H NMR (CDCl3) 6 1.65 (m, 1H), 1.98 (m, 1H), 2.02 (m, 1H) 2.19 (m, 1H), 2.42 (m, 2H), 2.78-2.87 (m, 4H), 3.31 (m, 2H), 3.55 and 3.73 (s, 3H), 4.03 (m, 3H), 7.13 (m, 3H), 7.40 (t, 1H, J = 8.1 Hz), 7.56 (m, 2H), 8.51 and 8.51 (d, J = 5.4 Hz, 5.3 Hz respectively, total of 1H); 13C NNM (both isomers - CDC13) 6 21.77, 23.51, 27.85, 29.58, 32.47, 43.34, 47.55, 49.09, 49.62, 49.94, 53.81, 61.60, 62.02, 122.07, 122.61, 132.33, 134.41, 137.79, 142.65, 147.04, 154.98.

Example 96 CN-~QH

COMPOUND 96: Preparation of (1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-amino-2-(cyclopropanyl)-butan-4-yl)-amine.
[0571] To an -7:1 mixture of benzoic acid 4-hydroxy-2-methylene-butyl ester and benzoic acid 3-hydroxymethyl-but-3-enyl ester (0.705 g, 3.42 mmol) in CH2C12 (17 mL) was added Et3N (1.00 mL, 7.17 mmol) followed by tert-butyldimethylsilyl chloride (0.792 g, 5.25 mmol) and 4-(dimethylamino)pyridine (84 mg, 0.69 mmol). The mixture was stirred at room temperature for 2 hours, diluted with CH2C12 (50 mL), washed with brine (3 x 20 mL), dried (Na2SO4), and concentrated. Purification of the crude material by column chromatography on silica gel (25:1 hexanes-ethyl acetate) provided 1.00 g (92%) of an -7:1 mixture of benzoic acid 4-(tert-butyldimethylsilyloxy.)-2-methylene-butyl ester and benzoic acid 3-(tert-butyldimethylsilyloxymethyl)-but-3-enyl ester as a colorless oil.
[0572] To an -7:1 mixture of benzoic acid 4-(teat-butyldimethylsilyloxy)-2-methylene-butyl ester and benzoic acid 3-(teat-butyldimethylsilyloxymethyl)-but-3-enyl ester (1.00 g, 3.13 mmol) in methanol (31 mL) was added NaOH (0.306 g, 7.64 mmol) and the mixture was stirred at room temperature for 2 hours. The mixture was diluted with ethyl acetate (75 mL) and saturated aqueous NaHCO3 (20 mL). The phases were separated and the organic phase was washed with brine (2 x 10 mL), dried (MgSO4), and concentrated.
Purification of the crude material by column chromatography on silica gel (9:1 hexanes-ethyl acetate) provided 0.58 g (58%) of 4-(tent-butyldimethylsilyloxy)-2-methylene-butan-l-ol as a colorless oil. 1H
NMR (CDC13) 6 0.06 (s, 6H), 0.90 (s, 9H), 2.34 (t, 2H, J= 6.0 Hz); 2.78 (br s, 111), 3.75 (t, 2H, J= 6.0 Hz), 4.07-4.11 (in, 2H), 4.90 (s, 1H), 5.04 (s, 1H);
[0573] To a cold (0 C), stirred solution of diethyl zinc (1.0 M in hexanes, 4.0 mL, 4.0 mmol) in CH2C12 (8 mL) was added neat C1CH2I (0.58 mL, 7.96 mmol) drop wise by syringe. After 1 hour, a solution of 4-(tert-butyldimethylsilyloxy)-2-methylene-butan-1-ol (0.395 g, 1.83 mmol) in CH2Cl2 (4 mL) was added by cannula. After 30 minutes, the reaction mixture was treated with saturated aqueous NH4C1(10 mL), diluted with CH2C12 (12 mL), and warmed to room temperature. The phases were separated and the aqueous phase was extracted with CH2C12 (3 x 10 mL). The combined organic extracts were dried (Na2SO4) and concentrated. The crude material was purified by column chromatography on silica gel (9:1 hexanes-ethyl acetate) and provided 0.41 g (97%) of {1-[2-(tert-butyldimethylsilyloxy.)-ethyl]-cyclopropyl}-methanol as a colorless oil.
[0574] To solution of 11 -[2-(tert-butyldimethylsilyloxy)-ethyl]-cyclopropyl} -methanol (0.41 g, 1.78 mmol) in CH2C12 (18 mL) was added Et3N (0.50 mL, 3.59 mmol) followed by methanesulfonyl chloride (0.21 mL, 2.71 mmol). The resultant mixture was stirred at room temperature for 17 hours. The mixture was diluted CH2C12 (50 mL), washed with brine (3 x 20 mL), dried (Na2SO4), and concentrated. The resultant oil was dissolved in DMF (16 mL), treated with potassium phthalimide (0.606 g, 3.27 mmol), and the mixture was heated at 80 C for 6 hours then cooled to room temperature. The mixture was diluted with ethyl acetate (40 mL), brine (20 mL), and water (10 mL) and the phases were separated. The organic phase was washed with brine (3 x 10 mL), dried (MgSO4), and concentrated. The crude material was purified by column chromatography on silica gel (20:1 hexanes-ethyl acetate) and provided 0.24 g (38%) of 2-{1-[2-(tent-butyldimethylsilyloxy)-ethyl]-cyclopropylmethyl}-isoindole-l,3-dione as a colorless oil.
[0575] To a solution of 2-{1-[2-(tent-butyldimethylsilyloxy)-ethyl]-cyclopropylmethyl}-isoindole-l,3-dione (0.24 g, 0.68 mmol) in THE (3 mL) was added 1.0 M HCl (3 mL). The resultant solution was stirred, at room temperature, for 3 hours. The mixture was diluted with saturated aqueous NH4Cl (10 mL) and extracted with CH2C12 (3 x 20 mL). The combined organic extracts were dried (Na2SO4) and concentrated. The crude material was purified by column chromatography on silica gel (2:1 hexanes-ethyl acetate) and provided 0.146 g (88%) of 2-[1-(2-hydroxy-ethyl)-cyclopropylmethyl]-isoindole-1,3-dione as a white solid. 1H
NMR (CDC13) 6 0.29-0.35 (m, 2H), 0.59-0.62 (m, 2H), 1.41 (t, 2H, J= 6.6 Hz), 2.80 (br s, 1H), 3.53 (s, 2H), 3.76 (t, 2H, J= 6.6 Hz), 7.59-7.63 (m, 2H), 7.69-7.74 (m, 2H);
[0576] To a solution of the alcohol from above (146 mg, 0.595 mmol) in dichloromethane (15 mL) was added Dess-Martin Periodinane (303 mg, 0.715 mmol). The mixture was then stirred at room temperature for 45 minutes. A 5% solution of sodium thiosulfate (10 mL) and a saturated sodium bicarbonate solution (10 mL) was added along with another 20 mL of dichloromethane. The mixture was then stirred rapidly for 20 minutes, and the aqueous and organic layers were separated. The aqueous layer was extracted twice with dichloromethane, and the combined organic fractions were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford N-(3-cyclopropanyl-butan- 1 -al-4-yl)-phthalimide as a yellow foam, which was used immediately in the next reaction without further purification. 1H NMR (CDC13) S 0.43 (m, 2H), 0.86 (m, 2H), 2.40 (s, 211), 3.65 (s, 2H), 7.68 (m, 2H), 7.83 (m, 2H), 9.79 (s, 1H).
[0577] To a solution ofN-(3-cyclopropanyl-butan-l-al-4-yl)-phthalimide (0.595 mmol) in dichloromethane (15 mL) was added (5,6,7,8-tetrahydroquinolin-8-yl)-[(N-t-butoxycarbonyl)-benzimidazol-2-yl)methyl]-amine (227 mg, 0.6 mmol). The mixture was stirred at room temperature for 30 minutes, then sodium triacetoxyborohydride (254 mg, 1.2 mmol) was added, and the reaction was allowed to stir for 16 hours. A
saturated sodium bicarbonate solution (10 mL) was added, and the aqueous and organic layers were separated.
The aqueous layer was then extracted twice with dichloromethane, and the combined organic fractions were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was then purified by silica gel flash chromatography (3% methanol in dichloromethane) to afford [(N-t-butoxycarbonyl)-benzimidazol-2-ylmethyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-[1-(N-phthalimidyl)-butan-2-(cyclopropanyl)-4-yl]-amine as, a pale yellow foam in a yield of 130 mg (36%). 1H NMR (CDC13) 8 0.23 (m, 2H), 0.55 (m, 2H), 1.15 (m, 1H), 1.35 (m, 1H), 1.66 (s, 9H), 1.70 (m, 2H), 2.00 (m, 2H), 2.16 (m, 1H), 2.69 (m, 1H), 2.97 (m, 2H), 3.31 (d, 1H, J=15.3 Hz), 3.51 (d, 1H, J= 15.3 Hz), 4.23 (in, 1H), 4.43 (d, 1H, J= 17.1 Hz), 4.62 (d, 1H, J= 17.1 Hz), 7.00 (m, 1H), 7.23 (m, 4H), 7.65 (m, 2H), 7.74 (m, 2H), 7.74 (m, 1H), 8.38 (m, 1H).

[0578] To a solution of [(N-t-butoxycarbonyl)-benzimidazol-2-ylmethyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-(N-phthalimidyl)-butan-2-(cyclopropanyl)-4-yl)-amine (187 mg, 0.31 mmol) in ethanol (8 mL) was added hydrazine hydrate (0.1 mL). The mixture was then heated to 60 C for 60 minutes. After cooling, the reaction was concentrated in vacuo, taken up in dichloromethane (20 mL) and washed with an aqueous sodium carbonate solution (5 mL). The aqueous layer was then extracted twice with dichloromethane, and the combined organic fractions were dried over anhydrous sodium sulfate, filtered and concentrated to afford a foamy residue which was purified by silica gel flash chromatography (10%
methanol, 0.5% ammonium hydroxide in dichloromethane) to afford (1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-(1-amino-2-(cyclopropanyl)-butan-4-yl)-amine as a white foam in a yield of 100 mg (86%). 1H NMR (CDC13) 8 0.17 (s, 2H), 0.25 (s, 2H), 1.32 (m, 1H), 1.61 (m, 2H), 1.85 (m, 1H), 1.93 (m, 1H), 2.19 (m, 1H), 2.39 (s, 1H), 2.86 (m, 4H), 3.99 (m, 4H), 5.40 (br s, 2H (NH2)), 7.03 (dd, 1H, J= 4.8, 8.1 Hz), 7.15 (m, 2H), 7.32 (d, 1H, J= 8.1 Hz), 7.54 (m, 2H), 8.48 (d, 1H, J= 4.8 Hz).

[0579] Following General Procedure D: To a solution of (1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-(1-amino-2-(cyclopropanyl)-butan-4-yl)-amine (100 mg, 0.267 mmol) in glacial acetic acid (2 mL) was added a saturated solution of HBr in acetic acid (0.5 mL) to yield, after precipitation and drying, (1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-(1 -amino-2-(cyclopropanyl)-butan-4-yl)-amine (HBr salt -COMPOUND 96) as a cream-coloured powder (126 mg, 69%). 1H NMR (D20) 8 0.36 (m, 1H), 0.52 (m, 211), 1.31 (m, 1H), 1.75 (m, 211), 2.01 (m, 1H), 2.06 (m, 1H), 2.63 (m, 1H), 2.64 (d, 1H, J= 13.5 Hz), 2.87 (d, 111, J= 13.5 Hz), 2.99 (m, 311), 4.36 (d, 1H, J= 16.8 Hz), 4.55 (m, 1H), 4.49 (d, 1H, J= 16.8 Hz), 7.60 (m, 2H), 7.79 (m, 211), 7.85 (dd, 1H, J= 7.8, 5.4 Hz), 8.32 (d, 1H, J= 7.8 Hz), 8.60 (d, 1H, J= 5.4 Hz); 13C NMR (D20) S
11.39, 11.52, 17.02, 20.44, 27.64, 32.22, 45.79, 47.91, 49.32, 49.82, 60.58, 114.26, 125.98, 126.97, 130.98, 139.32, 140.69, 148.15, 151.17, 151.72. ES-MS m/z 376 (M+H). Anal. Calcd. for x 1.41120 x 3.1HBr x 0.4Et20: C, 43.37; H, 5.76; N, 10.28; Br, 36.36. Found:
C, 43.41; H, 5.73; N, 10.27; Br, 36.37.

Example 97 ~N-QH

Z N NH

COMPOUND 97: Preparation of (1H-benzimidazol-2- ly methyl)-(5.6,7,8-tetrah quinolin-8-yl)-(1-amino-2-methyl-but-2-en-4-yl)-amine.
[0580] To a solution of N-(3-methylenyl-butan-l-ol-4-yl)-phthalimide (180 mg, 0.83 mmol - (See preparation of N'-(1H-Benzimidazol-2-ylmethyl)-2-methylene-Nl-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine, hydrobromide salt for details)) in dichloromethane (15 mL) was added Dess-Martin Periodinane (424 mg, 1.0 mmol).
A 5%
solution of sodium thiosulfate (10 mL) and a saturated sodium bicarbonate solution (10 mL) was added along with another 20 mL of dichloromethane. The mixture was then stirred rapidly for 20 minutes, and the aqueous and organic layers were separated. The aqueous layer was extracted twice with dichloromethane, and the combined organic fractions were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to afford N-(3-methylenyl-butan- 1 -al-4-yl)-phthalimide as a yellow foam, which was used immediately in the next reaction without further purification. 111 NMR (CDC13) S 3.19 (s, 211), 4.32 (s, 2H), 5.07 (s, 111), 5.24 (s, 111), 7.70 (m, 2H), 7.84 (s, 2H), 9.66 (s, 111).
[0581] To a solution ofN-(3-methylenyl-butan-1-al-4-yl)-phthalimide (0.83 mmol) in dichloromethane (15 mL) was added (5,6,7,8-tetrahydroquinolin-8-yl)-[(N-t-butoxycarbonyl)-benzimidazol-2-yl)methyl]-amine (227 mg, 0.6 mmol). The mixture was stirred at room temperature for 30 minutes, then sodium triacetoxyborohydride (254 mg, 1.2 mmol) was added, and the reaction was allowed to stir for 16 hours. A
saturated sodium bicarbonate solution (10 mL) was added, and the aqueous and organic layers were separated.
The aqueous layer was then extracted twice with dichloromethane, and the combined organic fractions were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was then purified by silica gel flash chromatography (3% methanol in dichloromethane) to afford [(N-t-butoxycarbonyl)-benzimidazol-2-ylmethyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-[1-(N-phthalimidyl)-2-methyl-but-2-en-4-yl]-amine as a pale yellow foam in a yield of 88 mg (26%). 1H NMR (CDC13) 8 1.26 (s, 3H) 1.48 (m, 3H), 1.68 (s, 9H), 2.04 (m, 1H), 2.74 (m, 2H), 3.47 (dd, 1H, J= 13.1, 5.9 Hz), 3.61 (dd, 1H, J= 13.1, 5.9 Hz), 4.19 (m, 1H), 4.33 (d, 1H, J =16.1 Hz), 4.49 (d, 1H, J = 16.1 Hz), 5.43 (t, 1H, J =
5.9 Hz), 6.95 (m, 1H), 7.13 (m, 2H), 7.64 (m, 2H), 7.73 (m, 2H), 7.81 (m, 2H), 8.22 (m, 1H), 8.61 (m, 1H).
[0582] To a solution of [(N-t-butoxycarbonyl)-benzimidazol-2-ylmethyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-[1-(N-phthalimidyl)-2-methyl-but-2-en-4-yl]-amine 88 mg, 0.15 mmol) in ethanol (8 mL) was added hydrazine hydrate (0.1 mL). The mixture was then heated to 60 C for 60 minutes. After cooling, the reaction was concentrated in vacuo, taken up in dichloromethane (20 mL) and washed with an aqueous sodium carbonate solution (5 mL). The aqueous layer was then extracted twice with dichloromethane, and the combined organic fractions were dried over anhydrous sodium sulfate, filtered and concentrated to afford a foamy residue which was purified by silica gel flash chromatography (10%
methanol, 0.5% ammonium hydroxide in dichloromethane).to afford [(N-t-butoxycarbonyl)-benzimidazol-2-ylmethyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-[ 1-amino-2-methyl-but-2-en-4-yl]-amine as a white foam in a yield of 33 mg (61 %). 1H NMR (CDC13) 8 1.57 (s, 9H), 1.71 (m, 1H), 1.89 (m, 1H), 2.01 (m, 2H), 2.27 (m, 1H), 2.74 (m, 3H), 3.01 (s, 3H), 3.16 (dd, 1H, J
= 7.1, 4.3 Hz), 3.31 (dd, 1H, J= 7.1, 4.3 Hz), 4.02 (m, 3H), 5.30 (m, 1H), 7.13 (m, 4H), 7.40 (d, 1H, J= 7.8 Hz), 7.54 (m, 1H), 8.54 (d, 1H, J= 4.8 Hz).
[0583] To a solution of [(N-t-butoxycarbonyl)-benzimidazol-2-ylmethyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-[1-amino-2-methyl-but-2-en-4-yl]-amine (33 mg, 0.091 mmol) in glacial acetic acid (2 mL) was added a saturated solution of HBr in acetic acid (0.5 mL). The resulting mixture was stirred and treated as per standard procedure D to yield, after precipitation and drying, [(1H-benzimidazol-2-yl)methyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-[1-amino-2-methyl-but-2-en-4-yl]-amine (HBr salt - COMPOUND 97) as a cream-coloured powder (28 mg, 46%). 'H NMR (D20) 5 1.63 (s, 3H), 1.83 (m, 1H), 2.06 (m, 1H), 2.17 (m, 1H), 2.40 (m, 1H), 3.01 (m, 5H), 3.21 (m, 1H), 4.30 (d, 1H, J= 16.8 Hz), 4.48 (d, 1H, J=
16.8 Hz), 4.49 (m, 1H), 5.47 (t, 1H, J= 5.8 Hz), 7.60 (m, 2H), 7.79 (m, 2H), 7.80 (m, 1H), 8.33 (d, 1H, J= 7.8 Hz), 8.63 (d, 1H, J= 5.1 Hz); 13C NMR (D20) & 14.12, 20.41, 20.69, 27.63, 46.26, 48.25, 49.15, 60.97, 114.24, 125.95, 127.10, 127.52, 130.87, 132.88, 139.45, 140.69, 148.08, 151.08, 151.73. ES-MS m/z 362 (M+H). Anal. Calcd. for C22H25N5 x 1.5H20 x 3.1HBr x 0.5Et20: C, 42.62; H, 5.68; N, 10.35; Br, 36.62. Found: C, 42.37; H, 5.31; N, 10.18; Br, 36.31.

Example 98 ccH

. NH

COMPOUND 98: Preparation of (1H-benzimidazol-2-ylmethy1)-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-amino-2-meth lenyl-butan-4-yl)-amine.

[05841 To a solution of N-(3-methylenyl-butan-l-ol-4-yl)-phthalimide (209 mg, 0.90 mmol - (See preparation of Nl-(1H-Benzimidazol-2-ylmethyl)-2-methylene-Nl-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-l,4-diamine, hydrobromide salt, for details) in dichloromethane (5 mL) was methanesulfonyl chloride (0.092 mL, 1.2 mmol). The mixture was then stirred for 30 minutes at room temperature before being treated with aqueous ammonium chloride (5 mL). The layers were then separated, and the aqueous layer was washed twice with 10 mL fractions of dichloromethane. The combined organic fractions were then dried over anhydrous sodium sulfate and concentrated. The residue was taken up in DMF (5 mL) to which sodium azide (25 mg, 0.38 mmol) was added. The mixture was then heated to 80 C and was stirred overnight. The reaction was then cooled and poured into ethyl acetate (100 mL). The solution was then extracted repeatedly (5x) with distilled water. The organic layer was then dried over anhydrous sodium sulfate and concentrated.
The residue was purified by silica gel flash chromatography using a 1:1 mixture of ethyl acetate:hexanes as an eluent. The product 1-N-phthalimidyl-(2-methylenyl-butan-4-yl)-azide was collected as a white solid. 1H NMR (CDC13) 6 2.36 (t, 2H, J= 6.9 Hz), 3.49 (t, 2H, J= 6.9 Hz), 4.13 (s, 2H), 5.03 (s, 1H), 5.08 (s, 1H), 7.72 (m, 2H), 7.88 (m, 2H).
[0585] To a solution of [1-N-phthalimidyl-(2-methylenyl-butan-4-yl)]-azide (199 mg, 0.78 mmol) in methanol (20 mL) was added palladium on calcium carbonate (Lindlar's Catalyst, 40 mg). The mixture was then placed under 1 atm hydrogen gas and was stirred rapidly for 3 hours. The mixture was then filtered and concentrated to afford the product [1-(N-phthalimidyl)-2-methylenyl-butan-4-yl]-amine as a yellow gum (160 mg, 84%).

(CDC13) 6 3.32 (t, 2H, J = 7.1 Hz), 3.76 (t, 2H, J = 7.1 Hz), 4.28 (s, 2H), 5.14 (s, 1H), 5.30 (s, 1H), 7.70 (m, 2H), 7.82 (m, 2H).
[0586] To a solution of [1-(N-phthalimidyl)-2-methylenyl-butan-4-yl]-amine (160 mg, 0.658 mmol) in dichloromethane (8 mL) was added 5,6,7,8-tetrahydroquinoline-8-one (58 mg, 0.4 mmol). The mixture was stirred at room temperature for 30 minutes, then sodium triacetoxyborohydride (348 mg, 1.65 mmol) was added, and the reaction was allowed to stir for 16 hours. A saturated sodium bicarbonate solution (10 mL) was added, and the aqueous and organic layers were separated. The aqueous layer was then extracted twice with dichloromethane, and the combined organic fractions were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was then purified by silica gel flash chromatography (3% methanol in dichloromethane) to afford (5,6,7,8-tetrahydro-quinolin-8-yl)-[1-(N-phthalimidyl)-2-methylenyl-butan-4-y_l]-amine as a pale yellow foam in a yield of 75 mg (52%). 1H NMR (CDC13) 6 1.74 (m, 1H), 2.02 (m, 1H), 2.52 (m, 2H), 2.77 (m, 4H), 3.41 (d, 1H, J= 7.7 Hz), 3.55 (d, 1H, J= 7.7 Hz), 3.78 (m, 3H), 4.86 (m, 1H), 5.05 (1H), 7.04 (m, 1H), 7.37 (m, 1H), 7.68 (m, 2H), 7.80 (m, 2H), 8.36 (m, 1H).
[0587] To a solution of (5,6,7,8-tetrahydro-quinolin-8-yl)-[1-(N-phthalimidyl)-methylenyl-butan-4-yl]-amine (75 mg, 0.21 mmol) in acetonitrile (5 mL) was added N-t-butoxycarbonyl-2-chloromethylbenzimidazole (80 mg, 0.3 mmol). Di-isopropylethylamine (0.052 mL, 0.3 mmol) was then added, and the resulting solution was warmed to 70 C and was stirred overnight. After cooling, a saturated ammonium solution (10 mL), and dichloromethane (30 mL) was added, and the aqueous and organic layers were separated.
The aqueous layer was then extracted twice with dichloromethane, and the combined organic fractions were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo. The residue was then purified by silica gel flash chromatography. (3% methanol in dichloromethane) to afford [(N-t-butoxycarbonyl)-benzimidazol-2-ylmethyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-[l-(N-phthalimidyl)-2-methylen-4-yl]-amine as a pale yellow foam in a yield of 62 mg (50%). 1H NMR (CDC13) S 1.68 (s, 9H), 1.89 (m, 1H), 2.03 (m, 2H), 2.11 (m, 1H), 2.40 (t, 2H, J = 6.9 Hz), 2.75 (m, 2H), 3.27 (d, 1H, J = 13.1 Hz), 3.46 (d, 1H, J =
13.1 Hz), 3.61 (in, 2H), 4.11 (m, 1H), 4.48 (d, 1H, J = 16.1 Hz), 4.63 (d, 1H, J =16.1 Hz), 6.95 (m, 1H), 7.23 (m, 2H), 7.64 (m, 2H), 7.76 (m, 3H), 8.61 (m, 2H).
[0588] To a solution of [(N-t-butoxycarbonyl)-benzimidazol-2-ylmethyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-[1-(N-phthalimidyl)-2-methylen-4-yl]-amine (62 mg, 0.10 mmol) in ethanol (8 mL) was added hydrazine hydrate (0.1 mL). The mixture was then heated to 80 C
for 60 minutes. After cooling, the reaction was concentrated in vacuo, taken up in dichloromethane (20 mL) and washed with an aqueous sodium carbonate solution (5 mL).
The aqueous layer was then extracted twice with dichloromethane, and the combined organic fractions were dried over anhydrous sodium sulfate, filtered and concentrated to afford a foamy residue which was purified by silica gel flash chromatography (10%
methanol, 0.5%
ammonium hydroxide in dichloromethane) to afford [(N-t-butoxycarbonyl)-benzimidazol-2-ylmethyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-[1-(amino)-2-methylen-4-yl]-amine as a white foam in a yield of 29 mg (74%). 1H NMR (CDC13) 6 1.64 (m, 1H), 1.89-2.02 (m, 3H), 2.08 (m, 1H), 2.35 (m, 2H), 2.77 (m, 1H), 2.81 (m, 1H), 2.94 (m, 1H), 3.04 (d, 1H, J= 13.1 Hz), 3.16 (d, 1H, J= 13.1 Hz), 4.03 (m, 3H), 4.87 (s, 1H), 5.06 (s, 1H), 7.12 (m, 3H), 7.40 (d, 1H, J= 8.1 Hz), 7.57 (m, 2H), 8.58 (m, lH).
[0589] To a solution of [(N-t-butoxycarbonyl)-benzimidazol-2-ylmethyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-[1-(amino)-2-methylen-4-yl]-amine (29 mg, 0.080 mmol) in glacial acetic acid (2 mL) was added a saturated solution of HBr in acetic acid (0.5 mL). The resulting mixture was stirred and treated as per standard procedure D to yield, after precipitation and drying, [(1H-benzimidazol-2-yl)methyl]-(5,6,7,8-tetrahydro-quinolin-8-yl)-[1-(amino)-2-methylen-4-yl]-amine (HBr salt - COMPOUND 98) as a cream-coloured powder (28 mg, 55%). 1H NMR (D20) S 1.81 (m, 1H), 2.05 (m, 2H), 2.23 (m, 3H), 2.79 (m, 1H), 2.94 (m, 3H), 3.18 (d, 1H, J= 14.1 Hz), 3.41 (d, 1H, J= 14.1 Hz), 4.34 (d, 1H, J= 16.1 Hz), 4.48 (d, 1H, J=16.1 Hz), 4.60 (m, 1H), 5.26 (m, 2H), 7.53 (m, 2H), 7.79 (m, 2H), 7.89 (dd, 1H, J= 5.1, 7,8 Hz), 8.54 (d, 1H, J= 7.8 Hz), 8.68 (d, 1H, J= 5.1 Hz);
13C NMR (D20) 8 20.05, 20.29, 27.81, 31.02, 37.45, 48.26, 57.09, 60.44, 114.26, 118.49, 126.09, 127.01, 131.00, 139.67, 139.79, 141.13, 148.25, 150.85, 151.38. ES-MS fn/z 362 (M+H).
Anal.
Calcd. for C22H25N5 x 1.8 H2O x 3.0 HBr: C, 41.50; H, 5.32; N, 11.00; Br, 37.65. Found: C, 41.54; H, 5.17; N, 10.85; Br, 37.55.

Example 99 N----~~NH2 N NH

COMPOUND 99: Preparation of (1H-benzimidazol-4-methoxy-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)- l-aminobutan-4-y)-amine NH

621-5 OMe [0590] To a 0 C solution of potassium t-butoxide (5.87g, 52.3 mmol) in DMF (40 mL) under an inert atmosphere of argon was added copper (I) chloride (0.2 g, 2.0 mmol). The resulting suspension was stirred for 10 minutes, then a solution of 3-nitroanisole (1.55 g, 10.1 mmol) and methoxylamine hydrochloride (1.08 g, 12.9 mmol) in DMF (15 mL) was added in a dropwise manner over 15 minutes. The mixture was then allowed to slowly warm to room temperature and was stirred for 48 hours. Water (20 mL) was then added to the reaction, and the mixture was poured into a separatory funnel containing 100. mL ethyl acetate. The aqueous and organic layers were then separated, and the organic layer was extracted 5 times with 20 mL portions of water. The organic layer was then dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel flash chromatography using a 3:1 hexanes:ethyl acetate mixture as an eluent. Three isomeric products were isolated consecutively from the column, the first being the desired 2-amino-3-nitroanisole, which was isolated as an orange powder in a yield of 465 mg (29%). 1H NMR
(CDC13) 6 3.95 (s, 3H), 6.44 (br s, 2H (NH)), 6.61 (dd, 1H, J= 7.8, 7.1 Hz), 6.87 (d, 1H, J=
7.1 Hz), 7.73 (d, 1H, J= 7.8 Hz) [0591] To a solution of 2-amino-3-nitroanisole (465 mg, 2.94 mmol) in methanol (50 mL) was added palladium on carbon (10% Pd, 100 mg). The mixture was then placed under an atmosphere of hydrogen gas (1 atm) and was stirred for one hour. The mixture was then filtered through celite and concentrated to give 2,3-diaminoanisole as a yellow foam in a yield of 400 mg (98%). 'H NMR (CDC13) 8 3.45 (br s, 4H (NH)), 3.84 (s, 3H), 6.40 (m, 2H), 6.67 (t, 1H, J = 7.8 Hz) C N CI
N
OMe [0592] A solution of 2,3-diaminoanisole (400 mg, 2.89 mmol) and chloroacetic acid (557 mg, 6 mmol) in 4 N HCl was heated to 105 C for 16 hours. The mixture was then cooled, neutralized (to a pH of 8) with aqueous sodium bicarbonate, and extracted twice with dichloromethane. The organic fractions were then dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel flash chromatography using a 1:1 mixture of hexanes:ethyl acetate as an eluent to give 1H-2-chloromethyl-methoxybenzimidazole as a yellow foam in a yield of 386 mg (68%). 'H NMR
(CDC13) 8 3.96 (s, 3H), 4.85 (s, 2H), 6.71 (m, 1H), 7.19 (m, 2H).
[0593] To a solution of 1H-2-chloromethyl-4-methoxybenzimidazole (138 mg, 0.7 mmol) and (5,6,7,8-tetrahydroquinolin-8-yl)-(l-(N-phthalimidyl)-butan-4-yl)-amine (180 mg, 0.515 mmol) in acetonitrile (8 mL) was added di-isopropylethylamine (0.13 mL, 0.75 mmol). The resulting solution was heated to 70 C for 6 hours. The reaction was then cooled, and partitioned between aqueous ammonium chloride and dichloromethane. After separation of the layers, the aqueous layer was extraced twice with dichloromethane. The combined organic fractions were then dried over anhydrous sodium sulfate, filtered and concentrated.
The residue was purified by silica gel flash chromatography using a 5%
methanol in dichloromethane solution as an eluent. The product (1H-benzimidazol-4-methoxy-ylmethyl)-(5,6,7,8-tetrahy. droquinolin-8-yl)-[ 1-(N-phthalimidyl)-aminobutan-4-yl]-amine was isolated as a pale yellow foam in a yield of 212 mg (8268 (m, 4H), 1.90-2.05 (m, 2H), 2.03 (m, 2H), 2.61-2.83 (m, 4H), 3.80-4.10 (m, 8H), 6,60 (m, 1H), 7.06 (m, 3H), 7.63 (m 1H), 7.63-7.77 (m, 4H), 8.40 (m, 1H).
[0594] To a solution of product (1H-benzimidazol-4-methoxy-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-[1-(N-phthalimidyl)-aminobutan-4-yl]-amine (212 mg, 0.417 mmol) in denatured ethanol (10 mL) was added hydrazine hydrate (0.25 mL). The resulting mixture was heated to 80 C for 60 minutes, then cooled and concentrated. The residue was filtered through a silica gel plug (5 g silica) using a 10:1 dichloromethane:methanol mixture as an eluent. The collected eluent (200 mL) was then concentrated, re-dissolved in THE (10 mL) and di-t-butyl carbonate (212 mg, 1.0 mmol) was added. The mixture was then stirred at room temperature overnight. The reaction was then concentrated, and the residue was purified by silica gel flash chromatography using a 5% methanol in dichloromethane mixture as an eluent to afford the desired (1-t-butoxycarbonyl-benzimidazol-4-methoxy-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-[1-(N-t-butoxycarbonyl)-aminobutan-4-yl]-amine as a pale foam in a yield of 68 mg (28%). 1H NMR (CDC13) 8 1.18-1.23 (in, 4H), 1.39 (s, 9H), 1.70 (s, 9H), 1.97-2.07 (m, 411), 2.58-2.95 (m, 6H), 4.01 (s, 3H), 4.18 (in, 1H), 4.58 (m, 2H), 4.92 (br s, 1H (NH)), 6.72 (d, 1H, J= 8.1 Hz), 6.91 (m, 1H), 7.16 (m, 2H), 7.35 (d, 1H, J= 8.1 Hz), 8.33 (m, 1H).
[0595] (1-t-Butoxycarbonyl-benzimidazol-4-methoxy-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-[l-(N-t-butoxycarbonyl)-aminobutan-4-yl]-amine (68 mg, 0.117 mmol) was taken up in acetic acid (1 mL), to which a saturated solution of HBr in acetic acid (0.1 mL) was added. The mixture was then stirred, precipitated and isolated as per procedure D to yield COMPOUND 99 as a white crystalline solid in a yield of 49 mg (65%). 1H NMR (D20). 81.52 (in, 4H), 1.79 (m, 1H), 1.98 (m, 1H), 2.14 (m, 1H), 2.35 (m, 1H), 2.53 (m, 1H), 2.79 (m, 3H), 2.99 (in, 2H), 4.03 (s, 3H), 4.36 (d, 1H, J
=16.8 Hz), 4.49 (m, 111), 4.50 (d, 1H, J = 16.8 Hz), 7.10 (d, 1H, J = 8.1 Hz), 7.34 (d, 1H, J
= 8.4 Hz), 7.51 (t, 1H, J = 8.4 Hz), 7.85 (dd,1H, J = 8.1, 5.4 Hz), 8.34 (d, 1H, J = 8.1 Hz), 8.60 (d, 1H, J = 5.4 Hz). 13C NMR (D20) 8 20.44, 20.84, 25.05, 25.41, 27.66, 39.54, 48.10, 51.76, 56.70, 60.54, 106.20, 107.45, 121.85, 125.90, 128.14, 132.39, 139.30, 140.56,147.45, 148.05, 150.89, 151.30. ES-MS m/z 380 (M+H); Anal. Calcd. for (C22H29N50 x 3.0 HBr x 1.0 H20):
C, 41.27; H, 5.35; N, 10.94; Br 37.44. Found: C, 41.28; H, 5.33; N, 10.67; Br, 37.24.

Example 100 o tq NHZ
N NH

COMPOUND 100: Preparation of N1-(1H-Benzimidazol-2-ylmethyl)-N1-(4-methoxy-6 7 8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine (hydrobromide salt).
[0596] 8-Amino-4-methoxy-5,6,7,8-tetrahydroquinoline was prepared in 68% yield from 8-hydroxy-4-methoxy-5,6,7,8-tetrahydroquinoline (preparation and characterization described by: Uchida, M., et al., Chem. Pharm. Bull. (1989) 37:1517-1523) using the same procedure employed to prepare 8-amino-5,6,7,8-tetrahydroquinoline (according to the procedures described in Bridger, et al., U.S. Patent Application USSN
09/535,314). 1H NMR
(CDC13) 6 1.59-2.15 (m, 6H), 2.60-2.65 (m, 2H), 3.84 (s, 3H), 3.95 (dd, 1H, J=
6.0, 9.0 Hz), 6.61 (d, 1H, J= 6.0 Hz). 8.32 (d, 1H, J= 6.0 Hz); 13C NMR (CDC13) S 19.53, 22.89, 31.94, 51.57,55.62,104.04,120.94,148.52,160.42,163.71; ES-MS m/z 179 (M+H).
[0597] Using General Procedure B: Reaction of 8-amino-4-methoxy-5,6,7,8-tetrahydroquinoline (0.297 g, 1.67 mmol) and 4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyraldehyde (0.371, 1.71 mmol) with NaBH(OAc)3 (0.493 g, 2.33 mmol) in CH2C12 (8 mL) for 60 minutes followed by purification of the crude material by column chromatography on silica gel (20:1 CH2C12-CH3OH) provided 0.345 g (54%) of 2-[4-(4-methoxy-5,6,7,8-tetrahydro-quinolin-8-ylamino)-butyl]-isoindole-1,3-dione as an off-white solid.
[0598] Using the General Procedure for N-alkylation: A solution of 2-[4-(4-methoxy-5,6,7,8-tetrahydro-quinolin-8-ylamino)-butyl]-isoindole-l,3-dione (0.340 g, 0.90 mmol), 1-tert-(butoxycarbonyl)-2-(chloromethyl)-benzimidazole (0.492 g, 1.84 mmol), and N,N-diisopropylethylamine (0.48 mL, 2.76 mmol) in CH3CN (9 mL) was heated at 80 C for 22 hours. Purification of the crude material by column chromatography on silica gel (20:1:1 CH2C12-CH3OH-NH4OH) followed by radial chromatography on silica gel (2 mm plate, 100:1:1 CH2C12- CH3OH -NH4OH) provided 133 mg (24%) of 2-{[[4-(1,3-dioxo-l,3-dihydro-isoindol-2-yl)-butyl]-(4-methoxy-5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-methyl} -benzimidazole-l-carboxylic acid tert-butyl ester a yellow solid.

[0599] To a solution of 2-{[[4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyl]-(4-methoxy-5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-methyl}-benzimidazole-l-carboxylic acid tert-butyl ester (0.133 g, 0.22 mmol) in ethanol (4 mL) was added hydrazine monohydrate (0.20 mL, 4.12 mmol) and the resultant mixture was stirred at room temperature overnight. The mixture was filtered through filter paper and concentrated. Purification of the crude material by column chromatography on silica gel (10:1:1 CH2C12-CH3OH-NH4OH) provided 56 mg (68%) of the free base of the title compound as a yellow oil.
[0600] Using General Procedure D: Conversion of the free base to the hydrobromide salt followed by reprecipitation of the intermediate solid from methanol/ether gave COMPOUND 100 (72 mg, 71%) as a tan solid. 1H NMR (D20) 8 1.53 (br s, 411), 1.64-1.74 (m, 1H), 1.86-1.98 (m, 1H), 2.14-2.19 (m, 1H), 2.28-2.32 (m, 1H), 2.50-2.63 (m, 2H), 2.71-2.8.7 (m, 4H), 4.09 (s, 3H), 4.31-4.40 (m, 2H), 4.48 (d, 1H, J= 16.8 Hz), 7.34 (d, 1H, J= 7.2 Hz), 7.56-7.61 (m, 2H), 7.76-7.80 (m, 2H), 8.49 (d, 1H, J 7.2 Hz); 13C NMR
(D2O) 8 19.74, 20.00, 21.76, 25.03, 25.37, 39.51, 47.98, 51.69, 58.09, 60.11, 107.55, 114.22, 126.91, 128.05,130.98,141.05,150.21,151.88,170.91; ES-MS m/z 380 (M+H). Anal. Calcd.
for C22H29N50=3.2HBr=2.2H20: C, 38.97; H, 5.44; N, 10.335; Br, 37.71. Found: C, 39.08; H, 5.13; N, 10.46; Br, 37.57.

Example 101 o OJN>JN JNH2 ():N
H
COMPOUND 101: Preparation ofN'-(1H-benzimidazol-2-ylmethyl)N'-(3-methoxy-5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine (hydrobromide salt) [0601] A solution of 3-bromoquinoline (24.4 g, 117 mmol) in anhydrous DMF (250 mL) was treated with sodium methoxide (12.7 g, 235 mmol) and stirred at 140 C for 40 hours.
The reaction mixture was then concentrated under reduced pressure and diluted with ethyl acetate (300 mL) and water (60 mL). The organic phase was separated, washed with brine (2 x 60 mL) and dried (MgSO4), filtered, and concentrated under reduced pressure.
This gave, after purification by column chromatography on silica gel (ethyl acetate/hexane; 1:4), 3-methoxyquinoline as a pale yellow liquid (1.15g, 6%). 1H NMR (CDC13) 8 3.95 (s, 3H), 7.38 (d, 1H, J= 1.5 Hz), 7.54 (m, 2H), 7.72 (d, 1H, J= 7.5 Hz), 8.04 (d, 1H, J= 7.5 Hz), 8.67 (d, 1H,J=1.5Hz).
[0602] A solution of 3-methoxyquinoline (1.15 g, 7.2 mmol) in TFA (24 mL) was prepared and the reaction flask was purged with argon. Platinum oxide (82 mg, 0.36 mmol) was then added, and hydrogen gas was bubbled through the solution for 16 h at room temperature. The mixture was then cooled to 0 C, basified to pH 12 with 15%
aqueous sodium hydroxide solution, and extracted with ethyl acetate (3 x 100 mL). The organic phase was then dried (MgSO4), filtered, and concentrated to yield 3-methoxy-5,6,7,8-tetrahydroquinoline (0.88 g, 74%). 1H NMR (CDC13) b 1.77 (m, 2H), 1.85 (m, 2H), 2.75 (t, 2H, J= 6.0 Hz), 2.85 (t, 2H, J= 6.0 Hz), 3.81 (s, 3H), 6.88 (d, 1H, J= 1.5 Hz), 8.07 (d, 1H, J
1.5 Hz).
[0603] 50% Hydrogen peroxide (0.30 mL, 5.4 mmol, 1 equivalent) was added to a solution of 3-methoxy-5,6,7,8-tetrahydroquinoline (0.87 g, 5.3 mmol) in acetic acid (12 mL) and heated to 70 C for 7h. A second equivalent of 50% hydrogen peroxide (0.30 mL, 5.4 mmol) was then added and the solution stirred another 16 h at 70 C. The solution was then concentrated under reduced pressure and chloroform (20 mL) and sodium carbonate (5 g) was added. The mixture was stirred for a short period and the supernatant was decanted and the solids washed with chloroform (50 mL). The organic was then dried (Na2SO4), filtered, and concentrated under reduced pressure to provide the N-oxide as a yellow crystalline solid (0.67 g, 70%). 1H NMR (CDC13) 6 1.76 (m, 2H), 1.86 (m, 2H), 2.74 (t, 2H, J=
6.0 Hz), 2.88 (t, 2H, J= 6.0 Hz), 3.81 (s, 3H), 6.67 (d, 1H, J= 1.5 Hz), 7.98 (d, 1H, J= 1.5 Hz).
[0604] A solution of 3-methoxy-5,6,7,8-tetrahydroquinolinium oxide (0.67 g, 17 mmol) in acetic anhydride (9 mL, 95 mmol) was heated to 90 C for 18 h followed by concentration under reduced pressure. This provided the rearranged 8-acetyl-3-methoxy-5,6,7,8-tetrahydroquinoline as a crude brown oil (0.83 g, 100%) that was again used immediately in the next reaction. 1H NMR (CDC13) 6 1.83 (m, 2H), 2.09 (s, 3H), 2.11 (in, 2H), 2.80 (m, 2H), 3.84 (s, 3H), 5.94 (t, 1H, J= 4.5 Hz), 6.94 (d, 1H, J= 1.5 Hz), 8.22 (d, 1H, J= 1.5 Hz).
[0605] A solution of 8-acetyl-3-methoxy-5,6,7,8-tetrahydroquinoline (0.83 g, 3.7 mmol) in anhydrous methanol (18 mL) was treated with potassium carbonate (1.03 g, 7.5 mmol) and stirred at room temperature for 16 h. The mixture was concentrated under reduced pressure and CH2C12 (30 mL) and water (15 ml) was added. The aqueous phase was then extracted with CH2C12 (2 x 30 mL) and the combined organic phases were dried (MgSO4), filtered, and concentrated to yield, after column chromatography (1:3 ethyl acetate/hexane), (3-methoxy-5,6,7,8-tetrahydroquinolin-8-yl)-alcohol as a pale yellow solid (0.35 g, 51 %). 1H NMR
(CDC13) S 1.81 (m, 2H), 1.99 (m, 1H), 2.22 (m, 1H), 2.77 (m, 2H), 3.83 (s, 3H), 4.69 (t, 1H, J
= 7.5 Hz), 6.92 (d, 1H, J= 3.0 Hz), 8.12 (d, 1H, J= 3.0 Hz).
[0606] The alcohol from above (0.35 g, 1.9 mmol) was then dissolved in anhydrous CH2C12 (19 mL) and treated with manganese dioxide (1.67 g, 19 mmol) for 18 h at room temperature. The black mixture was filtered through a celite pad and the filtrate concentrated under reduced pressure. This gave the desired 3-methoxy-5,6,7,8-tetrahydroquinolin-8-one (0.23 g, 68%) which was used in the next reaction unpurified. 1H NMR (CDC13) 6 2.18 (m, 2H), 2.74 (t, 2H, J= 6.0 Hz), 2.99 (t, 2H, J= 6.0 Hz), 3.90 (s, 3H), 7.00 (d, 1H, J= 3.0 Hz), 8.35 (d, 1H, J= 4.0 Hz).

[0607] Using General Procedure B from above, 3-methoxy-5,6,7,8-tetrahydroquinolin-8-one (0.23 g, 1.3 mmol), (4-aminobutyl)-carbamic acid tert-butyl ester (0.27 g, 1.4 mmol) and sodium triacetoxyborohydride (0.55 g, 2.6 minol) were stirred at room temperature in CH2C12 (7 mL) for 18 hours. This yielded, after work-up and column chromatography (3:97 McOH/CH2C12 to 15:1:84 McOH/NH4OH/CH2C12), [4-(3-methoxy-5,6,7,8-tetrahydroquinolin-8-ylamino)-butyl]-carbamic acid tent-butyl ester (0.38 g, 84%).
[0608] To a solution of the above secondary amine (0.15 g, 0.43 mmol), N-(t-butoxycarbonyl)-2-chloromethylbenzimidazole (0.18 g, 0.69 mmol), and potassium iodide (5 mg, 0.02 mmol) in anhydrous acetonitrile (4.3 mL) was added diisopropylethylamine (0.15 mL, 0.9 mmol) and stirred at 60 C for 16 hours. The mixture was then concentrated under reduced pressure and the residue partitioned between CH2C12 (10 mL) and brine (5 mL). The organic phase was separated and the aqueous phase was extracted with CH2C12 (2 x 10 mL).
The combined organic phases were then dried (Na2SO4), filtered, and concentrated under reduced pressure to give a crude residue that was purified by column chromatography with, silica gel (1:99 McOH/CH2C12) followed by a second column with silica gel (saturated NH3/Et2O). This gave 2-{[(4-tert-butoxycarbonylaminobutyl)-(3-methoxy-5,6,7,8-tetrahydroquinolin-8-yl)-amino]-methyl}-benzimidazole-l-carboxylic acid tert-butyl ester (98 mg, 39%). 1H NMR (CDC13) 6 1.40 (s, 9H), 1.43 (br in, 4H), 1. 62 (m, 1H), 1.69 (s, 9H), 1.87-2.05 (m, 3H), 2.62-2.80 (m, 4H), 3.01 (br, 2H), 3.75 (s, 3H), 4.16 (m, 1H), 4.44 (d, 1H, J= 15.0 Hz), 4.55 (d, 1H, J=15.0 Hz), 4.90 (br, 1H), 6.71 (d, 1H, J= 3.0 Hz), 7.27 (m, 2H), 7.70 (m, 1H), 7.79 (m, 1H), 8.08 (d, 1H, J= 3.0 Hz).

[0609] Using General Procedure D: The above material (97 mg, 0.17 mmol) was converted to the hydrobromide salt to provide COMPOUND 101 (85 mg) as a white solid.
1H NMR (D20) S 1.54 (br, 4H), 1.75 (m, 1H), 1.93 (m, 1H), 2.15 (m, 1H), 2.33 (m, 1H), 2.56 (br, 1H), 2.80 (br m, 1H), 2.87 (br, 2H), 2.96 (br d, 2H), 3.96 (s, 3H), 4.37 (d, 1H, J= 17.1 Hz), 4.43 (m, I H), 4.50 (d, 1H, J= 16.8 Hz), 7.60 (m, 2H), 7.79 (m, 2H), .7.93 (br, I H), 8.28 (d, 1H, J= 2.1 Hz). 13C NMR (D20) 8 20.54 (2C), 25.08, 25.43, 28.01, 39.54, 47.95, 51.73, 57.43, 60.13, 114.25 (2C), 126.95 (2C), 127.25, 131.00, 131.96, 141.38, 143.54, 151.85, 157.19. ES-MS m/z 380 (M+H). Anal. Calcd. for C22H29N50=3.2HBr=1.7H20: C, 39.50; H, 5.36; N, 10.47; Br, 38.22. Found: C, 39.77; H, 5.27; N, 10.34; Br, 37.96.

Example 102 N

-N'N

COMPOUND 102: Preparation ofN'-(l-Methyl-lH-benzoimidazol-2- lmethyl)-NI-(S) (5,6,7,8-tetrah do-quinolin-8-y )-butane-1 4-diamine hydrochloride salt [0610] Preparation of 2-{4-[(1-methyl-lH-benzoimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-butyl} -isoindole-1,3-dione:

[0611] To a solution of (S)-2-[4-(5,6,7,8-tetrahydro-quinolin-8-ylamino)-butyl]-isoindole-1,3-dione (3.89 g, 11.1 mmol) in acetonitrile (111 ml) was added 2-chloromethyl-l-methyl-1H-benzoimidazole (prepared by reaction of N-methyl-ortho-phenylenediamine with chloroacetic acid according to literature procedure Phillips, M.A., J. Chem.
Soc. (1928) 2393;
Goker, H., et al., Arch. Pharm. (Weinheim) (1995) 328:425-430) (2.42 g, 13.4 mmol), diisopropylethylamine (1.93 ml, 11.1 ml), and potassium iodide (0.18 g, 1.11 ml). The mixture was stirred for 16 hours at 50 C. The mixture was concentrated, redissolved in methylene chloride (200 ml) and diluted with saturated NaCl (400 ml). The reaction was extracted with methylene chloride (3 x 300 ml) and the combined organic extracts were dried (Na2SO4), filtered, and concentrated in vacuo to afford a dark red oil.
Purification via column chromatography on silica gel (CH2C12:MeOH:NH40H, 95:4:1, v/v/v) afforded the product as a light red foam (5.12g, 77%). 1H NMR (CDC13) S 1.63 (m, 8H), 2.65 (m, 4H), 3.54 (in, 2H), 4.10 (m, 6H), 6.98 (dd, 1H, J= 7.89, 4.38 Hz), 7.21 (m, 4H), 7.71 (m, 5H), 8.49 (d, 1H, J= 3.95 Hz).

Preparation of N-(1-Methyl-lH-benzoimidazol-2-ylmethyl)-N-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine:
[0612] To a solution of the material from above (5.12 g, 10.37 mmol) in ethanol (75 ml) was added hydrazine hydrate (1.94 ml, 62.2 mmol). The solution was stirred for 16 hours at room temperature under a N2 atmosphere. A white precipitate formed. Diethyl ether (75 ml) was added to the mixture and the reaction was stirred for 10 min. The mixture was filtered and concentrated. Purification via column chromatography on silica gel (CH2C12:MeOH:NH40H, 94:5:1, v/v/v) followed by a second purification by column chromatography on silica gel (CH2C12:MeOH:NH4OH, 94:5:1, v/v/v) afforded the product as a light yellow oil (2.63 g, 55%). 1H NMR (CDC13) 8 1.39 (m, 5H), 1.99 (m, 3H), 2.63 (m, 6H), 3.48 (s, 2H), 3.97 (s, 3H), 4.11 (m, 3H), 7.00 (dd, 1H, J= 7.45, 4.38 Hz),, 7.25 (m, 4H), 7.71 (d, 1H, J= 7.45 Hz), 8.46 (d, 1H, J= 4.38 Hz).

Preparation of COMPOUND 102:
[0613] To a solution of N-(1-methyl-lH-benzoimidazol-2-ylmethyl)-N-(5-,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine (2.63 g, 5.62 mmol) was added HO-saturated methanol (11 ml) and the mixture was stirred for 1 hour at room temperature under a N2 atmosphere. The solution was added dropwise to diethyl ether (1 L) to yield a chunky white precipitate. The white solid was isolated via suction filtration under a steady stream of nitrogen, washed with diethyl ether and dried at 40 C in vacuo overnight (2.75 g, 91%). 1H
NMR (D20) S 1.67 (m, 3H), 1.99 (m, 4H), 2.55 (m, 2H), 2.89 (m, 3H), 3.07 (m, 211), 3.31 (s, 1H), 4.07 (s, 3H), 4.43 (d, 1H, J= 17.9 Hz), 4.69 (m, 2H), 7.62 (m, 2H), 7.92 (m, 3H), 8.42 (d, 1H, J= 7.89 Hz), 8.85 (d, 1H, J=5.7 Hz). 13C NMR S (D20) 21.92, 26.65, 29.17, 32.42, 40.78, 53.61, 61.82, 113.89, 115.76, 127.15, 127.89, 128.11, 131.79, 135.1, 141.38, 141.91, 149.14, 152.75, 153.72. ES-MS m/z 364 (M + H). Anal. Calcd. For C22H29N5 3.05HC1 0.06C2H402 3.07H20: C, 49.80; H 7.26; N, 13.13; Cl, 20.24. Found. C, 49.80; , 7.25; N, 13.13; Cl, 20.24.

Exam lpe103 CI N

N "-~~ N H2 HN N

COMPOUND 103.: Preparation ofN1-(1H-benzimidazol-2-yhnethyl)-N1-(2-chloro-5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine (hydrobromide salt).

Preparation of methanesulfonic acid 2-chloro-5,6,7,8-tetrahydro-quinolin-8- 1 ester:
[0614] To a solution of 2-chloro-8-hydroxy-5,6,7,8-tetrahydroquinoline (prepared as described by Zimmerman, S. C., et al., J. Am. Chem. Soc. (1991) 113:183-196) (700 mg, 3.81 mmol) in CH2C12 (19 mL), cooled to 0 C under nitrogen, was added NEt3 (0.80 mL, 5.7 mmol) followed by MsCl (0.35 mL; 4.5 mmol). The solution was stirred at 0 C
for 40 minutes, then was diluted with saturated aqueous NaHCO3 (20 mL). The layers were separated and the aqueous solution was extracted with CH2C12 (20 mL x 2). The combined organic solution was dried (MgSO4), filtered and concentrated under reduced pressure.
Purification by flash column chromatography on silica (hexane/EtOAc, 2:1) gave the mesylate as a white solid (904 mg, 3.45 mmol, 91 %). 1H NMR (CDC13) 6 1.82-2.17 (m, 3H), 2.35-2.47" (m, 1H), 2.63-2.77 (m, 1H), 2.79-2.91 (m, 11-1), 3.29 (s, 3H), 5.62 (t, 1H, J= 3.9 Hz), 7.23 (d, 1H, J= 8.1 Hz), 7.45 (d, 1H, J= 8.1 Hz).

Preparation of 8-azido-2-chloro-5,6,7,8-tetrahydro-quinoline:
[0615] A solution of the mesylate (886 mg, 3.39 mmol) and NaN3 (285 mg, 4.38 mmol) in DMF (10 mL) was stirred at 80 C under nitrogen for 35 minutes. Once cooled, the mixture was diluted with brine (20 mL) and was extracted with EtOAc (20 mL x 3). The combined organic solution was dried (MgSO4), filtered and concentrated under reduced pressure.
Purification by flash column chromatography on silica (hexane/EtOAc, 2:1) gave the azide as a pale yellow oil (679 mg, 3.25 mmol, 96%). 1H NMR (CDC13) 6 1.75-2.11 (m, 4H), 2.63-2.86 (m, 2H), 4.66 (t, 1H, J= 4.2 Hz), 7.20 (d, 1H, J= 8.1 Hz), 7.42 (d, 1H, J= 8.1 Hz).

Preparation of 8-amino-2-chloro-5,6,7,8-tetrahydro-quinolin:
[0616] To a solution of the azide (351 mg, 1.68 mmol) in 10% H2O in THE (10 mL) was added PPh3 (867 mg, 3.31 mmol) and the reaction was stirred at room temperature for 18 hours. The solution was concentrated under reduced pressure and the residue was purified by flash column chromatography on silica (CH2C12/MeOH, 9:1) giving the amine as a pale yellow oil (276 mg, 1.51 mmol, 90%). 1H NMR (CDC13) 5 1.62-1.83 (m, 2H), 1.86-2.03 (m, 3H), 2.13-2.22 (in, 1H), 2.66-2.84 (m, 2H), 3.97 (dd, 1H, J= 7.5, 5.4 Hz), 7.09 (d, 1H, J=
8.1 Hz), 7.33 (d, 1H, J= 8.1 Hz).

Preparation of 2-[4-(2-chloro-5 6 7 8-tetrahydro-quinolin-8-ylamino)-butyl}-isoindole-1,3-dione:

[0617] A solution of the amine (269 mg, 1.47 mmol) and 4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyraldehyde (266 mg, 1.22 mmol) in CH2C12 (8 mL) was stirred at room temperature under nitrogen for 30 minutes. NaBH(OAc)3 (398 mg, 1.88 mmol) was then added in one portion as a solid and the reaction was stirred for a further 15 hours. The mixture was washed with 1M NaOH (10 mL x 2) and brine (10 mL), dried (Na2SO4), filtered and concentrated under reduced pressure. Purification by, flash column chromatography on silica (CH2Cl2/MeOH/NH4OH, 49:1:0.25) gave the secondary amine as a colourless oil (289 mg, 0.75 mmol, 62%). 1H NMR (CDC13) 8 1.55-1.81 (m, 6H), 1.93-2.03 (m, 1H), 2.06-2.14 (m, 1 H), 2.26 (br. s, 1 H), 2.73 (t, 4H, J = 7.1 Hz), 3.72 (t, 3H, J = 6.9 Hz), 7.07 (d, 1 H, J =
8.1 Hz), 7.32 (d, 1H, J= 8.1 Hz), 7.69 (dd, 2H, J= 5.4, 3.0 Hz), 7.83 (dd, 2H, J= 5.3, 3.0 Hz).

Preparation of 2-({(2-chloro-5,6,7,8-tetrah d~ ro-quinolin-8-yl)-[4-(1 3-dioxo-dihydro-isoindol-2-yl -butyl]-amino}-methyl)-benzimidazole-l-carboxylic acid tert-butyl ester:

[0618] A solution of the amine (274 mg, 0.72 mmol), 2-chloromethyl-benzimidazole-l-carboxylic acid tert-butyl ester (227 mg, 0.85 mmol), DIPEA (0.18 mL, 1.0 mmol) and KI
(24 mg, 0.14 mmol) in CH3CN (5 mL) was stirred at 60 C under nitrogen for 17 hours. Once cooled to room temperature, the solution was diluted with saturated aqueous NaHCO3 (10 mL) and extracted with CH2C12 (20 mL x3). The combined organic solution was dried (M9SO4), filtered and concentrated under reduced pressure. Purification by flash column chromatography on silica (CH2C12/MeOH, 19:1) gave the tertiary amine as an off-white foam (435 mg, 0.71 mmol, 99%). 1H NMR (CDC13) 8 1.28-1.41 (m, 2H), 1.50-1.61 (m, 2H), 1.64-1.76 (m, 10H), 1.80-1.91 (m, 1H), 1.93-2.05 (m, 111), 2.09-2.22 (m, 1H), 2.54-2.89 (m, 4H), 3.53 (t, 2H, J= 7.2 Hz), 4.18 (dd, 1H, J= 9.8, 6.2 Hz), 4.49 (d, 1H, J=15.6 Hz), 4.74 (d, 1H, J= 15.6 Hz), 6.93 (d, 1H, J= 8.1 Hz), 7.19 (d, 1H, J= 8.1 Hz), 7.22-7.26 (m, 2H), 7.63-7.71 (m, 3H), 7.74-7.85 (m, 311).

Preparation ofN1-(1H-benzimidazol-2- l~hyl)-N1-(2-chloro-5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine:
[0619] A solution of the amine (212 mg, 0.345 mmol) and hydrazine monohydrate (0.20 mL, 4.1 mmol) in EtOH was stirred at reflux under nitrogen for 75 minutes. The excess solvent was removed under reduced pressure, the residue was taken up into saturated aqueous NaHCO3 (10 mL) and was extracted with CH2C12 (20 mL x 3). The combined organic solution was dried (MgSO4), filtered and concentrated under reduced pressure.
Purification by flash column chromatography on silica (CH2C12/MeOH/NH40H, 9:1:0.05) gave the primary amine as a white foam (99.9 mg, 0.260 mmol, 75%). 1H NMR (CDC13) 8 1.29-1.52 (m, 4H), 1.61-1.77 (m, 1H), 1.79-1.94 (m, 111), 1.99-2.11 (m, 1H), 2.18-2.30 (m, 1H), 2.47-2.62 (m, 3H), 2.65-2.88 (m, 3H), 3.94-4.09 (m, 3H), 7.15 (d, 1H, J= 8.1 Hz), 7.19-7.23 (m, 2H), 7.38 (d, 1H, J= 8.1 Hz), 7.60-7.64 (m, 2H).

Preparation of COMPOUND 103:
[0620] To a solution of the amine (99.9 mg, 0.260 mmol) in glacial HOAc (1.5 mL) was added a saturated solution of HBr in HOAc (0.5 mL). The solution was stirred at room temperature for 30 minutes, then Et20 (5 mL) was added. The solvent was removed by pipette, the precipitate was washed with Et2O (2 mL x 2) and was then dissolved into MeOH

(2 mL). The mixture was stirred for about 5 minutes and the product was re-precipitated by the addition of Et20 (5 mL). The solvent was again removed by pipette and the precipitate was washed with Et2O (2 mL x 3). The product was dried under reduced pressure, giving COMPOUND 103 as a fine, off-white powder (156 mg, 0.240 mmol, 92%). 1H NMR
(D20) 8 1.67-2.00 (m, 511), 2.12-2.32 (m, 2H), 2.39-2.52 (m, 1H), 2.67-2.82 (m, 2H), 3.03 (t, 2H, J
= 7.4 Hz), 3.40-3.56 (m, 2H), 4.80-4.89 (m, 3H), 6.96 (d, 1H, J= 8.1 Hz), 7.35 (d, 1H, J=
8.1 Hz), 7.51-7.55 (m, 2H), 7.68-7.71 (m, 2H). 13C NMR (D20) 8 20.3, 21.1, 23.2, 24.6, 27.0, 39.3, 46.6, 54.1, 63.2, 114.9, 124.2, 126.9, 132.6, 134.5, 141.7, 144.4, 147.9, 150.2.
ES-MS m/z 384 (M+H), 386 (M+2+H). Anal. Calcd. for C21H26C1N5.3.1HBr=0.2C4H100: C, 40.31; H, 4.83; N, 10.78; Br 38.13. Found: C. 40.20; H, 4.91; N, 10.73; Br 38.44.

Example 104 CN

JN>N
N NH
H

COMPOUND 104: Preparation of 4-[(1H-Benzimidazol-2-ylmethyl -(5,6,7,8-tetrahydroquinolin-8-yl -amino]:piperidine-l-carboxamidine (hydrobromide salt) [0621] Using General Procedure B, [tert-butoxycarbonylimino-(4-oxo-piperidin-l-yl)-methyl]-carbamic acid tert-butyl ester (490 mg, 1.43 mmol), (5,6,7,8-tetrahydroquinolin-8-yl)-amine (210 mg, 1.43 mmol) and sodium triacetoxyborohydride (450 mg, 2.14 mmol) were stirred at room temperature in dichloromethane (4 mL) for 16 hours to yield, after work-up and column chromatography (2:0.5:97.5 McOH:NH4OH:CH2C12), {tent-butoxycarbonylimino-[4-(5,6,7, 8-tetrahydroquinolin-8-ylamino)-piperidin-1-yl]-methyl} -carbamic acid tert-butyl ester as a white solid (560 mg, 82%).
[0622] To a solution of the above secondary amine (560 mg, 1.18 mmol), 2-chloromethyl-benzimidazole-l-carboxylic acid tert-butyl ester (470 mg, 1.77 mmol), and potassium iodide (10 mg, 0.06 nimol) in anhydrous CH3CN (12 mL) was added diisopropylethylamine (0.41 mL, 2.35 mmol) and the reaction stirred at 40 C
for 16 hours.
The mixture was then concentrated under reduced pressure and the residue partitioned between CH2C12 (30 mL) and brine (15 mL). The organic phase was separated and the aqueous phase was extracted with CH2C12 (2 x 15 mL). The combined organic phases were then dried (Na2SO4), filtered, and concentrated under reduced pressure to give a crude residue that was purified by radial chromatography with silica gel (saturated NH3/Et2O). This gave 2- { [[l -(tert-butoxycarbonylimino-tert-butoxycarbonyliminomethyl)-piperidin-4-yl]-(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-methyl}-benzimidazole-l-carboxylic acid tert-butyl ester as a pale yellow oil (336 mg, 40%). 1H NMR (CDC13) 6 1.45 (s, 9H), 1.48 (s, 9H), 1.62 (br, 3H), 1.66 (s, 9H), 1.77 (m, 3H), 2.03 (m, 4H), 2.56 (m, 1H), 2.72 (m, 1H), 2.90 (br t, 2H, J= 12.0 Hz), 3.15 (br t, 1H), 4.22 (m, 1H), 4.34 (d, 1H, J= 15.0 Hz), 4.48 (d, 1H, J=
15.0 Hz), 6.85 (m, I H), 7.10 (d, 1H, J= 7.8 Hz), 7.24 (m, 2H), 7.64 (m, 1H), 7.75 (m, 1H), 8.31 (d, 1H, J
=5.4 Hz), 10.09 (s, 1H, NH).
[0623] Using General Procedure D: A portion of the above material (75 mg, 0.11 mmol) was converted to the hydrobromide salt to provide COMPOUND 104 (58 mg) as a white solid. 1H NMR (D20) 6 1.60 - 2.00 (m, 4H), 2.05 - 2.25 (m, 3H), 2.42 (m, 1H), 2.90 - 3.15 (m, 5H), 3.86 (m, 2H), 4.42 (d, 1H, J= 16.8 Hz), 4.53 (m, 1H), 4.56 (d, 1H, J=
16.8 Hz), 7.58 (m, 2H), 7.70 - 7.85 (m, 3H), 8.26 (d, 1H, J= 7.5 Hz), 8.54 (d, 1H, J=
5.4 Hz). 13C
NMR (D20) 8 20.69, 23.95, 27.54, 29.01, 30.59, 43.81, 45.51, 45.58, 58.32, 58.71, 114.24 (2C), 125.85, 127.01 (2C), 131.02, 139.19, 140.53 (2C), 148.02, 151.32, 151.75, 156.21. ES-MS m/z 404 (M+H). Anal. Calcd. for C23H29N7=3.OHBr=2.OH20: C, 40.49; H, 5.32;
N, 14.37;
Br, 35.13. Found: C, 40.57; H, 5.33; N, 14.15; Br, 35.25.

Example 105 (-NN

~N---/~NH2 HN N

COMPOUND 105: M-(lH-Benzoimidazol-2-yImpLh yl)-NI-(5,6,7,8-tetrahydroquinoxalin-5-yl)-butane-1,4-diamine.

Preparation of 5-bromo-5,6,7,8-tetrahydroquinoxaline:
[0624] To a solution of commercially available 5,6,7,8-tetrahydroquinoxaline (3.08 g, 23.0 mmol) in CC14 (200 mL) was added N-bromosuccinamide (4.09 g, 23.0 mmol) and a catalytic amount (56 mg) of benzoyl peroxide. The reaction mixture was heated at reflux for 17 hours. Saturated sodium bicarbonate solution was added (100 mL), the layers were separated and the aqueous phase was extracted with CH2C12 (2 x 200 mL). The organic extracts were dried and concentrated. The crude material contained 1:3:1 ratio (GC) of starting material, mono- and dibromo products which were separated by column chromatography on silica gel using a mixture of 1:1 EtOAc:hexanes to give 5-bromo-5,6,7,8-tetrahydroquinoxaline (3.03 g, 54%) as a brown liquid: 'H NMR (CDC13): 6 1.99-2.03 (m, 1H), 2.20-2.49 (m, 3H), 2.97-3.10 (m, 1H), 3.11-3.20 (m, 1H), 5.48 (t, 1H, J=
1.5 Hz), 8.40 (s, 2H). It should be noted that this material is unstable when exposed to air over 2-3 days and was used immediately in the next reaction.

Preparation of 5-azido-5,6,7,8-tetrahydroquinoxaline:
[0625] 5-Bromo-5,6,7,8-tetrahydroquinoxaline (2.75 g, 12.9 mmol) and sodium azide (1.68 g, 25.8 mmol) were dissolved in DMF (50 mL) under nitrogen atmosphere and the reaction mixture was warmed to 60 C for 2 days. The mixture was cooled to room temperature and poured over water (500 mL), and was extracted with CH2C12 (3 x 300 mL).
The organic extracts were washed with brine (2 x 200 mL), dried and concentrated in vacuo.
The crude material was purified by flash column chromatography on silica gel using 1:1 EtOAc/hexanes to afford 2.19 g (97%) of 5-azido-5,6,7,8-tetrahydroquinoxaline as a yellow liquid: 1H NMR (CDC13): 5 1.80-1.96 (m, 1H), 2.00-2.10 (m, 3H), 2.75-3.06 (m, 2H), 4.74 (t, 1H, J= 6.5 Hz), 8.44 (d, 1H, J= 3 Hz), 8.45 (d, 1H, J= 3 Hz); 13C NMR (CDC13):
618.6, 28.9, 31.7, 60.2, 142.6, 144.3, 150.3, 153.6.

Preparation of 5,6,7,8-tetrah droquinoxalin-5-ylamine.
[0626] A Parr shaker flask was charged with 5-azido-5,6,7,8-tetrahydroquinoxaline (1.81 g, 10.33 mmol) and 10% palladium on carbon (10 wt% of Pd/C; 0.18 g). The reaction vessel was evacuated and filled with nitrogen. Methanol (30 mL) was added and the reaction was hydrogenated at 30 psi for 40 minutes. The reaction mixture was flushed with nitrogen and filtered through a plug of Celite to provide 5,6,7,8-tetrahydroquinoxalin-5-ylamine as an orange liquid (1.54 g, 99%), which would rapidly turn dark brown. It was stored under an argon atmosphere at -20 C. 1H NIVIR (CDC13): 8 1.62-1.79 (m, 1H), 1.80-2.18 (m, 4H), 2.18-2.30 (m, 1H), 2.91-3.01 (in, 2H), 4.07 (dd, 1H, J= 8.4, 5.4 Hz), 8.32-8.38 (m, 2H); 13C NMR
(CDC13): 8 19.7, 31.7, 32.2, 51.5, 142.0, 142.5, 152.6, 155.4; MS in/z: 150 (M+H+), 133.

Preparation of 2-[4-(5,6,7,8-tetrahydro-quinoxalin-5-ylamino -butyl]-isoindole-1,3-dione:
[0627] To a solution of 5,6,7,8-tetrahydroquinoxalin-5-ylamine (313 mg, 2.09 mmol) in CH2C12 (20 mL) at room temperature under inert atmosphere was added 4-(1,3,-dioxo-1,3-dihydro-isoindol-2-yl)-butyraldehyde (227.8 mg, 1.05 mmol) followed by sodium triacetoxyborohydride (444 mg, 2.10 mmol). The reaction mixture was stirred at room temperature for 2 hours. Saturated sodium bicarbonate solution (10 mL) was added and the mixture was extracted with dichloromethane (3 x 20 mL). The combined organic extracts were washed with brine, dried (MgSO4), filtered and concentrated. The resultant material was purified by column chromatography on silica gel (10:1:0.5 CH2C12: MeOH:
NH4OH) to provide the product as a clear oil (298 mg, 81%): 1H NMR (CDC13): 8 1.56-1.66 (m, 2H), 1.70-1.95 (m, 4H), 2.04-2.22 (m, 4H), 2.71-2.85 (m, 2H), 2.87-3.05 (m, 2H), 7.69-7.73 (m, 2H), 7.80-7.85 (m, 2H), 8.34 (br s, 214).

Preparation of 2-{[[4-(l,3-dioxo-l,3-dihydro-isoindol-2-vl)-butyl]- 5 6 7 8-tetrahydroquinoxalin-5-yl)-aminol-methyl}-benzoimidazole-l-carboxylic acid tert-butyl ester.

[06281 To a solution of 2-[4-(5,6,7,8-tetrahydro-quinoxalin-5-ylamino)-butyl]-isoindole-1,3-dione (298 mg, 0.850 mmol) in CH3CN (12 mL) was added 2-chloromethyl-benzoimidazole-l-carboxylic acid tert-butyl ester (295 mg, 1.11 mmol), potassium iodide (14 mg), and diisopropylethylamine (0.296 ml, 1.70 mmol). The reaction mixture was stirred at 60 C for 17 hours. Saturated sodium bicarbonate (15 mL) was added and the mixture was extracted with CH2C12 (3 x 30 mL). The combined organic extracts were dried (MgSO4), filtered and concentrated. Purification of the crude material by column chromatography on silica gel (1:10 EtOAc:hexanes then EtOAc then 1:10 MeOH:EtOAc) provided the product as a clear oil (422 mg, 85%): 1H NMR (CDC13): 8 1.34-1.43 (m, 2H), 1.48-1.60 (m, 2H), 1.68 (s, 9H), 1.71-1.81 (m, 114), 1.88-1.97 (m, 111), 2.00-2.21 (m, 2H), 2.60-2.69 (m, 111), 2.76-2.93 (m, 3H), 3.55 (t, 2H, J= 6.9 Hz), 4.29 (dd, 1H, J= 9.6, 5.4 Hz), 4.46 (d, 1H, J= 15.3 Hz), 4.61 (d, 1H, J=15.3 Hz), 7.19-7.24 (m, 2H), 7.63-7.69 (m, 311), 7.74-7.81 (m, 3H), 8.18 (d, 1H, J= 2.1 Hz), 8.27 (d, 1H, J= 2.1 Hz).

Preparation of Nl-(1H-Benzoimidazol-2- l~yl)-N1-(5,6,? 8-tetrahydroc[uinoxalin-5-yl)-butane-l,4-diamine (COMPOUND 105).
[0629] To a solution of 2-{[[4-(1,3-dioxo-l,3-dihydro-isoindol-2-yl)-butyl]-(5,6,7,8-tetrahydroquinoxalin-5-yl)-amino]-methyl}-benzoimidazole-l-carboxylic acid tert-butyl ester (420 mg, 0.723 mmol) in ethanol (20 mL) at room temperature was added hydrazine hydrate (0.20 mL). The mixture was stirred for 17 hours. The mixture was concentrated in vaccuo and the resultant material was purified by column chromatography on silica gel (1:1:10 MeOH: NH4OH: CH2C12) to provide COMPOUND 105 as a colourless foam (161 mg, 64%): 1H NMR (CDC13) 8 1.37-1.48 (m, 5H), 1.70-1.79 (m, 1H), 1.81-1.97 (m, 1H), 2.07-2.16 (m, 1H), 2.18-2.31 (m, 1H), 2.49-2.59 (m, 4H), 2.71-2.78 (m, 1H), 2.90-3.08 (m, 211), 3.98 (d, 1H, J= 16.5 Hz), 4.07 (d, 1H, J=16.5 Hz), 4.06-4.12 (m, 1H), 7.18-7.21 (m, 2H), 7.57-7.59 (m, 2H), 8.41 (s, 1H), 8.54 (s, 1H); 13C NMR (CDC13) 8 21.2, 22.9, 26.3, 30.5, 32.6, 41.7, 49.8, 51.4, 62.0, 122.3, 142.1, 143.3, 153.8,155.4,155.5; ES-MS
m/z 351 (M+H).

Anal. Calcd. for C20H26N6Ø3CH2C12Ø2H2O: C 64.24, H 7.17, N 22.14. Found: C
64.16, H
7.41, N 22.15.

Example 106 (\ O
N
-(d C N --"-/NH2' N
H
COMPOUND 106: Preparation of Nl-(1H-Benzimidazol-2- lmethyl7 Nl-(3 4-dihydro-pyrano[3,2-blpyridin-4-yl)-butane-1,4-diamine (hydrobromide) [0630] To a solution of triphenylphosphine (10.9 g, 41.5 mmol), 3-buten-ol,(2.49 g, 34.6 mmol) and 2-bromo-3-pyridinol (6.01 g, 34.6 mmol) in THE (200 mL) at 0 C was added diisopropyl azodicarboxylate (7.49 mL, 38.0-mmol) very slowly. Ice bath was removed after addition of diisopropyl azodicarboxylate and the mixture was allowed to stir at 50 C for 20 hours under argon. The reaction mixture was diluted with EtOAc (300 mL), and washed with sat. NaHCO3 (2 x 150 mL), brine (2 x 150 mL) and dried over Na2SO4.
Evaporation of the solvent and purification of the residue by flash chromatography on silica gel (Hexanes/EtOAc, 90:10 followed by 85:15) afforded 2-bromo-3-but-3-enyloxy-pyridine (7.04 g, 89 %) as a colourless oil. 1H NMR (CDC13) & 2.58 - 2.66 (m, 2H), 4.08 (t, 211, J=
6.9 Hz), 5.13 - 5.24 (m, 2H), 5.87 - 5.98 (m, I H), 7.10 - 7.14 (m, 111), 7.18 - 7.22 (m,. 1H), 7.97 (dd, 1H, J= 6.0, 1.5 Hz).
[0631] An anhydrous DMF solution (120 mL) of 2-bromo-3-but-3-enyloxy-pyridine (6.43 g, 28.2 mmol) in a round bottom Schlenk flask was degassed with argon using the freeze/pump/thaw method. To this freshly degassed solution was added triphenylphosphine (2.66 g, 10.2 mmol), palladium acetate (696 mg, 3.10 mmol), potassium acetate (13.84 g, 141 mmol), and tetraethylammoniumchloride hydrate (9.35 g, 56.4 mmol). The resultant mixture was heated at 110 C under argon for 18 hours. The reaction mixture was cooled to room temperature and diluted with EtOAc (300 mL), brine (120 mL) and H2O (60 mL).
The organic phase was separated and washed with brine (3 x 120 mL) and dried over Na2SO4.
Evaporation of the solvent and purification of the residue by flash chromatograph on silica gel (Hexanes/EtOAc, 95:5) afforded 4-methylene-3,4-dihydro-2H-pyrano[3,2-b]pyridine (2.8 g, 67 %) as a white solid. 1H NMR (CDC13) 8 2.79 - 2.86 (m, 211), 4.25 (t, 2H, J= 5.7 Hz), 5.08 (d, 1H, J= 1.6 Hz), 6.19 (d, 1H, J= 1.6 Hz), 7.08 - 7.17 (m, 2H), 8.20 (dd, 1H, J= 4.7, 1.6 Hz).
[0632] To a solution of 4-methylene-3,4-dihy, dro-2H-pyrano[3,2-b]pyridine (2.77 g, 18.8 mmol) and 4-methylmorpholine N-oxide (6.61g, 56.5 mmol) in CH2C12 (45 mL) was added osmium tetroxide (2.5 wt. % solution in 2-methyl-2-propanol, 6.8 ML, 0.68 mmol). The resultant mixture was stirred at room temperature under N2 for 80 hours, diluted with EtOAc (300 mL), and then filtered through a pad of celite. Evaporation of the solvent and purification of the residue by flash chromatograph on silica gel (CH2C121MeOH/NH4OH, 95:4:1) afforded the 4-hydroxymethyl-3,4-dihydro-2H-pyrano[3,2-b]pyridinyl-4-ol (2.13 g, 62 %) as a yellow solid.
[0633] To a solution of 4-hydroxymethyl-3,4-dihydro-2H-pyrano[3,2-b]pyridinyl-4-ol (2.13 g, 11.8 mmol) in H2O (15 mL) was added sodium periodate (5.03 g, 23.5 mmol) and the mixture was allowed to stir at room temperature for 2 hours. The mixture was diluted with EtOAc (100 mL) and H2O (20 mL) and stirred vigorously, for 10 minutes.
The aqueous phase was separated and extracted with CH2C12 (2 x 50 mL). The combined organic extracts were dried (Na2SO4), filtered and concentrated. Purification of the residue by flash chromatograph on silica gel (Hexanes/EtOAc, 60:40 followed by 0:100} gave 2,3-dihydro-pyrano[3,2-b]pyridin-4-one (1.28 g, 73 %) as a white solid. 1H NMR (CDC13) 8 2.98 (t, 2H, J= 6.6 Hz), 4.62 (t, 2H, J= 6.6 Hz), 7.36 - 7.44 (m, 2H), 8.44 (dd, 1H, J=
12.6, 2.1 Hz).
[0634] Reaction of 2,3-dihydro-pyrano[3,2-bjpyridin-4-one (277 mg, 1.85 mmol) with (4-amino-butyl)-carbamic acid text-butyl ester (269 mg, 1.43 mmol) using General Procedure B for reductive amination with NaBH(OAc)3 (605 mg, 2.86 mmol), followed by flash chromatography on silica gel (CH2C12/MeOH/NH4OH, 97:2:1 followed by 95:4:1) afforded [4-(3,4-dihydro-2H- pyrano[3,2-b]pyridin-4-ylamino)-butyl]-carbamic acid tent-butyl ester (330 mg, 72 %) as a pale yellow oil.
[0635] To a solution of [4-(3,4-dihydro-2H-pyrano[3,2-b]pyridin-4-ylamino)-butyl]-carbamic acid tent-butyl ester (329 mg, 1.02 mmol) in CH3CN (5 mL) was added N,N
diisopropylethylamine (0.28 mL, 1.63 mmol) followed by, 2-chloromethyl-benzimidazole-l-carboxylic acid teat-butyl ester (328 mg, 1.23 mmol) and potassium iodide (20 mg, 0.1 mmol). The resultant mixture was heated to 60 C for 16 hours then cooled to room temperature. The mixture was concentrated and the residue was partitioned between CH2C12 (25 mL) and saturated aqueous NaHCO3 (20 mL). The phases were separated and the aqueous phase was extracted with CH2C12 (2 x 15 mL). The combined organic extracts were dried (Na2SO4), filtered, and concentrated. Purification of the crude material by flash column chromatography on silica gel (CH2C12/MeOH/NH40H, 95:4:1) provided 2-{[(4-tert-butoxycarbonylamino-butyl)-(3,4-dihydro-2H-pyrano [3,2-b]pyridin-4-yl)-amino]-methyl} -benzimidazole-l-carboxylic acid tert-butyl ester (380 mg, 67%) as a white foam.
[0636] Using General Procedure D: Conversion of the white foam from above (107 mg, 0.19 mmol) to the hydrobromide salt followed by re-precipitation of the intermediate solid from methanol/ether gave COMPOUND 106 (110 mg, 90%) as a cream solid. 1H NMR
(D20) 61.43-1.66 (m, 4H), 2.38-2.50 (m, 2H), 2.53-2.63 (m, 1H), 2.78-2.92 (m, 3H), 4.33-4.43 (m, 1H), 4.43 (d, 1H, J= 17.4 Hz), 4.55 (d, 1H, J= 17.1 Hz), 4.64-4.78 (m, 2H), 7.57-7.63 (m, 2H), 7.76-7.87 (m, 3H), 7.98 (dd, 1H, J= 8.7, 0.9 Hz), 8.40 (dd, 1H, J= 5.4, 0.9 Hz); 13C NMR (CDC13) 6 19.72, 24.98, 25.32, 39.52, 47.95, 51.48, 56.53, 67.48, 114.28, 126.93,127.55,131.03,134.75,134.84,138.80,151.75,155.80; ES-MS in/z 352 (M+H).
Anal. Calcd. for C20H25N50.3.1HBr = 1.0 H20 . 0.2C4H100: C, 39.34; H, 5.09; N, 11.03;
Br, 39.00. Found: C, 39.29; H, 4.92; N, 10.96; Br, 39.02.

Example 107 O

NX NH
xHCI
COMPOUND 107: Preparation of N1-(1H-Benzimidazol-2- llmethyl) Nl-(S)-3,4-dihydro-2H-Ryrano[3,2-b]pyridin-4-yl-butane-1,4-diamine (hydrochloride salt).

Preparation of 4-methylene-3,4-dihydro-2H-pyrano[3,2-b]p irdine:
[0637] To a stirred 0 C solution of 2-bromo-3-pyridinol (14.7 g, 84 mmol), 3-buten-l-ol (7.25 mL, 84 mmol), and triphenylphosphine (26.5 g, 100 mmol) in THE (420 mL) was added DIAD (18.3 mL, 93 mmol) over 5 min. The mixture was heated to 50 C under a nitrogen atmosphere for 21 h, cooled to room temperature, and concentrated.
The resultant brown oil was dissolved in ethyl acetate (1 L), washed with saturated sodium bicarbonate solution (2 x 500 mL), washed with brine (2 x 500 mL), dried over Na2SO4, and concentrated. Purification of the crude material by column chromatography over silica gel (5:1 hexanes/EtOAc) provided the desired bromide (20.2 g, 100%) as a yellow oil.
[0638] A solution of the bromide (19.2 g, 84 mmol) from above in anhydrous DMF
(170 mL) was frozen under an argon atmosphere, and thawed while under high vacuum to degas the solution. This freeze-thaw cycle was repeated four times. A pressure-flask was purged with argon and charged with triphenylphosphine 7.96 g, 30 mmol), potassium acetate (41.4 g, 420 mmol), tetraethylammonium chloride hydrate (27.9 g, 170 mmol), palladium (II) acetate (2.08 g, 9.3 mmol), and the degassed solution from above. The flask was evacuated and back-filled with argon four times, sealed, and heated to 110 C with stirring for 39 h. The mixture was cooled to room temperature, diluted with ethyl acetate (1 L) and stirred with a mixture of brine (500 mL) and water (200 mL) for 30 min. The layers were separated and the organic layer was washed with saturated sodium bicarbonate solution (500 mL) and brine (3 x 500 mL). The organic layer was dried over Na2SO4, concentrated, and dried under high vacuum for 1 h. Purification of the crude material (25 g) by column chromatography on silica gel (200:1 CH2C12/MeOH) provided the title compound (5.9 g, 47%) as a yellow oil.
1H NMR (CDC13) 6 2.80-2.85 (m, 2H), 4.25 (t, 2H, J= 5.7 Hz), 5.08 (s, 1H), 6.20 (s, 1H), 7.08-7.17 (m, 2H), 8.20 (dd, 1H, J= 4.0, 1.8 Hz).

Preparation of (S)-(3 4-Dihydro-2H-pyrano[3 2-b]pyridin-4-yl)amine:
[0639] A solution of 4-methylene-3,4-dihydro-2H-pyrano[3,2-b]pyridine (5.9 g, 40 mmol), 4-methylmorpholine-N-oxide (14.0 g, 120 mmol), and osmium tetroxide (15.4 mL, 2.5 wt % in tert-butanol, 1.2 mmol) in dichloromethane (100 mL) was stirred at room temperature under a nitrogen atmosphere for 7 days. The mixture was diluted with diethyl ether (100 mL), filtered through diatomaceous earth, and concentrated.
Purification of the crude material by column chromatography over silica gel (25:1 CH2C12/MeOH) provided the diol (4.5 g, 62 %) as a brown oil.
[0640] To a stirred solution of the diol (4.5 g, 25 mmol) from above in deionized water (100 mL) was carefully added sodium periodate (10.7 g, 50 mmol)-exothermic-and stirring was continued for 1.5 h. The mixture was diluted with ethyl acetate (200 mL), stirred for 2 h, and the layers were separated. The aqueous layer was extracted with dichloromethane (2 x 50 mL). The organic layers were combined, dried over Na2S04, and concentrated to give the desired ketone (2.9 g, 78%) as an off-white solid.
[0641] A solution of the ketone (2.9 g, 19 mmol) from above and hydroxylamine hydrochloride (1.6 g, 23 mmol) in methanol (100 mL) was stirred at room temperature for 1 h. Saturated sodium bicarbonate solution (80 mL) was added and the mixture was concentrated on a rotary evaporator to remove the methanol. The resultant mixture was extracted with dichloromethane (1 x 200 mL, 3 x 75 mL) and 9:1 CHC13/MeOH
(5 x 200 mL). The organic layers were combined, dried over Na2SO4, and concentrated to give the oxime (3.0 g, 94%) as a brown solid.
[0642] Zinc dust was added slowly to a stirred 0 C suspension of oxime (3.0 g, 18 mmol) from above, ammonium acetate (1.6 g, 20 mmol), ammonium hydroxide (85 mL), and ethanol (16 mL). The cooling bath was removed and stirring was continued for 2.5 h. The slurry was filtered through celite and the filtrate was extracted with dichloromethane (3 x 150 mL). The organic extracts were combined, dried over MgSO4, concentrated, and dried under high vacuum to provide the racemic amine (2.6 g, 94%).
[0643] A stirred slurry of the amine (2.6 g, 17 mmol) and CAL (0.80 g) in ethyl acetate (65 mL) was heated to 40 C for 3 h. The mixture was cooled to room temperature, filtered, and concentrated. Purification of the crude material by column chromatography on silica (20:1 CH2C12/MeOH, then 20:1:1 CH2C12/MeOH/NH4OH) afforded the title compound (1.14 g, 88%) as a red-brown oil. 1H NMR (CDC13) 8 1.90-2.02 (m, 1H), 2.24-2.35 (in, 1H), 4.13 (t, 1H, J= 6.4 Hz), 4.18-4.36 (m, 2H), 7.06-7.13 (m, 2H), 8.17 (dd, 1H, J=
3.9, 2.2 Hz).

Preparation ofN1-(1H-Benzimidazol-2- llmethyl)-N1-(S)-3,4-dihvdro-2H-pyrano{3,2-blpyridin-4-yl-butane-1,4-diamine hydrochloride salt (COMPOUND 107):
[0644] A slurry of (S)-(3,4-dihydro-2H-pyrano[3,2-b}pyridin-4-yl)amine (1.14 g, 7.6 mmol) from above, 4-(1,3-dioxo-1,3-dihvdro-isoindol-2-yl)-butyraldehyde (1.57 g, 7.2 mmol), and potassium carbonate (1.00 g, 7.2 mmol) in THE (15 mL) was stirred at room temperature for 1 h. The mixture was filtered through a glass-fritted funnel and the filter cake was washed with THE (15 mL). The combined filtrate was treated with sodium triacetoxyborohydride (4.7 g, 22 mmol) and the mixture was stirred for 1 h.
The reaction was quenched with saturated sodium bicarbonate solution (150 mL) and stirred for 15 min. The layers were separated and the aqueous layer was extracted with dichloromethane (3 x 75 mL).
The combined organic layers were dried over Na2SO4 and concentrated.
Purification of the crude brown oil by column chromatography on silica gel (EtOAc) gave the desired secondary amine (2.25 g, 89%) as a white solid.
[0645] A slurry of the amine (2.25 g, 6.4 mmol) from above, N-boc-2-chloromethyl-benzimidazole (1.87 g, 7.0 mmol), diisopropylethylamine (1.8 mL, 10 mmol), potassium iodide (50 mg, 0.3 mmol), and acetonitrile (65 mL) was stirred at 50 C under a nitrogen atmosphere for 40 h. The mixture was cooled to room temperature and concentrated. The resultant residue was dissolved in dichloromethane (75 mL), washed with saturated sodium bicarbonate solution (3 x 50 mL), and washed with brine (50 mL). The organic layer was dried over Na2SO4 and concentrated. Purification of the crude material by repetitive column chromatography on silica (first column: EtOAc, second column: 30:1 CH2C12/MeOH) provided the desired protected amine (2.97 g, 80%) as a pale yellow foamy solid.
[0646] To a stirred solution of the protected amine (2.97 g, 5.1 mmol) from above in ethanol (50 mL) was added hydrazine hydrate (2.5 mL, 50 mmol) and stirring was continued at room temperature for 66 h. The mixture was diluted with diethyl ether (50 mL). The resultant white slurry was filtered and concentrated. Purification of the crude material by column chromatography on silica gel (20:1:1 CH2C12/MeOH/NH4OH) gave the desired amine (1.80 g, 100%) as a white foamy solid.

[0647] Following General Procedure D: Conversion of the free base (1.80 g, 5.1 mmol) from above to the hydrochloride salt gave COMPOUND 107 (2.14 g, 82%) as a white solid.
1H NMR (D20) 5 1.49-1.60 (m, 4H), 2.39-2.49 (m, 2H), 2.52-2.63 (m, 1H), 2.78-2.91 (m, 3H), 4.32-4.42 (m, 1H), 4.48 (q, 2H, J= 17.2 Hz), 4.65-4.72 (m, 2H), 7.56-7.7.63 (m, 2H), 7.76-7.85 (m, 3H), 7.97 (dd, 111, J= 8.7, 1.2 Hz), 8.39 (dd, 1H, J= 5.7, 1.2 Hz); 13C NMR
(D20) 6 19.74, 24.95, 25.27, 39.48, 47.87, 51.46, 56.51, 67.41, 114.25(2), 126.92(2), 127.50, 131.04,134.66,134.82,138.84,151.77,155.74; ES-MS m/z 352 (M+H). Anal. Calcd.
for C2oH25N50.3.OHC1.2.5H20Ø1(C2H5)20: C, 47.74; H, 6.68; N, 13.64; Cl, 20.72.
Found: C, 47.74; H, 6.94; N, 13.33; Cl, 20.75.
[0648] The enantiomeric purity of COMPOUND 107 was determined to be 100% ee by chiral HPLC using the following conditions: Instrument: Hewlett Packard 1100 HPLC
(VWD1); Column: ChiralCel OD, 0.46 cm x 25 cm; Mobile Phases: A: 90:5:5 hexanes/reagent alcohol/methanol with 0.1 % DEA, B: hexanes; Isocratic: 80% A, 20%B;
Total Run Time: 25 min; Flow Rate: 1.0 mL/min; Temperature: 40 C; Detector:
UV @ 270 nm; Injection volume: 10 L.

[0649] Retention time of the S enantiomer = 12.0 min.
[0650] Retention time of the R enantiomer = 15.2 min.

Example 108 ~N"- ~ NH2 HN N

COMPOUND 108: N1-(1H-Benzoimidazol-2- 1~yl)-N1-(2-methyl-5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine (hydrobromide salt).
Preparation of N-(2-methyl-5,6,7,8-tetrahydroquinolin-8-yl)acetamide:
[0651] To a 3-neck, 500 mL round bottom flask containing a stir bar was added 2-methyl-8-acetamidoquinoline (5.69 g, 28.4 mmol) and platinum(IV) oxide (322 mg, mol%). The flask was equipped with two Teflon cannulae: one for purging of the reaction flask with nitrogen gas and introduction of hydrogen, and the other leading to a flask connected to a bubbler. Trifluoroacetic acid (100 mL) was added to the reaction flask under an atmosphere of nitrogen. The stirred reaction mixture was flushed with nitrogen gas and warmed to 60 C. Hydrogen gas was bubbled through the stirred reaction for 3 h.
The progress of the reaction was monitored by GC and/or TLC. The reaction mixture was cooled to room temperature, purged with nitrogen gas and the catalyst was filtered through a pad of Celite and washed with CH2C12 (100 mL). The solvent was removed in vacuo and the residue was basified with saturated NaOH (pH >14). The mixture was then extracted with CHCl3 (3 x 250 mL). The organic extracts were dried (MgSO4), filtered and concentrated.
The crude material was purified by flash chromatography using 10% MeOH in EtOAc to provide the product (3.83 g, 66%) as a white solid. 1H NMR 6 1.57-1.66 (m, 1H), 1.77-1.86 (m, 2H), 2.02 (s, 3H), 2.44 (s, 3H), 2.43-2.57 (m, 1H), 2.68-2.73 (m, 2H), 4.67-4.74 (m, 1H), 6.79 (br s, 1H), 6.92 (d, 1H, J= 8 Hz), 7.24 (d, 1H, J= 8 Hz); 13C NMR 8 21.6, 25.4, 25.8, 29.6, 31.0, 53.0, 123.4, 131.4, 139.2, 155.9, 157.2, 172.2; ES-MS m/z: 227 (M+Na+).

Preparation of 2-methyl-5,6,7,8-tetrahydroquinolin-8-ylamine:
[0652] N-(2-Methyl-5,6,7,8-tetrahydroquinolin-8-yl)acetamide (4.51 g, 22.1 mmol) was dissolved in 6 N HCl (40 mL). The mixture was heated at reflux for 17 h. The reaction mixture was cooled to room temperature, basified with saturated NaOH (pH>14) and extracted with chloroform (5 x 100 mL). The organic extracts were dried (MgSO4) and concentrated. The crude material was purified by distillation (bp 102-104 C at 0.20 mm Hg) to yield the product as a clear liquid (3.25 g, 99%). 'H NMR (CDC13, 300 MHz) S 1.62-1.82 (m, 2H), 1.84-2.00 (m, 3H), 2.11-2.20 (m, 1H), 2.49 (s, 3H), 2.61-2.82 (m, 2H), 3.93-4.00 (m, 1H), 6.91 (d, 1H, J= 7.8 Hz), 7.25 (d, 1H, J= 7.8 Hz); 13C NMR (CDC13) S
20.4, 24.6, 29.1, 32.6, 51.8, 121.7, 128.6, 137.6, 155.9, 159.0; ES-MS na/z: 163 (M+H+), 146 (M-NH2).

Preparation of 2-f 4-(2-methyl-5 6 7 8-tetrahydroquinolin-8-ylamino -butyll-isoindole-1,3-dione.

[0653] To a solution of 2-methyl-5,6,7,8-tetrahydroquinolin-8-ylamine (237 mg, 1.46 mmol) in CH2C12 (20 mL) at room temperature under inert atmosphere was added 4-(1,3,-dioxo-1,3-dihydro-isoindol-2-yl)-butyraldehyde (159 mg, 0.731 mmol) followed by sodium triacetoxyborohydride (309 mg, 2.92 mmol). The reaction mixture was.
stirred at room temperature for 2 hours. Saturated sodium bicarbonate solution (10 mL) was added and the mixture was extracted with dichloromethane (3 x 20 mL). The combined organic extracts were washed with brine, dried (MgSO4), filtered and concentrated. The resultant material was purified by column chromatography on silica gel (10:1:0.5 CH2C12: MeOH:
NH4OH) to provide the product as a yellow oil (210 mg, 79%): 1H NMR (CDC13): S 1.56-1.83 (m, 6H), 1.90-2.04 (m, 2H), 2.04-2.18 (m, 2H), 2.47 (s, 3H), 2.64-2.80 (m, 4H), 3.70-3.76 (m, 3H), 6.90 (d, 111, J= 7.8 Hz), 7.24 (d, 1H, J= 7.8 Hz), 7.69-7.73 (m, 2H), 7.81-7.85 (m, 2H).

Preparation of 2-{[[4-(1,3-dioxo-1,3-dihydro-isoindol-2-yll -butyl]-(2-methyl-tetrahydroguinolin-8-yl)-aminol-methyl}-benzoimidazole-l-carboxylic acid tert-butyl ester.
[0654] To a solution of 2-[4-(2-methyl-5,6,7,8-tetrahydroquinolin-8-ylamino)-butyl]-isoindole-1,3-dione (210 mg, 0.578 mmol) in,CH3CN (12 mL) was added 2-chloromethyl-benzoimidazole-1-carboxylic acid tent-butyl ester (200 mg, 0.751 mmol), potassium iodide (14 mg), and diisopropylethylamine (0.201 ml, 1.16 mmol). The reaction mixture was stirred at 60 C for 17 hours. Saturated sodium bicarbonate (15 mL) was added and the mixture was extracted with CH2C12 (3 x 30 mL). The combined organic extracts were dried (MgSO4), filtered and concentrated. Purification of the crude material by column chromatography on silica gel (1:10 EtOAc:hexanes then EtOAc then 1:10 MeOH:EtOAc) provided the product as a clear oil (228 mg, 66%): 1H NMR (CDC13): 6 1.23-1.31 (m, 2H), 1.46-1.58 (m, 2H), 1.63-1.73 (m, 1H), 1.68 (s, 9H), 1.73-1.85 (m, 1H), 1.89-1.98 (m, 1H), 2.10-2.18 (m, 1H), 2.40 (s, 3H), 2.60-2.83 (m, 5H), 3.50 (t, 2H, J= 7.2Hz), 4.20 (dd, 1H, J= 9.6, 6.0 Hz), 4.50 (d, 1H, J

15.6 Hz), 4.72 (d, 1H, J=15.6 Hz), 6.79 (d, 1H, J= 7.5 Hz), 7.14 (d, 1H, J=
7.5 Hz), 7.19-7.24 (m, 2H), 7.63-7.69 (m, 3H), 7.74-7.81 (m, 3H).

Preparation of N' -(1H-Benzoimidazol-2-ylmethyl)-N' -(2-methyl-5 6 7 8-tetrahydroguinolin-8-yl)-butane-1 4-diamine.

[0655) To a solution of 2-{[[4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyl]-(2-methyl-5,6,7,8-tetrahydroquinolin-8-yl)-amino}-methyl}-benzoimidazole-l-carboxylic acid tert-butyl ester (228 mg, 0.384 mmol) in ethanol (10 mL) at room temperature was added hydrazine hydrate (0.10 mL). The mixture was stirred for 4 days. The mixture was concentrated in vacuo and the resultant material was purified by column chromatography on silica gel (1:1:10 MeOH: NH4OH: CH2C12) to provide the product as a colourless oil (82 mg, 59%):

(CDCl3) 61.25-1.45 (m, 4H), 1.60-1.70 (m, 1H), 1.81-1.93 (m, 1H}, 1.97-2.04 (m, 1H), 2.10-2.18 (m, 1H), 2.46-2.56 (m, 3H), 2.62-2.82 (m, 6H), 3.95-3.99 (m, 1H), 4.00 (d, 1H, J=17'.1 Hz), 4.09 (d, 1H, J= 17.1 Hz), 6.98 (d, 1H, J= 7.8 Hz), 7.15-7.21 (m, 2H), 7.30 (d, 1H, J=
7.8 Hz), 7.57-7.60 (m, 2H).

Preparation of Nl-(1H-benzoimidazol-2-ylmethyl)-N~2-methyl-5 6 7 8-tetrahydroguinolin-8-yl)-butane-1,4-diamine (hydrobromide salt) (COMPOUND 108 [06561 To a solution ofNl-(1H-benzoimidazol-2-ylmethyl)-NI-(2-methyl-5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine (82 mg, 0.23 mmol) in glacial acetic acid (0.5 mL) was added HBr saturated acetic acid (1 mL). The reaction mixture was stirred for minutes, then diethyl ether was added (50 mL). The white precipitate was allowed to settle and the solvent was removed with a pipette. Et20 (50 mL) was again added then decanted. The resulting precipitate was dissolved in methanol (1.5 mL), ether was added (3 x 50 mL) then it was removed with a pipette. The resultant yellow powder was dried under reduced pressure to give 113 mg (76%) of the product: 1H NMR (D20) S 1.48-1.63 (m, 4H), 1.65-1.78 (m, 1H), 1.82-2.01 (m, 1H), 2.02-2.15 (m, 1H), 2.25-2.31 (m, 1H), 2.50-2.63 (m, 1H), 2.67-2.78 (m, 4H), 2.78-3.00 (m, 4H), 4.39 (d, 1H, J= 16.8 Hz), 4.49 (d, 1H, J= 16.8 Hz), 7.52-7.64 (m, 3H), 7.70-7.79 (m, 2H), &.13 (d, 1H, J= 7.8 Hz); 13C NMR
(D20) S 19.7, 20.3, 20.5, 25.1, 27.4, 39.6, 47.7, 51.8, 60.1, 114.3, 126.9, 130.9, 137.6, 147.8, 150.0, 151.7, 152.8; ES-MS m/z 365 (M+H). Anal. Calcd. for C17H22N4.3.OHBr= 2.3H20: C 40.80, H 5.70, N 10.81, Br 37.01. Found: C 40.78, H 5.82, N 10.54, Br 37.09.

Example 109 CI /
'N)-CLNI
C
HN"N O

COMPOUND 109: Preparation of (3-{[(1H-Benzimidazol-2-vlmethvl)-(5 6 7 8-tetrahydro-quinolin-8-yl)-amino]-methyll:pyrrolidin-1-v1)-(3 5-dichloro-pyridin-4-yl)-methanone Preparation of carbonic acid 1-benzyl-pyrrolidin-3-vlmethvl ester vinyl ester:
O

OA O--""CN

[0657] A solution of (1-benzyl-pyrrolidin-3-yl)-methanol (prepared as described by.
Wu, Y.-H., et al., Pyrrolidines 1(1961) 26:1519-1524) (455 mg, 2.38 mmol) and vinyl chloroformate (0.40 mL, 4.7 mmol) in 1,2-dichloroethane (10 mL) was heated to reflux for 2 h then concentrated in vacuo. Purification of the crude material by column chromatography on silica gel (5% MeOH/CH2CI2) gave a yellow oil (440 mg, 71%). 1H NMR (CDC13) 8 1.84 (m, 1H), 2.26 (m, 1H), 3.03 (m, 5H), 4.01 (br s, 2H), 4.23 (m, 2H)', 4.61 (dd, 1H, J= 6.2, 2.3 Hz), 4.93 (dd, 1H, J=14, 2.1 Hz), 7.06 (dd, 1H, J=14, 6.3 Hz), 7.41 (m, 3H), 7.53 (m, 2H).

Preparation of 3-vinyloxycarbonyloxymethyl-pyrrolidine-l-carboxylic acid vinyl ester:
O
O
O
'~"CN-~
O
[0658] A solution of carbonic acid 1-benzyl-pyrrolidin-3-ylmethyl ester vinyl ester (440 mg, 1.68 mmol) and vinyl chloroformate (0.30 mL, 3.5 mmol) in 1,2-dichloroethane (10 mL) was heated to reflux for 6 h then concentrated in vacuo. Purification of the crude material by column chromatography on silica gel (20% EtOAc/hexanes) gave a yellow oil (335 mg, 83%). 1H NMR (CDC13) 8 1.68-1.85 (m, 1H), 2.03-2.16 (m,-1H), 2.59-2.71 (m, 1H), 3.26 (m, 1H), 3.41-3.52 (in, 1H), 3.55-3.72 (m, 2H), 4.11-4.28 (m, 2H), 4.45 (dd, 1H, J= 6.3, 1.5 Hz), 4.61 (m, 1H), 4.78 (dd, 1H, J= 14, 1.5 Hz), 4.94 (m, 1H), 7.08 (m, 1H), 7.22 (dd, 1H, J
=14,6.3Hz).

Preparation of carbonic acid pyrrolidin-3- lmethyl ester vinyl ester hydrochloride:
O
HCI
O""'CNH

[0659] 3-Vinyloxycarbonyloxymethyl-pyrrolidine-l-carboxylic acid vinyl ester (335 mg, 1.39 mmol) was dissolved in CH2CI2 (10 mL), and HCI(g) was passed through the solution for 2 minutes then the solution was concentrated in vacuo. The residue was dissolved in MeOH (10 mL) and heated to reflux for 15 minutes then concentrated in vacuo to give a colourless oil (284 mg, 99%). 1H NMR (CD3OD) 81.78-1.91 (m, 1H), 2.17-2.28 (m, 1H), 2.79 (m, 1H), 3.09 (dd, 1H, J= 12, 7.8 Hz), 3.25-3.51 (m, 3H), 4.19-4.33 (m, 2H), 4.62 (dd, IH, J= 6.2, 2.0 Hz), 4.89 (m, 1H), 7.11 (dd, 111, J= 14, 6.0 Hz).

Preparation of (3 5-dichloro-p)ddin-4-yl)-(3-h ddroxymethyl-pyrrolidin-1-yl) methanone:

-N
CI

HON O CI

[0660] To a suspension of 3,5-dichloroisonicotinic acid (267 mg, 1.39 mmol) in (7.0 mL) was added DMF (cat.) and oxalyl chloride (0.49 mL, 5.6 nunol), and the mixture was stirred at room temperature for 2.5 h then concentrated in vacuo. To the residue was added THE (4 mL), Et3N (0.58 mL, 4.2 mmol), and a solution of carbonic acid pyrrolidin-3-ylmethyl ester vinyl ester hydrochloride (284 mg, 1.37 mmol) in THE (3 inL), and the mixture was stirred at room temperature for 21 h. The mixture was diluted with CH2C12 (50 mL) and brine (30 mL) and the phases were separated. The organic layer was washed with brine (2 x 50 mL) and saturated NaHCO3 (2 x 50 mL). The organic layer was dried (MgSO4), filtered, concentrated, and dried in vacuo to afford a yellow oil (315 mg).

[0661] To a solution of the crude amide from above (315 mg) in MeOH (10 mL) was added 10 N NaOH(aq) (1.0 mL, 10 mmol), and the solution was stirred at room temperature for 30 minutes. Water (15 mL) was added, the mixture was extracted with CH2Cl2 (4 x 15 mL), and the combined organic extracts were dried (MgSO4) and concentrated in vacuo.
Purification of the crude material by column chromatography on silica gel (100:5:1 CH2C12/MeOH/NH4OH) gave a yellow oil (mixture of isomers) (172 mg, 46%). 1H
NMR
(CDC13) S 1.44-4.24 (m, 1OH), 8.54 (s, 2H).

Preparation of 3 5-dichloro-pyridin-4-yl)-d3-[(S)-(5 6 7 8-tetrahydro-quinolin-ylamino)-methyll-pyrrolidin-l -yl }-methanone:

CN-!Q
NNCN O CI

[0662] To a solution of (3,5-dichloro-pyridin-4-yl)-(3-hydroxymethyl-pyrrolidin-l-yl)-methanone (172 mg, 0.625 mmol) in CH2Cl2 (6.3 mL) was added Dess-Martin periodinane (278 mg, 0.655 mmol) at room temperature. After stirring at room temperature for 40 minutes, the mixture was washed with 1. N NaOH(aq) (2 x 10 mL) then dried (MgSO4) and concentrated in vacuo to give a yellow oil (163 mg, 95%).
[0663] Using General Procedure A: To a stirred solution of the aldehyde from above (163 mg, 0.597 mmol) and 5,6,7,8-tetrahydro-quinolin-8-ylamine (106 mg, 0.715 mmol) in 4:1 McOH/trimethyl orthoformate (6.0 mL) was added NaBH3CN (150 mg, 2.39 mmol), and the mixture was heated to 60 C for 15 h. Purification of the crude material by column chromatography on silica gel (150:5:1 CH2C12/MeOH/NH4OH) gave a yellow oil (mixture of isomers) (86 mg, 36%). 1H NMR (CDC13) 6 1.57-3.96 (m, 16H), 7.06 (m, 1H), 7.37 (m, 1H), 8.36 (m, 1H), 8.51 (m, 2H).
[0664] A mixture of (3,5-dichloro-pyridin-4-yl)-{3-[(5,6,7,8-tetrahydro-quinolin-8-ylamino)-methyl]-pyrrolidin-l-yl}-methanone (85 mg, 0.21 mmol), 2-chloromethyl-benzimidazole-l-carboxylic acid tert-butyl ester (84 mg, 0.31 mmol), potassium iodide (2 mg, 0.01 mmol), and N,N-diisopropylethylamine (0.073 mL, 0.42 mmol) in acetonitrile (4.2 mL) was heated at 60 C for 24 h. Saturated NaHCO3(aq) (10 mL) was added, and the mixture was extracted with CH2Cl2 (3 x 12 mL). The combined organic extracts were dried (MgSO4) and concentrated in vacuo. Purification of the crude material by column chromatography on silica gel (300:5:1 CH2C12/MeOH/NH4OH) gave a yellow oil (124 mg).

[0665] A solution of the amine from above (124 mg) in 1:1 TFA/CH2C12 (4 mL) was stirred at room temperature for 1 h then concentrated in vacuo. The residue was dissolved in CH2Cl2 (15 mL) and washed with 1 N NaOH(aq) (10 mL). The aqueous phase was extracted with CH2Cl2 (2 x 10 mL), and the combined organic extracts were dried (MgSO4) and concentrated in vacuo to afford COMPOUND 109 as a yellow foam (mixture of isomers) (94 mg, 84%). 1H NMR (CDC13) 5 1.09-4.27 (m, 18H), 7.12-7.25 (m, 3H), 7.43-7.61 (m, 3H), 8.11-8.73 (m, 3H); 13C NMR (CDC13) S 21.37, 23.37, 23.73, 27.80, 28.27, 28.71, 29.16, 36.35, 37.82, 38.65, 44.13, 45.13, 45.41, 45.77, 49.18, 49.44, 49.62, 50.06, 50.50, 52.37, 52.89, 53.12, 53.45, 61.92, 62.01, 62.38, 62.55, 121.80, 122.37, 122.55, 122.65, 128.04, 128.41, 134.35, 134.67, 134.90, 137.41, 137.59, 137.70, 142.99, 146.05, 146.59, 147.44, 147.68, 147.77, 155.73, 155.86, 156.56, 157.01, 161.03, 161.31. ES-MS m/z 536 (M+H).
Anal. Calcd. for C28H28N6C12OØ1 CH2C12.1.1H20=0.1 C6H14: C, 60.22; H, 5.60;
N, 14.68;
Cl, 13.63. Found: C, 60.11; H, 5.39; N, 14.42; Cl, 13.85.

Example 110 N

N
H N
'--~~NH2 HN N

6COMPOUND 110: Nl-(1H-Benzoimidazol-2-ylmethyl -N1-(4,5,6,7-tetrahydro-3H-benzoimidazol-4-yl)-butane-1,4-diamine (hydrobromide salt).

Preparation of 4,5,6,7-tetrahydorbenzoimidazol-4-one:
[0666] Following a modified literature procedure (Hely. Chim. Acta (1979) 62:497), N204 was bubbled into a heterogeneous mixture of 1,3-cyclohexanedione (6.98 g, 62.3 mmol) (recrystallized from benzene) in dry diethyl ether (500 mL) at 0 C
for about 10 minutes. The mixture was warmed to room temperature and N204 was further bubbled until the reaction mixture became homogenous and orange in colour. The mixture was stirred for 0.5 hr. Excess N204 was removed by bubbling argon gas and the solvent was removed on roto-vap to provide a dark orange oil which rapidly turned black.

DEMANDE OU BREVET VOLUMINEUX

LA PRRSENTE PARTIE DE CETTE DEMANDE OU CE BREVET COMPREND
PLUS D'UN TOME.

NOTE : Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLICATIONS/PATENTS

THIS SECTION OF THE APPLICATION/PATENT CONTAINS MORE THAN ONE
VOLUME

NOTE: For additional volumes, please contact the Canadian Patent Office NOM DU FICHIER / FILE NAME:

NOTE POUR LE TOME / VOLUME NOTE:

Claims (39)

Claims
1. Use of a compound or a pharmaceutically acceptable salt of the compound, for mobilizing progenitor cells, stem cells or both into peripheral blood from bone marrow of a subject, wherein said compound is of formula IIIe or a stereoisomeric form thereof:
and wherein:
n4 is 2-4;

each R1 is independently H, halo, alkyl (C1-10), alkoxy (C1-10), or CF3;
each R2 is independently H or alkyl (C1-10);
R3 is H, alkyl (C1-10), alkenyl (C2-10), arylalkyl ("C"5-12-aryl-C1-4 alkyl), or aryl ("C"5-12);

each R4 is independently H or alkyl (C1-10), or the two R4 groups may be taken together with the ring to which they are attached to form an optionally substituted 6-membered aromatic or heteroaromatic ring; and each R6 is independently H, arylalkyl, acyl, arylacyl, or arylsulfonyl, wherein the aryl ("C"5-12) moieties thereof optionally contain one or more heteroatoms selected from the group consisting of O, S, and N.
2. Use of a compound or a pharmaceutically acceptable salt of the compound, to prepare a medicament for mobilizing progenitor cells, stem cells or both into peripheral blood from bone marrow of a subject, wherein said compound is of formula IIIe or a stereoisomeric form thereof:
and wherein:
n4 is 2-4;

each R1 is independently H, halo, alkyl (C1-10), alkoxy (C1-10), or CF3;
each R2 is independently H or alkyl (C1-10);

R3 is H, alkyl (C1-10), alkenyl (C2-10), arylalkyl ("C"5-12-aryl-C1-4 alkyl), or aryl ("C"5-12);

each R4 is independently H or alkyl (C1-10), or the two R4 groups may be taken together with the ring to which they are attached to form an optionally substituted 6-membered aromatic or heteroaromatic ring; and each R6 is independently H, arylalkyl, acyl, arylacyl, or arylsulfonyl, wherein the aryl ("C"5-12) moieties thereof optionally contain one or more heteroatoms selected from the group consisting of O, S, and N.
3. The use of claim 1 or 2, wherein each R1 is H.
4. The use of claim 1, 2 or 3, wherein each R2 is H.
5. The use of any one of claims 1 to 4, wherein R3 is H.
6. The use of any one of claims 1 to 5, wherein the two R4 taken together with the ring to which they are attached form an optionally substituted phenyl ring.
7. The use of any one of claims 1 to 6, wherein each R6 is H.
8. The use of any one of claims 1 to 7, wherein the subject exhibits a hematopoietic deficit from chemotherapy or radiation therapy.
9. The use of any one of claims 1 to 7, wherein the subject has aplastic anemia, leukemia or drug-induced anemia.
10. The use of any one of claims 1 to 7, wherein the subject is a transplantation recipient.
11. The use of any one of claims 1 to 7, wherein the subject is a healthy stem cell donor.
12. The use of any one of claims 1 to 11, wherein said subject is a recipient of G-CSF.
13. The use of any one of claims 1 to 11, wherein the compound or pharmaceutically acceptable salt thereof is for administration with one or more of: G-CSF, granulocyte-macrophage colony stimulating factor (GM-CSF), Interleukin-1 (IL-1), Interleukin-3 (IL-3), Interleukin-8 (IL-8), PIXY-321 (GM-CSF/IL-3 fusion protein), macrophage inflammatory protein, stem cell factor, thrombopoietin, or growth related oncogene.
14. The use of any one of claims 1 to 13, wherein the compound is N1-(1H-Benzimidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine.
15. The use of any one of claims 1 to 13, wherein the compound is N1-(1H-Benzimidazol-2-ylmethyl)-N1-(S)-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine.
16. The use of any one of claims 1 to 15, wherein the pharmaceutically acceptable salt of the compound is a hydrobromide salt.
17. The use of any one of claims 1 to 15, wherein the pharmaceutically acceptable salt of the compound is a hydrochloride salt.
18. The use of any one of claims 1 to 17, wherein the compound or pharmaceutically acceptable salt thereof is for administration by an intravenous route, a subcutaneous route or an oral route.
19. The use of any one of claims 1 to 17, wherein the compound or pharmaceutically acceptable salt thereof is for administration by an oral route.
20. The use of any one of claims 1 to 19, wherein the compound or pharmaceutically acceptable salt thereof is for administration in a dosage range of about 0.1 µg/kg-5 mg/kg of body weight.
21. A pharmaceutical composition in unit dosage form comprising a pharmaceutically acceptable carrier and an effective amount of a compound or a pharmaceutically acceptable salt of the compound for mobilizing progenitor cells, stem cells or both into peripheral blood from bone marrow of a subject;
wherein said compound is of formula IIIe or a stereoisomeric form thereof:

wherein:

n4 is 2-4;
each R1 is independently H, halo, alkyl (C1-10), alkoxy (C1-10), or CF3;
each R2 is independently H or alkyl (C1-10);
R3 is H, alkyl (C1-10), alkenyl (C2-10), arylalkyl ("C"5-12-aryl-C1-4 alkyl), or aryl ("C"5-12);
each R4 is independently H or alkyl (C1-10), or the two R4 groups may be taken together with the ring to which they are attached to form an optionally substituted 6-membered aromatic or heteroaromatic ring; and each R6 is independently H, arylalkyl, acyl, arylacyl, or arylsulfonyl, wherein the aryl ("C"5-12) moieties thereof optionally contain one or more heteroatoms selected from the group consisting of O, S, and N.
22. The composition of claim 21, wherein each R1 is H.
23. The composition of claim 21 or 22, wherein each R2 is H.
24. The composition of claim 21, 22 or 23, wherein R3 is H.
25. The composition of any one of claims 21 to 24, wherein the two R4 taken together with the ring to which they are attached form an optionally substituted phenyl ring.
26. The composition of any one of claims 21 to 25, wherein each R6 is H.
27. The composition of any one of claims 21 to 26, wherein said subject is the recipient of G-CSF.
28. The composition of any one of claims 21 to 26, which further comprises one or more of G-CSF, granulocyte-macrophage colony stimulating factor (GM-CSF), Interleukin-1(IL-1), Interleukin-3(IL-3), Interleukin-8(IL-8), PIXY-321(GM-fusion protein), macrophage inflammatory protein, stem cell factor, thrombopoietin, or growth related oncogene.
29. The composition of any one of claims 21 to 28, wherein the compound is N1-(1H-Benzimidazol-2-ylmethyl)-N1-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine.
30. The composition of any one of claims 21 to 28, wherein the compound is N1-(1H-Benzimidazol-2-ylmethyl)-N'-(S)-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine.
31. The composition of any one of claims 21 to 30, wherein the pharmaceutically acceptable salt of the compound is a hydrobromide salt.
32. The composition of any one of claims 21 to 30, wherein the pharmaceutically acceptable salt of the compound is a hydrochloride salt.
33. The composition of any one of claims 21 to 32, adapted for administration by an intravenous route, a subcutaneous route or an oral route.
34. The composition of any one of claims 21 to 32, adapted for administration by an oral route.
35. The composition of any one of claims 21 to 34, wherein the unit dosage form is for providing the compound of formula IIIe in a dosage range of about 0.1 µg/kg-5 mg/kg of body weight.
36. Use of the composition of any one of claims 21 to 35 for mobilizing progenitor cells, stem cells or both into peripheral blood from bone marrow of said subject, wherein the subject exhibits a hematopoietic deficit from chemotherapy or radiation therapy.
37. Use of the composition of any one of claims 21 to 35 for mobilizing progenitor cells, stem cells or both into peripheral blood from bone marrow of said subject, wherein the subject has aplastic anemia, leukemia or drug-induced anemia.
38. Use of the composition of any one of claims 21 to 35 for mobilizing progenitor cells, stem cells or both into peripheral blood from bone marrow of said subject, wherein the subject is a transplantation recipient.
39. Use of the composition of any one of claims 21 to 35 for mobilizing progenitor cells, stem cells or both into peripheral blood from bone marrow of said subject, wherein the subject is a healthy stem cell donor.
CA2522535A 2003-05-23 2004-05-21 Chemokine receptor binding heterocyclic compounds with enhanced efficacy Expired - Lifetime CA2522535C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44617003A 2003-05-23 2003-05-23
US10/446,170 2003-05-23
US10/457,034 US7354932B2 (en) 2001-12-21 2003-06-06 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US10/457,034 2003-06-06
PCT/US2004/015977 WO2004106493A2 (en) 2003-05-23 2004-05-21 Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Publications (2)

Publication Number Publication Date
CA2522535A1 CA2522535A1 (en) 2004-12-09
CA2522535C true CA2522535C (en) 2011-11-29

Family

ID=33493026

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2522535A Expired - Lifetime CA2522535C (en) 2003-05-23 2004-05-21 Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Country Status (5)

Country Link
US (6) US7354932B2 (en)
EP (1) EP1628533A4 (en)
JP (1) JP2007502864A (en)
CA (1) CA2522535C (en)
WO (1) WO2004106493A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220409589A1 (en) * 2001-12-21 2022-12-29 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
WO2004092169A1 (en) * 2003-04-18 2004-10-28 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
RU2006136381A (en) * 2004-03-15 2008-04-27 Анормед, Инк. (Ca) METHOD FOR PRODUCING AN ANTAGONIST CXCR4
DE102004023506A1 (en) 2004-05-10 2005-12-01 Grünenthal GmbH Chain-extended substituted cyclohexyl-1,4-diamine derivatives
JP5135795B2 (en) * 2004-08-27 2013-02-06 小野薬品工業株式会社 COMPOUND CONTAINING BASIC GROUP AND USE THEREOF
TW200619206A (en) * 2004-09-29 2006-06-16 Anormed Inc Chemokine-binding heterocyclic compound salts, and methods of use thereof
UA87884C2 (en) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Potassium salt of an hiv integrase inhibitor
AU2006203826A1 (en) 2005-01-07 2006-07-13 Emory University CXCR4 antagonists for the treatment of HIV infection
US20090093454A1 (en) * 2005-03-04 2009-04-09 Kristjan Gudmundsson Chemical Compounds
WO2007008539A2 (en) * 2005-07-11 2007-01-18 Smithkline Beecham Corporation Pyranopyridine compounds
ES2407115T3 (en) 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compound containing a basic group and its use
ES2385924T3 (en) 2006-02-02 2012-08-03 Allergan, Inc. CXCR4 activity inhibitors for use in the treatment of eye disorders
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
JP5257068B2 (en) * 2006-05-16 2013-08-07 小野薬品工業株式会社 Compound containing acidic group which may be protected and use thereof
WO2008008854A2 (en) 2006-07-11 2008-01-17 Emory University Cxcr4 antagonists including diazine and triazine structures for the treatment of medical disorders
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
EP2262808B1 (en) * 2008-03-28 2013-08-14 Altiris Therapeutics Chemokine receptor modulators
US8916605B2 (en) 2009-03-02 2014-12-23 William G. Tucker Compounds and methods for treating cancer and viral infections
NZ609448A (en) 2010-12-16 2015-07-31 Hoffmann La Roche Tricyclic pi3k inhibitor compounds and methods of use
KR20130116358A (en) 2011-02-09 2013-10-23 에프. 호프만-라 로슈 아게 Heterocyclic compounds as pi3 kinase inhibitors
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10953003B2 (en) 2015-12-14 2021-03-23 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017112894A1 (en) 2015-12-22 2017-06-29 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CA3027498A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CA3027495A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
EP3727381A4 (en) * 2017-12-19 2022-01-19 X4 Pharmaceuticals, Inc. ACYCLIC CXCR4 INHIBITORS AND USES THEREOF
AU2019298314B2 (en) 2018-07-05 2024-06-06 Abb Schweiz Ag Technologies for solar power system performance model tuning
US10548889B1 (en) * 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2020117782A1 (en) * 2018-12-03 2020-06-11 The University Of North Carolina At Chapel Hill Methods for attenuating graft-versus-host disease and opportunistic infections
JP2023517956A (en) 2020-03-10 2023-04-27 エックス４ ファーマシューティカルズ， インコーポレイテッド Methods of treating neutropenia

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4933447A (en) * 1987-09-24 1990-06-12 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) * 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
RU2209066C2 (en) 1997-06-02 2003-07-27 Янссен Фармацевтика Н.В. Derivatives of (imidazol-5-yl)methyl-2-quinolinone as inhibitors of smooth muscle cells proliferation
AU8576098A (en) 1997-07-25 1999-02-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
WO1999016747A1 (en) 1997-09-30 1999-04-08 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
IL145401A0 (en) 1999-03-24 2002-06-30 Anormed Inc Chemokine receptor binding heterocyclic compounds
US6683192B2 (en) * 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
AU2001294628B2 (en) * 2000-09-15 2007-06-07 Anormed Inc. Chemokine receptor binding heterocyclic compounds
IL154227A0 (en) * 2000-09-15 2003-07-31 Anormed Inc Chemokine receptor binding heterocyclic compounds
BR0113931A (en) 2000-09-15 2004-01-13 Anormed Inc Chemokine Receptor Binding Heterocyclic Compounds
NZ526622A (en) * 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
US6794379B2 (en) * 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
KR20040020075A (en) * 2001-07-31 2004-03-06 아노르메드 인코포레이티드 Methods to mobilize progenitor/stem cells
US8178123B2 (en) * 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
WO2003022785A2 (en) 2001-09-12 2003-03-20 Anormed Inc. Synthesis of enantiomerically pure amino-substituted fused bicyclic rings
AU2002357379A1 (en) * 2001-12-21 2003-07-15 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
EP1613613B1 (en) 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
RU2006136381A (en) 2004-03-15 2008-04-27 Анормед, Инк. (Ca) METHOD FOR PRODUCING AN ANTAGONIST CXCR4
TW200619206A (en) * 2004-09-29 2006-06-16 Anormed Inc Chemokine-binding heterocyclic compound salts, and methods of use thereof

Also Published As

Publication number Publication date
US8778967B2 (en) 2014-07-15
US10322111B2 (en) 2019-06-18
US7354932B2 (en) 2008-04-08
WO2004106493A3 (en) 2005-08-25
WO2004106493A2 (en) 2004-12-09
US20040019058A1 (en) 2004-01-29
CA2522535A1 (en) 2004-12-09
US20120301427A1 (en) 2012-11-29
EP1628533A4 (en) 2010-04-14
US20150038509A1 (en) 2015-02-05
JP2007502864A (en) 2007-02-15
US20160228413A1 (en) 2016-08-11
US20200000774A1 (en) 2020-01-02
US20080167341A1 (en) 2008-07-10
EP1628533A2 (en) 2006-03-01

Similar Documents

Publication Publication Date Title
CA2522535C (en) Chemokine receptor binding heterocyclic compounds with enhanced efficacy
CA2467718C (en) Chemokine receptor binding heterocyclic compounds with enhanced efficacy
DE60122175T2 (en) Chemokine receptor-binding heterocyclic compounds
EP1163238B1 (en) Chemokine recpetor binding heterocyclic compounds
US7550484B2 (en) Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US20040235823A1 (en) Chemokine receptor binding heterocyclic compounds
HUP0301094A2 (en) Chemokine receptor binding heterocyclic compounds, pharmaceutical compositions containing this compounds and their use
US20220409589A1 (en) Chemokine receptor binding heterocyclic compounds with enhanced efficacy
ZA200508518B (en) Chemokine receptor binding heterocyclic compounds with enhanced efficacy
HK1072249A (en) Chemokine receptor binding heterocyclic compounds with enhanced efficacy
HK1072249B (en) Chemokine receptor binding heterocyclic compounds with enhanced efficacy
HK1089930B (en) Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Legal Events

Date Code Title Description
EEER Examination request